FEDERAL REGISTER

VOLUME 35 • NUMBER 26

Friday, February 6, 1970 • Washington, D.C.

Pages 2637–2715

Agencies in this issue—

Detailed list of Contents appears inside.



FEDERAL REGISTER
Area Code 202 Phone 962-8626

Published daily, Tuesday through Saturday (no publication on Sundays, Mondays, or on the day after an official Federal holiday), by the Office of the Federal Register, National Archives and Records Service, General Services Administration, Washington, D.C. 20408, pursuant to the authority contained in the Federal Register Act, approved July 26, 1935 (49 Stat. 500, as amended; 44 U.S.C., Ch. 15), under regulations prescribed by the Administrative Committee of the Federal Register, approved by the President (1 CFR Ch. I). Distribution is made only by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.

The FEDERAL REGISTER will be furnished by mail to subscribers, free of postage, for $2.50 per month or $25 per year, payable in advance. The charge for individual copies is 20 cents for each issue, or 20 cents for each group of pages as actually bound. Remit check or money order, made payable to the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.

The regulatory material appearing herein is keyed to the CODE OF FEDERAL REGULATIONS, which is published, under 50 titles, pursuant to section 11 of the Federal Register Act, as amended (44 U.S.C. 1510). The CODE OF FEDERAL REGULATIONS is sold by the Superintendent of Documents. Prices of books and pocket supplements are listed in the first FEDERAL REGISTER issue of each month.

Contents

(Continued on next page)

List of CFR Parts Affected

The following numerical guide is a list of the parts of each title of the Code of Federal Regulations affected by documents published in today's issue. A cumulative list of parts affected, covering the current month to date, appears at the end of each issue beginning with the second issue of the month.

A cumulative guide is published separately at the end of each month. The guide lists the parts and sections affected by documents published since January 1, 1970, and specifies how they are affected.

3 CFR

PROCLAMATION:

3959 2641

5 CFR

213 (8 documents) 2643, 2644

7 CFR

PROPOSED RULES:

52 2668

1098 2669

9 CFR

76 2644

14 CFR

71 (4 documents) 2645

97 2647

PROPOSED RULES:

71 2670

16 CFR

15 (4 documents) 2655, 2656

PROPOSED RULES:

118 2673

17 CFR

PROPOSED RULES:

230 2672

21 CFR

3 (2 documents) 2656, 2657

146b 2657

147 2657

164 2658

191 2659

PROPOSED RULES:

141b 2670

146b 2670

32 CFR

536 2659

33 CFR

207 2660

47 CFR

15 2660

PROPOSED RULES:

25 2671

74 2672

49 CFR

71 2667

Presidential Documents

Title 3—THE PRESIDENT

Proclamation 3959

INTERNATIONAL CLERGY WEEK IN THE UNITED STATES

By the President of the United States of America

A Proclamation

On February 3, 1943, the troop transport *Dorchester* was torpedoed and sunk off the coast of Greenland. Among the six hundred and seventy-eight men lost in that disaster were four chaplains—a priest, a rabbi and two ministers. These men of God had given their life jackets to soldiers who had lost theirs.

The sacrifice of these brave men was great—but their example was even greater. They demonstrated that love of God knows no boundaries when fellow man is in need.

To encourage the participation of all Americans in honoring the world's clergymen, the Congress, by House Joint Resolution 1051, has requested the President to proclaim the week commencing February 1, 1970, as International Clergy Week in the United States.

It is therefore in the spirit of the four chaplains of the *Dorchester* that I, Richard Nixon, President of the United States, proclaim the week commencing February 1, 1970, as International Clergy Week. I call upon all Americans to honor these brave men by appropriate ceremonies and activities, and to honor clergymen of all faiths, in this country and throughout the world, in that spirit of international brotherhood and love of God that transcends all denominational and national boundaries.

IN WITNESS WHEREOF, I have hereunto set my hand this fourth day of February, in the year of our Lord nineteen hundred seventy and of the Independence of the United States of America the one hundred ninety-fourth.

Richard Nixon

[F.R. Doc. 70-1592; Filed, Feb. 4, 1970; 5:00 p.m.]

Rules and Regulations

Title 5—ADMINISTRATIVE PERSONNEL

Chapter I—Civil Service Commission

PART 213—EXCEPTED SERVICE

Department of Agriculture

Section 213.3313 is amended to show that the Schedule C position of Assistant to the Secretary (States Relations) has been retitled Assistant to the Secretary (States Relations and Emergency Preparedness); that the position of the Schedule C Private Secretary to the Assistant to the Secretary (States Relations) has been retitled Private Secretary to the Assistant to the Secretary (States Relations and Emergency Preparedness); and that the abolished position of Assistant to the Secretary (Defense Mobilization Planning) is no longer excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraphs (2) and (24) are amended and subparagraph (23) is revoked under paragraph (a) of § 213.3313 as set out below.

§ 213.3313 **Department of Agriculture.**

(a) *Office of the Secretary.* * * *

(2) Assistant to the Secretary (States Relations and Emergency Preparedness).

* * * * *

(23) [Revoked]

(24) One Private Secretary to the Assistant to the Secretary (States Relations and Emergency Preparedness).

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1537; Filed, Feb. 5, 1970; 8:50 a.m.]

PART 213—EXCEPTED SERVICE

Department of Health, Education, and Welfare

Section 213.3316 is amended to show that three additional positions of Confidential Assistant to the Under Secretary and one additional position of Confidential Assistant to the Deputy Under Secretary are excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraphs (6) and (16) of paragraph (a) of § 213.3316 are amended as set out below.

§ 213.3316 **Department of Health, Education, and Welfare.**

(a) *Office of the Secretary.* * * *

(6) Five Confidential Assistants to the Under Secretary.

* * * * *

(16) Two Confidential Assistants to the Deputy Under Secretary.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1535; Filed, Feb. 5, 1970; 8:49 a.m.]

PART 213—EXCEPTED SERVICE

Department of Health, Education, and Welfare

Section 213.3316 is amended to show that a second position of Confidential Secretary to the Assistant Secretary for Legislation is in Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraph (3) of paragraph (f) of § 213.3316 is amended as set out below.

§ 213.3316 **Department of Health, Education, and Welfare.**

* * * * *

(f) *Office of the Assistant Secretary for Legislation.* * * *

(3) Two Confidential Secretaries to the Assistant Secretary.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1534; Filed, Feb. 5, 1970; 8:49 a.m.]

PART 213—EXCEPTED SERVICE

Department of Health, Education, and Welfare

Section 213.3316 is amended to show that one position of Confidential Assistant to the Commissioner, Medical Services Administration of the Social and Rehabilitation Service, is excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraph (6) is added to paragraph (o) of § 213.3316, as set out below.

§ 213.3316 **Department of Health, Education, and Welfare.**

* * * * *

(o) *Social and Rehabilitation Service.* * * *

(6) One Confidential Assistant to the Commissioner, Medical Services Administration.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1536; Filed, Feb. 5, 1970; 8:49 a.m.]

PART 213—EXCEPTED SERVICE

Office of Economic Opportunity

Section 213.3373 is amended to show that one additional position of Confidential Secretary to the Director, one position of Confidential Assistant to the Executive Adviser (Programs), and one position of Confidential Assistant to the Associate Director for Public Affairs are excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraph (6) is amended and subparagraphs (9) and (10) are added to paragraph (a) of § 213.3373 as set out below.

§ 213.3373 **Office of Economic Opportunity.**

(a) *Office of the Director.* * * *

(6) Two Confidential Secretaries and one Private Secretary to the Director.

* * * * *

(9) One Confidential Assistant to the Executive Adviser (Programs).

(10) One Confidential Assistant to the Associate Director for Public Affairs.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1532; Filed, Feb. 5, 1970; 8:49 a.m.]

PART 213—EXCEPTED SERVICE

National Foundation on the Arts and the Humanities

Section 213.3382 is added to show that one position of Secretary to the Chairman of the National Endowment for the Arts is excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, § 213.3382 is added as set out below.

§ 213.3382 National Foundation on the Arts and the Humanities.

(a) One Secretary to the Chairman of the National Endowment for the Arts.

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1538; Filed, Feb. 5, 1970; 8:50 a.m.]

PART 213—EXCEPTED SERVICE

Department of Transportation

Section 213.3394 is amended to show that one position of Special Assistant to the Director of Intergovernmental Relations is excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraph (19) is added to paragraph (a) of § 213.3394 as set out below.

§ 213.3394 Department of Transportation.

(a) *Office of the Secretary.* * * *

(19) One Special Assistant to the Director of Intergovernmental Relations.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577, 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1533; Filed, Feb. 5, 1970; 8:49 a.m.]

PART 213—EXCEPTED SERVICE

Department of Health, Education, and Welfare

Section 213.3316 is amended to show that one position of Commissioner, Food and Drug Administration, is excepted under Schedule C. Effective on publication in the FEDERAL REGISTER, subparagraph (5) is added to paragraph (h) of § 213.3316 as set out below.

§ 213.3316 Department of Health, Education, and Welfare.

* * * * *

(h) *Office of the Assistant Secretary for Health and Scientific Affairs.* * * *

(5) The Commissioner, Food and Drug Administration.

* * * * *

(5 U.S.C. 3301, 3302, E.O. 10577; 3 CFR 1954–58 Comp., p. 218)

UNITED STATES CIVIL SERVICE COMMISSION,
[SEAL] JAMES C. SPRY,
Executive Assistant to the Commissioners.

[F.R. Doc. 70–1609; Filed, Feb. 5, 1970; 10:24 a.m.]

Title 9—ANIMALS AND ANIMAL PRODUCTS

Chapter I—Agricultural Research Service, Department of Agriculture

SUBCHAPTER C—INTERSTATE TRANSPORTATION OF ANIMALS AND POULTRY

PART 76—HOG CHOLERA AND OTHER COMMUNICABLE SWINE DISEASES

Areas Quarantined

Pursuant to provisions of the Act of May 29, 1884, as amended, the Act of February 2, 1903, as amended, the Act of March 3, 1905, as amended, the Act of September 6, 1961, and the Act of July 2, 1962 (21 U.S.C. 111–113, 114g, 115, 117, 120, 121, 123–126, 134b, 134f), Part 76, Title 9, Code of Federal Regulations, restricting the interstate movement of swine and certain products because of hog cholera and other communicable swine diseases, is hereby amended in the following respects:

1. In § 76.2, the introductory portion of paragraph (e) is amended by adding thereto the name of the State of New Hampshire, and paragraph (e)(17) is added to read:

(17) *New Hampshire.* That portion of Rockingham County comprised of Brentwood, Epping, and Exeter Townships.

2. In § 76.2, subdivision (x) of paragraph (e)(9) relating to the State of North Carolina is amended and a new subdivision (xi) is added to read:

(9) *North Carolina.* * * *

(x) The adjacent portions of Jones, Lenoir and Craven Counties bounded by a line beginning at the junction of U.S. Highway 70 with the Jones-Craven County line; thence, following U.S. Highway 70 in an easterly direction to Secondary Road 1262; thence, following Secondary Road 1262 in a northeasterly direction to Secondary Road 1275; thence, following Secondary Road 1275 in a northeasterly direction to State Highway 55; thence, following State Highway 55 in a northwesterly direction to Secondary Road 1803; thence, following Secondary Road 1803 in a northerly direction to the Craven-Lenoir County line; thence, following the Craven-Lenoir County line in a northeasterly direction to the Neuse River; thence, following the east bank of the Neuse River in a southwesterly direction to U.S. Highway 70; thence, following U.S. Highway 70 in a southwesterly direction to U.S. Highway 258; thence, following U.S. Highway 258 in a southwesterly direction to Secondary Road 1911; thence, following Secondary Road 1911 in a southeasterly direction to Secondary Road 1912; thence, following Secondary Road 1912 in a southwesterly direction to Secondary Road 1916; thence, following Secondary Road 1916 in an easterly direction to State Highway 58; thence, following State Highway 58 in a southeasterly direction to Secondary Road 1919; thence, following Secondary Road 1919 in a southeasterly direction to Secondary Road 1305; thence, following Secondary Road 1305 in an easterly direction to Secondary Road 1002; thence, following Secondary Road 1002 in a northerly direction to Secondary Road 1313; thence, following Secondary Road 1313 in a northeasterly direction to U.S. Highway 70; thence, following U.S. Highway 70 in an easterly direction to its junction with the Jones-Craven County line.

(xi) That portion of Nash County bounded by a line beginning at the junction of State Highway 58 and Secondary Road 1302; thence, following Secondary Road 1302 in a southwesterly direction to Secondary Road 1301; thence, following Secondary Road 1301 in a northwesterly direction to Secondary Road 1300; thence, following Secondary Road 1300 in a southwesterly direction to Secondary Road 1303; thence, following Secondary Road 1303 in a southwesterly direction to U.S. Highway 64; thence, following U.S. Highway 64 in an easterly direction to Secondary Road 1913; thence, following Secondary Road 1913 in a southwesterly direction to Secondary Road 1306; thence, following Secondary Road 1306 in a southeasterly direction to Secondary Road 1145; thence, following Secondary Road 1145 in a southwesterly direction to Sapony Creek; thence, following the northern bank of Sapony Creek in a generally northeasterly direction to State Highway 58; thence, following State Highway 58 in a northerly direction to Secondary Road 1145; thence, following Secondary Road 1145 in a northeasterly direction to Secondary Road 1700; thence, following Secondary Road 1700 in a northwesterly direction to Secondary Road 1003; thence, following Secondary Road 1003 in a northeasterly direction to U.S. Highway (Bypass) 64; thence, following U.S. Highway (Bypass) 64 in a northwesterly direction to Secondary Road 1435; thence, following Secondary Road 1435 in a northerly direction to Basket Creek; thence, following the south bank of Basket Creek in a northwesterly direction to Secondary Road 1004; thence, following Secondary Road 1004 in a southerly direction to State Highway 58; thence, following State Highway 58 in a northwesterly direction to its junction with Secondary Road 1302.

3. In § 76.2, paragraph (e)(14) relating to the State of Virginia, a new subdivision (iii) is added to read:

(14) *Virginia.* * * *

(iii) That portion of Nansemond County bounded by a line beginning at the junction of U.S. Highway 58 and Virginia Secondary Highway 647; thence, following Virginia Secondary Highway 647 in a southeasterly direction to Virginia Secondary Highway 643; thence, following Virginia Secondary Road 643 in a southwesterly direction to Virginia Secondary Highway 616; thence, following Virginia Secondary Highway 616 in a westerly direction to Virginia Secondary Highway 612; thence, following Virginia Secondary Highway 612 in a northwesterly direction to Virginia Primary Highway 189; thence, following Virginia

Primary Highway 189 in a northeasterly direction to U.S. Highway 58; thence, following U.S. Highway 58 in a northeasterly direction to its junction with Virginia Secondary Highway 647.

(Secs. 4–7, 23 Stat. 32, as amended, secs. 1, 2, 32 Stat. 791–792, as amended, secs. 1–4, 33 Stat. 1264, 1265, as amended, sec. 1, 75 Stat. 481, secs. 3 and 11, 76 Stat. 130, 132; 21 U.S.C. 111, 112, 113, 114g, 115, 117, 120, 121, 123–126, 134b, 134f; 29 F.R. 16210, as amended)

Effective date. The foregoing amendments shall become effective upon issuance.

The amendments quarantine portions of Rockingham County, New Hampshire; portions of Craven, Lenoir and Nash Counties in North Carolina; and a portion of Nansemond County in Virginia because of the existence of hog cholera. This action is deemed necessary to prevent further spread of the disease. The restrictions pertaining to the interstate movement of swine and swine products from or through quarantined areas as contained in 9 CFR Part 76, as amended, will apply to the quarantined areas designated herein.

The amendments impose certain further restrictions necessary to prevent the interstate spread of hog cholera and must be made effective immediately to accomplish their purpose in the public interest. Accordingly, under the administrative procedure provisions in 5 U.S.C. 553, it is found upon good cause that notice and other public procedure with respect to the amendments are impracticable and contrary to the public interest, and good cause is found for making them effective less than 30 days after publication in the FEDERAL REGISTER.

Done at Washington, D.C., this 2d day of February 1970.

R. J. ANDERSON,
Acting Administrator,
Agricultural Research Service.

[F.R. Doc. 70–1489; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 14—AERONAUTICS AND SPACE

Chapter I—Federal Aviation Administration, Department of Transportation

SUBCHAPTER E—AIRSPACE

[Airspace Docket No. 69–SO–140]

PART 71—DESIGNATION OF FEDERAL AIRWAYS, CONTROLLED AIRSPACE, AND REPORTING POINTS

Alteration of Control Zone and Transition Area

On December 19, 1969, a notice of proposed rule making was published in the FEDERAL REGISTER (34 F.R. 19911), stating that the Federal Aviation Administration was considering an amendment to Part 71 of the Federal Aviation Regulations that would alter the Jackson, Miss., control zone and transition area.

Interested persons were afforded an opportunity to participate in the rule making through the submission of comments. All comments received were favorable.

Subsequent to publication of the notice, it was determined that the direction "SE," used in describing the control zone extensions predicated on the Jackson VORTAC 157° and 160° radials, should read "SE" and "S" respectively. Additionally, the direction "SW," in relation to the Jackson VORTAC 195° radial, should read "S," and the direction "NE," in relation to the extension predicated on the 008° bearing from the Hawkins RBN, should read "N." Since these amendments are editorial in nature, notice and public procedure hereon are unnecessary and action is taken herein to alter the description accordingly.

In consideration of the foregoing, Part 71 of the Federal Aviation Regulations is amended, effective 0901 G.m.t., April 2, 1970, as hereinafter set forth.

In § 71.171 (35 F.R. 2054), the Jackson, Miss., control zone is amended to read:

JACKSON, MISS.

Within a 5-mile radius of Allen C. Thompson Field (lat. 32°18'40" N., long. 90°04'35" W.); within 2.5 miles each side of Jackson VORTAC 157° and 160° radials, extending from the 5-mile radius zone to 20 miles SE and S of the VORTAC; within a 5-mile radius of Hawkins Field (lat. 32°20'10" N., long. 90°13'15" W.); within 3 miles each side of the 008° bearing from Hawkins RBN, extending from the 5-mile radius zone to 8.5 miles N of the RBN; within 1.5 miles each side of the Jackson VORTAC 195° radial, extending from the 5-mile radius zone to 0.5 mile S of the VORTAC; within a 5-mile radius of Bruce Campbell Field (lat. 32°26'15" N., long. 90°06'05" W.).

In § 71.181 (35 F.R. 2134), the Jackson, Miss., transition area is amended to read:

JACKSON, MISS.

That airspace extending upward from 700 feet above the surface within a 10-mile radius of Allen C. Thompson Field (lat. 32°18'40" N., long. 90°04'35" W.); within an 8-mile radius of Hawkins Field (lat. 32°20'10" N., long. 90°13'15" W.); within 1.5 miles each side of the Jackson VORTAC 195° radial, extending from the 8-mile radius area to the VORTAC; within a 5.5-mile radius of Bruce Campbell Field (lat. 32°26'15" N., long. 90°06'05" W.); within 1.5 miles each side of the Jackson VORTAC 142° radial, extending from the 5.5-mile radius area to the VORTAC.

(Sec. 307(a), Federal Aviation Act of 1958, 49 U.S.C. 1348(a); sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in East Point, Ga., on January 27, 1970.

GORDON A. WILLIAMS, Jr.,
Acting Director, Southern Region.

[F.R. Doc. 70–1504; Filed, Feb. 5, 1970; 8:47 a.m.]

[Airspace Docket No. 69–SO–145]

PART 71—DESIGNATION OF FEDERAL AIRWAYS, CONTROLLED AIRSPACE, AND REPORTING POINTS

Redesignation of Transition Area and Revocation of Control Zone

On December 19, 1969, a notice of proposed rule making was published in the FEDERAL REGISTER (34 F.R. 19913), stating that the Federal Aviation Administration was considering an amendment to Part 71 of the Federal Aviation Regulations that would redesignate the McComb, Miss., transition area.

Interested persons were afforded an opportunity to participate in the rule making through the submission of comments. All comments received were favorable.

Subsequent to publication of the notice, it was determined that the proposal to revoke the McComb control zone, since it no longer met the criteria for retention, was inadvertently omitted. It was also determined that the State of Louisiana 1,200-foot transition area designation would become effective prior to this action, thus eliminating the requirement to make reference to the 700-foot transition area in the citation. Additionally, the geographic coordinate (lat. 31°10'35" N., long. 90°28'08" W.) for McComb-Pike County Airport was obtained from Coast and Geodetic Survey. It is necessary to amend Part 71 of the Federal Aviation Regulations to revoke the McComb control zone, amend the citation to delete the reference to the 700-foot transition area, and alter the transition area description to insert the geographic coordinate for the airport. Since these amendments are editorial and less restrictive in nature, notice and public procedure hereon are unnecessary and action is taken herein to revoke the control zone, amend the citation, and alter the transition area description.

In consideration of the foregoing, Part 71 of the Federal Aviation Regulations is amended, effective 0901 G.m.t., April 2, 1970, as hereinafter set forth.

In § 71.181 (35 F.R. 2134), the McComb, Miss., transition area is amended to read:

MCCOMB, MISS.

That airspace extending upward from 700 feet above the surface within a 6.5-mile radius of McComb-Pike County Airport (lat. 31°10'35" N., long. 90°28'08" W.); within 2 miles each side of McComb VORTAC 234° radial, extending from the 6.5-mile radius area to the VORTAC.

In § 71.171 (35 F.R. 2054), the McComb, Miss., control zone is revoked.

(Sec. 307(a), Federal Aviation Act of 1958, 49 U.S.C. 1348(a); sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in East Point, Ga., on January 27, 1970.

GORDON A. WILLIAMS, Jr.,
Acting Director, Southern Region.

[F.R. Doc. 70–1505; Filed, Feb. 5, 1970; 8:47 a.m.]

[Airspace Docket No. 69–SO–151]

PART 71—DESIGNATION OF FEDERAL AIRWAYS, CONTROLLED AIRSPACE, AND REPORTING POINTS

Alteration of Control Zone and Transition Area and Revocation of Transition Area

On December 18, 1969, a notice of proposed rule making was published in the

FEDERAL REGISTER (34 F.R. 19820), stating that the Federal Aviation Administration was considering an amendment to Part 71 of the Federal Aviation Regulations that would alter the Charlotte, N.C., control zone and transition area and revoke the Gastonia, N.C., and Rock Hill, S.C., transition areas.

Interested persons were afforded an opportunity to participate in the rule making through the submission of comments. All comments received were favorable.

In consideration of the foregoing, Part 71 of the Federal Aviation Regulations is amended, effective 0901 G.m.t., April 2, 1970, as hereinafter set forth.

In § 71.171 (35 F.R. 2054), the Charlotte, N.C., control zone is amended to read:

CHARLOTTE, N.C.

Within a 5-mile radius of Douglas Municipal Airport (lat. 35°12'53" N., long. 80°56'18" W.); within 3 miles each side of Charlotte VORTAC 003° radial, extending from the 5-mile radius zone to 8.5 miles north of the VORTAC; within 2 miles each side of Charlotte VORTAC 058° radial, extending from the 5-mile radius zone to 6 miles northeast of the VORTAC; within 2 miles each side of Charlotte VORTAC 223° radial, extending from the 5-mile radius zone to 6.5 miles southwest of the VORTAC; within 2 miles each side of Charlotte ILS localizer southwest course, extending from the 5-mile radius zone to 1 mile northeast of the OM.

In § 71.181 (35 F.R. 2134), the Charlotte, N.C., transition area is amended to read:

CHARLOTTE, N.C.

That airspace extending upward from 700 feet above the surface within an 8.5-mile radius of Douglas Municipal Airport (lat. 35°12'53" N., long. 80°56'18" W.); within 3 miles each side of Charlotte VORTAC 058° radial, extending from the 8.5-mile radius area to 14 miles northeast of the VORTAC; within 9.5 miles west and 4.5 miles east of Charlotte VORTAC 171° radial, extending from the 5.5 NM DME Fix to 24 miles south of the VORTAC; within 9.5 miles northwest and 4.5 miles southeast of Charlotte VORTAC 223° radial, extending from the 5.5 NM DME Fix to 24 miles southwest of the VORTAC; within 9.5 miles northwest and 4.5 miles southeast of Charlotte ILS localizer, southwest course, extending from the LOM to 18.5 miles southwest; within a 6.5-mile radius of Gastonia Municipal Airport, N.C. (lat. 35° 12'00" N., long. 81°09'05" W.); within a 6.5-mile radius of Rock Hill Municipal Airport, S.C. (lat. 34°59'05" N., long. 81°03'30" W.).

In § 71.181 (35 F.R. 2134), the Gastonia, N.C., and Rock Hill, S.C., transition areas are revoked.

(Sec. 307(a), Federal Aviation Act of 1958, 49 U.S.C. 1348(a); sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in East Point, Ga., on January 26, 1970.

JAMES G. ROGERS,
Director, Southern Region.

[F.R. Doc. 70-1506; Filed, Feb. 5, 1970; 8:47 a.m.]

[Airspace Docket No. 69-SO-69]

PART 71—DESIGNATION OF FEDERAL AIRWAYS, CONTROLLED AIRSPACE, AND REPORTING POINTS

Alteration of Control Zone and Transition Area

On October 30, 1969, a notice of proposed rule making was published in the FEDERAL REGISTER (34 F.R. 17528), stating that the Federal Aviation Administration was considering an amendment to Part 71 of the Federal Aviation Regulations that would alter the Savannah, Ga., control zone and transition area.

Interested persons were afforded an opportunity to participate in the rule making through the submission of comments. All comments receive were favorable except those submitted by the Department of the Army.

The Army objected on the basis that the restriction imposed by the proposed 700-foot transition area would reduce the limited available airspace for Army flight training and would impose unacceptable hazards to flight safety, thereby impairing their capability to accomplish their mission to meet pilot training requirements.

A review of the proposal, in the light of comments received, disclosed that the proposed 700-foot transition area basic radius circles are required to provide adequate controlled airspace protection for IFR operations in climb from 700 to 1,200 feet above the surface. Admittedly, it would derogate the Army's mission because training aircraft would be unable to transition from the control zone through the proposed 700-foot transition area to the training areas at altitudes above 700 feet when visibility was below 3 miles. Special VFR operations are permitted within the control zone configuration, but not within the transition area. The instrument approach procedures to Hunter AAF will be wholly contained within the proposed control zone configuration when commencing descent from 1,500 feet above the surface. To eliminate the requirement for the 700-foot transition area basic radius circle predicated on Hunter AAF, the U.S. Army developed departure procedures that will permit IFR operations to climb to 1,200 feet above the surface within the proposed control zone configuration. To reduce the requirement for the 700-foot transition area basic radius circle predicated on Savannah Municipal Airport, coordination has been effected with industry and other interested parties to restrict aircraft departing Runway 27 to maintain runway heading or execute a right turn until reaching 1,200 feet above the surface, thus eliminating a portion of the transition area to extend beyond the 5-mile control zone radius in the southwest quadrant. An extension to the control zone predicated on Runway 18 centerline extended must be designed to contain IFR aircraft within the control zone configuration until reaching 1,200 feet above the surface.

In view of the foregoing, the proposed 700-foot transition area basic radius circle predicated on Hunter AAF is no longer required and is hereby withdrawn. The 8.5-mile transition area basic radius circle predicated on Savannah Municipal Airport is no longer required, in its entirety, and is hereby altered to eliminate a portion of the southwest quadrant. An additional control zone extension predicated on Savannah Municipal Airport Runway 18 centerline extended will be designated to permit the successful performance of the U.S. Army's training mission. These alterations will result in a substantial reduction in controlled airspace designations. Since these amendments lessen the burden on the public, notice and public procedure hereon are unnecessary and action is taken herein to alter the control zone and transition area descriptions accordingly.

In consideration of the foregoing, Part 71 of the Federal Aviation Regulations is amended, effective 0901 G.m.t., April 2, 1970, as hereinafter set forth.

In § 71.171 (35 F.R. 2054), the Savannah, Ga., control zone is amended to read:

SAVANNAH, GA.

Within a 5-mile radius of Savannah Municipal Airport (lat. 32°07'35" N., long. 81°12'05" W.); within 3 miles each side of Runway 18 extended centerline, extending from the 5-mile radius zone to the arc of an 8.5-mile radius circle centered on Savannah Municipal Airport; within a 5-mile radius of Hunter AAF (lat. 32°00'30" N., long. 81°08'45" W.); within 2 miles each side of Hunter AAF ILS localizer east course, extending from the 5-mile radius zone to 3 miles west of the OM.

In § 71.181 (35 F.R. 2134), the Savannah, Ga., transition area is amended to read:

SAVANNAH, GA.

That airspace extending upward from 700 feet above the surface beginning at the intersection of a line 3 miles south of and parallel to Savannah Municipal Airport Runway 27 centerline extended and the arc of an 8.5-mile radius circle centered on Savannah Municipal Airport (lat. 32°07'35" N., long. 81°12'05" W.), to and clockwise along this arc, to and east along a line 2.5 miles north of and parallel to Savannah ILS localizer east course, to and south along a line 8.5 miles east of and perpendicular to the Savannah ILS localizer east course and its intersection with Savannah VORTAC 179° radial, to and west along a line 2.5 miles south of and parallel to Savannah ILS localizer east course, to and clockwise along the arc of an 8.5-mile radius circle centered on Savannah Municipal Airport, to and north along a line 3 miles west of and parallel to Runway 18 centerline extended, to and west along a line 3 miles south of and parallel to Runway 27 centerline extended, to point of beginning.

(Sec. 307(a), Federal Aviation Act of 1958, 49 U.S.C. 1348(a); sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in East Point, Ga., on January 26, 1970.

JAMES G. ROGERS,
Director, Southern Region.

[F.R. Doc. 70-1507; Filed, Feb. 5, 1970; 8:47 a.m.]

SUBCHAPTER F—AIR TRAFFIC AND GENERAL OPERATING RULES

[Reg. Docket No. 10104; Amdt. 687]

PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

Miscellaneous Amendments

The amendments to the standard instrument approach procedures contained herein are adopted to become effective when indicated in order to promote safety. The amended procedures supersede the existing procedures of the same classification now in effect for the airports specified therein. For the convenience of the users, the complete procedure is republished in this amendment indicating the changes to the existing procedures.

As a situation exists which demands immediate action in the interests of safety in air commerce, I find that compliance with the notice and procedure provisions of the Administrative Procedure Act is impracticable and that good cause exists for making this amendment effective within less than 30 days from publication.

In view of the foregoing and pursuant to the authority delegated to me by the Administrator (24 F.R. 5662), Part 97 (14 CFR Part 97) is amended as follows:

1. By amending § 97.11 of Subpart B to delete low or medium frequency range (L/MF), automatic direction finding (ADF) and very high frequency omnirange (VOR) procedures as follows:

Ocean City, Md.—Ocean City, VOR-1, 13 Jan. 1968 (established under Subpart C).
Readington, N.J.—Solberg-Hunterdon, VOR 1, Amdt. 3, 28 May 1966 (established under Subpart C).

2. By amending § 97.15 of Subpart B to cancel very high frequency omnirange-distance measuring equipment (VOR/DME) procedures as follows:

Ocean City, Md.—Ocean City, VOR/DME, No. 1, Orig. 5 June 1965, canceled, effective 26 Feb. 1970.

3. By amending § 97.17 of Subpart B to amend instrument landing system (ILS) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE ILS

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approaches shall be made over specified routes. Minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Transition				Ceiling and visibility minimums			
From—	To—	Course and distance	Minimum altitude (feet)	Condition	2-engine or less		More than 2-engine, more than 65 knots
					65 knots or less	More than 65 knots	
AMA VOR	LOM	Direct	5000	T-dn**	300-1	300-1	200-½
Canyon Int	LOM	Direct	5000	C-dn	500-1	500-1	500-1¼
Claude Int	LOM	Direct	5000	S-dn-03*#%	200-½	200-½	200-½
Finley Int	LOM	Direct	5000	A-dn	600-2	600-2	600-2
Palo Duro Int	LOM	Direct	5000				
Plant Int	LOM	Direct	6000				
Sam Int	LOM	Direct	5300				
Tower Int	LOM	Direct	5300				
West Side Int	LOM	Direct	5000				

ASR.
Procedure turn S side of crs, 215° Outbnd, 035° Inbnd, 5000′ within 10 miles.
Minimum altitude at glide slope interception Inbnd on final, 5000′.
Altitude of glide slope and distance to approach end of runway at OM, 5000′—5 miles; at MM, 3815′—0.6 mile.
If visual contact not established upon descent to authorized landing minimums or if landing not accomplished, climb to 5000′ on NE crs ILS within 20 miles or, when directed by ATC, (1) turn right, climb to 5000′ and intercept R 076° AMA VOR within 20 miles or (2) turn left, climb to 5300′ on R 307° AMA VOR within 20 miles.
CAUTION: Towers 3994′, 3.4 miles SW; 3886′, 2.1 miles SW; 3885′, 2.7 miles SW of airport. 3764′ grain elevator located adjacent to SW boundary of airport.
*300-¾ required when glide slope not received. 300-½ authorized with operative ALS, except for 4-engine turbojets.
#300-¾ required when approach lights inoperative.
**RVR 2400′ authorized runway 3.
%RVR 2400′. Descent below 3805′ not authorized unless approach lights are visible.
MSA within 25 miles of LOM: 000°-360°—6000′.
City, Amarillo; State, Tex.; Airport name, Amarillo Air Terminal; Elev., 3605′; Fac. Class., ILS; Ident., I-AMA; Procedure No. ILS Runway 3, Amdt. 10; Eff. date, 26 Feb. 70; Sup. Amdt. No. 9; Dated, 5 Dec. 68

4. By amending § 97.19 of Subpart B to cancel radar procedures as follows:

Oakland, Calif.—Oakland International, Radar 1, Amdt. 14, 4 Nov. 1967, canceled effective 26 Feb. 1970.

5. By amending § 97.23 of Subpart C to establish very high frequency omnirange (VOR) and very high frequency-distance measuring equipment (VOR/DME) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE VOR

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.
If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: 6 miles after passing Shoreline Int.
SBY VORTAC	Shoreline Int	Direct	1700	Climbing left turn to 1700′ direct to Shoreline Int and hold.
SWL VORTAC	Shoreline Int (NOPT)	Direct	1700	Supplementary charting information: Hold S, 1 minute, right turns, 055° Inbnd. Chart 157′ antenna 1.1 miles N of airport.

Procedure turn S side of crs, 235° Outbnd, 055° Inbnd, 1700′ within 10 miles of Shoreline Int.
FAF, Shoreline Int. Final approach crs, 055°. Distance FAF to MAP, 6 miles.
Minimum altitude over Shoreline Int, 1700′.
MSA: 000°–090°—1700′; 090°–180°—1600′; 180°–270°—1600′; 270°–360°—1700′.
NOTE: Use Salisbury FSS altimeter setting.
*Night minimums not authorized.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	VIS
C*	540	1	528	540	1¼	528	540	1¼	528	NA
A	Not authorized.		T 2-eng. or less—Standard.				T over 2-eng.—Standard.			

City, Ocean City; State, Md.; Airport name, Ocean City; Elev., 12′; Facility, SWL; Procedure No. VOR-1, Amdt. 1; Eff. date, 26 Feb. 70; Sup. Amdt. No. Orig.; Dated, 13 Jan. 68

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: SBJ VOR.
				Immediate right-climbing turn on SBJ R 130° to 1600′ within 5 miles, then direct to SBJ VOR at 2300′ and hold. Supplementary charting information: Hold SE, 1 minute, right turns, 310° Inbnd. 900′ terrain 3.7 miles NW of airport.

Procedure turn N side of crs, 130° Outbnd, 310° Inbnd, 2300′ within 10 miles of SBJ VORTAC.
Final approach crs, 310°
MSA: 000°–090°—2500′; 090°–180°—1800′; 180°–270°—2000′; 270°–360°—2800′.
NOTE: Use Newark altimeter setting.
*Night minimums not authorized.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C	D
	MDA	VIS	HAT	MDA	VIS	HAT	VIS	VIS
C*	740	1	545	740	1	545	NA	NA
A	Not authorized.		T 2-eng. or less—Standard.				T over 2-eng.—Standard.	

City, Readington; State, N.J.; Airport name, Solberg-Hunterdon; Elev., 195′; Facility, SBJ; Procedure No. VOR-1, Amdt. 4; Eff. date, 26 Feb. 70; Sup. Amdt. No. VOR 1, Amdt. 3; Dated, 28 May 66

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE VOR—Continued

Terminal route				Missed approach
From—	To—	Via	Minimum altitude (feet)	MAP: 4.6 miles after passing GVO VOR.
Goleta Int	Halibut Int	FIM R 253° and GVO R 163°	3500	Climbing left turn to 6000' heading 260° to intercept GVO R 306° to Howard Int and hold.*
Halibut Int	GVO VOR (NOPT)	Direct	3300	Supplementary Charting Information: *Hold NW, 1 minute, left turns, 126° Inbnd. Final approach crs to midpoint Runways 8/26. Chart 4.6-mile DME at missed approach point. Chart holding at Halibut Int. Hold S, 1 minute, right turns, 343° Inbnd, 3500'.

Procedure turn W side of crs, 163° Outbnd, 343° Inbnd, 4400' within 10 miles of GVO VOR.
FAF, GVO VOR. Final approach crs, 354°. Distance FAF to MAP, 4.6 miles.
Minimum altitude over GVO VOR, 3300'; over 2.5-mile DME Fix, 2300'.
MSA: 000°–090°—8000'; 090°–180°—5300'; 180°–270°—4800'; 270°–360°—6600'.
NOTES: (1) Radar vectoring. (2) Use Santa Barbara altimeter setting. (3) Approach from holding pattern at GVO VOR not authorized.
%IFR departure procedures: Runway 8, turn left; climb to 6000' via heading 260° to intercept GVO R 306° to Howard Int.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	VIS
C	2300	2¾	1657	2300	3	1657	2300	3¼	1657	NA
	VOR/DME Minimums:									
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	
C	1460	1	817	1460	1¼	817	1460	1½	817	NA
A	Not authorized.		T 2-eng. or less—Runway 8, Standard; Runway 26, 300–1.%				T over 2-eng.—Runway 8, Standard; Runway 26, 300–1.%			

City, Santa Ynie; State, Calif.; Airport name, Santa Ynie; Elev., 643'; Facility, GVO; Procedure No. VOR-1, Amdt. Orig.; Eff. date, 26 Feb. 1970

6. By amending § 97.23 of Subpart C to amend very high frequency omnirange (VOR) and very high frequency-distance measuring equipment (VOR/DME) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE VOR

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.
If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: 3.6 miles after passing HTO VOR.
				Climbing left turn to 1700' direct to HTO VOR and hold. Supplementary charting information: Hold SW, 1 minute, left turns, 064° Inbnd.

Procedure turn not authorized.
One minute holding pattern SW HTO VOR, 064° Inbnd, left turns, 1700'.
FAF, HTO VOR. Final approach crs, 064°. Distance FAF to MAP, 3.6 miles.
Minimum altitude over HTO VOR, 1700'.
MSA: 000°–090°—1600'; 090°–180°—1600'; 180°–270°—1600'; 270°–360°—1600'.
NOTES: (1) Use Long Island-MacArthur Airport altimeter setting. (2) Night operations authorized on Runway 10-28 only.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C	D
	MDA	VIS	HAA	MDA	VIS	HAA	VIS	VIS
C	640	1	585	640	1	585	NA	NA
A	Not authorized.		T 2-eng. or less—Standard.				T over 2-eng.—not authorized.	

City, East Hampton; State, N.Y.; Airport name, East Hampton; Elev., 55'; Facility, HTO; Procedure No. VOR-1, Amdt. 5; Eff. date, 26 Feb. 70; Sup. Amdt. No. 4; Dated, 18 Dec. 69

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE VOR/DME

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: OLM VORTAC.
McKenna Int	Centralia Int	OLM 15-mile DME Arc OLM, R 165° lead radial.	3800	Climb to 3000′ on R 348° OLM VORTAC within 15 miles.
OLM, R 198° CCW	Centralia Int	OLM 15-mile DME Arc OLM, R 181° lead radial.	3000	Supplementary charting information: LRCO, 122.1.
Centralia Int	10-mile DME, R 173° OLM	Direct	2000	Runway 35, TDZ elevation, 205′.

Procedure turn not authorized. Approach crs (profile) starts at OLM R 173° 10-mile DME.
Final approach crs, 353°.
Minimum altitude over OLM R 173°, 10-mile DME, 2000′; over OLM R 173°, 5-mile DME, 1300′.
Minimum altitude over OLM R 173°, 5-mile DME, 1300′.
MSA: 000°–090°—4800′; 090°–180°—5400′; 180°–270°—3700′; 270°–360°—4100′.
NOTE: Radar vectoring.
*Straight-in and circling MDA increased 100′ and alternate minimums not authorized when control zone not effective except operators with approved weather reporting service. Use McChord altimeter setting when Olympia altimeter setting not available.
% IFR departure procedures: Climb on R 348° OLM VORTAC within 10 miles so as to cross OLM VORTAC at or above 1500′ westbound V204, 1200′ eastbound V204.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT
S-35*	780	1	575	780	1	575	780	1	575	780	1¼	575
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C*	780	1	575	780	1	575	840	1½	635	880	2	675
A	1000-2.		T 2-eng. or less—Standard.%				T over 2-eng.—Standard.%					

City, Olympia; State, Wash.; Airport name, Olympia Municipal; Elev., 205′; OLM; Procedure No. VOR/DME Runway 35, Amdt. 5; Eff. date, 26 Feb. 70; Sup. Amdt. No. 4; Dated, 15 Jan. 70

7. By amending § 97.25 of Subpart C to amend localizer (LOC) and localizer-type directional aid (LDA) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE LOC

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: 6 miles after passing Derby Int.
Conifer Int	DEN VOR	Direct	11,400	Climb to 8000′ on S crs of SPO ILS to EWD NDB and hold,* or, when directed by ATC, climbing left turn to 7000′ direct to Altura LOM and hold.
DEN VOR	Derby Int	Direct	6,800	
DEN, R 063° CCW	Brighton Int	DEN 12-mile DME Arc	7,000	
Brighton Int	Derby Int (NOPT)	Direct	6,800	
				Supplementary charting information: *Hold S, left turns, 1 minute, 350° Inbnd. Runway 17, TDZ elevation, 5253′.

Procedure turn left side of crs, 350° Outbnd, 170° Inbnd, 6800′ within 10 miles of Derby Int.
FAF, Derby Int. Final approach crs, 170°. Distance FAF to MAP, 6 miles.
Minimum altitude over Derby Int, 6800′.
NOTE: ASR.
% IFR departure procedures: Westbound (194° through 321°) must comply with published Denver SID's.
# RVR 24′ authorized Runway 26L; RVR 18′ authorized Runway 35; RVR 50′ authorized Runway 17.
Runway 35, RVR 18; Runways 17 and 26L, RVR 24′.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT
LOC:												
S-17	5560	RVR 40	307	5560	RVR 40	307	5560	RVR 40	307	5560	RVR 50	307
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C	5860	1	530	5880	1	550	5880	1½	550	5880	2	550
A	Standard.		T 2-eng. or less—Standard. %#				T over 2-eng.—Standard. %##					

City, Denver; State, Colo.; Airport name, Stapleton International; Elev., 5330′; Facility, I-SPO; Procedure No. LOC (BC) Runway 17, Amdt. 6; Eff. date, 26 Feb. 70; Sup. Amdt. No. 5; Dated, 18 Sept. 69

8. By amending § 97.27 of Subpart C to establish nondirectional beacon (automatic direction finder) (NDB/ADF) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE NDB (ADF)

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: PT LMM.
IPT VORTAC	PT LMM	Direct	3200	Immediate right (North) climbing turn to 3700' direct to PIX NDB and hold. Supplementary charting information: Hold E, 1 minute, left turns, 266° Inbnd. 2000' ridge 2 miles S of airport.
PIX NDB/Int	PT LMM (NOPT)	Direct	1800	

Procedure turn S side of crs, 086° Outbnd, 266° Inbnd, 3200' within 10 miles of PT LMM.
Final approach crs, 266°.
Minimum altitude over OM, 1800'.
MSA: 000°–180°—3700'; 180°–360°—3500'.
NOTES: (1) Sliding scale not authorized for takeoff and landings. (2) Runways 15/33 closed to air carrier operations. (3) Inoperative table does not apply to ALS Runway 27.
*Circling S Runways 9/27 prohibited.
%Climb visually to 1300' in the immediate vicinity of the airport before departing IFR as cleared by ATC. Runways 9 and 12 climb out Localizer front crs to PIX NDB/Int crossing at 2100'. Runways 27 and 30 right turn heading 300° to intercept MIP R 325°, climb Outbnd on MIP R 325° to 2100'. All runways: Direct to IPT VORTAC; cross IPT 4-mile DME Arc at or above 2000'.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C*	1800	2	1271	1800	2¼	1271	1800	2½	1271	1800	2¾	1271
	Outer marker Minimums:											
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C*	1580	1½	1051	1580	1¾	1051	1580	2	1051	1580	2¼	1051
A	1500-2 Day; 1500-3 Night.		T 2-eng. or less—800-1.%				T over 2-eng.—800-1.%					

City, Williamsport; State, Pa.; Airport name, Williamsport-Lycoming County; Elev., 529'; Facility, PT; Procedure No. NDB (ADF) Runway 27, Amdt. Orig.; Eff. date, 26 Feb. 70

9. By amending § 97.27 of Subpart C to amend nondirectional beacon (automatic direction finder) (NDB/ADF) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE NDB (ADF)

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: 5.6 miles after passing River Grove/RV LOM.
ORD VORTAC	Stack Int	Direct	3500	Turn left to 300° heading, climb to 2000' then make left-climbing turn to 3500' and proceed direct to DPA VOR. Supplementary charting information: 1460' tower 4.7 miles WNW of airport; 1413' tower 4.1 miles W of airport; 1508' tower 7 miles WSW of airport; 848' control-tower on airport. RV LOM named River Grove. Runway 32L, TDZ elevation, 656'.
ADI VOR	Stack Int	Direct	3500	
OBK VORTAC	Stack Int	Direct	3500	
CGT VORTAC	Stack Int (NOPT)	CGT R 003° and bearing 318°	3500	
Niles Int	Stack Int (NOPT)	API R 087° and bearing 318°	3500	
Stack Int	RV LOM	Direct	2200	

Procedure turn E side of crs, 138° Outbnd, 318° Inbnd, 3500' within 10 miles of Stack Int.
FAF, River Grove/RV LOM. Final approach crs., 318°. Distance FAF to MAP, 5.6 miles.
Minimum altitude over Stack Int, 3500'; over RV LOM, 2200'.
MSA: 000°–180°—3100'; 180°–360°—2600'.
NOTES: (1) ASR/PAR. (2) ADF and VOR receivers or Radar required.
% IFR departures: Takeoffs on Runway 32L, when weather is below 1000-3, climb to 2000' on runway heading prior to making left turn.
# Runways 32L, 32R, 27R, visibility 2400'.
# Runways 14L, 14R, visibility 1800'.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT
S-32L	1140	RVR 40	484	1140	RVR 40	484	1140	RVR 40	484	1140	RVR 40	484
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C	1160	1	493	1160	1	493	1160	1½	493	1220	2	553
A	Standard.		T 2-eng. or less—Standard.%#				T over 2-eng.—Standard. %#					

City, Chicago; State, Ill.; Airport name, Chicago O'Hare International; Elev., 667'; Facility RV; Procedure No. NDB (ADF) Runway 32L, Amdt. 8; Eff. date, 26 Feb. 70; Sup. Amdt. No. 7; Dated, 30 Oct. 69

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE NDB (ADF)—Continued

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: COV NDB.
Indianhead VORTAC	COV NDB	Direct	4600	Left-climbing turn to 3500′ on heading 235°,
Garard Int	COV NDB	Direct	4000	then left turn direct to Connellsville
Newton Int	COV NDB	Direct	4000	NDB and hold.
Chalkhill Int	COV NDB	Direct	4300	Supplementary charting information:
Morgantown VORTAC	COV NDB	MGW VORTAC R 027°	4300	Hold SW, 1 minute, left turns, 055° Inbnd.
				Final approach crs intercepts runway centerline 3200′ from threshold.
				Chart 2260′ terrain 2.5 miles SE of airport.
				Runway 5, TDZ elevation, 1265′.

Procedure turn N side of crs, 235° Outbnd, 055° Inbnd, 3500′ within 11 miles of COV NDB.
Final approach crs, 055°.
MSA: 000°–090°—4100′; 090°–180°—4300′; 180°–270°—4200′; 270°–360°—3100′.
NOTE: Use Morgantown, W. Va., altimeter setting.
*Night takeoff Runway 14 not authorized.
%IFR departure procedure: Runways 5, 23, and 32, climb on runway heading; Runway 14, immediate left-climbing turn to heading 235°; climb to 3000′ or above then continue climb as cleared.
CAUTION: Unlighted ridge E of airport.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D
	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	VIS
S-5	1940	1	675	1940	1	675	1940	1¼	675	NA
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	
C	2020	1	753	2180	1¼	913	2260	1½	993	NA
A	Not authorized.			T 2-eng. or less—Runway 14, 800–2;* Standard all others.%			T over 2-eng.—Runway 14, 800–2;* Standard all others.%			

City, Connellsville; State, Pa.; Airport name, Connellsville; Elev., 1267′; Facility, COV; Procedure No. NDB (ADF) Runway 5, Amdt. 1; Eff. date, 26 Feb. 70; Sup. Amdt No. Orig.; Dated, 18 Dec. 69

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: SDA NDB.
Coin Int	SDA NDB	Direct	2700	Climbing left turn to 2700′ on bearing 125°
Emerson Int	SDA NDB	Direct	2700	within 10 miles; return to SDA NDB.
PWE VORTAC	SDA NDB	Direct	3000	Supplementary charting information:
				Runway 30, TDZ elevation, 963′.

Procedure turn S side of crs, 125° Outbnd, 305° Inbnd, 2700′ within 10 miles of SDA NDB.
Final approach crs, 305°.
MSA: 000°–090°—2700′; 090°–360°—2600′.
NOTE: Use Shenandoah altimeter setting through UNICOM. When not available, use Omaha, Nebr., altimeter setting and circling and straight-in MDA becomes 1680′.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D
	MDA	VIS	HAT	MDA	VIS	HAT		VIS		VIS
S-30	1500	1	537	1500	1	537	1500	1	537	NA
	MDA	VIS	HAA	MDA	VIS	HAA				
C	1500	1	537	1500	1	537	1500	1½	537	NA
A	Not authorized.			T 2-eng. or less—Standard.			T over 2-eng.—Standard.			

City, Shenandoah; State, Iowa; Airport name, Municipal; Elev., 963′; Facility, SDA; Procedure No. NDB (ADF) Runway 30, Amdt. 2; Eff. date, 26 Feb. 70; Sup. Amdt. No. 1; Dated, 12 Dec. 68

10. By amending § 97.29 of Subpart C to establish instrument landing system (ILS) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE ILS

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: ILS DH, 1327'; LOC 9.4 miles after passing PIX NDB.
MIP VORTAC	PIX NDB/Int	Direct	3700	Immediate right (North) climbing turn to 3700'. Direct to PIX NDB and hold; or, when directed by ATC, right (NW) climbing turn to 4000'. Intercept MIP R 325° to Trout Run Int. Hold W, 1 minute, right turns, 110° Inbnd.
IPT VORTAC	PIX NDB/Int	Direct	3700	
Linden Int	PIX NDB/Int	Direct	4000	
Muncy Int	PIX NDB/Int (NOPT)	Direct	3600	

Supplementary charting information: Hold E, 1 minute, left turns, 266° Inbnd. Runway 27, TDZ elevation, 527'.

Procedure turn S side of crs, 086° Outbnd, 266° Inbnd, 3700' within 10 miles of PIX NDB/Int.
FAF, PIX NDB/Int. Final approach crs, 266°. Distance FAF to MAP, 9.4 miles.
Minimum altitude over glide slope at PIX NDB, 3648'.
Minimum glide slope interception altitude, 3600'. Glide slope altitude at OM, 1812'; at MM, 766'.
Distance to runway threshold at OM, 3.8 miles; at MM, 0.6 mile.
MSA: 000°-090°—3700'; 090°-180°—3700'; 180°-270°—3300'; 270°-360°—3700'.
Procedure restricted to aircraft capable of simultaneous reception of ILS and VOR when PIX NDB inoperative.
NOTES: (1) Inoperative table does not apply to ALS Runway 27. (2) Sliding scale not authorized for takeoffs and landings. (3) Runways 15/33 closed to air carrier operations.
*Circling S of Runways 9/27 prohibited.
#Maintain 2000' until past Outer Marker. 2000' ridge approximately 2 miles S of airport.
%Climb visually to 1300' in the immediate vicinity of the airport before departing IFR as cleared by ATC. Runways 9 and 12 climb out Localizer front crs to PIX NDB/Int crossing at 2100'. Runways 27 and 30 right turn heading 300° to intercept MIP R 325°, climb Outbnd on MIP R 325° to 2100'. All runways: Direct to IPT VORTAC; cross IPT 4-mile DME Arc at or above 2000'.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	DH	VIS	HAT	DH	VIS	HAT	DH	VIS	HAT	DH	VIS	HAT
S-27	1327	1	800	1327	1¼	800	1327	1½	800	1327	1¾	800
LOC:	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT
S-27#	1420	1¼	893	1420	1½	893	1420	1¾	893	1420	2	893
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C*	1420	1¼	891	1420	1½	891	1420	1¾	891	1420	2	89
A	1500-2 Day; 1500-3 Night.		T 2-eng. or less—800-1.%				T over 2-eng.—800-1.%					

City, Williamsport; State, Pa.; Airport name, Williamsport-Lycoming County; Elev., 529'; Facility, I-IPT; Procedure No. ILS Runway 27, Amdt. 7; Eff. date, 26 Feb. 70; Sup. Amdt. No. ILS-27, Amdt. 6; Dated, 20 Aug. 66

11. By amending § 97.29 of Subpart C to amend instrument landing system (ILS) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE ILS

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If an instrument approach procedure of the above type is conducted at the below named airport, it shall be in accordance with the following instrument approach procedure, unless an approach is conducted in accordance with a different procedure for such airport authorized by the Administrator. Initial approach minimum altitudes shall correspond with those established for en route operation in the particular area or as set forth below.

Terminal routes				Missed approach
From—	To—	Via	Minimum altitudes (feet)	MAP: ILS DH, 1264'; LOC 5.8 miles after passing RN LOM.
R 223°, MKC VORTAC CW	RNI LOC	20-mile Arc MKC, R 262° lead radial.	2700	Climbing right turn to 2700', proceed to Manchester (MC) LOM.
R 331°, MKC VORTAC CCW	RNI LOC	20-mile Arc MKC, R 273° lead radial.	2700	Supplementary charting information: Runway 9, TDZ elevation, 1014'.
20-mile Arc	Rondell (RN) LOM	LOC crs	2700	
Camden Int	Rondell (RN) LOM	Direct	2700	
New Market Int	Rondell (RN) LOM	Direct	2700	
Wood Int	Rondell (RN) LOM (NOPT)	Direct	2700	
Lansing Int	Rondell (RN) LOM	Direct	2700	
DeSoto Int	Rondell (RN) LOM	Direct	2700	
MKC VORTAC	Rondell (RN) LOM	Direct	2700	
BSP VORTAC	Rondell (RN) LOM	Direct	2900	
Manchester (MC) LOM	Rondell (RN) LOM	Direct	2700	

Procedure turn S side of crs, 268° Outbnd, 088° Inbnd, 2700' within 10 miles of RN LOM.
FAF, RN LOM. Final approach crs, 088°. Distance FAF to MAP, 5.8 miles.
Minimum glide slope interception altitude, 2700'. Glide slope altitude at OM, 2614'; at MM, 1214'.
Distance to runway threshold at OM, 5.8 miles; at MM, 0.6 mile.
MSA: 045°–135°—3100'; 135°–315°—2700'; 315°–045°—2800'.

NOTES: (1) Radar vectoring. (2) Inoperative components table does not apply to HIRL OM and MM.

DAY AND NIGHT MINIMUMS

Cond.	A			B			C			D		
	DH	VIS	HAT	DH	VIS	HAT	DH	VIS	HAT	DH	VIS	HAT
S-9	1264	1	250	1264	1	250	1264	1	250	1264	1	250
LOC:	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT	MDA	VIS	HAT
S-9	1280	1	266	1280	1	266	1280	1	266	1280	1	266
	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA	MDA	VIS	HAA
C	1540	1	515	1540	1	515	1540	1½	515	1580	2	555
A	Standard.		T 2-eng. or less—RVR 24', Runway 36; Standard all other runways.				T over 2-eng.—RVR 24', Runway 36; Standard all other runways.					

City, Kansas City; State, Mo.; Airport name, Kansas City International; Elev., 1025'; Facility I-RNI; Procedure No. ILS Runway 9, Amdt. 1; Eff. date, 26 Feb. 70; Sup. Amdt. No. Orig.; Dated, 1 May 1969

12. By amending § 97.31 of Subpart C to establish precision approach radar (PAR) and airport surveillance radar (ASR) procedures as follows:

STANDARD INSTRUMENT APPROACH PROCEDURE—TYPE RADAR

Bearings, headings, courses and radials are magnetic. Elevations and altitudes are in feet MSL, except HAT, HAA, and RA. Ceilings are in feet above airport elevation. Distances are in nautical miles unless otherwise indicated, except visibilities which are in statute miles or hundreds of feet RVR.

If a radar instrument approach is conducted at the below named airport, it shall be in accordance with the following instrument procedure, unless an approach is conducted in accordance with a different procedure authorized for such airport by the Administrator. Initial approach minimum altitude(s) shall correspond with those established for en route operation in the particular area or as set forth below. Positive identification must be established with the radar controller. From initial contact with radar to final authorized landing minimums, the instructions of the radar controller are mandatory except when (A) visual contact is established on final approach at or before descent to the authorized landing minimums, or (B) at Pilot's discretion if it appears desirable to discontinue the approach. Except when the radar controller may direct otherwise prior to final approach, a missed approach shall be executed as provided below when (A) communication on final approach is lost for more than 5 seconds during a precision approach, or for more than 30 seconds during a surveillance approach; (B) directed by radar controller; (C) visual contact is not established upon descent to authorized landing minimums; or (D) if landing is not accomplished.

Radar terminal area maneuvering sectors and altitudes (sectors and distances measured from radar antenna)										Notes
From—	To—	Distance	Altitude	Distance	Altitude	Distance	Altitude	Distance	Altitude	
As established by Houston ASR minimum altitude vectoring charts.										Descend aircraft to MDA after FAF, 5 miles from airport. Supplementary charting information: *Hold NE, 1 minute, right turns, 246° Inbnd. Use Houston altimeter setting.

Missed approach: Climbing right or left turn to 1600' direct to Fry Int and hold.*

DAY AND NIGHT MINIMUMS

Cond.	A			B			C	D
	MDA	VIS	HAA	MDA	VIS	HAA	VIS	VIS
C	740	1	705	740	1	705	NA	NA
A	Not authorized.		T 2-eng. or less—Standard.				T over 2-eng.—Standard.	

City, Baytown; State, Tex.; Airport name, Humphrey; Elev., 35'; Facility HOU Radar; Procedure No. Radar-1, Amdt. Orig.; Eff. date, 26 Feb. 70

These procedures shall become effective on the dates specified therein.

(Secs. 307(c), 313(a), 601, Federal Aviation Act of 1958 (49 U.S.C. 1348(c), 1354(a), 1421; 72 Stat. 749, 752, 775))

Issued in Washington, D.C., on January 23, 1970.

R. S. SLIFF,
Acting Director, Flight Standards Service.

[F.R. Doc. 70-1133; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 16—COMMERCIAL PRACTICES

Chapter I—Federal Trade Commission

PART 15—ADMINISTRATIVE OPINIONS AND RULINGS

Labeling of Imported Magnetic Recording Tape

§ 15.400 Labeling of imported magnetic recording tape.

(a) Modifying the position announced in Advisory Opinion Digest No. 366 (§ 15.366), the Commission advised that:

(1) Tape accompanying an imported tape recorder, if packaged to show country of origin, is not required to express quantity of contents as described in Advisory Opinion Digest No. 366 (§ 15.366), provided the description of contents does not constitute an unfair or deceptive practice which would violate the Federal Trade Commission Act.

(2) Cartridge tapes may be expressed in terms of playing time in lieu of a linear measurement.

(3) Imported packaged magnetic recording tapes may continue to be distributed provided the country of origin is appropriately shown.

(b) This action was taken to conform the opinion with the Commission's Statement of General Policy and Interpretation, § 503.2 of this chapter.

(38 Stat. 717, as amended; 15 U.S.C. 41-58)

Issued: February 5, 1970.

By direction of the Commission.

[SEAL] JOSEPH W. SHEA,
Secretary.

[F.R. Doc. 70-1412; Filed, Feb. 5, 1970; 8:45 a.m.]

PART 15—ADMINISTRATIVE OPINIONS AND RULINGS

Designation of Landscaping Material by Volume on Containers

§ 15.401 Designation of landscaping material by volume on containers.

(a) In a previous advisory opinion the Commission advised that to designate the contents on containers of landscaping material by cubic measurement rather than by weight would be objectionable under section 5, Federal Trade Commission Act.

(b) The proposal considered involved the marketing of a processed clay material in physical form varying from pieces of approximateiy 2 inches down to 1/10 of an inch in diameter for use as a landscaping material, particularly around shrubs, trees, walkways and other non-grassed areas. Because the density of the product by volume is less and the area of coverage by weight greater than competing materials used for the same purpose it was represented that it would be more beneficial and informative to consumers to stipulate the container contents in cubic measurement instead of by the traditional contents by weight designation. Specifically, the Commission was asked:

(1) May the product be marketed by showing the contents of the bags in which it is contained by way of cubic measurement and not by weight, leaving off all reference to weight?

(2) Also, may the area the material will cover in square inches, feet, or yards to a specified depth be shown on the bags?

(c) The Commission expressed the view that the product, being used mainly for ground covering purposes, is classified as a type of lawn and garden commodity and as such is not considered a "consumer commodity" as defined by the Fair Packaging and Labeling Act. Whether the proposed labeling would be an unfair or deceptive act must, therefore, be tested against the criteria of section 5, FTC Act. Controlling in matters of this nature is whether the proposed course of action is fair to consumers according to recognized principles, not that it might be unfair according to tradition and the morals of the market place. The concept of "Unfair or deceptive acts or practices" stresses business integrity, encourages legitimate trading, and protects consumers against commercial spoliation.

(d) The Commission expressed the view that it would be more beneficial and informative to consumers if the contents were designated on the product

containers by both weight and volume. Although not essential, it would also be beneficial and informative to consumers if the extent of area coverage to a predetermined depth by weight and by volume were included in such content designation.

(e) The Commission further advised that its opinion is confined to so much of the request as falls within its jurisdiction and the xtent, if any, to which another governmental agency, either local, State, or Federal, may be concerned is a matter to be determined by reference to that agency.

(38 Stat. 717, as amended; 15 U.S.C. 41–58)

Issued: February 5, 1970.

By direction of the Commission.

[SEAL] JOSEPH W. SHEA, *Secretary.*

[F.R. Doc. 70–1413; Filed, Feb. 5, 1970; 8:45 a.m.]

PART 15—ADMINISTRATIVE OPINIONS AND RULINGS

Marking of Shoe Soles Composed of Ground Leather

§ 15.402 Marking of shoe soles composed of ground leather.

(a) The Commission issued an advisory opinion in regard to the proper marking of a material to be used in the manufacture of shoe soles.

(b) The material in question is not leather but a man-made fibrous leather material bonded with an adhesive. It will be manufactured and sold in its natural form to manufacturers for use as shoe soles and/or heels. Shoe manufacturers will in all probability dye or stain the material so as to give it the appearance of leather or any other material as desired. Under no circumstances will the manufacturer of the material have any control over its appearance once it has been sold to shoe manufacturers.

(c) Specifically, the following questions were raised in regard to the proper marking of the material:

(1) When the material is used for shoe soles and/or heels but does not have the appearance of natural leather, need there be any marking or labeling whatsoever?

(2) In those instances where the material is used for shoe soles and/or heels and does have the appearance of natural leather, is it necessary to mark or label the material with a designation indicating that it is not natural leather?

(3) In all cases where the answer to question 2 is in the affirmative and assuming that the material is easily visible, is it sufficient to mark the shoe part made from this material with its trade name?

(4) If the answer to question 3 is in the negative, what would constitute adequate and sufficient disclosure of the nature of the material?

(d) In regard to the first question, where a manufacturer produces a leather-type product for use in shoes and knows or has reason to believe that after processing it will look like leather, the manufacturer must label the product as indicated in question 2.

(e) Second, when the material is used for shoe soles and does have the appearance of leather, it is necessary for the shoe manufacturers to mark or label such materials with a designation which clearly discloses either: (1) The material is simulated or imitation leather, or (2) the general nature of the material in such manner as to show it is not leather or split leather. This requirement is imposed by Guide II of the Shoe Guides, but it should be noted that heels are specifically exempted from the marking provisions thereof.

(f) Third, marking the shoe soles with the trade name would not be sufficient to remove the deception created by the false impression where the material is finished to have the appearance of leather. In short, there is nothing in the use of the trade name alone which would meet the requirements set forth in answer to question 2.

(g) In response to the fourth question, Guide VI of the Shoe Guides sets forth a number of terms which would be acceptable in describing the nature of the material when it is finished to have the appearance of leather. Those terms are as follows: "simulated leather," "imitation leather," or that it is "ground, pulverized or shredded leather" (as the case may be). There are a variety of ways in which this objective could be accomplished and the foregoing quoted language is merely suggestive of some ways in which this could be done.

(38 Stat. 717, as amended; 15 U.S.C. 41–58)

Issued: February 5, 1970.

By direction of the Commission.

[SEAL] JOSEPH W. SHEA, *Secretary.*

[F.R. Doc. 70–1414; Filed, Feb. 5, 1970; 8:45 a.m.]

PART 15—ADMINISTRATIVE OPINIONS AND RULINGS

Union-Employer Agreement To Cease Importing Competitive Product

§ 15.403 Union-employer agreement to cease importing a competitive product.

(a) The Federal Trade Commission rendered an advisory opinion in regard to the legality of labor unions entering into collective bargaining agreements with their employer manufacturers whereby the manufacturers will agree to cease importing products of the type they manufacture.

(b) It is alleged that the unions have made such a proposal to their employer manufacturers because of the increased imports which have resulted in decreased domestic production, increased domestic unemployment, loss of wages, etc. It is contemplated that penalties will be assessed against any manufacturer who violates the proposed agreement.

(c) The Commission concluded that the immunity afforded to labor unions for certain labor activities is lost if the union combines with non-labor groups to effect a restraint of trade not intimately related to wages, hours, and working conditions and otherwise prohibited by the antitrust laws or Federal Trade Commission Act.

(38 Stat. 717, as amended; 15 U.S.C. 41–58)

Issued: February 5, 1970.

By direction of the Commission.

[SEAL] JOSEPH W. SHEA, *Secretary.*

[F.R. Doc. 70–1415; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 21—FOOD AND DRUGS

Chapter I—Food and Drug Administration, Department of Health, Education, and Welfare

SUBCHAPTER A—GENERAL

PART 3—STATEMENTS OF GENERAL POLICY OR INTERPRETATION

Labeling for Prescription Drugs Used in Man

In the FEDERAL REGISTER of September 26, 1969 (34 F.R. 14850), the Commissioner of Food and Drugs proposed a statement of policy to serve as a guideline to industry for the kinds of information and the sequence and headings of the sections of information presented in prescription drug labeling. Having considered the comments received in response to the proposal, and other relevant information, the Commissioner concludes that the proposal should be adopted as set forth below.

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 503, 701(a), 52 Stat. 1050–52, as amended, 1055; 21 U.S.C. 352, 353, 371(a)) and under authority delegated to the Commissioner (21 CFR 2.120), the following new section is added to Part 3:

§ 3.74 Labeling for prescription drugs used in man.

(a) To be most useful to practitioners, labeling information for prescription drugs should be orderly and uniform in the sequence and kinds of information presented. For this reason, the Food and Drug Administration recommends that prescription drug labeling purporting to furnish adequate information for the safe and effective use of a drug, as required under § 1.106(b) of this chapter, should ordinarily contain information in substantially the format and order and with the section headings as follows:

DESCRIPTION
ACTIONS
INDICATIONS
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION
OVERDOSAGE (WHERE APPLICABLE)
HOW SUPPLIED

(b) The following sections are optional. If used, they should be placed after the information described above.

ANIMAL PHARMACOLOGY AND TOXICOLOGY
CLINICAL STUDIES
REFERENCES

(c) Although ordinarily prescription drug labeling should employ the format, order, and section headings described above, in the case of some drugs special warnings may be required to appear conspicuously in the beginning of the labeling for special attention by physicians for the safety of patients. In the case of a drug for which there is no information applicable to a section heading described in paragraph (a) of this section, such heading and section may be omitted.

(Secs. 502, 503, 701(a), 52 Stat. 1050–52, as amended, 1055; 21 U.S.C. 352, 353, 371(a))

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70–1501; Filed, Feb. 5, 1970; 8:46 a.m.]

PART 3—STATEMENTS OF GENERAL POLICY OR INTERPRETATION

Labeling Exemption Regarding Drug-Use Carbon Dioxide, Cyclopropane, Ethylene, Helium, and Nitrous Oxide Gases

The Commissioner of Food and Drugs published in the FEDERAL REGISTER of November 6, 1968 (33 F.R. 16284), a proposal that would permit a general warning statement in the labeling of carbon dioxide, cyclopropane, ethlyene, helium, and nitrous oxide gases used as drugs in lieu of full information for use by physicians; namely, the description of the drug, chemistry, actions, animal pharmacology, indications, contraindications, warnings (including use in pregnancy), precautions, adverse reactions, dosage, and administration.

Responses to the proposal included a recommendation to have the labeling exemption apply to mixtures of oxygen with any one of either nitrous oxide, helium, or carbon dioxide gases. This recommendation was presented to the Respiratory and Anesthetic Drugs Advisory Committee on May 12, 1969. The Committee recommended, and the Commissioner agrees, that the labeling exemption should not be granted to these mixed gases. The commissioner also agrees with and has adopted a suggestion that the final order exempt such articles from stating the route of administration as required by § 1.106(b)(2)(iii) (21 CFR 1.106).

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502(f), 701(a), 52 Stat. 1051, 1055; 21 U.S.C. 352(f), 371(a)) and under authority delegated to the Commissioner (21 CFR 2.120), the following new section is added to Part 3:

§ 3.518 Labeling exemption for carbon dioxide, cyclopropane, ethylene, helium, and nitrous oxide gases for drug use.

(a) Carbon dioxide, cyclopropane, ethylene, helium, and nitrous oxide gases intended for drug use are exempted from the requirements of § 1.106(b)(2)(ii), (iii), and 3(i) of this chapter provided the labeling bears, in addition to any other information required by the Federal Food, Drug, and Cosmetic Act, the following:

(1) The warning statement "Warning—Administration of (name of gas) may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of (name of gas) and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken"; and

(2) Any needed directions concerning the conditions for storage and warnings against the inherent dangers in the handling of the specific compressed gas.

(b) This labeling exemption does not apply to mixtures of any one or more of these gases with oxygen or with each other.

(c) Regulatory action may be initiated with respect to any article shipped within the jurisdiction of the Act contrary to the provisions of this section after 60 days following publication of this section in the FEDERAL REGISTER.

(Secs. 502(f), 701(a), 52 Stat. 1051, 1055; 21 U.S.C. 352(f), 371(a))

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70–1502; Filed, Feb. 5, 1970; 8:46 a.m.]

SUBCHAPTER C—DRUGS

PART 146b—CERTIFICATION OF STREPTOMYCIN (OR DIHYDROSTREPTOMYCIN) AND STREPTOMYCIN- (OR DIHYDROSTREPTOMYCIN-) CONTAINING DRUGS

Streptomycin Sulfate for Injection

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 507, 59 Stat. 463, as amended; 21 U.S.C. 357) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120), § 146b.134 (b) and (c) is revised to read as follows to provide for certification of the subject antibiotic drug in bulk packages:

§ 146b.134 Streptomycin sulfate for injection.

* * * * *

(b) *Packaging.* It shall be packaged in accordance with the requirements of § 148.2 of this chapter.

(c) *Labeling*—(1) *It is packaged for dispensing.* In addition to the labeling requirements prescribed by § 1.106(b) of this chapter (regulations issued under section 502(f) of the act), each package shall bear on its label or labeling, as hereinafter indicated, the following:

(i) On the outside wrapper or container and the immediate container, the statement "Expiration date _____" the blank being filled in with the date that is 24 months after the month during which the batch was certified.

(ii) On the circular or labeling within or attached to the package, the conditions under which solutions of the drug should be stored, including the statement "Sterile solutions may be stored at room temperature for 4 weeks without significant loss of potency."

(2) *It is packaged solely for manufacturing use and/or repacking.* Each package shall bear on its outside wrapper or container and the immediate container the following:

(i) The potency per gram and the number of grams in the immediate container.

(ii) The statement "Caution: Federal law prohibits dispensing without prescription."

(iii) The statement "For manufacturing use," "For repacking," or "For manufacturing use or repacking."

(iv) The information required by subparagraph (1)(i) of this paragraph.

* * * * *

This order provides for certification of an additional form of the subject antibiotic drug. Since it would serve no purpose to delay in so providing and since this order is noncontroversial and nonrestrictive in nature, notice and public procedure and delayed effective date are not prerequisites to this promulgation.

Effective date. This order shall be effective upon publication in the FEDERAL REGISTER.

(Sec. 507, 59 Stat. 463, as amended; 21 U.S.C. 357)

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70–1496; Filed, Feb. 5, 1970; 8:46 a.m.]

PART 147—ANTIBIOTICS INTENDED FOR USE IN THE LABORATORY DIAGNOSIS OF DISEASE

Diagnostic Sensitivity Powders

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 507, 59 Stat. 463, as amended; 21 U.S.C. 357) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120), the following two new sections are added to Part 147 of the antibiotic drug regulations to provide for certification of the subject diagnostic sensitivity powders:

§ 147.14 Oxytetracycline hydrochloride diagnostic sensitivity powder.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity.* Oxytetracycline hydrochloride diagnostic sensitivity powder is crystalline oxytetracycline hydrochloride, with or without one or more suitable buffers and diluents, packaged in vials and intended for use in clinical laboratories for determining in vitro the sensitivity of micro-organisms to oxytetracycline. Each vial contains oxytetracycline hydrochloride equivalent to 20 milligrams of oxytetracycline. The potency of each immediate container is satisfactory if it contains not less than 90 percent and not more than 115 percent of its labeled content. It is sterile. Its loss on drying is not more than 2.0 percent. When reconstituted as directed in the labeling, its pH is not less than 2.0 percent. When reconstituted as directed in the labeling, its pH is not less than 2.0 and not more than 3.5. The oxytetracycline hydrochloride used conforms to the standards prescribed by § 148n.2(a)(1)(i), (vi), (vii), (viii), and (ix) of this chapter.

(2) *Packaging.* The immediate container shall be of colorless, transparent glass and it shall be a tight container as defined by the U.S.P. It shall be so sealed that the contents cannot be used without destroying such seal. It shall be of appropriate size to permit the addition of 20 milliliters of sterile diluent when preparing a stock solution for use in making further dilutions for microbial susceptibility testing.

(3) *Labeling.* In addition to the requirements of § 148.3(a)(3) of this chapter, each package shall bear on its label or labeling, as hereinafter indicated, the following:

(i) On its outside wrapper or container and on the immediate container:

(*a*) The statement "For laboratory diagnostic use only."

(*b*) The statement "Sterile."

(*c*) The batch mark.

(*d*) The number of milligrams of oxytetracycline in each immediate container.

(ii) On the circular or other labeling within or attached to the package, adequate information for use of the drug in the clinical laboratory.

(4) *Requests for certification; samples.* In addition to complying with the requirements of § 146.2 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(*a*) The oxytetracycline hydrochloride used in making the batch for potency, moisture, pH, crystallinity, absorptivity, and identity.

(*b*) The batch for potency, sterility, loss on drying, and pH.

(ii) Samples required:

(*a*) The oxytetracycline hydrochloride used in making the batch: 10 packages, each containing approximately 300 milligrams.

(*b*) The batch:

(*1*) For all tests except sterility: A minimum of 30 immediate containers.

(*2*) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation.

(b) *Tests and methods of assay*—(1) *Potency.* Proceed as directed in § 141.111 of this chapter, preparing the sample for assay as follows: Reconstitute as directed in the labeling. Dilute an aliquot with 0.1*M* potassium phosphate buffer, pH 4.5 (solution 4), to the prescribed reference concentration.

(2) *Sterility.* Proceed as directed in § 141.2 of this chapter, using the method described in paragraph (e)(1) of that section.

(3) *Loss on drying.* Proceed as directed in § 141.501(b) of this chapter.

(4) *pH.* Proceed as directed in § 141.503 of this chapter, using the drug reconstituted as directed in the labeling.

§ 147.15 Potassium penicillin G diagnostic sensitivity powder.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity.* Potassium penicillin G diagnostic sensitivity powder is crystalline potassium penicillin G, with or without one or more suitable buffers and diluents, packaged in vials and intended for use in clinical laboratories for determining in vitro the sensitivity of micro-organisms to penicillin G. Each vial contains 20,000 units of penicillin G. The potency of each immediate container is satisfactory if it contains not less than 90 percent and not more than 115 percent of its labeled content. It is sterile. Its loss on drying is not more than 1.5 percent. When reconstituted as directed in the labeling, its pH is not less than 5.0 and not more than 7.5. The potassium penicillin G used conforms to the standards prescribed by § 146a.24(a)(1), (5), and (6) of this chapter.

(2) *Packaging.* The immediate container shall be of colorless, transparent glass and it shall be a tight container as defined by the U.S.P. It shall be so sealed that the contents cannot be used without destroying such seal. It shall be of appropriate size to permit the addition of 20 milliliters of sterile diluent when preparing a stock solution for use in making further dilutions for microbial susceptibility testing.

(3) *Labeling.* In addition to the requirements of § 148.3(a)(3) of this chapter, each package shall bear on its label or labeling, as hereinafter indicated, the following:

(i) On its outside wrapper or container and on the immediate container:

(*a*) The statement "For laboratory diagnostic use only."

(*b*) The statement "Sterile."

(*c*) The batch mark.

(*d*) The number of units of penicillin G in each immediate container.

(ii) On the circular or other labeling within or attached to the package, adequate information for use of the drug in the clinical laboratory.

(4) *Requests for certification; samples.* In addition to complying with the requirements of § 146.2 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(*a*) The penicillin G used in making the batch for potency, moisture, pH, and crystallinity.

(*b*) The batch for potency, sterility, loss on drying, and pH.

(ii) Samples required:

(*a*) The potassium penicillin G used in making the batch: 10 packages, each containing approximately 300 milligrams.

(*b*) The batch:

(*1*) For all tests except sterility: A minimum of 20 immediate containers.

(*2*) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation.

(b) *Tests and methods of assay*—(1) Potency. Proceed as directed in § 141.110 of this chapter, preparing the sample for assay as follows: Reconstitute as directed in the labeling. Dilute an aliquot with 1 percent potassium phosphate buffer, pH 6.0 (solution 1), to the prescribed reference concentration.

(2) *Sterility.* Proceed as directed in § 141.2 of this chapter, using the method described in paragraph (e)(1) or (2) of that section, except if using the method in paragraph (e)(2), use medium B in lieu of medium A.

(3) *Loss on drying.* Proceed as directed in § 141.501(b) of this chapter.

(4) *pH.* Proceed as directed in § 141.503 of this chapter, using the drug reconstituted as directed in the labeling.

Data supplied by the manufacturer concerning the subject diagnostic sensitivity powders have been evaluated. Since the conditions prerequisite to providing for certification have been complied with and since it is in the public interest not to delay in so providing, notice and public procedure and delayed effective date are not prerequisites to this promulgation.

Effective date. This order shall be effective upon publication in the FEDERAL REGISTER.

(Sec. 507, 59 Stat. 463, as amended; 21 U.S.C. 357)

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1495; Filed, Feb. 5, 1970; 8:45 a.m.]

PART 164—CERTIFICATION OF BATCHES OF DRUGS COMPOSED WHOLLY OR PARTLY OF INSULIN

Tests and Methods of Assay

Section 164.15 requires that the tests and methods of assay used for certification of insulin batches be those set forth in the U.S.P. or N.F. The regulation is amended as follows to permit use, when authorized by the Commissioner of Food and Drugs, of test methods not described in the U.S.P. or N.F. to enable analysts to use improved assay and test procedures pending their inclusion in the U.S.P. or N.F.

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 506, 55 Stat. 851; 21 U.S.C. 356) and under authority delegated to the Commissioner (21 CFR 2.120), § 164.15(a) is revised to read as follows:

§ 164.15 Tests and methods of assay.

* * * * *

(a) *Tests and methods of assay for insulin injection, protamine zinc insulin suspension, globin zinc insulin injection, isophane insulin suspension, insulin zinc suspension, prompt insulin zinc suspension, and extended insulin zinc suspension.* The tests and methods of assay for insulin injection, protamine zinc insulin suspension, globin zinc insulin injection, isophane insulin suspension, insulin zinc suspension, prompt insulin zinc suspension, and extended insulin zinc suspension shall be those set forth therefor in the U.S.P. or N.F., except that alternative test procedures may be employed when such have been authorized by the Commissioner.

* * * * *

Since this order is nonrestrictive and noncontroversial in nature and since its provision cannot be implemented unless and until authorized by the Commissioner, notice and public procedure and delayed effective date are not prerequisites to this promulgation.

Effective date. This order shall be effective upon publication in the FEDERAL REGISTER.

(Sec. 506, 55 Stat. 851; 21 U.S.C. 356)

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1494; Filed, Feb. 5, 1970; 8:45 a.m.]

SUBCHAPTER D—HAZARDOUS SUBSTANCES

PART 191—HAZARDOUS SUBSTANCES: DEFINITIONS AND PROCEDURAL AND INTERPRETATIVE REGULATIONS

Viscous Products Containing Methyl Alcohol; Expansion of Exemption

The Commissioner of Food and Drugs has received a request, submitted pursuant to section 3(c) of the Federal Hazardous Substances Act and § 191.62 of the regulations thereunder, to exempt spray containers of adhesives and similar products from the special labeling required because of their methyl alcohol content. These products contain, among other ingredients, more than 4 percent by weight methyl alcohol and under § 191.7(b)(2) special warning labeling is required based on the history or use of methyl alcohol products as a beverage.

Based on data supplied by the petitioners and developed by independent investigations, the Commissioner concludes that no reasonably foreseeable hazard by ingestion of these products exists and therefore compliance with § 191.7(b)(2) is unnecessary for these products for the adequate protection of the public health and safety. Accordingly, pursuant to provisions of the Act (sec. 3(c), 74 Stat. 374; 15 U.S.C. 1262) and under authority delegated to the Commissioner (21 CFR 2.120), § 191.63(a)(34)(iii) is revised to read as follows:

§ 191.63 Exemptions for small packages, minor hazards, and special circumstances.

(a) * * *

(34) * * *

(iii) The viscosity of the product is not less than 7,000 centipoises at 77° F., unless the product is packaged in a pressurized container and is dispensed as a liquid unsuitable for drinking.

* * * * *

Notice and public procedure and delayed effective date are unnecessary prerequisites to this promulgation, and I so find, since the Federal Hazardous Substances Act contemplates such modification of labeling requirements under certain conditions.

Effective date. This order shall be effective upon publication in the FEDERAL REGISTER.

(Sec. 3(c), 74 Stat. 374; 15 U.S.C. 1262)

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1493; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 32—NATIONAL DEFENSE

Chapter V—Department of the Army

SUBCHAPTER B—CLAIMS AND ACCOUNTS

PART 536—CLAIMS AGAINST THE UNITED STATES

Military Payment Certificates

1. Section 536.80 (a) is revised; in § 536.83 a new paragraph (b) is added and the present paragraph "(b)" is redesignated as "(c)", as follows:

§ 536.80 Use of military payment certificates.

(a) *Areas in which used.* Military payment certificates are to be used only in the Department of Defense by authorized personnel in the following areas:

Korea.
Libya.
South Vietnam.

* * * * *

§ 536.83 Convertibility of military payment certificates.

* * * * *

(b) *Conversion of military payment certificates suspected of being acquired illegitimately.* Military payment certificates will not be converted at any time into dollars, dollar instruments, other media of exchange or a new series of military payment certificates under circumstances where doubt exists as to their legitimate acquisition by the authorized holders. In this respect, amounts of military payment certificates which exceed those which the holder would normally acquire or hold under applicable circumstances will not be approved for conversion in the absence of preponderance of evidence submitted by the individual supporting the legitimate acquisition of the military payment certificates. See § 536.87(b) for impounding military payment certificates seized from authorized holders.

(c) *Transactions with disbursing officers of other services.* * * *

2. Section 536.84 is revised; § 536.84–1 is added; and § 536.85 is revoked; as follows:

§ 536.84 Conditions under which military payment certificates may be converted.

(a) Authorized personnel may exchange military payment certificates, in amounts legitimately in their possession for U.S. currency, coin, or dollar instruments, including U.S. Treasury checks as provided in pertinent Army regulations, under the following conditions:

(1) Upon depature for United States.

(2) When traveling under competent orders to areas where military payment certificates are not designated for use.

(3) When traveling under competent orders to military payment certificate areas where finance and accounting officers, class B agent officers, including military attaché agent officers, or exchange facilities are not readily available to the traveler.

(b) The provisions of this section will not be construed as authorizing finance and accounting officers or their agents in areas outside of military payment certificate areas listed in § 536.80(a) to convert military payment certificates for authorized personnel returning from military payment certificate areas. Such exchange must be made prior to departure from the military payment certificate area, except as provided in § 536.84–1.

§ 536.84–1 Medical evacuees.

When medical evacuees from military payment certificate areas arrive in nonmilitary payment certificate areas with military payment certificates in their possession which they were precluded from converting prior to evacuation, finance and accounting officers or their agents located at U.S. Army General Hospitals and finance and accounting officers or their agents servicing Class I installation hospitals are authorized to convert military payment certificates of a current series to U.S. dollars or dollar instruments. Prior to redemption, the finance and accounting officer or his agent will obtain a certificate from each medical evacuee satisfactorily establishing that the military payment certificates were obtained from official sources and could not have been redeemed prior to departure from the military payment certificate area. This certificate will be retained in the files of the finance and accounting officer. In the event the medical evacuee is unconscious or otherwise

physically unable to initiate the required documentation, the provisions of AR 40–2 will be followed. Military payment certificates converted under this section will be forwarded to the Finance and Accounting Officer (Symbol No. 5053), Finance and Accounting Office, Finance Center, U.S. Army, Indianapolis, IN 46249, on the 15th and last day of each month.

§ 536.85 Conversion of invalidated military payment certificates. [Revoked]

3. The citation and text of § 536.87 are revised as follows:

§ 536.87 Impounding or confiscation of military payment certificates.

(a) *Unauthorized persons.* Military payment certificates will not be confiscated on mere suspicion of unauthorized possession. Whenever such suspicion exists, the military payment certificates will be impounded and retained by the investigative command pending determination of the status of the concerned individuals. If the investigating command considers it desirable to temporarily deposit a portion (or all) of the impounded military payment certificates with the local finance officer, deposits will be held in the suspense account 21X6875 until the status of the concerned individuals is determined. Depositing agencies will be informed that funds deposited to this suspense account lose their identity for purposes of evidence. When the investigation produces evidence that the individuals are not "authorized personnel," the military payment certificates will be confiscated and the dollar proceeds deposited in the Treasury to the General Fund (Misc.) Receipt Account 211099 "Fines, penalties and forfeitures not otherwise classified." Subsequent claims for recovery of these funds will be forwarded to the FCUSA, Attention: FINCY, for adjudication. If it is determined that the impounded military payment certificates belong to an "authorized person," they will be returned to the owner as stated in paragraph (b) of this section, providing there is no evidence of illegal acquisition.

(b) *Authorized persons.* Military payment certificates seized from authorized persons who are suspected of illegal dealings in military payment certificates will be impounded and held pending a finding, either by court-martial or through administrative proceedings, as to whether the impounded certificates were obtained in a manner prohibited either by §§ 536.-79–536.87 or by local regulations. The impounded certificates may be temporarily deposited to suspense account 21X6875 pending such decision, as stated in paragraph (a) of this section. The suspected individual will be afforded a full and complete opportunity to disprove the allegation of unlawful acquisition. Impounded military payment certificates found to have been illegally acquired, will be confiscated and the dollar proceeds will be deposited to Treasury account 211099 as stated in paragraph (a) of this section. Impounded certificates found to have been legally acquired will be returned to the individual from whom they were seized. In those cases where the returned certificates were invalidated, as a result of a conversion program, on or subsequent to the date of seizure, the individual will submit a claim for conversion of the invalidated certificates, with complete information, through appropriate channels. A copy of the court-martial findings, or administrative proceedings, whichever is appropriate, will be forwarded with these claims. Adjudication and final determination on such claims in amounts of $1,000 and less will be made by the FCUSA, under authority delegated by the Comptroller of the Army, or by the headquarters of the overseas command when so authorized by the Comptroller of the Army. Adjudication and final determination on such claims in excess of $1,000 will be made by the Comptroller of the Army, ACOA/FFA.

[C 66, AR 37–103, Oct. 20, 1969] (Sec. 3012, 70A Stat. 157; 10 U.S.C. 3012)

For the Adjutant General.

RICHARD B. BELNAP,
Special Adviser to TAG.

[F.R. Doc. 70–1491; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 33—NAVIGATION AND NAVIGABLE WATERS

Chapter II—Corps of Engineers, Department of the Army

PART 207—NAVIGATION REGULATIONS

Elizabeth River, Va.

Pursuant to the provisions of section 7 of the River and Harbor Act of August 8, 1917 (40 Stat. 266; 33 U.S.C. 1), § 207.153 governing the use and navigation of restricted areas in the Southern Branch of the Elizabeth River, Va., is hereby amended with respect to paragraphs (a)(2) and (b)(1), effective upon publication in the FEDERAL REGISTER in order to provide immediate security for these areas, as follows:

§ 207.153 Elizabeth River, Southern Branch, Va., naval restricted areas.

(a) *The areas.* * * *

(2) *Norfolk Naval Shipyard Area.* Beginning at a point on the shore at the northeast corner of the Norfolk Naval Shipyard, at latitude 36°49'43.5", longitude 76°17'41.5"; thence due east approximately 100 feet to the western boundary of Elizabeth River channel; thence in a southerly direction along the western boundary of the channel to the point where it passes through the draw of the Norfolk and Portsmouth Belt Line Railroad bridge, thence in a southwesterly direction along the northerly side of the bridge to the western shore of Southern Branch of Elizabeth River; and thence along the shore in a northerly direction to the point of beginning.

* * * * *

(b) *The regulations.* (1) No vessels other than Naval vessels and other vessels authorized to move to and from piers at the Norfolk Naval Shipyard and its two annexes described in paragraph (a)(1) and (3) of this section, and no person other than persons embarked in such vessels, shall enter the restricted areas.

(2) This section shall be enforced by the Commander, Norfolk Naval Shipyard, Portsmouth, Va., and such agencies as he may designate.

[Regs, Jan. 13, 1970, ENGCW–ON] (Sec. 7, 40 Stat. 266; 33 U.S.C. 1)

For the Adjutant General.

RICHARD B. BELNAP,
Special Adviser to TAG.

[F.R. Doc. 70–1492; Filed, Feb. 5, 1970; 8:45 a.m.]

Title 47—TELECOMMUNICATION

Chapter I—Federal Communications Commission

[Docket No. 18433; FCC 70–113]

PART 15—RADIO FREQUENCY DEVICES

All-Channel Television Broadcast Receivers

Report and order. 1. A notice of proposed rule making in this proceeding was adopted by the Commission on January 29, 1969 (FCC 69–88, 34 F.R. 1732, Feb. 5, 1969). In the notice, the Commission announced its intention, subject to information received in this proceeding, to adopt regulations which would require that systems provided in television broadcast receivers for tuning the VHF channels and the UHF channels be comparable in ease of use. Interested persons were invited to file comments by March 21, 1969, and reply comments by April 4, 1969. Pursuant to a motion filed by the Electronic Industries Association, the period for filing comments was subsequently extended to May 23, 1969, and the period for filing reply comments was extended to June 6, 1969 (34 F.R. 5746, Mar. 27, 1969).

2. Comments have been filed by a number of firms and organizations associated with the television receiver manufacturing industry and with the television broadcast industry. They are listed below:

TELEVISION RECEIVER MANUFACTURING INDUSTRY

Electronic Industries Association (EIA).
General Electric Co.
F. W. Sickles Division of General Instrument Corp. (General Instrument), a tuner manufacturer.
Philco-Ford Corp.
Sylvania Electric Products, Inc.
Zenith Radio Corp.

The Sylvania comments and a single page of the Philco comments were submitted in confidence pursuant to procedures set out in paragraph 11 of the

notice. Because of the requests for confidentiality, these materials are not discussed in this report. We have taken them into consideration. They do not so differ from the comments of other receiver manufacturers, however, as to have affected our conclusions herein.

TELEVISION BROADCAST INDUSTRY

All-Channel Television Society (ACTS).
American Broadcasting Co. (ABC).
Association of Maximum Service Telecasters, Inc. (AMST).
Bay Broadcasting Co. (KUDO).
Community Television of Southern California (KCET).
Kaiser Broadcasting Corp.
Midcontinent Broadcasting Co. of Wisconsin, Inc.
National Association of Broadcasters (NAB).
National Association of Educational Broadcasters (NAEB).
Nebraska Educational Television Commission (lead party), with four other educational and commercial UHF broadcasters.
North Alabama Broadcasters, Inc.
Plains Television Corp., jointly with Winnebago Television Corp.
RKO General, Inc.
Storer Broadcasting Co.,
Transamerica Corp.
U.S. Communications Corp.
Welch & Morgan, on behalf of 39 UHF licensees, permittees and applicants.
Westport Television, Inc.
WKY Television System, Inc.

Brief letters of support for the proposed rules were also received from several individuals. Reply comments were filed by the Kaiser Broadcasting Corp. In its consideration of the matters at issue, the Commission has considered additional sources of information, as reflected herein, and has, in particular, had recourse to the transcript of the March 6, 1969 meeting of the Committee for the Full Development of All-Channel Broadcasting, a copy of which is available for inspection in the Commission's Broadcast and Dockets Reference Room.

3. *Background.* In this proceeding, we are considering further regulations to implement legislation enacted by the Congress in 1962 which authorizes the Commission, "to require that apparatus designed to receive television pictures broadcast simultaneously with sound be capable of adequately receiving all frequencies allocated by the Commission to television broadcasting * * *."[1] To appreciate the significance of such regulation and to place it in context, it is important to understand the circumstances and policy objectives leading to enactment of this law, the specific consequences Congress sought to achieve, and the results actually achieved over the last 7 years. It is thus appropriate to commence this report with a brief review of these considerations.

4. It was appreciated in 1962, as it is today, that the public interest requires that there be a sufficient number of operating television broadcast stations to provide the diversity in programing which is important to the viewer and, in particular, the diversity in sources of views on public issues which is vitally necessary in a representative democracy. The development of a television system utilizing very high frequency (VHF) and ultra high frequency (UHF) channels had been selected as the best means of achieving a satisfactory degree of diversity. The UHF part of this system, however, labored under serious handicaps and had developed at a far slower pace than its VHF counterpart; and it was apparent by 1962 that development of a combined VHF–UHF system would require that steps be taken to encourage development of the UHF channels.

5. One of the most serious difficulties confronting UHF broadcasters at that time and discouraging the development of UHF broadcasting was the general lack of television sets capable of receiving the UHF channels.[2] Most receivers then being used or produced were capable of receiving only the 12 VHF channels. This deprived UHF broadcasters of the mass audience required to obtain advertising revenue needed to pay for popular programing which would attract a mass audience and encourage the manufacture and purchase of television sets capable of receiving UHF channels. Such problems naturally discouraged the construction of new UHF stations, and the resulting paucity of UHF broadcast stations likewise discouraged the manufacture and purchase of all-channel receivers. The lack of receiving capability was obviously a critical part of the total picture. This part of the problem, moreover, was susceptible to a legislative solution, and it was through such legislation that the Congress attempted to obtain the combined VHF–UHF system needed to achieve the diversity in broadcasting considered essential in the public interest.

6. In enacting the all-channel receiver law, the Congress established, as a matter of national policy, that all television receivers should be able to provide comparable receiving capability on VHF and UHF channels. It made clear its intention that, "the performance capabilities of such sets for receiving UHF signals should be adequate to assure that the purchaser of these sets will in fact get comparable reception from the UHF and VHF stations."[3] The word "adequately" was added to the legislation to assure this result.[4] As this indicates, Congress fully appreciated that adequate receiving capability on the UHF channels—a capability comparable to that on the VHF channels in fact as well as theory—would be needed to achieve the purposes of the statute. It sought to eliminate the differences in receiving capability which were discouraging use of the UHF channels—by the viewer, and consequently by the broadcaster—and thereby to make a significant and realistic contribution toward achieving a truly competitive nationwide all-channel television system. So far as receiving equipment is concerned, the Congress intended that UHF be put on a competitive footing with VHF in all respects.

7. As indicated in the notice (at paragraph 8), we are satisfied that disparities in the electrical performance of UHF and VHF tuners are not so great as to materially affect the audience levels of UHF stations and that additional regulation directed to the electrical performance characteristics of UHF receivers is not now warranted. Comparable electrical performance alone, however, does not meet the all-channel receiver law's requirement of adequate UHF receiving capability. For reception of a television signal, electrical performance potential must be actualized through the tuning process; and if the UHF tuning process is inadequate by comparison with the VHF tuning process, UHF receiving capability is likewise inadequate. Receiving potential which cannot be translated into an audience for UHF programing does not effectuate the purposes of the all-channel receiver law. A failure to consider and provide for adequacy of the tuning process would, indeed, undermine congressional efforts in this area.

8. Regulations adopted by the Commission in 1962 to implement the all-channel receiver law specified noise figure and peak picture sensitivity standards for the UHF portion of the receiver.[5] We did not impose additional requirements concerning comparability in tuning at that time primarily because of the necessity of concentrating on the basic task of conversion to all-channel receiver production. It was determined that additional requirements which might unduly burden the industry or compromise the conversion schedule should not be imposed. Moreover, the Commission had been advised by the industry that advances in the ease of tuning would be actively pursued and had reason to believe that greatly augmented UHF receiver and tuner production would result in such advances.

9. During the 7-year period since adoption of regulations, there have been a number of technical advances in the ease of tuning receivers, but comparability has not been achieved, except in some of the most expensive receiver models which constitute a small percentage of total industry output. The basic disparity between VHF detent and UHF continuous tuning remains.[6] And in many respects, due to advances which have generally been limited to VHF tuning, the comparability gap has been enlarged. Additional requirements have not been imposed by the Commission during this period. Our purpose in this proceeding

[1] Public Law 87–529, July 10, 1962, 76 Stat. 150, 47 U.S.C. 303(s) and 330, commonly referred to as the "all-channel receiver law."

[2] Receiver capability was not, of course, the sole handicap under which UHF television labored.

[3] S. Rep. No. 1526, 87th Cong., 2d Sess., May 24, 1962, at page 8.

[4] Ibid.

[5] 47 CFR 15.4 (h) and (i) and 15.65.

[6] As used in this report, the term "detent" is used to describe the system customarily used in tuning the VHF channels which employs a rotary control with notches or other mechanical stops which provide a discrete setting for each channel. The term "continuous" is used to describe the system customarily used in tuning the UHF channels which employs a rotary control lacking discrete settings.

has been to take a fresh look at the ease of tuning aspect of the adequate receiving capability question—to examine existing disparities; to determine whether and to what extent it is technically feasible to eliminate these disparities without undue burden upon the public or the receiver manufacturing industry; to determine whether additional regulation is required to achieve this objective; and to prescribe such standards as may be appropriate, in light of these considerations, to advance the purposes of the all-channel receiver law.

10. *Disparities in ease of tuning.* The fundamental and most important point of disparity, of course, is that between VHF detent tuning and the UHF continuous tuning. Continuous tuning is more demanding and time-consuming, and requires more patience, a finer touch and greater mechanical skill. For many persons, to a degree varying with the individual, the greater difficulty in tuning UHF stations diminishes the likelihood that the user will opt for programing offered by such stations. Assuming the user does decide on viewing UHF programing, moreover, it is more difficult for him to tune the UHF station properly. As a result, the picture obtained on a UHF channel is likely to be inferior to its VHF counterpart—even though the receiver, if properly tuned, is capable of producing a picture of comparable quality. This factor, in addition to the intrinsically more complicated and time-consuming nature of continuous tuning, tends to deter the use of UHF channels.[7]

11. The comparative difficulty of UHF continuous tuning is compounded by the imprecise marking of the channel indicator dial associated with continuous tuners. Typically, the channel number is shown for only a limited number of channels, and channels are closely bunched on the dial. It can in these circumstances be difficult to determine which available UHF channel has been tuned.

12. Over and above the basic disparity between continuous and detent tuning, a variety of tuning aids have been designed into VHF tuning systems which are not generally available to the user in tuning UHF channels. Quality tuning aids can materially simplify and expedite the tuning process and can very considerably enhance the user's ability to tune accurately. Developed largely since 1962, and coming now into more common use, they exemplify the process by which tuning disparities are enlarged by improvements in VHF tuning systems. A number of these tuning aids are discussed below.

(a) *VHF-only memory tuning.* With memory tuning, after each channel has been fine-tuned once, when the user switches from one channel to another, the need for fine-tuning the new channel is eliminated or materially reduced. It helps provide superior results quickly and with less effort. Memory tuning is adaptable primarily to use with a detent tuner.

(b) *VHF-only AFC.* Color television receivers are now frequently equipped with electronic devices which go by such names as AFT (automatic fine tuning) or AFC (automatic frequency control). When a receiver is so equipped, it must still be tuned manually within the control range of the AFC circuit, and for maximum benefit, it should be manually tuned as precisely as possible. Nevertheless, if a receiver is equipped with a good quality device of this kind, the necessity for precise manual tuning is materially reduced. When the desired channel is tuned approximately and the device is activated, it senses the tuning error and corrects it electronically by a given factor (i.e., if the factor is ten, the tuning error is reduced to one-tenth of that produced by manual tuning). Good quality AFC can greatly reduce substantial tuning errors, transforming a poor quality picture into one of near perfect quality.[8]

(c) *VHF-only visual tuning aids.* These devices utilize a voltage meter and appropriate indicator dial to inform the user visually when he has tuned the strongest signal.

(d) *13-position remote control.* Most receivers now in use are equipped with a rotary control knob with detented positions for the 12 VHF channels and one position for switching to the UHF band. Remote control operation generally affords access to these 13 positions, including one preselected UHF channel. This system introduces a bias against the remaining UHF stations, which must be tuned at the set, and against UHF generally by providing access by remote control to multiple VHF stations and denying the same advantage to multiple UHF stations.

(e) *The VHF-only signal seeking tuner.* With a signal seeking tuner, the user depresses a single button and the tuner is power-driven to the next highest active channel available in the community. As an adjunct to a manual tuning system, the signal seeking tuner would make tuning easier.

13. It should be appreciated that these tuning aids can be used in various combinations and that tuning a television receiver can thus be reduced to an extremely simple, expeditious process with near perfect results. When such aids are combined with a detent tuning system, and when the result is compared with an unaided continuous tuning system, the disparity in tuning capability is large indeed. To the extent that the VHF portion of a receiver is equipped with such aids and the UHF portion is not, it is apparent that UHF stations are at a comparative disadvantage in their competition with VHF stations for the viewing audience.

14. *Technological and cost considerations.* It is apparent from the information available that comparability in tuning ease is technologically feasible. Various mechanical and electronic tuning systems which meet the objectives of the all-channel receiver law are either in limited production or in an advanced stage of development. Considerable information is, in particular, available concerning UHF detent tuners affording access to a limited number of preset UHF channels which, in the current state of the art, would be considered comparable to VHF tuners now commonly in use. Such tuners have been, and are being, utilized in receivers offered to the public in limited numbers, and this is equally true of tuning aids most often associated with VHF tuning. In view of present and projected usage of UHF detent and other satisfactory tuning systems in high-priced receivers, contentions by manufacturers that available, comparable UHF tuners do not meet their performance or reliability standards or that a requirement of tuning comparability would disrupt research efforts devoted to development of suitable tuning systems are not persuasive. On the technical side, the only apparent limiting factor at this time is the size of the receiver cabinet, and even this limitation is clearly temporary. As indicated below, moreover, it appears that cost increases necessitated by comparability would not unreasonably burden the receiver manufacturing industry or the public. The information available to the Commission is summarized below.

15. The Electronic Industries Association indicates generally that UHF tuning improvements, including AFC, detent tuning, pushbutton tuning, and "automatic tuning" have been made available. The General Instrument Co. states that a requirement of comparable tuning ease is "generally consistent with the technological capabilities of the TV industry in the near term future." Philco states that it has the capability to eliminate or reduce disparities in tuning ease by development of all-channel detent tuning, pushbutton UHF tuning, or all-channel "programed" continuous tuning. Zenith reports that it produced black and white and color receivers with detent tuning and digital readout on all channels from 1966 to 1968. Detented UHF tuning proved sufficiently accurate for correction by additional fine-tuning but not through use of AFC alone. These models were discontinued due to inadequate demand. In 1968, Zenith introduced its "Ultramatic" system in high-end sets only, at an additional cost of

[7] What concerns us is not simply convenience, but that UHF tuning is more difficult and that the viewer is consequently less able or less willing to tune the UHF channels. While the actual programing is of course a most critical factor, we must take into account the consideration that viewers do tend, to a significant degree, to use the channels on which they get good results with the least effort. It is thus of the utmost importance in developing a competitive all-channel television system that such differences in tuning capability be eliminated. While we employ the term, "ease of tuning," we stress that the matter is not one simply of convenience or ease, but rather of real significant effects upon "the public interest in the larger and more effective use of radio" (47 U.S.C. 303(g)).

[8] Trade press reports indicate, in addition, that some 1970 model receivers are equipped with automatic color intensity and tint controls. David Lachenbruch, "The sets of the '70's," TV Digest, Sept. 20, 1969, at page 46. We do not have information as to whether these automatic features are available to the user in tuning UHF channels.

"at least $20." This system provides for "automatic" selection of the 12 VHF and any six UHF channels by mechanical means at the set or by remote control.

16. The General Electric Co. has reported in considerable detail on the present technological capability of the television receiver and tuner industries. It notes that AFC is available for use in UHF tuning systems and assumes its use in each of the tuning systems discussed. We are informed by General Electric that the following mechanical tuning systems are currently on the market in a limited number of models from various manufacturers:

(a) *The six-position UHF detent tuner.* This tuning system combines the usual 12-channel VHF detent tuner with a six-channel UHF detent tuner. Separate control knobs are utilized. The user initially tunes each available UHF channel with the fine tuning control and locks in the channel on one of the six UHF detent positions. Thereafter, aided by memory tuning and AFC, he tunes that channel by rotating the control knob to the appropriate detented position. The UHF readout is by calibrated dial and pointer. It would appear, however, that "stick on" or "slide in" channel designators could be provided by the manufacturer and added to the control knob. Tuners of this type are expected to have some usage in middle and high end models produced later in 1969 and in 1970. The added cost at retail is estimated at $10–$12.

(b) *The 24-position UHF detent tuner.* This tuning system combines a 24-position UHF detent tuner with the usual 12-position VHF detent tuner. Separate control knobs are utilized. Three channel numbers are shown on a lighted drum at each position on the UHF tuner (except the first and the last, which show two). The fine tuning control is used to select the appropriate channel at each position. No information with respect to cost or prospective usage was furnished.

(c) *Pushbutton UHF tuner.* Except that five pushbuttons replace the six-position rotary dial, this tuning system is essentially the same as the six-position UHF detent tuner (supra, item (a)). No information with respect to cost or prospective usage was furnished.

(d) *Signal seeking UHF tuner.* This system would function in the same manner as the signal seeking VHF tuner described in paragraph 12(e), supra. Read-out is on an illuminated drum or wheel appearing in a window. No information with respect to cost or prospective usage was furnished.

General Electric further states that the following mechanical tuning systems are "proposed":

(e) *Continuous all-channel tuner.* With this system, all channels (UHF and VHF) are tuned continuously. A single control knob is utilized. Comparability would be achieved by reducing VHF tuning ease. A compensating feature, we note, is the possibility of including in such a receiver the ability to tune stations in the FM broadcast band. This system may be utilized in some low end models later in 1969 and in 1970.

(f) *Single knob all-channel tuning.* With this tuning system, the familiar VHF detent and UHF continuous tuners are controlled by a single knob. Receivers of this design are known to be in use. Additional cost at retail is estimated at $2–$3.

Electronic tuners are said by General Electric to have reached the state of development where it can be expected that some of them will be used in production receivers starting this year.[9] Such tuners have no moving parts or mechanical linkage and are therefore easier to manufacture and tend to be more reliable. Their use would also minimize the problem of cabinet size. As costs are reduced, it is expected that they will replace mechanical tuners and provide a long range solution to the problem of comparabiltiy in tuning. The following electronic systems are discussed in the General Electric comments:

(g) *The 18-position all-channel detent tuner.* With this system, all 12 VHF channels and any six UHF channels can be tuned electronically with a single control knob. It is in other respects similar to the six-position UHF mechanical tuner described in item (a), supra. Usage is expected on some middle and high end models beginning in 1970. Additional cost at retail is estimated at $13–$15.

(h) *The 18-pushbutton all-channel tuner.* This tuner is essentially the same as the 18-channel detent tuner described above (Item (g)), except that pushbuttons replace the rotary switch control utilized on detent tuners. Additional retail cost is estimated at $35–$40. Usage is expected on some high end models beginning in 1970.[10]

(i) *The signal seeking tuner.* This is an electronic version of the tuner described in paragraph 12(e), supra. No information was furnished with respect to cost or prospective usage.[11]

(j) *The continuous all-channel tuner.* This is an electronic version of item (e), supra. This system may be utilized in some low end models in 1970. Cost information was not furnished.

17. Information is also available concerning a six-position mechanical UHF detent tuner developed by Sarkes Tarzian, Inc.[12] Although General Electric states that this type of tuner involves problems of cabinet size in 16" and smaller receivers, and Zenith states that it involves such problems in 19" or smaller receivers, Sarkes Tarzian states that its tuner is sufficiently compact for use in 9" or larger receivers. As of March 1969, this unit had been made available to all major receiver manufacturers for evaluation. Sarkes Tarzian had received no orders in March but was prepared then to supply receiver manufacturers with production units at a cost of $6.25. This cost figure, which would be reduced with mass production, compares with a cost of approximately $2–$4 for UHF tuners currently in use. UHF detent tuners comparable in size to this unit were displayed by other tuner manufacturers in June of this year at the Chicago Spring Conference on Broadcast and Television Receivers. Sarkes Tarzian also stated at the March meeting of the CAB that an 18-position all-channel mechanical tuner utilizing a single tuning knob would be available in the near future. However, information concerning the cost and size of this tuning system has not been furnished.

18. On the basis of information available to the Commission, as summarized above, it would appear that at least two tuning systems are available whose use would produce comparability in tuning without unduly increasing the cost of television receivers. The mechanical tuning system utilizing a six-position UHF detent tuner with the customary 12- position VHF detent turner (see paragraphs 16(a) and 17, supra) has been used in receivers offered for sale, is available now, and (one manufacturer states) can be used in 9" or larger receivers without major change in receiver design. In terms of what is practicable in the

[9] Reports in the trade press, we note, indicate that 95 percent of the receivers produced in 1970 by European manufacturers will be equipped with electronic tuners. N. P. Doyle and T. B. Mills, "TV Receiver Tuning Systems of the Future," paper delivered at the Chicago Spring Conference on Broadcast and Television Receivers, June 1969; Walt Bohne, "Tuning Advances Key Chicago Spring Parley," Electronic News, June 16, 1969, page 24. Trade press reports further indicate that a Canadian manufacturer is offering two models this year (selling for about $800) which utilize an 18-pushbutton electronic tuner; and that an American manufacturer is offering one limited production model (selling for $2,000) which utilizes an all-channel electronic signal seeking tuner. "The Sets of the 70's," note 8, supra, at page 48.

On Sept. 18, 1968, the Norfolk Ledger-Star reported that the Standard Components Division of Standard Kollsman Industries had developed a solid state varactor tuner "that makes precise selection of UHF color and black-and-white programs as simple and easy as tuning channels 2 through 13." This tuner, it was reported, contained no moving parts, was about the size of a penny box of matches, offered AFC with no cost penalty, and could be placed at any location in the receiver chassis. At the time of the article, field tests had been completed and a pilot production run had been scheduled to provide a quantity of samples for detailed engineering studies by receiver manufacturers. No information concerning this tuner has been furnished to the Commission in this proceeding.

[10] See note 9, supra.

[11] But see, note 9, supra.

[12] See the transcript of the Mar. 6, 1969, meeting of the Committee for the Full Development of All-Channel Broadcasting (CAB), at pages 13–16, 30–33; Comments of ACTS, at paragraphs 38–42; and Comments of Storer, at paragraph 3. Oak Electronics, Inc., is also said to have developed such a tuner. ACTS Comments, at paragraph 38.

present state of the tuner art, this tuning system would meet the objectives of the all-channel receiver law.[12] The maximum additional cost, at retail, is estimated to be $12. The rule of thumb followed by the industry in estimating retail costs is that retail costs are three times the cost to the manufacturer. This would indicate that use of a six-position UHF detent tuner involves a maximum additional cost of $4 to the receiver manufacturer. This figure is consistent with other available information indicating a difference of approximately $4 in the cost of a UHF detent tuner and the least expensive UHF continuous tuner now in use. The difference in cost between the UHF detent tuner and the more expensive UHF continuous tuners appears to be closer to $2, indicating that an additional retail cost of $6 would be involved in replacing such tuners. With mass production, moreover, the additional cost of the UHF detent tuner can be expected to be subbstantially reduced (apparently by at least 25 percent). Nevertheless, following the industry rule of thumb, use of the UHF detent tuner would appear to involve an initial price increase of $12 for at least some low cost receivers. Clearly, however, a $12 price increase would not be required to maintain industry profit per receiver at its current level, and it will be for the industry to determine, in light of all factors, including sales volume, whether, or to what extent, the full $12 increase is passed on to the consumer. In any event, in view of the options available to the industry in these circumstances, it would seem that, in making the regulatory determination for which we are responsible, we need not be limited by an assumed price increase of $12. We think it reasonable to assume that the indicated price increase of $4 (or perhaps a somewhat larger amount, to the extent the manufacturer incurs additional expenses for testing or installing the new tuner) required to maintain profiit per receiver would not unduly burden the consumer or have any substantial effect on the sale of even lower-priced receivers. Price increases coupled with product improvements do not necessarily result in a sales decline. Indeed, the consumer may well be advantaged and sales may well increase; for, whatever the additional cost, it will be for a more satisfactory receiver. In any event, the manufacturer would not be required to apply price increases equally across the product line and might well determine to minimize the effect on the consumer and any adverse effect on sales by concentrating price increases on higher-priced sets where sales volume is less sensitive to price changes.[14] We wish to stress that the matter does not turn on the precise correctness of the foregoing analysis. Comparability is clearly called for, and could appropriately be postponed only if it is presently either technically infeasible or, while feasible, only at a cost which is so large and burdensome as to be inconsistent with the overall public interest. In our judgment, on the facts available, comparability is technically feasible, and costs on the order of those discussed above will not impose an unreasonable burden either on receiver manufacturers or the public. This being the case, anything less than comparability is inadequate under the all-channel receiver law and would disserve its purpose.

19. Though any of the electronic tuning systems described in the comments would at this time meet the objectives of the all-channel receiver law, the 18-position electronic detent tuner (see paragraph 16(g), supra) would appear to be most feasible in terms of availability and cost.[15] It would apparently be sufficiently compact for use in the smallest receivers. Comparability in tuning would be enhanced by a single control knob. The maximum additional cost at retail is said to be $15, which by usual industry reckoning indicates an additional cost of $5 to the receiver manufacturer. General Electric states that use of such a tuner is expected in some models by 1970. Extensive use of electronic tuners by European manufacturers is projected for the same year. That the use of such systems is expected in the near future would seem to undermine the position that a requirement of comparability could delay their development. Indeed, in meeting a requirement of comparable tuning, it would seem that the industry might find it feasible and desirable to expedite introduction of the electronic tuner, thereby matching general tuning advances as well as comparable tuning against such price increases as may prove necessary. However, it appears from the comments that development of the electronic tuner for extensive commercial use in this country is not so far advanced as that of the six-position UHF mechanical tuner discussed in the preceding paragraph. For this reason, and because comparability in smaller receivers is now apparently dependent on use of electronic tuners, the requirement of comparability in smaller receivers (less than 9 inches) is being deferred. Until such time as the industry can or chooses to introduce the electronic tuner or as use of the electronic tuner proves necessary to meet a requirement of comparability for smaller receivers, appropriate mechanical tuners are available.[16]

20. A requirement of comparability with respect to tuning aids would not appear to involve any serious technical or commercial problem. The technical capability exists to provide AFC, visual tuning aids, remote control operation or signal seeking systems for assistance in tuning UHF as well as VHF channels, and to provide memory tuning with a detented UHF tuning system. On the commercial side, tuning aids are optional features. Comparability does not require the introduction of such improvements and, therefore, does not necessitate a cost increase in the price-sensitive lower price ranges. The manufacturer retains the option of offering tuning aids in any combination, provided only that comparable assistance is provided in tuning UHF and VHF channels on a given receiver.

21. *The need for regulation.* The television receiver and tuner manufacturers, in their comments, generally contend

[12] Generally speaking, any tuning system selected by a manufacturer would be satisfactory in terms of comparable tuning ease; *Provided*, That controls of the same type and comparable capability and quality were used for tuning the VHF and UHF channels. We concentrate on the six-position UHF detent tuner because it is comparable to the VHF detent tuner currently in use, because more (and more definite) information as to its cost and availability has been furnished, and because some other UHF systems discussed would not appear to be comparable in tuning ease if combined with the current VHF detent tuner. The 24-position UHF detent tuner, for example, affords access to all UHF channels and would be entirely satisfactory if equipped with memory tuning. To the extent that continuous tuning among the three (or two) channels at each detent position were required, however, this tuner would be less than satisfactory in terms of comparable tuning. The single knob tuner (with detened VHF and continuous UHF tuning), though inexpensive, would not provide comparability. The continuous all-channel tuner achieves comparability by reducing VHF tuning ease. Though cost data is not available, this is presumably less expensive than improving UHF tuning ease. Some manufacturers take the position that the purchaser of low-priced receivers does not need or want tuning ease improvements at added cost and should not be burdened with them. Should this be the case, market forces will presumably lead to production of some low-priced models utilizing a continuous all-channel tuner. Though we doubt there would be widespread interest in such receivers, since tuning advances appear to be well worth their additional cost, they would be satisfactory in terms of comparable tuning.

[14] Recent developments evidence the receiver industry's willingness to introduce technical improvements involving cost increases and design changes, and to increase the price of receivers as these improvements are introduced. See, e.g., 9 Television Digest No. 37, Sept. 15, 1969, at page 7; and Wall Street Journal, Sept. 16, 1969, at page 15. In some cases, price increases appear to have been limited to what is required to cover additional costs. We note simply that numerous factors enter into selling price determinations and that the industry seems sufficiently sophisticated in its marketing techniques to sensibly accommodate its pricing structure to a requirement of comparability without serious impact on sales volume. Past experience, moreover, indicates a tendency on the part of receiver manufacturers to exaggerate the price increases which would result from regulation. Basic UHF tuners required in 1962 turned out to involve price increases on the order of $10 (actually more than offset by abolition of the receiver excise tax) rather than the $25–$30 predicted by manufacturers.

[15] Electronic pushbutton tuning is an attractive, but apparently an expensive, alternative. Information as to the cost of other electronic tuning systems is not available.

[16] Under the all-channel law, of course, any tuning system by which comparable tuning is achieved is satisfactory. We repeat that the method for achieving comparability is one for the judgment of individual manufacturers.

that regulation to require comparability in tuning is neither necessary nor desirable. They discount disparities in tuning as a major factor deterring UHF viewing and call attention to other factors, such as UHF program content, the technical quality of UHF broadcast transmission, and inferior UHF antennas.[17] They point to their past record and to some future plans for improving UHF continuous tuners and introducing UHF tuning aids (notably AFC). Without regulation, they indicate, tuning improvements (including comparability through use of the electronic tuner) would be introduced gradually, beginning at the top of the color line, and, over a period of years, would be added to an increasingly larger number of models. This, they say, is a better, more orderly way of achieving comparability, since it avoids the disruption of research and development programs and risks inherent in the use of unproven equipment.[18] Regulation applicable to all receivers, they assert, would work a hardship on the consumer as well as the industry by burdening him with the cost of tuning improvements that he does not need or want.

22. Considered with the general lack of progress since 1962 toward the goal of tuning comparability, these comments convince us that regulation is needed to effectuate the requirements and fulfill the purposes of the all-channel receiver law, which are discussed at length above. In 1962, we imposed minimum standards with respect to all-channel capability and have since relied on industry promises that voluntary industry action would achieve national policy objectives. While the law and regulations have been achieving the desired objectives insofar as basic UHF capability is concerned, the voluntary approach thus far adopted has not succeeded in bringing about comparable UHF tuning capability, except in a small number of the most expensive available models. UHF has not been placed on a competitive footing with VHF in this respect. Our review of the comments, moreover, indicates that the industry does not share with us the belief that comparable tuning capability is an important, or even a desirable, objective, warranting implementation on an expedited basis.

23. In view of the rapid advances in comparable tuning capability projected by the industry in 1962, it could reasonably have been assumed that product planning and introduction programs would have been reoriented toward this goal. This does not appear to have been the case. Though much effort appears to have been devoted to the general improvement of tuning systems, the comments and our experience since 1962 indicate that improvements in comparability are viewed only as a sometimes by-product of these efforts. As tuning aids have been developed, they have frequently been applied only to VHF tuning, thereby enlarging the gap in comparability. VHF detent tuning is almost the universal mode, and though UHF detent capability has existed for some time, there has been virtually no progress toward comparability in this respect since 1962. Efforts by one manufacturer to merchandise a UHF detent tuner between 1966 and 1968 were unsuccessful because the consumer was reluctant to pay the higher prices asked. As a result, these models were discontinued. This result illustrates the difficulty of achieving comparability solely through the interaction of market forces. With regulation requiring comparability, on the other hand, all manufacturers are placed on an equal footing, and no manufacturer will have cause for concern that he will suffer a competitive disadvantage through his efforts to achieve comparability. Nor is there reason to believe that regulation will diminish competition among receiver manufacturers seeking to produce the best and cheapest tuning devices. Different degrees of tuning convenience will continue to be offered in different models at various price levels, limited only by the requirement that systems used for tuning VHF and UHF channels in the same receiver be comparable.

24. The comments indicate that manufacturers, while planning to continue VHF detent tuning, have no definite plans for UHF detent tuning except in high and (to a lesser extent) medium price lines, either now or at any foreseeable future date. Generally, it would appear, meaningful progress toward comparability during the next several years on a voluntary basis would be achieved in only a small percentage of the receivers produced.

25. In these circumstances, we conclude that there is an urgent need for regulation, to achieve comparability and to get on with progress toward full utilization of the UHF channels allocated to television broadcasting.[19] It is understood that additional costs will result from a requirement of comparability. In the present circumstances, however, cost and effort on the order of that required do not appear to constitute an unreasonable burden.

26. *Substance of regulations.* The regulations set out below[20] require that the same type basic mechanism be used for tuning VHF and UHF channels. If a continuous, detent or pushbutton system is provided for tuning the VHF channels, the same type of system must be provided for tuning the UHF channels. Likewise, if electronic tuning is provided for tuning VHF channels, the same type of system must be provided for tuning UHF channels. In the present state of the art, six-position UHF detent or pushbutton capability is considered adequate, provided that the detent positions or pushbuttons can be readily adjusted by the user so that any six UHF channels can be received. The regulations do not require that tuners be engineered around a single control knob.

27. If equipment and controls which tend to simplify, expedite or perfect the reception of television signals are provided, the regulations require that comparable equipment and controls be provided for tuning the VHF and UHF channels. This requirement applies to tuning aids such as memory tuning, AFC, visual aids, remote control and signal seeking capability. It also applies to such matters as the size, location, accessibility, and legibility of the controls.

28. VHF and UHF tuning mechanisms and tuning aids are required to be of comparable capability and quality.[21] This requirement will be construed reasonably in the public interest. We have in this proceeding endeavored to discern from the information available the state of the art as it now exists and to impose only such requirements as are reasonable in the light thereof. We will in the future guard against imposing a degree of comparability which cannot be fulfilled. However, the regulations are intended to encompass progressively higher degrees of comparability as they prove to be achievable and to apply to such tuning systems and tuning aids as may be developed and introduced in the future, and they will be so construed.[22]

29. *Effective date.* Comments relating to the effective date of regulations to require comparable tuning were submitted by General Electric and Zenith. General

---

[17] The existence of several problems is not a basis for ignoring even the least of them. As indicated in paragraphs 10–13, supra, moreover, there is ample basis for our conclusion that disparities in tuning have a substantial adverse effect on UHF viewing.

[18] As indicated above, prior use of appropriate tuning systems, as described in the comments, gives ample reason to believe that proven UHF tuners are available and that a massive research effort is not required for their development.

[19] The urgency of getting on with this matter deserves to be stressed. From the effective date of regulation, it is estimated that a period of approximately 7 years is required to replace existing receivers with those which have comparable receiving capability.

[20] Requirements with respect to comparable tuning capability are set out in § 15.68. Section 15.69 provides that receivers shall be certificated to comply with the requirements and details the information to be submitted to the Commission in connection with the certification process. Section 15.71 now provides for the identification of certificated receivers and the cartons in which they are shipped, and will not be amended. No change will be required after May 1, 1971, in the seal or label currently used to identify certificated receivers or in the marking of cartons in which they are shipped. However, receivers manufactured on or after May 1, 1971, and so identified must, of course, meet the tuning capability requirements set forth in the attached appendix, as well as requirements in effect prior to that date.

[21] As used in the rules, the term "comparable" means similar and worthy of comparison.

[22] A number of the comments urge that the Commission give early consideration to the question of equivalence in antenna capability. Though this is an important area of concern warranting further study, it is beyond the scope of this proceeding. Such action as may be appropriate with respect to antennas will be reserved for consideration at a later date.

Electric recommends that such regulations be made effective not less than 2 years after their adoption. Zenith states that an 18- to 24-month period is required between the decision to utilize a new component and the manufacture of receivers containing that component, exclusive of the time required for development of the component itself. General Electric urges that any regulations adopted not be applied to all receiver models simultaneously. Zenith states that regulations applied simultaneously to all receiver models, effective in June of 1971, could overtax tooling capacity in the United States and could require a partial shutdown of the receiver manufacturing industry. If regulations were applied to a large number of product categories, it says, more than 2 years would be required. Such statements appear to be based on the assumption that regulation will require major changes in receiver design.

30. On the basis of information furnished to the Commission in this proceeding, it appears that suitable UHF tuning equipment is available and that an extended period of time is not required for further development to meet the requirements of the regulations. The regulations apply to a large percentage of total receiver production. However, as indicated below, they require basic tuning system changes, at the present, in 9-inch or larger receivers only, and sufficiently compact UHF tuners are available for use in meeting this requirement. The new regulations therefore do not create a need for major changes in receiver design.

31. The receiver modifications required to comply with the regulations are, in any event, certainly less extensive than those required in 1962 in adding a basic UHF receiving capability. Those regulations were adopted in November 1962 and applied to all receivers manufactured after April 30, 1964, that is, to receivers produced for the 1965 model year. In arriving at this effective date, the Commission at that time considered the industry's regular design schedule for new model receivers and the time required for a tenfold to fifteenfold expansion in UHF tuner production. This effective date was not only met by industry but was sufficiently liberal to allow time for interim improvement of UHF tuners. As expected, there was a substantial increase in all-channel receiver production prior to that effective date.[23]

32. In view of the foregoing, we conclude that an effective date of May 1, 1971, for a requirement of comparable tuning capability would afford the industry an ample period in which to make such changes in receiver design as may prove necessary. Except as noted below, the regulations will apply to receivers manufactured on or after that date. For receivers which furnish a picture smaller than 9 inches measured diagonally, the requirement of comparability with respect to the basic tuning mechanism, and with respect to tuning aids such as memory tuning which can be used effectively only with a detent or pushbutton tuning system, will apply to receivers manufactured on or after May 1, 1973.

33. In view of the foregoing: *It is ordered*, Effective March 13, 1970, that Part 15 of the rules and regulations is amended as set forth below. Authority for these amendments is contained in sections 4(i), 303 (r) and (s), and 330 of the Communications Act of 1934, as amended, 47 U.S.C. 154(i), 303 (r) and (s), and 330. This proceeding is hereby terminated.

(Secs. 4, 303, 48 Stat., as amended, 1066, 1082; sec. 330, 76 Stat., 151; 47 U.S.C. 154, 303, 330)

Adopted: January 28, 1970.

Released: February 2, 1970.

FEDERAL COMMUNICATIONS COMMISSION,[24]
[SEAL] BEN F. WAPLE,
Secretary.

Part 15 of Chapter I of Title 47 of the Code of Federal Regulations is revised as follows:

1. Section 15.65 is revised to read as follows:

§ 15.65 All-channel television broadcast reception: general requirement.

Except as provided in § 15.66, all television broadcast receivers manufactured after April 30, 1964, and shipped in interstate commerce or imported from any foreign country into the United States, for sale or resale to the public, shall be capable of adequately receiving all channels allocated by the Commission to the television broadcast service. A television broadcast receiver is capable of adequately receiving all channels if it meets the requirements of §§ 15.67 and 15.68 in effect on the day of its manufacture.

2. Section 15.67 is added to read as follows:

§ 15.67 All-channel television broadcast reception: receivers manufactured after April 30, 1964.

Television broadcast receivers manufactured after April 30, 1964, shall comply with the following specifications:

(a) *Noise figure.* The noise figure for any television channel between 14 and 83 inclusive, shall not be larger than 18 db.

(b) *Peak picture sensitivity.* The peak picture sensitivity of any television broadcast receiver, average for all channels between 14 and 83 inclusive, shall not be more than 8 db larger than the peak picture sensitivity of that receiver averaged for all television channels between 2 and 13 inclusive.

3. Section 15.68 is added to read as follows:

§ 15.68 All-channel television broadcast reception: receivers manufactured on or after May 1, 1971.

Television broadcast receivers manufactured on or after May 1, 1971, shall comply with the requirements of § 15.67 and shall, in addition, comply with the following requirements:

(a) *Basic tuning mechanism*—(1) *General rule.* The basic tuning mechanism for the UHF television channels (14–83) shall be of the same type (e.g., continuous, detent, pushbutton) as the basic tuning mechanism for the VHF television channels (2–13), and shall be of comparable capability and quality.

(2) *Deferred effective date for smaller receivers.* This requirement shall not apply to receivers manufactured prior to May 1, 1973, which furnish a picture smaller than 9 inches measured diagonally.

(b) *Tuning aids*—(1) *General rule.* If equipment and controls which tend to simplify, expedite or perfect the reception of television signals (e.g., AFC, visual aids, remote control, signal seeking capability) are incorporated into the design of a television broadcast receiver, tuning aids of comparable capability and quality shall be provided for tuning both the VHF television channels (2–13) and the UHF television channels (14–83).

(2) *Deferred effective date for certain tuning aids used in small receivers.* In the case of tuning aids such as memory tuning which can be used effectively only with a detent or pushbutton tuning system, this requirement shall not apply to receivers manufactured prior to May 1, 1973, which furnish a picture smaller than 9 inches measured diagonally.

4. In § 15.69, paragraph (a)(2) is revised, and new paragraphs (a)(3) and (e)(10) are added, to read as follows:

§ 15.69 Certification of receivers.

(a) * * *

(2) Except as provided in § 15.66, no television broadcast receiver manufactured after April 30, 1964, shall be shipped in interstate commerce or imported from any foreign country into the United States, for sale or resale to the public, unless it has been certificated to comply with the noise figure and peak picture sensitivity requirements set forth in § 15.67. (This provision does not apply to carriers which transport television broadcast receivers without trading in them.)

(3) No television broadcast receiver manufactured on or after May 1, 1971, shall be shipped in interstate commerce or imported from any foreign country, for sale or resale to the public, unless it has been certificated to comply with the requirements of § 15.68. This provision does not apply to carriers which transport television broadcast receivers without trading in them.

* * * * *

(e) * * *

(10) In the case of a television broadcast receiver, the type number of the picture tube; a description of the basic

[23] Effective date considerations were extensively discussed in the notice of proposed rule making in Docket No. 14769, 27 F.R. 9222, Sept. 18, 1962, at paragraphs 7–11.

[24] Commissioner Wells absent.

mechanism for tuning the VHF and UHF channels; a description of tuning aids provided for tuning VHF and UHF channels; at least two suitable photographs, one showing the tuning controls on the outside of the cabinet, the other showing the tuning mechanism inside the cabinet; and a statement certifying that the receiver meets the requirements of § 15.68.

* * * * *

[F.R. Doc. 70-1511; Filed, Feb. 5, 1970; 8:47 a.m.]

Title 49—TRANSPORTATION

Subtitle A—Office of the Secretary of Transportation

[OST Docket No. 8; Amdt. 71-8]

PART 71—STANDARD TIME ZONE BOUNDARIES

Relocation of Mountain-Central Standard Time Zone Boundary in Kearny County, Kans.

The purpose of this amendment to Part 71 of Title 49 of the Code of Federal Regulations is to change the existing boundary line between the mountain time zone and the central time zone as it applies to Kearny County, Kans.

On November 27, 1969, the Department of Transportation published in the FEDERAL REGISTER (34 F.R. 18942), a notice of proposed rule making requesting comments on a proposal to relocate the boundary between the central and mountain time zones from its present location on the eastern line of Kearny County, Kans., to the dividing line between Unified School Districts No. 215 and 216 in that county, so as to place Unified School District No. 216 (the eastern one-fourth of Kearney County including the community of Deerfield) in the central time zone.

The proposal was based on a petition containing 216 signatures, which the petition's preamble indicated were those of "duly qualified voters of Unified School District #216". It stated that "[T]he west boundary of Unified School District #216 is approved by [the] Kansas State Board of Education and thus offers a workable solution to the needs of residents of this part of Kearny County, Kansas". By separate correspondence the mayor and city clerk of the city of Deerfield advised the Department of Transportation that the city council of Deerfield, at regular session on July 7, 1969, passed a resolution favoring the inclusion of Deerfield in the central time zone.

Public comments received on the proposal during the period from November 27, 1969, through January 12, 1970, were nearly unanimously in support of the proposed relocation. In addition, the Department has been advised by the Chairman of the Board of County Commissioners for Kearny County that "The proposal to place that part of Kearny County which lies within Unified School District No. 216 in the central time zone would not present any problems in the administration of county government".

It is the policy of the Department to establish time zone boundaries along State or county lines, so far as possible. In most cases there are compelling reasons why all of the residents of a county sohuld observe the same standard time. Kearny County, however, presents a unique problem because of Deerfield's nearness to and its social and economic ties with Garden City, a community of significant size a few miles to the east in the central time zone, and because of its corresponding lack of those ties to the western areas of the county.

In consideration of the foregoing, the boundary line between the mountain and central time zones in Kearny County, Kans., is being changed so as to place so much of that county as lies within Unified School District No. 216 in the central time zone. Accordingly, effective at 2 a.m. on March 8, 1970, § 71.6(d) of Title 49, Code of Federal Regulations is amended to read as follows:

§ 71.6 Boundary line between central and mountain zones.

* * * * *

(d) *Kansas.* From the intersection of the west line of Hitchcock County, Nebr., with the boundary line between Nebraska and Kansas westerly along that boundary to the northwest corner of the State of Kansas; thence southerly along the western boundary of the State of Kansas to the north line of Sherman County, Kans.; thence easterly along the north line of Sherman County to the east line of Sherman County; thence southerly along the east line of Sherman County to the north line of Logan County; thence westerly along the north line of Logan County to the east line of Wallace County; thence southerly along the east line of Wallace County to the north line of Wichita County; thence westerly along the north line of Wichita County to the east line of Greeley County; thence southerly along the east line of Greeley County to the north line of Hamilton County; thence easterly along the north line of Hamilton and Kearny Counties to the intersection of the east line of R. 36 W.; thence southerly along the range line between Rs. 35 and 36 W. with its offset to the south line of Kearny County; thence westerly along the south line of Kearny and Hamilton Counties to the Kansas-Colorado boundary; thence southerly along the Kansas-Colorado boundary to the intersection of that boundary with the north boundary of the State of Oklahoma.

* * * * *

This amendment does not concern adherence to or exemption from advanced (daylight saving) time. The Uniform Time Act of 1966 requires observance of advanced time within each established time zone from the last Sunday in April to the last Sunday in October, but permits any State to exempt itself, by law, from observing advanced time within that State. The Department has no administrative authority with respect to this requirement.

(Act of Mar. 19, 1918, as amended by Uniform Time Act of 1966 (15 U.S.C. 260-267); sec. 6(e)(5), Department of Transportation Act (49 U.S.C. 1655(e)(5))).

Issued in Washington, D.C., on February 2, 1970.

JOHN A. VOLPE,
Secretary of Transportation.

[F.R. Doc. 70-1515; Filed, Feb. 5, 1970; 8:48 a.m.]

Proposed Rule Making

DEPARTMENT OF AGRICULTURE

Consumer and Marketing Service

[7 CFR Part 52]

FROZEN ASPARAGUS

Proposed Standards for Grades [1]

Notice is hereby given that the U.S. Department of Agriculture is considering amendments to the U.S. Standards for Grades of Frozen Asparagus which became effective December 31, 1969. These standards were revised by publication in the FEDERAL REGISTER of March 13, 1969 (34 F.R. 5151), to become effective 30 days thereafter. Subsequently, by a notice in the FEDERAL REGISTER of April 12, 1969 (34 F.R. 6437), a change in the effective date to that of December 31, 1969, was announced.

Statement of consideration leading to this action. The National Association of Frozen Food Packers, on behalf of several major freezers of asparagus, has requested changes in the standards, which have just become effective, to:

(1) Increase the tolerances for size compliance in some respects for asparagus spears or tips that would be classified as to a single size or blends of sizes;

(2) Provide for definite amounts of loose material: a maximum of 5 percent in U.S. Grade A, and 10 percent in U.S. Grade B;

(3) Modify uniformity of length classifications for the styles of cut spears and cuts;

(4) Add classifications for poorly developed character in the style of cut spears to cover seedy and flowered units; and

(5) Increase the total number of defects permitted in U.S. Grade A with respect to color, uniformity of length, character or development, damage, and harmless extraneous material.

After considering these suggestions, the Department hereby proposes the changes in (1), (2), (3), and (4) within the meaning and intent of the Association's request. Minor amendments in definitions and in text are proposed to coincide with the intent of these proposed provisions.

With respect to the provisions under (5), the Department—in the absence of supporting data and evidence—does not consider that the relaxation to the degree requested would reflect proper limits for U.S. Grade A frozen asparagus. The Department proposes some relaxation—but not to the extent requested by the Association—that should give buyers, particularly for institutional size-packs, as well as processors, an equitable basis on which to process and market a good quality product.

All persons who desire to submit written data, views, or arguments for consideration in connection with this proposal should file the same in duplicate, not later than 45 days after publication hereof in the FEDERAL REGISTER, with the Hearing Clerk, U.S. Department of Agriculture, Room 112, Administration Building, Washington, D.C. 20250. All written submissions made pursuant to this notice will be available for public inspection at the office of the Hearing Clerk during regular business hours (7 CFR 1.27 (b)).

The proposed amendment are as follows:

1. In § 52.384, add the following new paragraphs:

§ 52.384 **Definitions of terms.**

* * * * *

(f) *Unit.* The term "unit", not otherwise qualified, means any individual portion of an asparagus shoot three-eighths inch of more in length.

(g) *Loose material.* "Loose material" means any loose or shattered asparagus material and cut or broken pieces that are less than three-eighths inch in length.

§ 52.386 [Amended]

2. In § 52.386, change the last word, "stalk", in the first sentence to read "unit".

3. Replace Table III in its entirety with the table III which follows:

TABLE III

Tolerances for size compliance		Single sizes		Blends of sizes	
		Maximum defects permitted			
In any sample unit (AL) [1]		10	5	15	10
Number of sample units	Number of spears or tips	Major	Severe	Total [2]	Minor or Total [2]
		In the total sample			*In the total sample*
1	50	7	3	12	7
2	100	13	5	21	13
3	150	18	7	30	18
4	200	22	9	39	22
5	250	27	10	47	27
6	300	32	12	55	32
7	350	36	14	63	36
8	400	41	15	72	41
9	450	45	17	80	45
10	500	50	18	90	50
11	550	54	20	96	54
12	600	59	21	104	59
13	650	63	23	112	63
14	700	68	24	121	68
15	750	72	26	129	72
16	800	76	27	140	76
17	850	81	29	145	81
18	900	85	30	153	85
19	950	90	32	161	90
20	1,000	94	33	169	94
21	1,050	98	35	177	98

[1] In any sample unit, except the first one of 50 spears or tips.
[2] "Total"—the sum of "Severe", "Major", and "Minor" defects, as applicable.
[3] In "Blends of Sizes", "Minor" and "Total" defects are the same.

4. In § 52.388, revise paragraphs (a) and (b) in their entirety to read as follows:

§ 52.388 **Grades.**

(a) "U.S. Grade A" (or "U.S. Fancy") is the quality of frozen asparagus that is of similar varietal characteristics; that has a good flavor and odor; that has no grit or silt present that affects the appearance or edibility of the product; in which no more than 5 percent, by weight, of loose material may be present; and that has an attractive appearance and eating quality within the limits specified for the various quality factors.

(b) "U.S. Grade B" or ("U.S. Extra Standard") is the quality of frozen asparagus that is of similar varietal characteristics; that has a good flavor and odor; that has no more than a trace of grit or silt present that slightly affects the appearance or edibility of the product; in which no more than 10 percent, by weight, of loose material may be present; and that has a reasonably attractive appearance and eating quality within the limits specified for the various quality factors.

* * * * *

[1] Compliance with the provisions of these standards shall not excuse failure to comply with the provisions of the Federal Food, Drug, and Cosmetic Act or with applicable State laws and regulations.

5. In table IV, change the last four lines to read as follows:

Any unit of cut asparagus, less than ½ inch in length (excluding head material or loose material)	X [Under Minor]
Any unit of cut asparagus, more than 2 inches in length	X [Under Major]

6. In Table V, delete the first five lines which follow the caption "Character ------" and substitute the following:

Spears and Tips styles:	
In Grade A only—	
Reasonably well developed (worse than Plate 1 but not worse than Plate 2 or 3)	X [Under Minor]
In all grades—	
Poorly developed (worse than Plate 2 or 3):	
Seedy	X [Under Major]
Flowered	X [Under Severe]
Cut spears or Cuts and Tips style:	
In all grades—	
Poorly developed (worse than Plate 2 or 3):	
Seedy	X [Under Minor]
Flowered	X [Under Major]

7. Replace Table VII and Table VIII in their entirety with the Table VII and VIII which follow:

TABLE VII

Grade compliance Spears; and Tips		U.S. Grade A				U.S. Grade B			
		Maximum defects permitted							
In any sample unit (AL) [1]		0	5	8	15	2	8	13	25
Number of sample units	Number of spears or tips	Critical	Severe	Major	Total [2]	Critical	Severe	Major	Total [2]
		In the total sample				*In the total sample*			
1	50	0	3	6	12	1	6	10	20
2	100	0	5	11	21	2	11	18	37
3	150	0	7	15	30	2	15	25	53
4	200	0	9	19	39	3	19	33	68
5	250	0	10	23	47	4	23	40	84
6	300	0	12	27	55	4	27	47	99
7	350	0	14	30	63	5	30	54	114
8	400	0	15	34	72	5	34	61	130
9	450	0	17	38	80	6	38	68	145
10	500	0	18	42	90	6	42	76	165
11	550	0	20	45	96	7	45	81	175
12	600	0	21	49	104	7	49	88	190
13	650	0	23	53	112	8	53	95	204
14	700	0	24	56	121	8	56	102	219
15	750	0	26	60	129	9	60	108	234
16	800	0	27	64	140	9	64	117	249
17	850	0	29	67	145	9	67	122	264
18	900	0	30	71	153	10	71	129	278
19	950	0	32	74	161	10	74	136	293
20	1000	0	33	78	169	11	78	142	308
21	1050	0	35	81	177	11	81	149	322

[1] In any sample unit, except the first one of 50 spears or tips.
[2] "Total"—the sum of "Critical", "Severe", "Major", and "Minor" defects, as applicable.

TABLE VIII

Grade Compliance Cut Spears; and Cuts		U.S. Grade A				U.S. Grade B			
		Maximum defects permitted							
In any sample unit (AL) [1]		0	7	14	25	3	14	22	44
Number of sample units	Number of cuts	Critical	Severe	Major	Total [2]	Critical	Severe	Major	Total [2]
		In the total sample				*In the total sample*			
1	100	0	5	11	21	2	11	18	37
2	200	0	9	19	39	3	19	33	68
3	300	0	12	27	55	4	27	47	99
4	400	0	15	34	72	5	34	61	130
5	500	0	18	42	90	6	42	76	160
6	600	0	21	49	104	7	49	88	190
7	700	0	24	56	121	8	56	102	219
8	800	0	27	64	140	9	64	117	249
9	900	0	30	71	153	10	71	129	278
10	1,000	0	33	78	169	11	78	142	308
11	1,100	0	36	85	185	12	85	156	337
12	1,200	0	39	92	200	12	92	169	366
13	1,300	0	42	99	216	13	99	182	396
14	1,400	0	45	106	232	14	106	195	425
15	1,500	0	47	113	248	15	113	209	454
16	1,600	0	50	120	264	16	120	222	483
17	1,700	0	53	127	279	17	127	235	512
18	1,800	0	56	134	295	17	134	248	541
19	1,900	0	59	141	311	18	141	261	570
20	2,000	0	62	148	326	19	148	274	599
21	2,100	0	64	155	342	20	155	287	628

[1] In any sample unit, except the first one of 100 cuts.
[2] "Total"—the sum of "Critical", "Severe", "Major", and "Minor" defects, as applicable.

§§ 52.394, 52.395 [Redesignated]

8. Renumber § 52.393 to 52.394 and § 52.394 to 52.395, and add a new § 52.393 as follows:

§ 52.393 Lot acceptance for "Percent loose material".

The percent of loose material, by weight, is determined by averaging the percentage by weight of loose material in the total weight of all of the sample units comprising the sample.

9. In § 52.393, now renumbered 52.394, revise paragraph (b), redesignate existing paragraph (c) as (d), and add a new paragraph (c) as follows:

§ 52.394 Lot acceptance for quality.

* * * * *

(b) The product is free of grit or silt that affects the appearance or edibility within the limits specified for either U.S. Grade A or U.S. Grade B; and

(c) The product complies with the limits specified for loose material for either U.S. Grade A or U.S. Grade B; and

* * * * *

(Sec. 205, 60 Stat. 1090, as amended; 7 U.S.C. 1624)

Dated: February 2, 1970.

G. R. GRANGE,
Deputy Administrator,
Marketing Services.

[F.R. Doc. 70-1475; Filed, Feb. 5, 1970; 8:45 a.m.]

[7 CFR Part 1098]

MILK IN NASHVILLE, TENN., MARKETING AREA

Notice of Proposed Suspension or Termination of Certain Provisions of Order

Notice is hereby given that, pursuant to the provisions of the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601 et seq.), the suspension or termination of certain provisions of the order regulating the handling of milk in the Nashville, Tenn. marketing area is being considered.

All persons who desire to submit written data, views, or arguments in connection with the proposed suspension or termination should file the same with the Hearing Clerk, Room 112-A, Administration Building, U.S. Department of Agriculture, Washington, D.C. 20250, not later than 7 days from the date of publication of this notice in the FEDERAL REGISTER. All documents filed should be in quadruplicate.

All written submissions made pursuant to this notice will be made available for public inspection at the office of the Hearing Clerk during regular business hours (7 CFR 1.27(b)).

The provisions proposed to be suspended are as follows:

1. In § 1098.7 "not an other order plant";

2. In § 1098.13(b) "(except a plant at which such milk is fully subject to the pricing provisions of another order issued pursuant to the Act)"; and

3. In § 1098.44(d), in the introductory text "that is neither an other order plant nor a producer-handler plant".

The provisions proposed to be suspended or terminated are as follows:

In § 1098.51, in the introductory text of paragraph (a) "and plus or minus a supply-demand adjustment calculated for that month as follows:" and all of subparagraphs (1) and (2) of paragraph (a).

The proposed suspension of specified provisions would permit handlers and cooperative associations to divert milk to any milk plant, including an other order plant.

Dairymen, Inc., requested the suspension. This cooperative association, representing most of the producers in this market, states that the proposed suspension would provide needed flexibility in the efficient movement of milk of their members in that milk not required for Class I purposes is available for processing at a manufacturing plant regulated by another order. The order presently does not provide for diversions of milk to an other order plant. By allowing diversion of milk to an other order plant for Class II purposes it is contended that considerable savings and efficiency in such movement of milk can be obtained.

The suspension or termination of the provisions in § 1098.51(a) would eliminate the supply-demand adjustment now provided in the order. The effect of such suspension or termination would reduce Class I milk prices 2 cents per hundredweight on the basis of the 12-month average for 1969. Dairymen, Inc., requested this suspension or termination. It is their contention that elimination of the supply-demand adjustment provisions would prevent erratic adjustments in the Class I price. The cooperative states such erratic adjustments might result from the movement of milk into and out of the order by the cooperative association in an effort to efficiently supply the Nashville market and other nearby markets.

Signed at Washington, D.C., on February 3, 1970.

JOHN C. BLUM,
Deputy Administrator,
Regulatory Programs.

[F.R. Doc. 70-1490; Filed, Feb. 5, 1970; 8:45 a.m.]

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[14 CFR Part 71]

[Airspace Docket No. 70-WE-2]

TRANSITION AREA

Proposed Designation

The Federal Aviation Administration is considering an amendment to Part 71 of the Federal Aviation Regulations that would designate a transition area for Hanford, Calif., Airport.

Interested persons may participate in the proposed rule-making by submitting such written data, views, or arguments as they may desire. Communications should be submitted in triplicate to the Chief, Airspace and Program Standards Branch, Federal Aviation Administration, 5651 West Manchester Avenue, Post Office Box 92007, Worldway Postal Center, Los Angeles, Calif. 90009. All communications received within 30 days after publication of this notice in the FEDERAL REGISTER will be considered before action is taken on the proposed amendment. No public hearing is contemplated at this time, but arrangements for informal conferences with Federal Aviation Administration officials may be made by contacting the Regional Airspace and Program Standards Branch Chief. Any data, views, or arguments presented during such conferences must also be submitted in writing in accordance with this notice in order to become part of the record for consideration. The proposal contained in this notice may be changed in the light of comments received.

A public docket will be available for examination by interested persons in the office of the Regional Counsel, Federal Aviation Administration, 5651 West Manchester Avenue, Los Angeles, Calif. 90045.

A new instrument approach procedure has been developed for Hanford Airport utilizing the Visalia, Calif., TVOR 230° radial. The proposed 700-foot transition area is necessary to provide controlled airspace protection for aircraft executing this instrument procedure.

In consideration of the foregoing the FAA proposes the following airspace action.

In § 71.181 (35 F.R. 2134) the following transition area is added.

HANFORD, CALIF.

That airspace extending upward from 700 feet above the surface within a 3-mile radius of the Hanford Municipal Airport (latitude 36°19'04" N., longitude 119°37'39" W.), and within 2 miles each side of the Visalia TVOR 214° radial extending from the 3-mile radius area toward the Visalia TVOR to abut the currently designated Visalia 700-foot transition area, excluding that airspace within a 1-mile radius of the Blair (private) Airport (latitude 36°16'31" N., longitude 119°38'23" W.).

This amendment is proposed under the authority of section 307(a) of the Federal Aviation Act of 1958, as amended (49 U.S.C. 1348(a)), and of section 6(c) of the Department of Transportation Act (49 U.S.C. 1655(c)).

Issued in Los Angeles, Calif., on January 24, 1970.

LEE E. WARREN,
Acting Director, Western Region.

[F.R. Doc. 70-1508; Filed, Feb. 5, 1970; 8:47 a.m.]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[21 CFR Parts 141b, 146b]

[DESI 60109]

DIHYDROSTREPTOMYCIN SULFATE AND DIHYDROSTREPTOMYCIN SULFATE IN COMBINATION WITH STREPTOMYCIN SULFATE FOR PARENTERAL USE

Announcement of Drug Efficacy Study Findings and Proposal To Repeal Certain Antibiotic Drug Provisions

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences—National Research Council, Drug Efficacy Study Group, on the following antiinfective drugs offered for intramuscular use:

1. Dihydrostreptomycin sulfate powder, equivalent to 1.0 gram dihydrostreptomycin base per vial; by Chas. Pfizer & Co., Inc., 235 East 42d Street, New York, N.Y. 10017.

2a. Dihydrostreptomycin sulfate powder, equivalent to 1.0 gram and 5.0 grams dihydrostreptomycin base per vial; and

b. Dihydrostreptomycin sulfate solution 2.5 cc. (1 gram) and 12.5 cc. (5 grams); both by Merck & Co., Inc., Rahway, N.J. 07065.

3a. Dihydrostreptomycin sulfate powder, equivalent to 1.0 gram and 5.0 grams dihydrostreptomycin base per vial; and

b. Dihydrostreptomycin sulfate solution, equivalent to 0.4 gram or 0.5 gram dihydrostreptomycin base per cc.; both by Philadelphia Labs., Inc., 9815 Roosevelt Bouelvard, Philadelphia, Pa. 19114.

4. Dihydrostreptomycin sulfate powder, equivalent to 1.0 gram and 5.0 grams dihydrostreptomycin base per vial; by E. R. Squibb & Sons, Inc., Georges Road, New Brunswick, N.J. 08903.

5a. Dihydrostreptomycin sulfate powder, equivalent to 1.0 gram and 5.0 grams dihydrostreptomycin base per vial; and

b. Dihydrostreptomycin sulfate solution, equivalent to 0.5 gram dihydrostreptomycin base per cc.; both by Pure Laboratories, Inc., 50 Intervale Road, Parsippany, N.J. 07054.

6. Dihydrostreptomycin sulfate powder with streptomycin sulfate powder, equivalent to 0.5 gram dihydrostreptomycin base and 0.5 gram streptomycin base per vial; by Merck & Co., Inc., Rahway, N.J. 07065.

7. Dihydrostreptomycin sulfate powder with streptomycin sulfate powder, equivalent to 0.5 gram dihydrostreptomycin base and 0.5 gram streptomycin base per vial, or 2.5 grams dihydrostreptomycin base and 2.5 grams streptomycin base per vial; by E. R. Squibb & Sons, Inc., Georges Road, New Brunswick, N.J. 08903.

The Academy evaluates (1) dihydrostreptomycin sulfate as effective for nontuberculous infections caused by susceptible organisms and (2) dihydrostreptomycin sulfate, alone or in combination

with streptomycin sulfate, as effective against all forms of tuberculosis in which the organisms are susceptible to the action of streptomycin.

The Academy also points out that dihydrostreptomycin therapy is attended by increased risk of cochlear damage and deafness, which is irreversible and may even appear after discontinuation of the drug.

The Academy finds that the dihydrostreptomycin sulfate-streptomycin sulfate combination does not serve a unique and useful purpose that justifies its being marketed. One of the drugs is toxic primarily to the auditory division of the eighth cranial nerve and the other drug is potentially toxic to the vestibular division of the eighth cranial nerve. Administering the combination of the drugs potentially compromises the whole eighth cranial nerve function. The clinical evidence is not convincing that the combination of the two drugs offers less total toxicity to the eighth cranial nerve than does the independent administration of either drug alone.

Although these drugs have been evaluated as effective for certain indications, the Commissioner of Food and Drugs concludes that the risks involved in their use outweigh any benefits that might be derived from such use and that provision for their certification should be repealed. Dihydrostreptomycin sulfate, alone or in combination, is regarded as unsafe for its recommended uses because such uses expose patients to the drug's ototoxic hazard.

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 507, 52 Stat. 1050–51, as amended, 59 Stat. 463, as amended; 21 U.S.C. 352, 357) and under authority delegated to him (21 CFR 2.120), the Commissioner proposes that Parts 141b and 146b be amended:

1. By revising the section headings of §§ 141b.111, 141b.118, and 141b.122 to read as follows:

§ 141b.111 Streptomycin sulfate solution; dihydrostreptomycin sulfate solution veterinary; crystalline dihydrostreptomycin sulfate solution veterinary.

§ 141b.118 Dihydrostreptomycin-streptomycin sulfates veterinary.

§ 141b.122 Dihydrostreptomycin-streptomycin sulfates solution veterinary.

2. By revoking § 141b.125 *Dihydrostreptomycin-streptomycin sulfates with isonicotinic acid hydrazide.*

3. In § 146b.103 *Dihdrostreptomycin sulfate, crystalline dihydrostreptomycin sulfate, dihydrostreptomycin hydrochloride:*

a. By adding to paragraph (a) a new subparagraph reading as follows:

( ) Its labeling shall conform to the requirements of § 146b.101(c) (2) or (3).

b. By deleting paragraph (b).

4. In § 146b.106:

a. By revising the section heading and paragraphs (b) and (c)(1) to read as follows:

§ 146b.106 Streptomycin sulfate solution; dihydrostreptomycin sulfate solution (crystalline dihydrostreptomycin sulfate solution) veterinary.

* * * * *

(b) *Packaging.* In all cases the immediate container shall be a tight container as defined by the U.S.P., shall be sterile at the time of filling and closing, shall be so sealed that the contents cannot be used without destroying the seal, and shall be of such composition as will not cause any change in the strength, quality, or purity of the contents beyond any limit therefor in applicable standards, except that minor changes so caused which are normal and unavoidable in good packaging, storage, and distribution practice shall be disregarded.

(c) *Labeling*—(1) *If it is intended for use by man.* It does not contain dihydrostreptomycin and in addition to the labeling requirements prescribed by § 1.106(b) of this chapter (regulations issued under section 502(f) of the act), each package shall bear on its label or labeling, as hereinafter indicated, the following:

(i) On the outside wrapper or container and the immediate container, the statement "Expiration date ------," the blank being filled in with the date that is 12 months after the month during which the batch was certified except that the blank may be filled in with the date that is 18 months, 24 months, 36 months, 48 months, or 60 months after the month during which the batch was certified if the person who requests certification has submitted to the Commissioner results of tests and assays showing that after having been stored for such period such drug as prepared by him complies with the standards prescribed by paragraph (a) of this section.

(ii) On the outside wrapper or container the statement "Store in refrigerator not above 15° C. (59° F.)" or "Store below 15° C. (59° F.)" unless the person who requests certification has submitted to the Commissioner results of tests and assays showing that such drug as prepared by him complies with the standards prescribed by paragraph (a) of this section after having been stored at room temperature.

b. By deleting "(1)(*a*) and (ii)" from paragraph (c)(2).

c. By deleting "(1)(*a*) and (1)(ii)" from paragraph (c)(3)(iv).

d. By changing in the second sentence of paragraph (d)(3)(iii) the phrase "requirements of" to "requirements for veterinary use of".

5. In § 146b.113, by revising the section heading and paragraphs (c) and (d)(4) to read as follows:

§ 146b.113 Dihydrostreptomycin-streptomycin sulfates veterinary.

* * * * *

(c) *Labeling.* It shall be labeled in accordance with § 146b.101(c) (2) or (3), except that each package shall bear on the outside wrapper or container the number of grams of dihydrostreptomycin, the number of grams of streptomycin, and the total number of grams of both salts in the immediate container.

(d) * * *

(4) If such batch is packaged for repacking, such person shall submit with his request a sample consisting of the following:

(i) For all tests except sterility: 6 packages.

(ii) For sterility testing: 20 packages.

Each such package shall contain not less than 0.5 gram of dihydrostreptomycin and 0.5 gram of streptomycin taken from different parts of such batch, and each shall be packaged in accordance with the requirements for veterinary use of § 146b.101(b).

6. In § 146b.117, by deleting paragraph (a)(1) and by revising the section heading and paragraph (c) to read as follows:

§ 146b.117 Dihydrostreptomycin-streptomycin sulfates solution veterinary.

(a) * * *

(1) [Deleted]

* * * * *

(c) *Labeling.* It shall be labeled in accordance with the requirements of § 146b.101(c) (2) or (3).

7. By revoking § 146b.120 *Dihydrostreptomycin-streptomycin sulfates with isonicotinic acid hydrazide.*

The Commissioner also proposes that certificates of safety and effectiveness heretofore issued for such drugs for use in man be revoked.

Any interested person may, within 30 days from the date of publication of this notice in the FEDERAL REGISTER, file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 5440, 330 Independence Avenue SW., Washington, D.C. 20201, written comments (preferably in quintuplicate) regarding this proposal. Comments may be accompanied by a memorandum or brief in support thereof.

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1497; Filed, Feb. 5, 1970; 8:46 a.m.]

FEDERAL COMMUNICATIONS COMMISSION

[47 CFR Part 25]

[Docket No. 15735]

OWNERSHIP AND OPERATION OF INITIAL U.S. EARTH STATIONS

Order Granting Extension of Time

In the matter of amendment of Part 25 of the Commission's rules and regulations with respect to ownership and operation of initial earth stations in the United States for use in connection with the proposed global commercial communication-satellite system; Docket No. 15735.

1. On January 28, 1970, Western Union International, Inc., filed a motion for extension of time to March 4, 1970, in which to file comments in the captioned rule-making proceeding.

2. Good cause has been shown for affording Western Union International, Inc., and other interested parties additional time within which to file such initial comments.

3. Accordingly, pursuant to § 0.303(c) of the Commission's rules on delegations of authority, Western Union International, Inc.'s motion is granted and the time for filing initial comments is extended from January 31, 1970, to March 4, 1970, and the time for filing reply comments is hereby extended from February 28, 1970, to March 31, 1970.

Adopted: January 28, 1970.

Released: January 30, 1970.

FEDERAL COMMUNICATIONS COMMISSION,
[SEAL] A. C. ROSEMAN,
Chief, International and Satellite Communications Division, for Chief, Common Carrier Bureau.

[F.R. Doc. 70-1513; Filed, Feb. 5, 1970; 8:47 a.m.]

[47 CFR Part 74]

[Docket No. 18785]

CATV SYSTEMS WITH FEWER THAN 500 SUBSCRIBERS

Order Granting Extension of Time

In the matter of amendment of § 74.1103 of the Commission's rules and regulations as it relates to CATV systems with fewer than 500 subscribers; Docket No. 18785.

1. KTVB, Inc., KMSO-TV, Inc., The Brockway Co., and Bi-States Co., have requested a 7-day extension of time for filing comments on the issues raised in the notice of proposed rule making in this docket. Comments are presently due on or before February 2, 1970, and reply comments on or before February 16, 1970. In view of the circumstances that the delay will be brief and that the notice of proposed rule making did not appear in the FEDERAL REGISTER until January 21, 1970, it appears that the public interest would be served by a grant of this request. We will likewise extend the time for filing reply comments.

Accordingly, it is ordered, Pursuant to § 0.289(c)(4) of the Commission's rules and regulations, that the time for filing comments in this docket is extended to and including February 9, 1970, and the time for filing reply comments is extended to and including February 24, 1970.

Adopted: January 29, 1970.

Released: January 30, 1970.

FEDERAL COMMUNICATIONS COMMISSION,
[SEAL] SOL SCHILDHAUSE,
Chief, CATV Task Force.

[F.R. Doc. 70-1514; Filed, Feb. 5, 1970; 8:47 a.m.]

SECURITIES AND EXCHANGE COMMISSION

[17 CFR Part 230]

[Release No. 33-5038]

FILING OF PROSPECTUSES AND OF AMENDMENTS TO REGISTRATION STATEMENTS

Notice of Proposed Rule Making

Notice is hereby given that the Securities and Exchange Commission has under consideration certain proposed amendments to Rules 402 (17 CFR 230.402), 424 (17 CFR 230.424), 470 (17 CFR 230.470) and 472 (17 CFR 230.472) under the Securities Act of 1933. These rules relate to the mechanics of filing registration statements and amendments to such statements. In order to facilitate compliance with those rules and expedite the examination of registration statements and amendments, it is proposed to amend the rules in the respects indicated below.

Rule 424(a) requires the filing of five copies of the proposed prospectus in addition to those included in the "three" copies of the registration statement. Since Rule 402(a) requires the filing of a total of eight copies of the registration statement (which includes copies of the proposed prospectus), Rule 424(a) would be amended to make clear that five copies of the prospectus must be filed in addition to the eight required by Rule 402(a). A note would be added to Rule 402(a) calling attention to the requirement in Rule 424(a).

Rule 470 sets forth the formal requirements with respect to amendments. It is proposed to amend this rule to require the file number of the registration statement to be indicated on all amendments. This will assist the staff of the Commission in filing and processing amendments. The rule would be further amended to require that post-effective amendments filed to update the prospectus to meet the requirements of section 10(a)(3) of the Act shall be prepared in accordance with the requirements of the appropriate registration form as then in effect.

Rule 472 requires the filing of three copies of every amendment to a registration statement. If the amendment relates to the prospectus or to a financial statement not included in the prospectus, five additional copies of the prospectus or financial statement must be filed. Two additional copies (or three additional copies, in the case of an investment company) of such prospectus or financial statement, marked to indicate the changes, must also be filed. It is proposed to revise the rule to require the filing of eight copies of every amendment, four of which must be marked to indicate the changes effected by the amendment. The revised rule would provide also that where a certified financial statement is amended, the certifying accountant's consent to the use of his certificate in connection with the amended statement and to being named as having certified such financial statement shall be filed with the amendment.

The provision of Rule 472(a) permitting the filing of only the changed pages of a prospectus for securities to be reoffered after competitive bidding would be deleted since copies of the complete prospectus must be available for the reoffering and would be more useful for review and copying.

The text of the proposed amendments is set forth below.

I. The following note is to be inserted immediately following paragraph (a) of § 230.402 of this chapter:

§ 230.402 Number of copies; binding; signatures.

(a) * * *

NOTE: Attention is directed to § 230.424(a) which requires the filing of five copies of the proposed prospectus in addition to those contained in the registration statement or required by this section.

* * * * *

II. Paragraph (a) of § 230.424 of this chapter would be amended as follows:

§ 230.424 Filing of prospectuses; number of copies.

(a) In addition to the eight copies of the proposed prospectus included in the registration statement as required by § 230.402(a), five copies of such prospectus shall be filed with the registration statement at the time the statement is filed. A copy of the cross reference sheet required by § 230.404(c) shall accompany each copy of the prospectus so filed.

* * * * *

III. Section 230.470 of this chapter would be amended to read as follows:

§ 230.470 Formal requirements for amendments.

Except as provided in § 230.473, amendments to a registration statement shall be filed under cover of an appropriate facing sheet, shall be numbered consecutively in the order in which filed, shall indicate on the facing sheet the file number of the registration statement, and shall conform to all pertinent rules applicable to the original registration statement, except that an amendment relating to the prospectus which is filed for the purpose of meeting the requirements of section 10(a)(3) of the Act or an amendment filed pursuant to section 24(e)(1) of the Investment Company Act of 1940 shall conform to the appropriate form for registration as in effect at the time of filing of the amendment.

IV. Section 230.472 of this chapter would be revised to read as set forth below.

§ 230.472 Filing of amendments—number of copies.

(a) Except for telegraphic amendments filed pursuant to § 230.473, there shall be filed with the Commission four unmarked copies of every amendment and four additional copies of such amendment marked to indicate clearly and precisely, by underlining or in some other appropriate manner, the changes effected in the registration statement by the amendments. Each copy of the amendment shall include all papers and

documents comprising a part of the amendment.

(b) Every amendment which relates to a prospectus shall include a copy of the prospectus as amended. Each copy of every amended prospectus so filed shall be accompanied by a copy of the cross reference sheet required by § 230.404(c) if the amendment of the prospectus resulted in any change in the accuracy of the cross reference sheet previously filed.

(c) Every amendment of a financial statement which is not included in the prospectus shall include a copy of the financial statement as amended. Every amendment relating to a certified financial statement shall include the consent of the certifying accountant to the use of his certificate in connection with the amended financial statement in the registration statement or prospectus and to being named as having certified such financial statement.

(d) If an exhibit to a registration statement (other than an opinion or consent), filed in preliminary form, has been changed only (1) to insert information as to interest, dividend or conversion rates, redemption or conversion prices, purchase or offering prices, underwriters' or dealers' commission, names, addresses or participations of underwriters or similar matters, which information appears elsewhere in an amendment to the registration statement, or (2) to correct typographical errors, insert signatures or make other similar immaterial changes, then, notwithstanding any contrary requirement of any rule or form, the registrant need not refile such exhibit as so amended; provided the registrant states in the amendment the basis provided by this section exhibit. Any such incomplete exhibit may not, however, be incorporated by reference in any subsequent filing under any act administered by the Commission.

This foregoing action would be taken pursuant to the authority contained in sections 6, 7, 10, and 19(a) of the Securities Act of 1933; 48 Stat. 78, 81, and 85, as amended; 15 U.S.C. 77f, 77g, 77j, and 77s(a).

All interested persons are invited to submit their views and comments on the proposed amendments, in writing, to the Securities and Exchange Commission, Washington, D.C. 20549, on or before February 21, 1970. All such communications will be available for public inspection.

By the Commission, January 21, 1970.

[SEAL] ORVAL L. DUBOIS,
Secretary.

[F.R. Doc. 70-1510; Filed, Feb. 5, 1970; 8:47 a.m.]

FEDERAL TRADE COMMISSION

[16 CFR Part 118]

MIRROR INDUSTRY

Notice of Opportunity To Submit Written Views, Suggestions, or Objections Concerning Requested Amendment of Trade Practice Rules

The Commission has received requests for changes in its Trade Practice Rules for the Mirror Industry, 16 CFR Part 118. The Commission is not proposing changes, but desires comments in this direction before reaching a tentative position.

The principal requested change calls for deletion of the definitions of plate glass and float glass now contained in the rules. These definitions would be replaced by a new definition reading as follows: "Plate/float glass—a transparent glass, the two surfaces of which are flat and parallel so as to give clear and undistorted vision and reflection." The rules also would be changed to allow interchangeable use of the terms "plate," "float," or "plate/float" in designating or describing such glass.

In addition to comments on the requested changes outlined above, comments are desired on whether there exists a need for affirmative disclosures, in advertising and/or labeling, concerning the properties, performance, or safety hazards of mirrors.

Opportunity is hereby extended by the Federal Trade Commission to any and all persons, firms, corporations, organizations, or other parties affected by or having an interest in the Trade Practice Rules for the Mirror Industry to present to the Commission their views concerning the rules, including such pertinent information, suggestions, or objections as they may desire to submit. For this purpose, copies of the rules, which are advisory in nature as to the applicability of legal requirements, may be obtained upon request to the Commission. Such data, views, information, and suggestions may be submitted by letter, memorandum, brief, or other written communication not later than April 7, 1970, to the Chief, Division of Industry Guides, Bureau of Industry Guidance, Federal Trade Commission, Pennsylvania Avenue and Sixth Street NW., Washington, D.C. 20580.

Written comments received will be available for examination by interested parties at the Commission's Washington address and will be fully considered by the Commission.

Issued: February 5, 1970.

By direction of the Commission.

[SEAL] JOSEPH W. SHEA,
Secretary.

[F.R. Doc. 70-1416; Filed, Feb. 5, 1970; 8:45 a.m.]

Notices

DEPARTMENT OF THE TREASURY

Office of Foreign Assets Control

HAIR OF CERTAIN ANIMALS, COTTON AND SILK WASTE, AND CARPET WOOL

Importation From Countries Not in Authorized Trade Territory; Applications for Licenses

Licenses under the Foreign Assets Control Regulations (31 CFR 500.101—500.808) for the importation of the following commodities produced in the U.S.S.R. or Outer Mongolia will be issued during 1970 in the same aggregate quantities as in previous years. These quantities, based on importations during the period 1946 through 1951, are as follows:

	Pounds
Badger hair	200
Carpet wool	1,800,000
Cotton waste	4,550,000
Goat hair	610,000
Horse mane hair	660,000
Horse tail hair	70,000
Silk waste	435,000
Yak hair	525,000

Licenses will be issued to any person, and will not be limited to persons with a previous history of importation. The following conditions will apply:

(1) Applications must be filed before September 1, 1970, and must be accompanied by a copy of a firm contract with the seller subject only to the obtaining of the necessary license.

(2) No one applicant will be licensed to import more than 25 percent of the total quota for any one commodity. However, more than one contract can be entered into by any applicant, up to the 25 percent limit.

(3) Licenses will be nontransferable and imports may be made only in the name of and for the account of the licensee.

(4) The contract must provide for shipment from the U.S.S.R. If the contract is made with a seller in a third country any license issued will require that the goods be shipped directly from the U.S.S.R. to the United States or, if not, that they remain in continuous carriers' custody during the entire period of transshipment.

Licenses will be valid until the date of shipment specified in the contract and will be extended to permit Customs entry and transactions under a letter of credit for goods shipped pursuant to the contract.

Applications for licenses must be filed in duplicate on Form TFAC–1 with the Federal Reserve Bank of New York, 33 Liberty Street, New York, N.Y. 10045. Applications will be considered in the order in which they are received. Persons applying for a license to import more than one commodity should file a separate application for each such commodity.

Since for one reason or another some licenses may expire unused or the full quota of a commodity may not be applied for by qualified applicants (i.e., by persons who have not reached the 25 percent limit) announcement will be made in the FEDERAL REGISTER on or before September 15, 1970, of any balances still available for licensing. At that time any person may apply for any portion of an available balance irrespective of the fact that he may have already received licenses to import as much as 25 percent of the quota. Applications for licenses filed after September 15, 1970, are subject to all conditions set forth above other than the 25 percent limit.

Additional information and license application forms may be obtained from the Federal Reserve Bank of New York or from the Office of Foreign Assets Control, Treasury Department, Washington, D.C. 20220.

[SEAL] MARGARET W. SCHWARTZ,
Director,
Office of Foreign Assets Control.

[F.R. Doc. 70–1539; Filed, Feb. 5, 1970; 8:50 a.m.]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[Docket No. FDC–D–135; Various NDA's]

NEW-DRUG APPLICATIONS

Notice of Opportunity for Hearing

Notice is hereby given to each holder of a "deemed approved" new-drug application listed herein, that the Commissioner of Food and Drugs proposes to issue an order under the provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act withdrawing approval of such applications and all approved amendments and supplements thereto on the grounds that:

The applicants have repeatedly failed to make required reports under section 505(j) of the act (21 U.S.C. 355(j)) and § 130.35 (a), (b), (e), and (f) of the new-drug regulations (21 CFR 130.35) for each new drug listed herein.

The objective of this action is to close a large number of new-drug files that have been inactive for several years. Some of the drugs involved may classify as not new drugs or no longer new drugs, depending upon composition and labeling claims. Withdrawal of approval of these applications is not for the purpose of classifying the products as new drugs or of applying the efficacy provisions of the act to drugs of the same composition marketed by other firms.

Upon request, the Commissioner will supply to any interested person directly concerned, a statement of the composition of any of the drugs listed herein, to the extent that such information was disclosed or required by law to be disclosed in the labeling.

In accordance with the provisions of section 505 of the act (21 U.S.C. 355) and the new-drug regulations (21 CFR Part 130), the Commissioner will give the applicants named, and any interested person who would be adversely affected by an order withdrawing such approvals, an opportunity for a hearing to show cause why approval of the following new-drug applications should not be withdrawn:

4–H Co., 3433 Liberty Heights Avenue, Baltimore, Md.
NDA 1–596, 4–H Household Cough Syrup.

A & M Moss Co., Box 684, Ocala, Fla.
NDA 1–062, Curich Powder.

Abmo Eye Drop Co., 508–9 Omaha Loan & Building Association, Omaha, Nebr.
NDA 0–733, ABMO Eye Drops.

Aciform Sales Corp., 520 North Michigan Avenue, Chicago, Ill.
NDA's:
0–060, Aciform 1 Injection.
0–061, Aciform 2 Injection.
0–848, Norozan-Lyss Ointment.
0–849, Lorisan-Lyss Ointment.
1–127, Sanasan-Lyss Ointment.
1–128, Pactil-Lyss Tablets.

Aciquick Ointment Co., Martinsburgh, W. Va.
NDA 3–535, Aciquick Ointment.

Acme Products Co., Post Office Drawer 390, West Frankfurt, Ill.
NDA 1–124, X-Pel Ointment.

Adams Co., The, Land Title Building, 100 South Broad Street, Philadelphia, Pa.
NDA 9–930, Relaxerpine Tablets.

Adams Pharmacal Co., 838 Malcolm Avenue, Los Angeles, Calif.
NDA's:
0–680, Ritol Ointment.
4–972, Rytex Ointment.

Adams Pharmacy (Wilbur Coble Adams), 314 Laurel Street, Conway, S.C.
NDA 3–159, Alkareka Liquid.

Addisone, Arthur S., 815 South Negley Avenue, Pittsburgh, Pa.
NDA 2–049, Salphytox Ointment.

Adson-Intrasol Labs, Inc., Now known as Bio-Intrasol Labs., Inc., 209 West 26th Street, New York, N.Y.
NDA 4–613, Stilbestrol in Sesame Oil Injection 0.5 and 1.0 mg./cc.

Agar Products, Freeda, 110 East 41st Street, New York, N.Y.
NDA 3–397, Fortrun Capsules.

Aiellos Pedo-Vale Co., 139 South Main Street, Archbald, Pa.
NDA 0–407, Aiellos Pedo-Vale Liquid.

Ajem Drug Co., 508 55th Street, Oakland, Calif.
NDA 12–018, Formula-12 Tablets (phenylpropanolamine 75 mg.).

Akatos, Inc., 114 Liberty Street, New York, N.Y.
NDA's:
0–451, Demotube A Ointment.
0–452, Demotube B Ointment.

Akshun Co., 509 Fifth Avenue, New York, N.Y.
NDA 0–578, Akshun Rectal Ointment.

Albin, Fred L., 1116 East Monument Street, Colorado Springs, Colo.
NDA 0-470, Kolorok Powder.
Algaeloin Corp., 140 Front Street, New York, N.Y.
NDA 5-197, Fasta Lotion.
Algene Labs., 3810 West 13th Street, Chicago, Ill.
NDA 2-052, Algene Ointment.
Al-Jax Chemical Co., Second and Broadway, Semour, Ind.
NDA 1-456, Aljene Powder.
Alka-Algae Corp., Medical Dental Building, Portland, Org.
NDA 1-171, Alka-Algae Tablets.
Alkalax Co., First National Bank Building, Colorado Springs, Colo.
NDA 3-330, Alkalax Tablets.
Allan & Co., Inc., Now known as Allan Pharmaceuticals, 3719 North 14th Street, St. Louis, Mo.
NDA 7-425, Allan's Anti-Hista Tablets (pyrilamine maleate 25 mg.)
Allen Labs, 67 Irving Place, Brooklyn, N.Y.
NDA's:
1-457 Medipax Vaginal Tampon w/Metaphen Suppos.
1-458, Medipax Vaginal Tampon w/Merthiolate Suppos.
3-623, Metaphen Vaginal Suppositories.
3-624, Merthiolate Vaginal Suppositories.
3-810, Medipax Tampons w/Acetarsone Tablets and Suppositories.
Allergan Pharmaceuticals, Inc., 1000 South Grand Avenue, Santa Ana, Calif.
NDA 7-900, Allergan Nasal Drops.
Allergy & Medical Products Co., Post Office Box 1399, Cincinnati, Ohio.
NDA's:
5-367, Controlex Inhalant.
7-781, Al-Med-In Plus Tablets.
Allfoods Labs., 671 Downing Street, Denver, Colo.
NDA 0-342, MCM Tablets.
Allied Biochemical Labs., San Francisco, Calif.
NDA 9-936, Rautension Tablets, 50 mg. and 100 mg.
Allied-Davy Products Co., 16th and Pierce Street, Chattanooga, Tenn.
NDA 7-303, Pyrilamine Maleate Tablets 25 mg.
Allied Pharmacal Co., 1735 East 12th Street, Cleveland, Ohio.
NDA's:
2-437, A.A.A. Tablets.
2-727, Ruvena Oil Ointment.
3-152, Laxative Pills (Posophyllin, Aloes, Etc.).
7-200, Histonex Tablets.
7-775, Histonex Plus Tablets (Hista-Kol).
7-793, Histonex Cough Syrup.
Almotone Chemical Co., 1010 East Costilla Street, Colorado Springs, Colo.
NDA's:
0-531, Fagras Botane Liquid.
0-532, Oreton-F Ointment.
0-533, Fagras Salve.
Alol Products, Inc., Carmel, N.Y.
NDA 7-539, Poison Ivy Alol Liquid.
Alphaden, 154 East Erie Street, Chicago, Ill.
NDA 4-532, Trycogen Powder and Suppositories.
Altman, Edward M., 235 Benefit Street, Providence, R.I.
NDA 1-423, Prevence Baby Powder.
American Bandage Corp., 1701 North Damen Drive, Chicago, Ill.
NDA 5-087, A.B.C. Gauzband Dressing.
American Biochemical Corp., 1133 Venice Boulevard, Los Angeles, Calif.
NDA's:
9-491, Cortisone Acetate Injection, 25 mg./cc.
10-919, Concevim-12 Injection.
American Chemical Co., 433 East Erie Street, Chicago, Ill.
NDA 3-638, Sulfathiazole Tablets.
American Chemicals, Indianapolis, Ind.
NDA 3-950, Amphetamine Sulfate (batch).
American Cyanamid Co., Pearl River, N.Y.
NDA 3-912, Sulfaguanidine Powder.
American Cystoscope Makers, Inc., 1241 Lafayette Avenue, Bronx, N.Y.
NDA 5-912, Urolocide Solution and Tincture, 0.1%.
American Disinfecting Co., 902 West Main Street, Sedalia, Mo.
NDA 0-834, Stera-Futz Liquid.
American Electrochem Co., 509 Fifth Avenue, New York, N.Y.
NDA 0-025, Auralysin Liquid.
American Intercontinental Co., 254 West 31st Street, New York, N.Y.
NDA's:
4-587, Fertinic Tablets.
4-622, Pextrose w/Vitamins A, D, and B_1 Granules.
American Lecithin Co., Inc., Elmhurst, Long Island, N.Y.
NDA 3-932, Alco (Lexo) Cookies and Wafers.
American Ointment Co., New Castle, Pa.
NDA 0-353, Milk of Magnesia Tablets.
American Pharmacal Co., 425 Main Street, Poughkeepsie, N.Y.
NDA 3-650, Stomarol Liquid.
American Products Co. (Zanol Products Co.), 3265 Colerain Avenue, Cincinnati, Ohio.
NDA 0-949, Mouthwash Antiseptic #42.
American Quinine Co., 99 Hudson Street, New York, N.Y.
NDA 9-644, Reserpine Tablets.
American Roland Corp., New York 13, N.Y.
NDA's:
8-588, Isonicotinic Acid Hydrazide Tablets 50 & 100 mg.
8-803, Meparafynol Capsules.
Amfre Drug Co. (Amfre—Grant), 924 Rogers Avenue, Brooklyn, N.Y.
NDA's:
0-312, Simacol Solution.
2-355, Quidrin Solution and Injection.
2-356, Amfrin Tablets, 300 mg.
5-258, Ketobile Tablets, 250 mg.
Amick, W., 5260 12th Street, Seattle, Wash.
NDA 1-701, Imp Tago Ointment.
Amino Products Co., Division International Mineral & Chemical Corp., Chicago, Ill.
NDA's:
9-186, Betasymine Tablets.
9-187, Betasymine Emulsion.
Ammen Co., Ltd., Charles, Alexandria, La.
NDA 3-261, Ammen's Powder.
Amo Products Co., 18th Danforth Place, Massena, N.Y.
NDA 2-183, Amo Tablets.
Amsco Labs., Milledgeville, Ga.
NDA 12-355, Silicone Coated ACD (Heparin) Solution.
Anabolic Inc., 514 Riverdale Drive, Glendale, Calif.
NDA 3-002, Cilobana N-12 Capsules.
Anacin Co., The, 257 Cornelison Avenue, Jersey City, N.J.
NDA 4-275, Benefax Tablets (B Complex).
Analmine Co., Post Office Box 1430, Hollywood, Calif.
NDA 1-935 Analmine Capsules.
Anderson Food & Chemical Co., 938 Meridian Street, Anderson, Ind.
NDA 1-699, Cream of Whey Liquid.
Anderson-Stolz Corp., 1535 Walnut Street, Kansas City, Mo.
NDA 2-032 Aero-Klenz Solution.
Andrews-Goodykoontz Co., 412 Princeton Avenue, Bluefield, W. Va.
NDA 1-192, Ped Powder.
Andromachus Corp., 11 West 42d Street, New York, N.Y.
NDA's:
1-558, Vitamin Capsules (A, B, C, D, G).
1-559, Ampules Vitamin B_1 Injection.
1-561, Bes-Min Liquid.
1-562, Supervitamin Capsules.
1-563, Vitamin C Tablets.
1-564, B & Nicotinic Acid Tablet.
2-790, Herison Ointment.
Angelica Chemical Co., 1311 South Broad Street, Philadelphia, Pa.
NDA 1-305, Angelica Salts.
Anglo-American Drug Co., 47 Fulton Street, New York, N.Y.
NDA's:
2-374, Mrs. Winslow's Elixir.
2-375, Mrs. Winslow's Anodyne Tablets.
Anglo-French Drug Co., 1270 Broadway, New York, N.Y.
NDA's:
1-586, Enterosalicyl ECC.
4-158, Vi-Mi Capsules.
4-654, Neocaine Injection.
4-728, Hemobrom Tablets.
An-Rey Co., 742 South Hill Street, Los Angeles, Calif.
NDA's:
1-144, An-Rey #4 Tablets.
1-145, An-Rey #29 Tablets.
1-146, An-Rey #38 Tablets.
1-147, An-Rey #47 Tablets.
1-148, An-Rey #55 Tablets.
1-149, An-Rey #7 and #77 Tablets.
1-150, An-Rey #8 and #88 Tablets.
1-151, An-Rey #9 and #99 Tablets.
Antara Chemicals—Division General Aniline & Film Corp., New York, N.Y.
NDA 9-544, Sarcoside Dental Cream.
Approved Pharmacal Corp., 114 Gifford Street, Syracuse, N.Y.
NDA 7-754, Histacomp Tablets.
Approved Products Inc., 26 North Ninth Street, Philadelphia, Pa.
NDA 5-548, Approved Antiseptic Mouthwash.
Arcum Pharm. Corp., Post Office Box 267, Vienna, Va.
NDA 11-354, Arcum R-S Tablets (Reserpine).
Argus Labs., Inc., Joseph, 1050 Dorchester Avenue, Boston, Mass.
NDA 10-472, Argo-Serpine Sustained Release Capsules 0.25, 0.5, 0.75 mg.
Argyrios, D., 1325 Adams Street, Gary, Ind.
NDA 0-530, Enzo-Cal Liquid and Lotion.
Arlington Chemical Co., Yonkers, N.Y.
NDA 6-937, Gustamine Powder.
Armand Co., 124 Des Moines Street, Des Moines, Iowa.
NDA's:
5-383, Alertin Solution.
5-388, Alertin Compound Solution.
5-433, Alertin Powder.
5-434, Tropic Breeze Lotion.
5-435, Alerton Cream.
Armour Labs., Post Office Box 511, Kankakee, Ill.
NDA's:
3-509, Thiamine HCl Injection.
3-775, Vitamin E Capsules.
8-186, Acthar Gel Injection, 20 and 40 U/cc.
Aro Products Co., 555 Salem Avenue, Dayton, Ohio.
NDA 1-852, Aro Ointment.
Artemisia Bitters Co., 139 Pine Avenue, Chicago, Ill.
NDA 0-264, Artemisia Bitters.
Asbon Co., 207 Bloomfield Avenue, Bloomfield, N.J.
NDA 0-123 Asbon's Lozenges.
Asmex Co., 308 White Horse Pike, Berlin, N.J.
NDA 3-427, Asmex Capsules.
Associated Dental Supply, 1802 Geary Street, San Francisco, Calif.
NDA 4-237, Painless Parker Mouthwash.
Associated Labs., Inc., 880 Broadway, New York, N.Y.
NDA 7-101, Onteen Tablets.
Atblake Labs., Inc., 107 North Franklin Street, Syracuse, N.Y.
NDA's:
0-613, Formula #256 Capsules.
1-223, Formula #257 Capsules.
1-224, Formula #258 Capsules.
2-106, Formula #260 Capsules.
2-107, Formula #261 Capsules.
2-108, Formula #262 Capsules.

Atha-Spray Co., 19 North Limestone Street, Springfield, Ohio.
NDA 1-315, Atha-Spray.
Athleeta Labs., 1158 Howard Street, San Francisco, Calif.
NDA 2-360, Breezo Scalp Ointment.
Athlene Labs., 205 Bussantz Building, Wichita, Kans.
NDA 2-662, Athazon Liquid.
Athletike Labs., 210 Eleanor Street, San Antonio, Tex.
NDA 0-710 Athletika Powder.
Athlex Co., 1809 Nueces Street, Austin, Tex.
NDA 2-850, Athlex Powder.
Atkinson, Harold L., 13650 Stevens Creek Canyon Road, Cupertino, Calif.
NDA 1-413, Atkinson's Anti-Bin Capsules.
Atlas Labs.—Hayes Labs., 236 West Exchange Street, Akron, Ohio.
NDA's:
1-353, Atlas Lubricant.
5-800, Atlas Chemical Prophylactic Kit Ointment.
Attwood, J. K., 1024 Park Street, Jacksonville, Fla.
NDA 5-629, Mercuriben 33 Mouthwash.
Aurox Co., 307 Fifth Avenue, New York, N.Y.
NDA 0-492, Aurox Drops.
Avedis Ointment Co., 649 Massachusetts Avenue, Cambridge, Mass.
NDA 4-744, Avedis Ointment.
Averitt, Herbert C., 1518 Mission Avenue, Spokane, Wash.
NDA 3-085, Ring-Go Liquid.
Awad Manufacturing Co., L. J., 576 East Dupont Street, Philadelphia, Pa.
NDA 0-093, Lejaw Liquid.
Ayolray Co., 58 West 91st Street, New York, N.Y.
NDA 0-716, Santophen Powder.
BB Labs., 1225 Venice Boulevard, Los Angeles, Calif.
NDA 1-576, BB Liquid.
B-K-T Products Corp., 308 Tootle Building, St. Joseph, Mo.
NDA 3-165, Bishop's Tablets.
B & W Pharmacal Co., Dayton, Ohio.
NDA's:
3-478, Methanate Tablets.
3-479, Emulsoid Mentholated Emulsion.
3-481, Septagil.
3-483, Analgene Liquid.
3-484, Pangone Liquid.
3-486, Vedene Liquid.
3-487, Beosol Liquid.
3-489, Glycosine Liquid.
3-490, Glycerophos w/Thiamine Chloride Elixir.
3-491, Ammoniated Mercury Suspension.
Babylon Pharm. Co., Inc., Babylon, N.Y.
NDA 7-889, Premens Tablets.
Bac-Mart Co., 224¼ South Beach Street, Daytona Beach, Fla.
NDA 2-027, Nine-O-Nine Solution.
Baker Chemical Co., J. T., 600 North Broad Street, Phillipsburg, N.J.
NDA's:
4-373, Sol-Aspirin Tablets.
8-421, Dextran Injection.
Baker & Co., S. F., Keokuk, Iowa.
NDA's:
1-396, Baker's Astringent.
1-583, Baker's Cream Balm.
1-584, Baker's Salve Balm.
1-585, Baker's Ointment.
3-422, Baker's Tonic Solution.
4-216, Baker's Ointment.
Baldus, Simon A., 2003 Lunt Avenue, Chicago, Ill.
NDA 3-295, Sims Ointment.
Baldwin Medicine, Inc., 2120 Pine Street, Texarkana, Tex.
NDA's:
1-099, Soudan Compound Liquid.
1-100, Baldwin's Soudan Corn Medicine.
1-101, Soudan Liniment.
1-102, Baldwin's Soudan Tablets.
Ball Drug Co., 538 Florida Street, Baton Rouge, La.
NDA's:
1-636, Balco Ointment.
1-638, Balco Tablets.
3-191, Ballco Tablets.
3-199, Ballco Inhalant Drops.
Ballard, Nicholas C., Marion County, St. Francis, Ky.
NDA 0-517, Nick's Rub Ointment.
Bard Pharmaceuticals, 99-101 Saw Mill River Road, Yonkers, N.Y.
NDA 10-033, Reserpine Tablets.
Bard Saratoga Laboratories, Inc., Saratoga Springs, N.Y.
NDA 10-295, Harvepine Tablets.
Barnes & Sons, S. O., 17250 South Main Street, Gardena, Calif.
NDA 10-047, Reserpine Tablets 0.25 mg.
Barre Drug Co., The, 3635 Woodland Avenue, Baltimore, Md.
NDA 12-120, Offat Capsules.
Barry Labs, 9100 Kercheval, Detroit, Mich.
NDA's:
10-225, Reserpine Injection.
10-722, Vitamin B_{12} for Injection.
Bassett, W. L., 20 [illegible]in Street, Norwood, N.Y.
NDA 1-232, Henry's Headache Powder.
Bates Co., L. W., 905 Eye Street, Modesto, Calif.
NDA 2-227, Bates Internal Formula.
Battle Creek Dietetic Co., 10-14-16 Court Street, Battle Creek, Mich.
NDA 7-229, Mihista Tablets.
Bay springs Mineral Products Co., Mr. R. E. Hogan, Box 2034, Miami, Fla. (Also Salerfal Sales Agency Mineral Products.)
NDA 0-265, Oxiron Solution.
Bay State Labs., Inc., 25 Huntington Avenue, Boston, Mass.
NDA 4-633, Codoil Ointment.
Beamola Labs., 309-311 South Main Street, Lima, Ohio.
NDA 0-114, Licitrate Liquid.
Bel Clare Products Co., 118 North Alexandria, Los Angeles, Calif.
NDA's:
6-533, Bel Clare Foot Powder.
6-554, Bel Clare Fungicide Solution.
6-555, Bel Clare Deodorant Liquid.
Bell Mfg., George N., 1417 Cornell Avenue, Indianapolis, Ind.
NDA 9-475, Tablets Raupesine (Reserpine Tablets).
Bellak, George, 538 South 20th Street, Newark, N.J.
NDA's:
1-243, Bellakol Mild Laxative Tea.
1-244, Bellak's Bitter Mild Cathartic.
Benedict, Antonucil, 218 East Front Street, Youngstown, Ohio.
NDA 3-725, Salugene Liquid.
Ben-Foy Labs., Inc., 351 West Penn Avenue, Wernersville, Pa.
NDA 10-444, Zepine Injection.
Benjamin, F. A., 104 Main Street, Danville, Ill.
NDA 0-017, Grandma's Salve.

Benson Labs., Inc., Post Road, Madison, Conn.
NDA 7-195, Pyrahist Tablets.
Bergen Pharmacal Co., Inc., 354 Mercer Street, Jersey City, N.J.
NDA's:
7-123, Historal Tablets.
9-620, Rauwolfia Serpentina Tablets, 50 mg., and 100 mg.
9-688, Reserpine Tablets.
Beringer, Inc., George M., 1251 Sycamore Street, Camden, N.J.
NDA 1-061, Potassium Iodide and Sodium Bromide Compound Solution.
Berkeley Drug So. (Now Alton Products, Inc.), 159 Norfolk Street, Dorchester, Mass.
NDA 7-398, Anistabs (Pyrilamine Maleate, 25 mg.).
Berolzheimer, Ruth, 600 South Michigan Avenue, Chicago, Ill.
NDA 3-065, Eyeglo Solution.
Betan Co., 400 Market Street, Chattanooga, Tenn.
NDA's:
2-425, Betan Capsules.
2-426, Betan Inhalant.
Bethel Clinic, 210 South Pine Street, Newton, Kans.
NDA 1-534, Medicinal Tablets.
Big Four Labs. (Big Four Mills Ltd.), 219 Marietta Street NW., Atlanta, Ga.
NDA's:
1-475, Shur-Lex Liquid.
1-476, Vinco Liquid.
1-477, Green Marsh Liquid.
1-621, Big Four Liniment Liquid.
1-697, Big Four Band Nasal Drops.
1-698, Big Four Liquid.
Bigelow-Clark, Inc., 360 Meacham Avenue, Elmont, N.Y.
NDA 0-951, Podosol Liquid.
Biochemical Research Labs., Inc., 1 East Walton Place, Chicago, Ill.
NDA 0-567, Ganassinis Hair Lotion.
Bioplastic Labs., 458 Broadway, New York, N.Y.
NDA 4-779, Rubicide Liquid 0.5%, 1.0%.
Bio-Prod Labs., Inc., 644 Pacific Street, Brooklyn, N.Y.
NDA 5-498, Formula 333 Capsules.
Bio-Ramo Drug Co. (Now known as Copanos, John, Inc.), 9 North Eutaw Street, Baltimore, Md.
NDA's:
7-019, Clareton-12 Injection, 10, 15, and 30 mgc./cc.
7-088, Rametin-12 Tablets.
Bioresearch, Inc., 415 Lexington Avenue, New York, N.Y.
NDA 8-075, Coromist Solution.
Biosante Chemical Specialties, 465 Lexington Avenue, New York, N.Y.
NDA's:
0-170, Byosan Tablets.
3-220, Opovitam Tablets.
Bio-Terapico Latina-Americano Risan (Cuba), San Lazaro 955 Bajos, Havana, Cuba.
NDA 1-335, Chirolgine Injection.
Bischoff Co., Inc., Ernst, Ivoryton, Conn. (Firm dissolved.)
NDA's:
1-870, Sulfanilamide Tablets.
1-978, Trisima Tablets.
5-339, Aquakay ECT and Injection.
5-704, Aquinone Bischoff Injection.
Bishop Labs., Inc., 80 Greenwich Street, New York, N.Y.
NDA's:
2-502, Be-Vin Complex Elixir.
4-671, Nitrallium Tablets.
Bisogno, Fedele, 299 Broadway, New York, N.Y.
NDA 5-173, Marvel Liquid.
Bi-Tone Corp., 107 Federal Street, Bluefield, W. Va.
NDA 0-814, Bi-Tone Tonic.
Blue Line Chemical Co., The, No. 302 South Broadway, St. Louis, Mo.
NDA's:
0-068, Carzanthine Tablets.
1-160, Private Formula for M. J. Buckley, M.D.
2-752, Sulfanilamide and Sodium Bicarbonate Tablets.
2-823, Ferrous Sulfate Tablets.
2-825, Ferrous Sulfate Elixir.
2-846, Sulfapyridine Tablets.
2-981, Oxycholin Tablets.
3-098, Stramonium Capsules.
3-197, Thiamine HCl Elixir.
4-200, Rotocide Lotion.
4-292, Thiamine HCl Tablets.
4-459, Diethylstilbestrol Tablets.
Bobo, J. H. (Mrs.), 322 North Cherry Street, Florence, Ala.
NDA 0-305, Bobo's BVCA Ointment.

Boehringer, C. H., & Sohn, Chemische Fabbik, Germany. Laboratories for Pharmaceutical Development, Inc. (Agents), New York, N.Y.
NDA 10-162, Reserpine Tablets.
Boericke & Runyon, Inc., 6327 Conlon Street, El Cerrito, Calif.
NDA's:
0-655, Special Formula #6803 Tablets (Nux Vomica, Belladonna, Bryonia, and Garlic).
0-656, Special Formula #6805 Tablets (Ignata, Quillata).
0-670, Special Formula Tablets for Dr. John D. Hubbard (Colocynth, Nux Vomica).
0-671, Special Formula Capsules for Dr. John D. Hubbard (Powdered Ginger, $NaHCO_3$, Ext. Hyocyamus, Peppermint oil).
0-923, Special Formula Tablets for J. W. Gardam, M.D. (Ferrum Arsenicum, Strychnine Phosphate).
0-924, Special Formula Tablets for J. W. Gardam, M.D. (Causticum, Spongia, Etc.).
0-967, Special Formula Tablets (Opium, Camphor, Tannic Acid).
1-008, Special Formula Tablets (Calcium Iodide, Calcium Carbonate).
1-233, Potassium Chloride Tablets.
1-360, Special Formula Rx Capsules for R. W. Larer, M.D. (Strychnine, Nitroglycerine, Acetanilide, Etc.).
1-376, Special Formula Tablets for J. B. Comins, M.D. (Macrotin, Bryonia Alba, Etc.).
1-399, Special Rx Ointment for A. D. Gugliemelli, M.D. (Salicylic Acid, Oil of Cade).
1-793, B & R Tablets #326.
1-794, B & R Tablets #327.
1-795, B & R Tablets #328.
1-796, B & R Tablets #329.
1-888, B & R Tablets #331.
1-889, B & R Tablets #332.
1-890, B & R Tablets #333.
1-891, B & R Tablets #334.
1-925, Special Formula #6807 Tablets for I. N. Griscom, M.D. (Ethylmorphine HCl, Digitalis Extract, Strychnine HCl).
2-223, Homeopathic Special Formula Tablets (Aconitum, Napellus, Gelsemium, Belladonna).
2-233, Special Formula Tablets for A. E. Biddinger, M.D. (Sanguinaria, Lacheses, Amyl Nitrate, Sepia).
2-444, Special Formula Tablets for P. G. Attinson, M.D. (Macrotin, Bryonia, Alba, Hypericum Perforatum).
2-534, B & R Tablets #337.
3-099, Special Medicinal Syrup (Chloral Hydrate, NaBr, KBr, Cascara Sagrada).
3-135, B & R Tablets # 338.
3-988, Estrogenic Substance Injection.
3-606, Special Combination Tablets (sodium phosphate, NaCl, $NaHCO_3$, $KHCO_3$, lithium benzoate, pyridoxine HCl).
3-607, Special Combination Tablets (Tr. Cantharides, Oil of Santal, Pyridoxine HCl, Palmetto Berries).
4-018, Homeopathic Trituration tablets (Hydrastis Candensis).
1-926, B & R #335 Tablets.
1-927, B & R #336 Tablets.
Bomtex Co., 3540 Troost, Kansas City, Mo.
NDA 3-551, Bomtex Ointment.
Bonded Labs, Inc., Brooklyn, N.Y.
NDA's:
9-445, Rauwolfia Serpentina Tablets, 50 and 100 mg.
9-606, Rauwolfia-Veratrum Viride Tablets.
Booth Pharm. Co. (No longer in business), 164 South Central Avenue, Los Angeles, Calif.
NDA's:
1-624, Gastro-Jel Gel.
3-855, Cascaperls.

Borum Brothers (Now known as Salahist Labs), 1340 East Seventh Street, Los Angeles, Calif.
NDA 8-368, Salahist Capsules.
Boston Balm Co., Post Office Box 7 Brookline Branch, Boston, Mass.
NDA 1-685, Boston Balm Ointment.
Botan Pharmaceutical Co., Providence, R.I.
NDA 10-523, Kin Ointment.
Botanical Labs, Chicago, Ill.
NDA's:
0-727, Cross Capsules.
0-728, Cross Fluid.
0-729, Cross Tablets.
3-230, Mafoliata.
Boulder Colorado Sanitarium, Fourth and Mapleton, Boulder, Colo.
NDA 3-323, Glyk-O-Dene Liquid.
Bovinine Co., 8134 McCormack Boulevard, Chicago, Ill.
NDA 4-277, Panoplex Capsules.
Boyd & Co., M. B., 1500 Northwest 27th Street, Oklahoma City, Okla.
NDA 3-095, Numocol Medicated Drops.
Boyett, C. G., Cleveland, Miss.
NDA 0-775, Boyett's Headache Powder.
B-Ramni Co., 333 Maple Avenue, Itasca, Ill.
NDA 2-722, B-Ramni Tablets.
Breon & Co., Inc. (George A.).
NDA 4-010, Becaplets with Ascorbic Acid and Biotin.
Bridge & Co., H. L., 214 Green Street, Tipton, Ind.
NDA 3-732, HE-AB Solution.
Bristol-Myers Co., New York, N.Y.
NDA's:
5-835, Elixir of Phenolphthalein Beta Diglucoside.
7-079, Resistab.
10-505, Sentry Fluoride Dentifrice.
Broad Research Labs., Inc., 39-41 West 38th Street, New York, N.Y.
NDA 4-735, Stilbestrol Batch.
Bronk-Aid Pharmacal Co., 1317 O Street, Lincoln, Nebr.
NDA 1-107, Bronk-Aid Liquid.
Bronner, Paul, 324 South Clark Street, or 5332 Cornell Avenue, Chicago, Ill.
NDA 2-557, Braxon Paste.
Brooklyn Scientific Products Co., Inc., 70 Fifth Avenue, New York, N.Y.
NDA 1-829, Trisilac Tablets.
Brooks, D. B., Haxtun, Colo.
NDA 2-159, Nuwa Hair Tonic Solution.
Brooks, Paul, 411 East Maumee Street, Angola, Ind.
NDA 2-689, Aggewa Salve.
Brouillet, Eleanor, 168 Main Street, Gardener, Mass.
NDA 1-394, Ebrouillet's Ointment.
Brown, Angel P., Labs, 417½ Avenue, Endicott, N.Y.
NDA 3-694, Za-Hoy Ointment.
Brown, C. S., Cumby, Tex.
NDA 2-069, Dr. Brown's Fungus Ointment.
Brown Herb Co., Inc., 68 Murray Street, New York, N.Y.
NDA 1-461, Brown Herb Tablets.
Brown, John C., 1530 Acushnet Avenue, New Bedford, Mass.
NDA 0-398, Brown-Sol-In Spray.
Brown Specialty Co., 1209 Second Street, Perry, Iowa.
NDA 2-601, HY-ON Tablets.
Bruce Co., Robert, 58 Imperial Avenue, West Port, Conn.
NDA 0-309, Zincad Salicthol Ointment.
Bryan, J. H., Spencer, W. Va.
NDA's:
2-050, Vigor-Lax Liquid.
2-208, Herb Lax Powder.
Bryson & Serinis Manufacturing Chemists, 218 North Brown Street, Gloucester City, N.J.
NDA 2-351, Dermozoy Lotion.
Buckhold Bros., 215 East Third Street, The Dalles, Oreg.
NDA 1-506, M-O Cough Drops.

Buckman Labs., Inc., 1256 North McLean, Memphis, Tenn.
NDA 7-833, Buderma Ointment.
Buckner, W. T., Dr., Shelbyville, Ky.
NDA 2-592, Allergol Solution.
Buckthorpe Co., Tom C., Van Buren, Mo.
NDA 0-459.
Buford, Fred, M.D., 1434 Q Street NW., Washington, D.C.
NDA 0-162, Buford's Liniment Ointment.
Bullock-Walker Manufacturing Co., Division Blistex, Inc., 75 East Wacher Drive, Chicago, Ill.
NDA 4-965, Sulfathiazole Ointment 5%.
Burbot Liver Products Co., Baudette, Minn.
NDA 1-658, Vio Cal Wafers.
Burch, Thomas B., Sour Lake, Tex.
NDA 0-168, Formula 12 Liquid.
Burco Products Co., Platte City, Mo.
NDA 0-148, Burco Cold Tablets.
Burnbalm Labs., 270 Northwest Eighth Street, Boca Raton, Fla.
NDA 0-797, Burnbalm Cream.
Burnell, Rex James, 616 East Boston Street, Yale, Okla.
NDA 3-001, Burnell's Pylo Ointment.
Burnham Soluble Iodine Co., 30 Lexington Avenue, Auburndale, Mass.
NDA's:
4-005, Glyochloride.
5-035, Glyco—Chloride Capsules.
5-135, Glyco—Iodine Capsules.
5-861, Bursoline Tablets.
7-115, Lugol Capsules.
Burp Co., 2360 Northwest Glisan Street, Portland, Oreg.
NDA 0-739, Burp's Tablets.
Burrough Brothers Manufacturing Co., 123 Market Place, Baltimore, Md.
NDA 2-378, Sulfapyridine Tablets 0.5 gm.
Burt, Clement P., 2905 Louisiana Street, Houston, Tex.
NDA 2-920, Happy Home Liniment Solution.
Burtnett Drug Co., 1720 West Douglas Avenue, Wichita, Kans.
NDA 0-981, VPS Cough Syrup.
Burton—Levin Foundation, Inc., 211 West Monument Avenue, Baltimore, Md.
NDA 0-067, Ca-Ma-Sil Powder.
Butler Products Co., Box 571, Hamilton, Ohio.
NDA 1-383, Vita-Septic.
By's of California (Broemmel), 1235 Sutter Street, San Francisco, Calif.
NDA 1-695, Tri-B-Les Liquid.
CCA Products Co., 1000 Merrick Street, Detroit, Mich.
NDA 3-360, Permatene Oil Liquid.
Caine Co., S. Roy, 720 West 170th Street, New York, N.Y.
NDA 8-875, Calgitex Alginate Wool Dressing.
C.J.D. Chemical Co., 1301 Massachusetts Avenue NW., Washington, D.C.
NDA 3-228, Pulvis C.J.D. Astringent Compound Powder.
Calagel Co., Arnold J. Luehmann, Stewartsville, Minn.
NDA 3-829, Calagel Gel.
Calces Corp., 4134 University Way, Seattle, Wash.
NDA 3-655, Natural Calces Solution Injection.
Calco Chemical Division of American Cyanamid Co., Bound Brook, N.J.
NDA 4-626, Calcium or Sodium Pantothenate.
Calide Co., 2588 Grove Street, Oakland, Calif.
NDA 1-648, Escalon Solution.
Campanella, Carmello D., 3656A Shenandoah Street, St. Louis, Mo.
NDA 4-285, Alulin Powder.
Campbell & Co., 405 Washington Street, Karcher Hotel Building, Waukegan, Ill.
NDA 3-373, Campbell Powder.
Canada Balsam Products Co., Ltd., 23 Scott Street, Toronto, Ontario, Canada.
NDA 0-862, Nurub Ointment.

Canadian Radium & Uranium Corp., 630 Fifth Avenue, New York, N.Y.
NDA's:
5–889, Radon Ointment.
5–924, Alphatron Radon Ointment.
6–568, Alphatron.

Canright-Canright Corp., E. H., 1701 West Glenoaks Boulevard, Glendale, Calif.
NDA 10–272, Elserpine-Prab Tablets.

Caphenin Chemical Co., Waverly, Iowa.
NDA's:
2–192, Phenobarbital, Atropine Papain Charcoal Tablets
2–581, Sulfanilamide and Sodium Bicarbonate Tablets.
3–408, Thiamine HCl Tablets 3 mg.

Capital Medicine Co., 9½ South Perry Street, Montgomery, Ala.
NDA 3–018, ABXX Decoction of Willow and Cherry Liquid.

Carbide & Carbon Chemical Co. (Product now made by Union Carbide Consumer Products Co.), 270 Park Avenue, New York, N.Y.
NDA 6–424 and 6–12, Insect Repellant w/ Sun Screen.

Carbisulphoil Co., 2917 Swiss Avenue, Dallas, Tex.
NDA 0–632, Foille Ointment.

Carborose Co., 9023 Third Avenue, Brooklyn, N.Y.
NDA 4–860, Carborose Liquid.

Carey Labs., Inc., Hutchinson, Kans.
NDA 1–430, Medisalt Powder.

Carls Liniment Co., 1402 West Colorado Avenue, Colorado Springs, Colo.
NDA 3–547, Carl's Liniment.

Carolina Medicine Co., Asheboro, N.C.
NDA's:
0–056, Ease-It Solution.
0–057, Lip Ease Solution.
0–058, Woodley's Sunburn Lotion.
0–059, Woodley's Hair Tonic Lotion.
0–271, Tee Ease.
0–883, Cor-No.

Carrtone Labs., Inc., 4936 Veterans Memorial Highway, Metairie, La.
NDA 11–720, Carr-Serp Tablets 0.25, 0.5 mg.

Carvoline Co., Peanut Products Co., Tuskegee, Ala.
NDA 0–467, Peanut Massaging Oil.

Casco Co., 312 South Court Street, Marion, Ill.
NDA 7–194, Casco Antihistamine Tablets.

Caspe, Saul, 170 West 73d Street, New York, N.Y.
NDA 9–371, Cicatrase.

Castill Chemical Co., 1307 North Calvert Street, Baltimore, Md.
NDA 1–858, Retolor Liquid.

Ceebo Manufacturing Co., Inc., 1317 North Kings Highway, St. Louis, Mo.
NDA's:
3–649, Charm-Ay Ointment, Liquid, Shampoo.
3–822, Ceebo Liquid.

Cerbini & Co., 68 First Street, New Rochelle, N.Y.
NDA 8–325, New Cerbartrol Injection.

Cervusin Labs., 119–01 Rockaway Boulevard, South Ozone Park, N.Y.
NDA 10–268, Reserpine Tablets 0.1, 0.25, 0.5, 0.1 mg.

Chaf-O Co., 330 North Wells, Chicago, Ill.
NDA 3–676, Chaf-O Ointment.

Chalybeate Manufacturing Co., Inc., 5918 San Pablo Avenue, Oakland, Calif.
NDA 1–060, Ferro Ferri Sulfas Solution and Tincture.

Cole Drug Co., Charles W. (Out of business.)
NDA 7–460, Co-Histen Tablets.

Charleyhorse Co., 245 West 38th Street, New York, N.Y.
NDA 2–098, Charleyhorse Liniment Ointment.

Chemcult Labs., 2026 West End Avenue, Nashville, Tenn.
NDA 4–312, Panto Drops Solution.

Chemical Manufacturing and Distributing Co., Sixth and Bushkill Drive, Easton, Pa.
NDA 6–263, Target Handi-Terge Solution.

Chemical Specialties Co., Inc., 22 East 40th Street, New York, N.Y.
NDA 8–488, Neodrol Suspension for Injection 50 mg./cc.

Chemo-Puro Manufacturing Co., Long Island City, N.Y.
NDA's:
8–050, Sodium Gentisate Tablets and Powder.
8–510, Hexamethonium Chloride 250 mg. Tablets.

Cheplin Biological Labs., Inc., 401 West Taylor Street, Syracuse, N.Y.
NDA 2–741, Cheplin's Estrogenic Substance Injection 2,000, 5,000, 10,000, 20,000 IU/cc.

Chicago Dietetic Supply House, 1750 West Van Buren Street, Chicago, Ill.
NDA 7–075, Cellu-K Salt Granules.

Chicago Pharmacal Co., Inc., Division Conal Pharm Inc., 5547 North Ravenswood Avenue, Chicago, Ill.
NDA 1–358, Special Formula Sodium Sulphocyanate for Dr. Roth.

Child-Dent Corp., 1109 Commerce Building, Rochester, N.Y.
NDA 9–797, Child-Dent Toothpaste.

Chimax Products, 9503 Roosevelt Avenue, Jackson Heights, Long Island, N.Y.
NDA 1–325, Hydra Cream.

Chlorine Products Co., Newark, Calif.
NDA 5–382, Hydrogen Peroxide Solution 3%.

Chrisalty Labs., Inc., 49 Dickerson Street, Newark, N.J.
NDA 5–386, Typotin Tablets.

Christie, James, and Albion, Charles M., 52–62 Haverhill Street, Brockton, Mass.
NDA 6–091, Chal Yon Solution.

Christmann, Ben F., 4959 Cote Brilliante Avenue, St. Louis, Mo.
NDA 1–017, Sunshine Corn and Callous Ointment.

Chunn Co., Thomas H., Walter Reed Hospital, Washington, D.C.
NDA 4–411, Servise Formula #114 Liquid.

Cincinnati Chemical Works, Inc., 1743 Cleneay Avenue, Norwood, Ohio.
NDA 4–717, Sulfathiazole Batch.

Citadel Color and Chemical Corp., 154 Nassau Street, New York, N.Y.
NDA 8–587, Tubercit Tablets 50 mg.

Citrus Research Labs., 409 East 47th Street, New York, N.Y.
NDA 4–539, C-Plex Tablets and Powder.

Clark, Mary W., 76 Steuben Street, East Orange, N.J.
NDA 2–037, Clark's Cough Mixture Liquid.

Clark, Peffer and Brown, Inc. (Out of business), Claremont Road, Carlisle, Pa.
NDA 11–096, CPIRON Tablets.

Clark, Russel B., M.D., 1022 Argyle Street, Chicago, Ill.
NDA 3–352, Actall Capsules.

Clay Adams Co., 44 East 23d Street, New York, N.Y.
NDA 5–438, Sealskin Dressing Plastic Adhesive.

Cleveland Colloids Co., 13023 Cedar Road, Cleveland, Ohio.
NDA 3–385, Nu-Tro-Gel Solution.

Clo-Fil Products, Inc., Box 158, Canal Street Station, New York, N.Y.
NDA 2–070, Clo-Fil Tablets.

Clover Labs., 817 Perdido Street, New Orleans, La.
NDA's:
0–283, Clover Stomach Tablets.
0–284, Clover Pile Ointment.
0–406, Clover SF Solution.
1–422, Otalagia Solution.
1–454, Clover's Nu-Frit-Co Mixture.

Coast Chemical Co., Inc., 8745 Sunset Boulevard, Los Angeles, Calif.
NDA 11–005, Cobalamine 1,000 mcg./cc.

Coe Labs, Inc., Chicago, Ill.
NDA 8–413, Hemolox Powder.

Coffin-Redington Co., 301 Folsom Street, San Francisco, Calif.
NDA's:
0–691, Vita-Phos Liquid.
2–118, Coreco Iso Fed Drops.
2–119, Coreco Milk of Magnesia Tablets.

Cokers Drug Manufacturing Co., Post Office Box 3002, Houston, Tex.
NDA 2–377, Coker's Dermo Ointment.

Colby, Albert P., 1155 Chelsea Avenue, Memphis, Tenn.
NDA's:
3–242, Colby's Palamento Liniment.
4–371, Palamento Ointment.

Cole Chemical Co., 3715–31 Laclede Avenue, St. Louis, Mo.
NDA's:
4–020, Aminoacetic Acid Tablets 15 gr.
4–716, Econ Capsules.
8–590, Retozide Tablets 50 and 100 mg.

Coleman, M. T., 726 Snelling Avenue, St. Paul, Minn.
NDA 2–128, Coleman's Ointment.

Collette and Markle, 3 Flint Street, Eureka, Springs, Ark.
NDA's:
1–552, Common Horse Sense for Piles Salve.
1–553, Common Horse Sense for Pyorrhea Bucc. Solution.
1–554, Common Horse Sense for Rupture.

Collins Co., Thomas E., San Francisco, Calif.
NDA's:
2–160, Mokara Tablets and Powder.
2–485, Peptolin Tablets (Eupepsis Tablets).
3–184, Heartburn Tablets.

Columbia Products Corp., 221–49 McKibben Street, Brooklyn, N.Y.
NDA 0–746, Sanford's Eye Peps Lotion.

The Columbus Pharmacal Co., Columbus, Ohio.
NDA 11–032, Rauroscin.

Commercial Solvents Corp., 260 Madison Avenue, New York, N.Y.
NDA's:
6–501, Choline Bicarbonate Syrup.
6–624, Metabarin Suspension.
6–995, Glucurone Tablets.
8–008, Expandex.
10–339, Dextran 12% w/v salt free injection.

Commonwealth Research Labs., 103 College Avenue SE., Grand Rapids, Mich.
NDA 1–639, Pru-Jel.

Compton, B. C., Decatur, Ala.
NDA 1–663, Compton's Healing Oil Suspension.

Conadwell Labs., Inc., 270 Broadway, New York, N.Y.
NDA 2–580, Sunviro Formula #4 Elixir.

Conant, G. H., 2076 Massachusetts Avenue, North Cambridge, Mass.
NDA 10–320, Rauwolfcon Tablets.

Conover Distributing Co., 3653 Northeast Sandy, Portland, Oreg.
NDA 4–143, Kons Solution.

Cook Co., Inc., W. H., 223 Coffman Street, Watertown, N.Y.
NDA's:
1–354, Thycitol Syrup.
1–355, Benbutane Ointment.
2–101, W. H. Coo's Tycol Syrup.

Consolidated Chemical Co., Elm and Winslow, Cleveland, Ohio.
NDA's:
5–246, B-R-N Ointment.
5–862, A-K-X Ointment.

Consolidated Midland Corp., 195 East Main Street, Brewster, N.Y.
NDA 7–321, Tuberculocide Sodium.

Continental Chemical Co., 12065 82d Avenue, North Largo, Fla.
NDA 6–133, Benzium 0.1% and 6.4%.

Continental Distributing Co., 26 Que Street NW., Washington, D.C.
NDA 0-171, Glisensun Ointment.
Continental Pharmacal Co., 1400 West 25th Street, Cleveland, Ohio.
NDA 7-129, PSL Solution.
Cook and Eppele, 8124 Wade Park, Cleveland, Ohio.
NDA 2-080, Kepp Solution.
Cook, Thomas W., 1230 West Eighth Street, Des Moines, Iowa.
NDA 0-611, Hatex Drops.
Cooper, G. R., M.D., 215 Southwestern Life Building, Dallas, Tex.
NDA 1-887, Dr. Cooper's Mineral Salts Compound Powder.
Correa, George, 7 Clive Street, Jamaica Plain, Mass.
NDA 5-644, Flo-Gum Tablets.
Cortisol Co., 209 State Street, Binghamton, N.Y.
NDA 2-382, Cortisol Solution.
Cosmetest Inc., 16-22 Ash Street, Brooklyn, N.Y.
NDA 7-213, Antihistamine Tablets (Pyrilamine Maleate) 25 mg.
Cosmetic Co., 803 Sumner Street, South Boston, Mass.
NDA 4-658, Ivy-Glo Solution.
Cosmos Chemical Corp., 625 Broadway, New York, N.Y.
NDA's:
8-595, Isoniazid Cosmos Tablets 50 and 100 mg.
9-365, Raupersin Tablets 50 and 100 mg.
Cosylor, Inc., 100 West Chicago Avenue, Chicago, Ill.
NDA 12-045, Pealette Capsules (phenylpropanolamine HCl 75 mg.).
Cotterman, A. I. (Mr.), Nuco Products, West Union, Ohio.
NDA 0-447, Nucone Drops.
Coughlan Co., G. N., 29 Spring Street, West Orange, N.J.
NDA 7-642, Spandy Solution.
Cowley Pharm. Inc., 65 Southbridge Street, Auburn, Mass.
NDA's:
7-251, Cowley Antihistamine Tablets 25 mg. (pyrilamine maleate).
7-332, PASA and Sodium PASA Tablets (salamin).
9-202, Rauwoserp Tablets 50 and 100 mg.
9-653, Reserpine Tablets 0.1, 0.25. 0.5, 1.0 mg.
Crawford Food, Inc., 2775 West Broadway, Eagle Rock, Calif.
NDA 3-818, Sevren Solution.
Crawford, G. Wray, Dr., 2262 Magnolia Avenue, Long Beach, Calif.
NDA 3-430, Hydro-Gene Tablets.
Creviston-Davis Labs., 5161 North Ashland Avenue, Chicago, Ill.
NDA 10-429, Decoressate Sterile Suspension.
Crookes Labs., Union and Liberty Streets, Mineola, N.Y.
NDA 8-984, Raupena.
Crosby, George H., 910 Fidelity Building, Duluth, Minn.
NDA 2-573, Tropical Balm Liquid.
Crowe Chemical Co., 6 East 10th Street, Tulsa, Okla.
NDA's:
0-310, S Suspensoid #4 Emulsion.
2-768, Castor Oil Emulsion.
2-769, WP Emulsion #8.
2-770, WP Emulsion #9.
2-771, Calomel Suspensoid Emulsion.
Croydon Labs., Inc., Post Office No. 2163, Midcity, Philadelphia, Pa.
NDA 0-019, Lan-O-Derm Ointment.
Crump, Armistead C., Dr., 555 Park Avenue, New York, N.Y.
NDA 0-100, Dr. A. C. Crump's Tablets for Ulcers of the Stomach and Duodenum.
Crystal Pharmacal Co., 222 South Elmwood Avenue, Oak Park, Ill.
NDA's:
2-135, Crystal Headache Powder.
2-429 Hall's Green Cold Capsules.
Crystal Soap and Chemical Co., Inc., 8th Street and Moyers Road, Lansdale, Pa.
NDA 9-387, Crystal (CS-190) Liquid.
Cudahay Packing Co., 22d and Broadway, Wichita, Kans.
NDA 9-201, Hyaluronidase Injection.
Cugil Labs., Inc., Post Office Box 281, Palo Alto, Calif.
NDA 8-921, Cugilex Tablets 3 and 6 mg., Cugilex Suppositories Vaginal and Rectal 3 and 5 mg.
Cummings, Inc., Ed, Cummings Building, Flint, Mich.
NDA 1-665, Thujoil Solution.
Curital, Inc., 303 West 42d Street, New York, N.Y.
NDA 0-811, Soothay.
Curtis, Co., A. W., 454 Farnsworth Street, Detroit, Mich.
NDA 1-130, Curtis Rubbing Oil Liquid.
D & B Labs, 15 Hayes Street, Norwich, N.Y.
NA 1-610 D & B Ideal Germicide Solution.
D-W Products Inc. (Now known as H. V. Waggener Distributing Co.), 4645 East 23d Avenue, Denver, Colo.
NDA's:
0-564, Ferri-Heptol with Vitamin B_1.
0-565, Ferri-Heptol with Vitamin B_1 and Cod Liver Oil.
Dakowicz, Bernard, 11325 Moran Street, Detroit, Mich.
NDA 1-810, Facial Ointment (Skin Remedy).
Dalar Medical Labs., Inc., 41 Union Square, New York, N.Y.
NDA 2-182, Crimic Ointment.
Daly—Herring Co., Post Office Box 428, Neuse Road, Kingston, N.C.
NDA 7-741 Pinee Antihistamine Tablets.
Dampf, John, 2957 North Fourth Street, Philadelphia, Pa.
NDA 0-666, Dampf's 20th Century Discovery Ointment.
Dand-R-Off Pharmacal Co. (Now Saffo Pharmacal), 139 101st Street, Jamaica, N.Y.
NDA 1-856, Saffro Hair Lotion.
Dandrug Co., 4109 Amos Avenue, Baltimore, Md.
NDA 6-473, Sulfodandrug Solution.
Daniels & Co., Robert, 1280 Randall Avenue, Bronx, N.Y.
NDA 11-904, Sylphe Capsules.
Danforth, 5299 Fountain Avenue, Hollywood, Calif.
NDA 3-140, Estrohormone Cream.
Darby, E. H., Box 169, Florence, Ala.
NDA 1-867, Famous Old South Laxative.
Daro Industries, Inc., 19 West Randolph Building, Chicago, Ill.
NDA 8-916, Acaid Ointment.
Dart Labs., 519 12th Street, Red Wing, Minn.
NDA 2-781, Dartconc Solution.
Darworth, Inc., 660 Hopmeadow Street, Simsbury, Conn.
NDA 5-131, Kopertox.
David Research Labs., 1022 David Whitney Building, Detroit, Mich.
NDA 0-888, Chaysol Solution.
Davis Drug Co., Inc., 601 Harrison Avenue, Leadville, Colo.
NDA 1-172, Canfield's Preparation Liquid.
Davis & Pitann, Ltd. (Not in drug registration.).
NDA 2-126, Salvus Dermal Sutures.
Davis Emergency Equipment Co., Inc., 45 Hallock Street, Newark, N.J.
NDA's:
10-658, Isodine Antiseptic Solution.
10-659, Isodine Applicators and Swabs Dre.
Davis Pharmacal Co., Miami, Fla.
NDA 1-597, Otamma Ointment.
Davison Chemical Corp., 20 Hopkins Place, Baltimore, Md.
NDA 0-628, Sylox Powder.
Davison, G. M., 320 Cypress Street, North Little Rock, Ark.
NDA 3-302, Digitalis Tablets.
Day Chemical Co., Inc., 480 Washington Street, Newark, N.J.
NDA's:
5-029, Sulfathiazole Ointment, 5%.
5-782, V-Tox Lotion (Fennex Lotion).
Decyl Pharmacal Co., Princeton, N.J.
NDA 6-699, Declid Capsules.
De Feet Co., 197 Park Avenue, Wilkes-Barre, Pa.
NDA 3-461, De-Feet Powder.
Deknatel and Son, Inc., J. A., 96-20 222d Street, Queens Village, N.Y.
NDA 2-303, Deknatel Surgical Nylon.
De La Mota, Francisco Espaillat, 507 West 130th Street, New York, N.Y.
NDA's:
1-291, Eureka Hair Tonic Liquid.
1-609, Eureka After Shave Lotion.
Delavau Co., Inc., J. W. S., 2116-26 Nicholas Street, Philadelphia, Pa.
NDA 10-502, Reserpine Tablets 0.1, 0.25, 0.5, 1.0 mg.
Deltalon Specialties, 7640 South Eggelston Avenue, Chicago, Ill.
NDA 6-591, Endopoints DCO.
Demmel Co., E. K., 303 Fourth Avenue, New York, N.Y.
NDA 0-311, Cruricast Bandages Dressing.
Denne Labs., Drawer 701, Abbeville, La.
NDA 1-591, Inertest Tablets.
Dentalac Co., 8 Arcade Building, Little Rock, Ark.
NDA 1-294, Dentalac Mouthwash.
Denthol Co., 3820 Scott Street, San Francisco, Calif.
NDA 0-867, Denthol Mouthwash.
De Pree Co., 130 Central Avenue, Holland, Mich.
NDA 7-342, De Pree Antihistamine Tablets (pyrilamine Maleate 25 mg.)
Derington, L. L., 225 West Walnut, Enid, Okla.
NDA 1-088, Derington's Compound Liquid.
Dermal Products Co., 523 Mills Building, Topeka, Kans.
NDA 4-471, Derma-Protex Ointment.
Dermatol Chemical Co., Inc., 3747 College Avenue, Indianapolis, Ind.
NDA 1-642, Cala Corn Solution.
Dewey Products Co. (TNF Muir Drug Labs, Inc.), 532 Cottage Grove SE., Grand Rapids, Mich.
NDA's:
0-220, Kalin Antacid Tablets.
7-147, Orkutt Antihistamine Tablets.
7-823, Histop Antihistamine Syrup.
8-079, Histop Compound Tablets.
DeWolf Co., C. H., 35 Dodge Avenue, East Haven, Conn.
NDA 3-496, Exl Ointment.
Dickinson Co., E. E., 40-46 North Main Street, Essex, Conn.
NDA 1-739, Dixatone Liquid.
Dickman, I. S., 15 West 38th Street, New York, N.Y.
NDA 0-184, Vital Vitamins Tablet.
Dicol Chemical Co., 20 West 22d Street, New York, N.Y.
NDA's:
2-578, Dicol Ease Burn Ointment.
2-621, Dicol S Cream.
Diefenbach Labs., 80 Hamilton Street, Rochester, N.Y.
NDA 1-090, Kreso-Tol Solution.
Dietetic Research Labs., Inc., YNF U.S. Vitamin and Pharmaceutical Corp., 800 Second Avenue, New York, N.Y.
NDA's:
0-106, M.V.M. Diet Supplement Perles.
0-428, Hypervitam w/minerals Capsules.

Dietetic Supplements, Inc., 816 West Fifth Street, Los Angeles, Calif.
NDA 1–284, Fe-Cu-Phyll Tablets.

Dietz Co., Inc., Charles H., First and Pine Streets, St. Louis, Mo.
NDA's:
1–427, Calsamate Solution.
5–280, Aeron Tablets.
7–124, Pyranisamine Maleate Tablets 25 mg.
7–788, Pyrilamine Compound Tablets.

Difco Labs., 920 Henry Street, Detroit, Mich.
NDA's:
2–514, Chorionic Gonadatropin Injection (5000 IU/cc.).
2–515, Chorionic Gonadotropin Injection (1000 IU/cc.).
4–408, Stilbestrol Bulk.

Diketan Labs. (out of business), Culver City, Calif.
NDA's:
7–314, Pyrilamine Maleate 25 mg. Tablets.
9–641, Elserpine Tablets 0.25 mg.
11–203, Rescinnamine Tablets.

Dill Co., Washington and McKinley Avenues, Morristown, Pa.
NDA's:
7–489, Antihistamine Tablets 25 mg. (pyrilamine maleate).
7–854, Dil-Hist Tablets.

Dilling, Mary E., 2743 Curtis Street, Denver, Colo.
NDA 2–231, Visco Ointment (Eczemol Ointment).

Dimaio, Antonio, 148 Elm Street, Bradford, Pa.
NDA 0–069, Miracolo Hair Tonic Emulsion.

Direct Sales Co. (not in drug registration). (Direct Laboratories is listed in Drug Registration Book at 277 Genesee Street, Buffalo, N.Y.)
NDA's:
2–366, Vitamin B_1 Thiamin Chloride.
3–335, Magnesium Trisilicate.
3–336, Theophylline and Ethylenediamine Tablets.
3–346, Estrogenic Substance in Oil.
3–347, Theobromine and Phenobarbital Tablets.
3–403, Aminophylline and Phenobarbital.
3–404,Theobromine with Sodium Salicylate.
3–405, Theophylline and Ethylenediamine 3 gr. Tablets.
3–424, Elixir Thiamin Chloride.
3–611, Theophylline and Ethylenediamine Ampules.
3–675, Brewer's Yeast Tablets 7½ gr.
3–924, Nicotinic Acid.
3–925, Ascorbic Acid.
3–926, Nicotinamide 50 mg.
4–794, Stilbestrol Tablets.

Distillation Products Industries, Eastman Kodak Co., 755 Ridge Road West, Rochester, N.Y.
NDA's:
0–415, Vitamin A Concentrate Bulk for manufacturing use only.
3–216, Concentrate of Natural Mixed Tocopherols Bulk.
5–185, Vitamin A Acetate Bulk for manufacturing use only.
6–463, Myvax Bulk for manufacturing use only.

Dixie Medicine Corp., 401 East Trade Street, Charlotte, N.C.
NDA 3–319, DMC Inhalant.

Dolge Co., C. B., West Ferry Lane, Westport, Conn.
NDA's:
0–292, Alta-CO Powder.
1–444, White Alta-CO Powder Bulk.

Dome Chemicals, Inc., 125 West End Avenue, New York, N.Y.
NDA 3–151, Domung Ointment.

Donahue, Nellie B., 12 Hudson Street, Ossining, N.Y.
NDA 1–227, Spar-Don.

Donley-Evans & Co., 6026 Enright Avenue, St. Louis, Mo.
NDA's:
0–868, Gluco-Sulfanilamide Solution.
5–759, Gluco-Sulfathiazole Liquid.
5–760, Gluco-Sulfamerazine Liquid.
5–761, Gluco Sulfadiazine Liquid.
6–455, Glucosulfas Liquid.

Dorsey Co., Smith, Division Wander Co., 233 South 10th Street, Lincoln, Nebr.
NDA's:
4–268, Rx 1896 for Corn States Serum Co., Omaha, Nebr.
4–269, Rx 1897 for Corn States Serum Co., Omaha, Nebr.
4–270, Rx 1898 for Corn States Serum Co., Omaha, Nebr.
3–552, Sulfathiazole Tablets.

Dorton Co., 154 East Erie Street, Chicago, Ill.
NDA 5–247, Pre-Eez.

Dott Pormenti Spa, Vincent A. Kleinfeld, Agent, Law Office of Bernstein, Kleinfeld, and Alper, 1725 I Street NW., Washington, D.C.
NDA 12–842, Nitrofurantoin USP Tablets, 100 mg.

Douglass Manufacturing Co., 2906 Portland Avenue, Minneapolis, Minn.
NDA 1–667 Sa-So-Na Solution.

Doyle, Theodore, 1380 Washington Street, San Francisco, Calif.
NDA 2–405 Wunder Foot Soap.

Dra-Sum Co., 72 Hickory Street, Chillicothe, Mo.
NDA 1–162, Regular Dra-Sum Ointment.

Drug Packaging, Inc. (Out of business), Pittsburgh, Pa.
NDA 7–534, Hanist Tablets.

Drugmaster, Inc., St. Louis, Mo.
NDA 7–135, Histapro (Anapro) Tablets.

Drug Products Co., 2632 Skillman Avenue, Long Island, N.Y.
NDA's:
0–641, Hyposol S Injection.
0–642, Vitamin B_1 Crystalline Injection.
1–287, Potassium Chloride Tablets.
2–985, Thiamine HCl Crystalline for Injection.
2–986, Hyposol S Nicotinamide Injection.
2–987, Nicotinamide Injection.
3–010, Hyposol S Menaquinone Injection.
3–011, Hyposol S Thiamidin Injection.
3–126, Pulvoids Menaquinone Capsules.
3–145, Pulvoida Vi-B-Quad Capsules.
3–146, Pulvoids Chosal Tablets.
3–333, Vin-B-Complex Liquid.
4–184, Hyposol Formac Injection.
4–338, Stilbestrol Tablets.
4–339, Stilbestrol Injection.
4–537, Hyposol S Solution Thiamine HCl Injection.
4–625, Sulfarea Ointment.
4–631, Hexanitrol Tablets.
4–660, Hexanitrol w/Phenobarbital Tablets.

Drug & Proprietary Products, Robert O. Ellis Co., Owner, 1010 Fourth Avenue, Huntington, W. Va.
NDA's:
2–626, Atoxa Mouthwash.
2–702, Nipasol Liquid.

Duke Labs., Inc., Duke Place, South Norwalk, Conn.
NDA 5–532, Elastoplast Dressing.

DuMont Pharmacal Co., Inc., 2048–2056 Abigail Street, Philadelphia, Pa.
NDA's:
9–730, Reserpine Tablets 0.1, 0.25, 0.5, 1, 2, 5 mg.
10–082, Hexamethonium Chloride Tablets 250 mg.
11–099, Reserpine Elixir.
11–101, Rauwolfia Serpentina Tablets 50 and 100 mg.

Dunwody & Sons, Inc., R. G., 235 Forsyth Street SW., Atlanta, Ga.
NDA 0–962, Duleet Liquid.

Durex Products Inc., 684 Broadway, New York, N.Y.
NDA's:
5–568, Methakol Jel.
5–600, Lactikol B Jel.
5–601, Lactikol Cream.

Dynogen Co., 3936 Locust Street, Kansas City, Mo.
NDA 1–236, Dynogen Powder.

Eagle Products Co., Box 162, Chattanooga, Tenn.
NDA's:
7–309, Pyrilamine Maleate Tablets 25 mg.
7–332, Eagle's Antihistaminic Analgesic Compound Tablets.

Easaprods, Ltd., 708 Temple Building, 62 Richmond Street, West Toronto, Canada.
NDA 0–144, Easafoot Powder.

Eastern Chemical Co., 318–320 Littleton Avenue, Newark, N.J.
NDA 4–946, Fleet Foot Ointment.

Eastern Labs., 302 South Central Avenue, Baltimore, Md.
NDA 1–611, Methenz Tablets.

Eastern Pharmacal Co., 100 Broadway, San Antonio, Tex.
NDA 5–328, Sulfa-Nico Tablets.

Eaton Laboratories, Norwich, N.Y.
NDA 9–827, Tricofuron.

Ebco Products, Pasadena, Calif.
NDA 10–111, Cortodon Powder.

Eckler, Gardner L., 27½ Exchange Place, Atlanta, Ga.
NDA 1–310, Pop Eckler's Majik Foot Powder.

Eddy Herb Co., Dr., 2462 North 24th Street, Milwaukee, Wis.
NDA's:
0–945, Dr. Eddy's Herb Tablets.
1–377, Dr. Eddy's Gas Tablets.
1–378, Dr. Eddy's Ant-Acid Powder.

Edgewater Radioisotope Center (The Edgewater Hospital, Inc.) Chicago, Ill.
NDA 9–595, Sodium Radio-iodide (I^{131}).

Edmondson, Edward Everett, M.D., Canon City, Colo.
NDA 2–473, Aqcuzin Compound Solution.

Edom Labs, Inc., 95–39 40th Road, Elmhurst, N.J.
NDA 10–147, Tranquilin Liquid 0.25 mg./5cc.

Elder Co., Paul B., Post Office Box 31, Bryan, Ohio.
NDA's:
0–774, Strych-tails Compound Tablets.
1–043, Rafilyn Sugar Coated Tablets (green).
7–770, Phenacamine Tablets (A.P.C. w/pyranisamine maleate).
7–798, Palleate Tablets.

El Modelo Medicine and Drug Co., 2221 Perez Street, San Antonio, Tex.
NDA 1–049, Rinatin.

Elo Products Co., Box 1720, Little Rock, Ark.
NDA 0–735, Elo Liquid.

Emblidge, Norman, 859 Washington Avenue, Rochester, N.Y.
NDA 2–866, Ne Me Liquid.

Empire Chemical Co., Inc., 2560 Tara Lane, Brunswick, Ga.
NDA's:
5–908, Thiouracil Tablets.
7–136, Pyranisamine Tablets.
7–818, Pyranisamine Maleate A.P.C. Tablets.

Empree, Paul J., 792 Geary Street, San Francisco, Calif.
NDA 2–011, Empree's Hair and Scalp Prep. Sol.

Emulsol Corp., 59 East Madison Street, Chicago, Ill.
NDA 5–374, Emulsept Solution.

Ennis Coffee Co., 115 Independence Avenue, Kansas City, Mo.
NDA 2–836, Salas Granules.

Eno Ltd., J. C. (Beecham Products, Inc.), New York, N.Y.
NDA's:
0–585 Eno, New Formula.
4–579 Lucozade Solution.
Enzytrase, Inc., New York, N.Y.
NDA 11–916, Quimotrase (chymotrypsin) ophthalmic.
Erie Labs., TNF Allied Pharmacal Co., 4419 Perkins Avenue, Cleveland, Ohio.
NDA 2–349, Analgesic Liquid (methyl salicylate, salicylic acid, benzoic acid) Topical.
Erspamer, A. C., Tacoma, Wash.
NDA's:
2–234, Ridagerm Cream.
3–357, Erspamer's Cough Remedy Syrup.
Essential Products, 360 North Michigan Avenue, Chicago, Ill.
NDA 3–693, Axter Tablets.
Ethical Pharmacal Co., San Antonio, Tex.
NDA 10–419, Raucap Time Disintegrating Capsules 0.25, 0.5, 0.75 mg.
E–Vac Co., 3955 Brunswick Avenue, Los Angeles, Calif.
NDA 1–944, E–Vac.
Evans, Milton C., Route 1, Box 74, Roland, Ark.
NDA's:
1–473, Eagle Brand Kwia Pain Liniment.
1–474, Evans Famous Salve.
Evron Co., 7475 North Rogers Avenue, Chicago, Ill.
NDA's:
4–642, Evron Vaginal Jelly.
9–258, Isonicotinic Acid Hydrazide Tabs.
9–259, Hexamethonium Chloride Tablets.
Ewert, John S., Dolton, S. Dak.
NDA 0–293, The Ewert Salve.
Faber & Co., Anton, 1287 East 79th Street, Cleveland, Ohio.
NDA 0–920, Faber's Calfo-Salve.
Falcon Chemical Co. (Out of business), Pittsburgh, Pa.
NDA 2–511, Pekal Suspension.
Faraday Labs., Inc., 223 High Street, Newark, N.J.
NDA 9–876, Reserpine Tablets.
Faram Co., 221 West Ninth Street, Erie, Pa.
NDA 2–764, Sportbalm Ointment.
Farmochimica Cutolo-Calosi, Joseph C. Anselmi, Agent, 2 Broadway, New York, N.Y.
NDA 12–425, Meprobamate Tablets, 400 mg.
Farnham and Weeks Labs., James Thomas Weeks, 123 McTyere Avenue, Jackson, Miss.
NDA 6–011, Trich-O-Stat Solution.
Farris Products, Inc., Cambridge, Mass.
NDA 4–324, Algaederm Solution.
Fellows Medical Manufacturing Co., Inc., 1354 West Lafayette Boulevard, Detroit, Mich.
NDA's:
1–850, Bejen Elixir (Vitamin B). 1–918, B-Qua Elixir.
4–140, Liqua Phedra Drops.
4–141, Vitamin B Complex Solution.
Fermex Labs., R. C. Blackie, Owner, West Springfield, Mass.
NDA 1–842, Fermex Antacid Capsules.
Ferromin Co., Alfred A. Pfeiffer, President, 145 Main Street, Monroe, N.Y.
NDA 1–868, Viberon B Capsules.
Ferron Drug Co., 1 Thomas Street, New York, N.Y.
NDA 3–591, Ferron Tablets.
Fesler Co., Inc., George C. V., 912 South Donough, Montgomery, Ala.
NDA 2–033, Hydrocol Powder.
Fidelity Medical Supply Co., 213 South Main Street, Dayton, Ohio.
NDA's:
2–031, Ceebee Medicaps Capsules.
2–396, Polethesin (Trithesin) Rectal suppositories.
2–550, Sodium Pentobarbital Capsules.
3–865, Estrogenic Hormones IM Injection.
4–928, Sulfathiazole-Urea Ointment.
5–222, Stilbestrol Injection.
Fillauer Surgical Supplies, 930 East Third Street, Chattanooga, Tenn.
NDA 3–456, Morkazo Ointment.
Finaf Labs., 901 Pennsylvania Avenue, St. Albans, W. Va.
NDA 1–828, Finaf Solution.
Fine Chemicals of Canada, Ltd., 124 Pharmacy Avenue, Toronto, Ontario, Canada.
NDA 10–544, Reserpine Tablets 0.25 mg.
First Texas Chemical Manufacturing Co., Dallas, Tex.
NDA 0–276, Private Formula Tablets containing: Brewer's yeast, phenolphthalein, sodium glycocholate, sodium taurocholate.
Fite, Robert H., 11 Claremont Drive, Short Hills, N.J.
NDA 4–250, Walkex Solution.
Fitzgerald, Clarence, 2461 Jefferson Street, Gary, Ind.
NDA 2–908, Caribbean Liniment Solution.
Fitzpatrick, W. B., Dr., 433 Thompson Avenue, Excelsior Springs, Mo.
NDA 1–004, Derma-Coat Salve.
Fitzsimmons Products, 16 East 18th Street, New York, N.Y.
NDA 0–950, Podinol Liquid.
Fjeldstad Medicine Co., 3451 Cedar Avenue, Minneapolis, Minn.
NDA 0–248, Mesaba Oil.
Fleetfoot Co., 227 West 18th Street, Kansas City, Mo.
NDA 2–843, Fleetfoot Foot Powder.
Flint Eaton Division Baxter Labs., 6301 Lincoln Avenue, Morton Grove, Ill.
NDA 0–934, Calcium Mandelate Tablets.
Flodas Chem Labs., 215 East 12th Street, New York, N.Y.
NDA 0–626, Flodas Ear Drops.
Fluordent Inc., 312 Balter Building, New Orleans, La.
NDA's:
5–679, Desensito Toothpaste.
5–771, Flene Tooth Powder.
5–788, Flene Dental Topical Solution.
Foley and Co., Chicago, Ill.
NDA's:
3–737, Vita-Bilds Cap.
3–869, S-Kape Lotion.
7–380, Pyrilamine Maleate 25 mg. tablets.
Foot-King Co., Robert M. King, 3622 West 32d Street, Minneapolis, Minn.
NDA 1–594 Foot King Ointment.
Foot-Rem Labs, 801 World Herald Building, Omaha, Nebr.
NDA 2–750, Foot-Rem Powder.
Forrest Labs., Inc., 2025 Fifth Avenue, New York, N.Y.
NDA 0–547, BiLaticol Tablets.
Foster, N.C., Post Office Box 763, Hendersonville, N.C.
NDA 2–480, Car Bor Tann Ointment.
Foster, Jr, William, 52 Groshon Avenue, Yonkers, N.Y.
NDA 0–982, Foster's Pile Remedy Capsules.
Fox-Paw Products, 3124 Hirsch Place NW., Canton, Ohio.
NDA 2–079, Fox Paw Powder.
Fox Supply Co., St. Charles, Ill.
NDA 2–994, Mus-L Eaz Ointment.
Frankay Laboratories, Nutley, N.J.
NDA 10–518, Theopheral Reserpine Caps.
Franklin Chavett and Co., 612 North Michigan Avenue, Chicago, Ill.
NDA 1–675, Cascaperls Liquid.
Franklin Pharmaceutical Co., Division of Wynn Pharmacal, 5051 Lancaster, Philadelphia, Pa.
NDA 11–941, Slim Time Capsules.
Fredenburgh Hecht Co., 7 Hawthorne Lane, Concord, Mass.
NDA 8–061, PH Hair Prep Liquid.
Freese, Herman W., 235 South Avenue 51, Los Angeles, Calif.
NDA 1–157, Freeses Eez-U Powder.
Frosst Co., Charles E., 101 Richmond Trust Building, Richmond, Va.
NDA's:
1–077, Neo Chemical Tonic.
3–231, Neusorb Suspension.
3–233, Neusorb w/Mineral Oil Suspension.
4–061, Diestrene ECT 0.1, 0.25, 0.5, 1.0 mg./Tab.
Diestrene inj. 0.5, 1.0 mg.
Diestrene vag. sup. 0.5 mg.
4–144, Vermilet Tablets.
4–174, Ostoforte Capsules.
7–172, Danilone Tablets 50 mg.
Fulcom Labs Inc., % Endo Laboratories, 84–40 101st Street, Richmond Hill, N.Y.
NDA 2–015, Fulcom Tablets.
Fuld Brothers, Inc., 702 South Wolfe Street, Baltimore, Md.
NDA's:
0–425, Anti-Fect Disinfectant & Treatment for Athletes Foot Solution.
4–315, Anti-Fect Powder.
Furst-McNess Co., 120 East Clark Street, Freeport, Ill.
NDA 7–230, McNess Antihistamine Tablets (pyrilamine).
G & G Pharmacal Co., Inc. (out of business), Now known as Gilroy May Co., Inc., 1725 South Michigan Street, South Bend, Ind.
NDA 12–016, Pyrilamine Maleate Capsules, 75 mg.
G & W Co., Lovington Station, Des Moines, Iowa.
NDA 0–349, Kao Cream.
Gaebl, William L., 30 West Pennsylvania Avenue, Towson, Md.
NDA's:
5–660, Amfluor Fluoride Tablets.
6–299, Amfluor Fluoride Solution.
6–300, Amfluor Fluoride Toothpaste.
Gale Co., 918 Grandview Avenue, Duluth, Minn.
NDA 1–938, Gale Ointment.
Games Chemical Works, 611 Broad Street, Carlstadt, N.J.
NDA's:
3–009, Nicotinic Acid Amide Bulk for Mfg. use only.
4–720, Ascorvite (coselite) Ampoules.
4–721, Ascorvite (foselite) Dragees.
4–722, Thiavite (boselite) Ampoules.
Gar Co., 105 Bryant Street, Malden, Mass.
NDA 3–012, Gar Solution.
Garde Drug Co., 171 West Jefferson Street, Philadelphia, Pa.
NDA 10–946, Reserpine Elixir.
Garlex Co., 92 West 174th Street, New York, N.Y.
NDA 2–321, Garlex Brand Tablets of Anhydrous Garlic Tab.
Garrick, Lillian, 1140½ North Gardner, Hollywood, Calif.
NDA 3–245, Trim Solution.
Gates Medicine Co., Charleston, W. Va.
NDA's:
1–820, White Ribbon Remedy Powder.
1–821, White Ribbon Remedy Aromatic Powder.
1–885, Iron-O-Vita Liquid.
Gebauer Chemical Co., 9408–10 St. Catherine Avenue, Cleveland, Ohio.
NDA 3–763, Gebauer's Astringent Spray.
Gee Chemical Co., T. Gerald Magner, 175 West Jackson Boulevard, Chicago, Ill.
NDA 1–884, Gee Powder.
Gelatin Products Co., Division R. P. Scherer Corp., 9425 Grinnell Avenue, Detroit, Mich.
NDA's:
4–115, D1-Calcium Pantothenate Batch.
4–657, Tocopherol Concentrate Cap.
4–832, Stilbestrol ECC.
4–913, Deacin Caps.
Gena Labs, Inc., 1341 Plowman, Dallas, Tex.
NDA 3–192, Merc-O-Dine Liquid.
General and Marine Labs, Now known as the Alvagel Laboratories, Miami, Fla.
NDA 5–967, Alvagel Ointment.

General Cosmetics Corp., 612 North Michigan Avenue, Chicago, Ill.
NDA 9-844, Medicspray Transparent Spray Bandage.
General Products Labs., Columbus, Ohio.
NDA's:
0-969, Zonex Ointment.
0-970, Z-Rin Liquid.
Gens, Adolph-Helligol Importers, 3504 31st Avenue, Astoria, Long Island, N.Y.
NDA 1-416, Sulphur Bath.
Gerson Stewart Corp., Cleveland, Ohio.
NDA's:
9-063, 2% Actamer in 40% Surgical Soap.
1% Actamer in 40% Surgical Soap.
1% Actamer in 20% Surgical Soap.
0.3% Actamer in 15% Surgical Soap.
Gerst, David Dr., 915 West End Avenue, New York, N.Y.
NDA 2-380, Vericoaid or Varico Powder.
Giant Chemical Corp., 2 East Second Street, Coudersport, Pa.
NDA 0-661, Respanol Liquid.
Gill, Richard C. (deceased), Now known as Menlo Pharmaceuticals, Mr. Jack Robertson, 717 Keating Building, Menlo Park, Calif.
NDA 7-022, Solution d-Tubocurarine Cl.
Gish-Kerney, N. A., 342 Madison Avenue, New York, N.Y.
NDA 4-310, Hemoton Liquid.
Givaudan-Delawanna, Inc., 321 West 44th Street, New York, N.Y.
NDA 5-192, Racemic Menthol Bulk.
Glassman, Jacob A., 3930 Gladys Avenue, Chicago, Ill.
NDA 2-153, Aspirin-Saccharin Compound Tablets.
Glaxo Labs., Ltd., Grennford, Middlesex, England.
NDA 4-939, Stilbestrol Bulk.
Glenn Poducts Co., Box 25, Rockaway Park, N.Y.
NDA's:
2-117, Glenn Kaps, Capsules.
2-247, Glenn Skin Aid.
2-982, Glenn Formula 158 Capsules.
3-179, Glenn Scalp Lotion for Dry Hair.
3-180, Glenn Scalp Lotion for Oily Hair.
4-527, Glenn Nu-Tra Powder.
Glidden Co. (Soya Products Division), 1825 North Laramie Avenue, Chicago, Ill.
NDA 8-179, Cortisone Acetate Tablets, 25 mg.
Golden Peacock Inc., 206 West Blythe Street, Paris, Tenn.
NDA 8-212, Pyrilocaine Cream.
Goodling, D. W.., Richfield, Pa.
NDA 0-873, Keystone Cold Ointment.
Goodman Chemical Co., M. C., Winston-Salem, N.C.
NDA 4-046, Ready Headache Powder.
Goodwin Labs., Inc., N. C., 90 Prince Street, New York, N.Y.
NDA 4-743, Tobene Ointment.
Gordon, John H., 53 West Harriet, Altadena, Calif.
NDA 1-034, Erb-All Capsules.
Goshorn Co., H. R., 1020 McGee Street, Kansas City, Kans.
NDA 1-813, Dr. Goshorn's Golden Eagle Ointment.
Gotham Pharmacal Co., Inc., 1840 McDonald Avenue, Brooklyn, N.Y.
NDA 10-778, Antinem Fortis-50 Inj.
Antinem-100 Inj.
Antinem-1,000 Inj.
Gotham Pharmacal Co., Wilton, Conn.
NDA 4-302, Bertrex.
Gould, Verna, 5009 South Zenith, Minneapolis, Minn.
NDA 1-801, Mertric Ointment.
Gould, William L., M.D., Albany, N.Y.
NDA 5-817, Flavettes Tablets.
Gould Witch Hazel Co. TNF E. E. Dickinson, Old South Building, Boston, Mass.
NDA, 0-940, GO-CO Ointment.
Gourielli Apothecary Inc., 16 East 55th Street, New York, N.Y.
NDA's:
4-497, Sulfo-Collodio Hair Cleanser Shampoo.
4-498, Sulfo-Collodio Hair Lotion.
4-499, Sulfo-Collodio Bath Lotion.
4-500, Sulfo-Collodio Cream.
4-501, Sulfo-Deoderant Lotion.
Champoo.
Graham, H. L., 9302 Lake Highland Drive, Dallas, Tex.
NDA's:
3-237, Plant Oleoresins-Patch Testing Solution.
3-774, Rhusresin Solution.
Grant Chemical Co. (Now Amfre-Grant), 924 Rogers Avenue, Brooklyn, N.Y.
NDA's:
0-165, Theobromine, Calcium Gluconate Powder.
0-246, Theobromine, Calcium Gluconate, Phenobarbital ECT.
3-423, Corogrant Solution.
3-987, Beophylline ECT.
6-496, DES Tablets, 0.25 mg.
7-168, Grantsal Tablets.
9-154, Granbloc 250 mg.
Gray Pharmaceutical Co., Inc., Newton, Mass.
NDA 10-549, Glutavene.
Great Christopher Co., 5245 North 47th Street, Milwaukee, Wis.
NDA's:
1-175, Kings Ointment.
1-602, Kimo Tablets.
3-401, Great Christopher Athletes Foot Salve.
Grey, Thomas W., Box 1224, Pittsburgh, Pa.
NDA 1-293, Gray's Linement.
Grimm, Valentine, 186 East 93d Street, New York, N.Y.
NDA's:
0-154, Dojco Tonic.
0-456, Grimm's Iodcoegg Liquid.
2-057, Grimm's Eggsoycol Powder.
Gross Lab, 17316 Archdale Avenue, Cleveland, Ohio.
NDA 3-711, Imuno Nasal Spray.
Grove Laboratories, Inc., The (Bristol Myers Products), 8877 LaDue Road, St. Louis, Mo.
NDA's:
7-077, Grove's Antihistamine Tablets.
7-699, Bromo-Quinine Tablets with Antihistamine.
7-700, 4-Way Cold Tablets with Antihistamine.
Guadaloupe Bissoneaux, 1771 Madison Avenue, New York, N.Y.
NDA 1-924, Loupe Hair Oil Liquid.
Gudebrod Brothers Silk Co., Inc., Old Reading Pike, Stowe, Pa.
NDA 4-902, Champion Nylon Sutures.
Gurian Lab, Inc., 324 Broome Street, New York, N.Y.
NDA 4-473, Gurian's Preparation Solution.
H & B Drug and Prod. Co., Indian Trail, N.C.
NDA 1-359, Ichy-Tutsy Salve.
Haack Bros. Manufacturing Pharmacist, Haack Laboratories, Inc., 3217 Northwest Yeon Avenue Box 3286, Portland, Oreg.
NDA's:
1-580 B.C.N. Tablets.
1-949 Nima Tablets.
2-478 Sulfapyridine.
2-479 B.C.N. with G.
2-658 Thyroid Tablets 1 gr.
4-464 B.C.N.
Haack Laboratories, Inc., 3217 Northwest Yeon Avenue Box 3286, Portland, Oreg.
NDA 6-436, Urethane USP Enteric Coated.
Haffner, Carl F., 720 West Chestnut Street, Bloomington, Ill.
NDA 2-322, Haffner's Osma Prep Solution.
Haist & Co., Henry C., 3135 Main Street, Kansas City, Mo.
NDA 1-505, Aspirin Compound Tablets.
Halberstadt and Co., 2307 Third Avenue, Terre Haute, Ind.
NDA 6-375, Blitz Medicated Oil.
Halo-San Labs, 6777 Hollywood Boulevard, Los Angeles, Calif.
NDA 1-812, Halo-San Powder.
Hampshire and Co. Ltd., F. W., Perry Goodell, Agent, Post Office Box 948, Springfield, Mass
NDA 1-373, Snowfire Tablets.
Hampton Drug Co., Hampton, S.C.
NDA 2-156, F Ton Foot Solution.
Hanford Manufacturing Co., G. C., 304 Oneida Street, Syracuse, N.Y.
NDA 7-154, Hanford's Antihistamine Tablets 24 mg.
Hannon Medicines Inc., Storm Avenue, Brookhaven, Miss.
NDA 1-245, Hannons Rub Liquid.
Harrower Labs. Inc., St. Louis, Mo.
NDA's:
2-430, Compestrin in Oil Injection.
2-489, Sulfapyridine Tablets.
2-656, Compestrin Oral Capsules.
2-967, Apestrin Injection.
3-474, Plurizyme Tables.
3-646, Estrothyrin Tablets.
3-647, Menocrin-E Tablets.
3-648, Cortothyrin Capsules.
3-876, Homatrocin Solution Injection.
3-877, Bilicholan Tablets.
3-878, Citropectin with Magnesium Trisilicate Caps.
4-374, Synthestrin Tablets.
4-375, Synthestrin Injection.
Hart Drug Co., 35 Southwest Second Street, Miami, Fla.
NDA's:
0-042, Iso Efemist Solution.
0-219, Zinc Chloride, Alcohol, Formaldehyde Solution.
0-928, Ephenate elixir.
0-999, Unguentum Livvral Emulsion.
1-687, Thiron Tablets.
2-157, Elixir Betaferrum.
2-884, Scabenzate Lotion.
3-809, Thiazoint Ointment.
4-099, Sulfapyridine Tablets.
4-100, Sulfathiazole Tablets.
4-509, Thiazinic Cream.
5-216, Otozole Drops.
5-418, Sulfa-Urea-Glycol Solution.
Hartmen, Eugenia, 4031 Central Street, Kansas City, Mo.
NDA 3-298, Cozo Drops.
J. F. Hartz Co., 1529 Broadway, Detroit, Mich.
NDA's:
4-573, Tablets Stilbestrol.
4-574, Sterile Solution Stilbestrol.
5-199, Tablets of Para Aminobenzoic Acid.
6-068, Desoxyephedrine HCl Tabs.
G. F. Harvey Co., Inc., 9 Wells Street, Saratoga Springs, N.Y.
NDA's:
231, Karula (Granules).
2-706, Estrogenic Substance Harvey.
3-599, Sulfapyridine.
9-740, Corticotrophin (ACTH) Lyophilized.
Harvey Co., Inc., G. F., 99-101 Sawmill River Road, Yonkers, N.Y.
NDA 5-391, Analbis Suppositories.
Harvey Labs., 428-30 South 13th Street, Philadelphia, Pa.
NDA's:
5-988, Dolamin Injection.
2-434, Thio-C Drops.
2-978, Beplex (Benaplex) Elixir.
3-493, Benaplex Capsules.
4-412, Stilbestrol Injection.
7-053, Ion B (crystalline synthetic Vit. B_{12}) Injection.
8-844, Zonazid Injection.
9-082, Harvadase.
10-748 Reserpine Tablets 0.25, 0.5, 1.0 mg.

Harvin Co., 56 West 45th Street, New York, N.Y. (Now part of United States Nature Prod. Corp.)
NDA 1-839, Orotune Drops.
Hathaway Allied Products, 2024 Westgate Avenue, Los Angeles, Calif.
NDA 8-456, Hemalgin Ointment.
Haug Drug Co. (now Madland Labs.), 4905 North 31st Street, Milwaukee, Wis.
NDA 8-782, Premtal Improved Tablets.
Haver-Glover Labs, Now Haver-Lockhart Labs., Division Cutter Laboratories, Kansas City, Mo.
NDA 5-119, Sulfathiazole Cream 5%.
Hawley, Adelaide J., 6513 Hollywood Boulevard, Hollywood, Calif.
NDA's:
0-805, LaKen Jel.
0-807, LaKen Powder.
0-808, LaKen Cleansing Douche Powder.
Hayes, Walter M., 18231 Santa Barbara, Detroit, Mich.
NDA 2-732, Ex-It Liquid.
Hay-X Co., 1715 15th Street, Denver, Colo.
NDA 1-840, Davex Tablets.
Heacox, Charles C., Dulzura, Calif. Also: C. C. Heacox, 724 Seventh Avenue, San Diego, Calif.
NDA 2-889, Heacox Ban Solution.
Hed Pharm Inc., 2 Hamilton Avenue, New Rochelle, N.Y.
NDA 8-371, Hedulin Tablets, 50 mg.
Heifan Labs Inc., 11024 Magnolia Boulevard, North Hollywood, Calif.
NDA 5-248, Cactogen Injection.
Heinecke, Frederick G., Chamber of Commerce Building, Alexandria, Minn.
NDA 0-095, Heinecke's Foundation Tonic Liquid.
Heitink, Harry A., Eddyville, Iowa.
NDA 1-872, H-Line Liniment.
Heliogen Products Inc., 35-10 Astoria Boulevard, Queens, N.Y.
NDA 8-267, Heliogen Tablets.
Heneph Corp., New York, N.Y.
NDA 3-915, Hepps.
Hennen Products, Riley Law Building, Wheeling, W. Va.
NDA's:
0-515, Hennen's Dentifrice Powder.
0-521, Hennen's Saline Powder.
0-748, Hennen's Mouth Solution.
0-766, Viogreen.
0-839, Hennen's Skin Cream.
0-840, Hennen's Hand Lotion.
1-280, Hennen's Ointment.
1-484, Hennen's All Weather Skin Ointment.
1-485, Hennen Antacid Tablets.
2-062, Hennen's Foot Powder.
2-093, Hennen's Hair and Scalp Lotion.
Herbosan Co., 263 Claremont Avenue, Verona, N.J.
NDA 0-985, Herbosan Liquid.
Herschner Pharmaceutical Co., Frederick, 411-415 South Wells Street, Chicago, Ill.
NDA 7-472, VI-VI-Bx Tablets (Pyrilamine Maleate 25 mg.).
Hertneck and Geer, 1334 West Lawrence, Los Angeles, Calif.
NDA 1-649, Minshower Powder.
Hess, M. H., Jr., 130 East 72d Street, New York, N.Y.
NDA 5-718, Dermax Cream.
Hetman and Co., 3615 Harding Avenue, Chicago, Ill.
NDA 3-739, Dr. Hetman's Powder.
E. W. Heun Co., St. Louis, Mo.
NDA 6-942, Spasmolyn.
Hewitt, Edward R., 127 East 21st Street, New York, N.Y.
NDA 1-265, Vitamin Tribasic Ca Phosphate (Hewitt Formula).
Hexagon Labs., Inc., 3536 Peartree Avenue, Bronx, N.Y.
NDA's:
2-056, Iso-Nasol Solution.
7-969, Magent Tablets.
8-516, Hexamethonium Chloride Tablets 250 mg.

Hilbert, W. B., Curtis, Nebr.
NDA 1-761, Hilbertnox Mis.
Hill Labs., 742 East 20th Street, Houston, Tex.
NDA 1-549, Biff Ointment.
Hillcrest Labs., 33 Commerce Street, Spring Valley, N.Y.
NDA 0-395, Sabetal (topical).
Hillman Pharmaceutical Co., 185 North Wabash, Chicago, Ill.
NDA 3-170, Hillman's D-Compound Capsules.
Hillyard Sales Co., Attention: Robert B. Hillyard, St. Joseph, Mo.
NDA 3-682, Hillyard's Concentrate Disinfectant Solution.
Hiskey and Co., George Nye, 9113 Commercial Avenue, Chicago, Ill.
NDA's:
1-768, Rose Drops Capsulets Cap.
1-769, Pheno-Calene Tablets.
1-770, Gyacol Blue Cap.
1-771, Speckled Capsulets Capsules.
Histex Corp., 604 North Wells Street, Chicago, Ill.
NDA 2-254, Histeen Tablets.
Histosan Inc., New York, N.Y.
NDA's:
0-267, Chiniofon Tablets and Powder.
0-514, Aminophylline Tablets 1.5 gr.
Hogbin, Ida, 229 West 112th Street, New York, N.Y.
NDA 3-096, Saravent Ointment.
Hogshead Chemical Co., Norfolk, Va.
NDA 4-214, Rub-It-On Ointment.
Holcomb Manufacturing Co., J. I., Indianapolis, Ind.
NDA 3-933, Holcomb's Foot-Bath Fungicide Lotion.
Holdens Ointment, Inc., 147 Delaware Street, Tonawanda, N.Y.
NDA 0-052, Holden's Ointment.
Holland-Rantos Co., Inc., 393 Seventh Avenue, New York, N.Y.
NDA's:
3-033, Koro Jel.
5-088, Nylmerate Tincture.
Hollingshead Corp., R. M., 16th and Mickle Street, Camden, N.J.
NDA 2-778, Loyd's Solution of Medicinal Oils.
Holtgren, Richard W., 7369 West Colfax, Lakewood, Colo.
NDA 2-655, Duz Liquid.
Hooper, Carroll I., Paris, Maine.
NDA 0-662, Hooper's Salve.
Hoosier Pharm. Co. (now known as Dabney Pharmacal Co., Inc.), 315 North Capitol Avenue, Indianapolis, Ind.
NDA's:
4-879, Solution Thiamine HCl.
4-881, Stilbestrol Injection.
Hoover Mfg. Pharm. Inc., George D., 209 East Locust Street, Des Moines, Iowa.
NDA 1-491, Hoover's Improved Preparation Liquid.
Hopkins and Co., J. L., New York, N.Y.
NDA 0-699, Blosser's Pen-E-Fume Powder.
Hopkins and Hopkins Pharmaceutical Co. (now Reed Pharmacal), 5622 Wyndale Avenue, Philadelphia, Pa.
NDA's:
7-089, Pyrilamine Maleate tablets 25 mg. (Hopkincol).
8-487, Isoniazid tablets.
9-824, Reserpine tablets.
Horley, George H., 14 Caroline Avenue, Trenton, N.J.
NDA 0-877, Athleam Powder.
Horner, Inc., Frank W., 91 Willow Street, Lynn, Mass.
NDA's:
0-297, Trisorbol Powder.
2-456, Motuol Liquid.
5-346, Zetol Paste.
5-470, Lokol Drops.
5-576, Hexestrol Tablets.

Horton & Converse, 621 West Pico Street, Los Angeles, Calif.
NDA's:
2-483, Sulfapyridine Tablets 0.5 gm.
4-341, Alpha Tocopherol Tablets.
5-157, Stilbestrol Compressed Tablets, Enteric Coated Tablets, Inj.
7-526, Histapacq Tablets.
Hosford, Faye E., 103 Poplar Avenue, Buffalo, N.Y.
NDA 2-523, Faye's Foot Powder.
Hospital Liquids Inc., 843 West Adams Street, Chicago, Ill. (Above firm bought out by: American Sterilizer Co., Erie, Pa.)
NDA's:
3-248, Physiologic NaCl Sol With Alcohol 5% and Dextrose 5%.
3-249, Physiologic NaCl Sol with Alcohol 10% and Dextrose 5%.
5-406, Suspensoid Vehicle.
5-407, Sulfathiazole Spc. Eml.
5-408, Sulfathiazole Eml. 5%.
5-409, Croleum/Sulfur Eml.
5-410, Croleum Eml.
5-411, Croleum Suspension.
Houchins, John C. (Dr. John and Co.), Welch, W. Va.
NDA 0-756, Doctor John's Dental Asepticize Solution.
Household Remedy Co., 2257 West Madison Street, Chicago, Ill.
NDA's:
2-154, Polaxo Liquid.
2-155, Koleto Ointment.
House of Hollywood Inc., 5971 East Third, Los Angeles, Calif.
NDA 5-729, Sulfa-Aid Dressing.
Howe, William H., 122 Jewett Street, Lowell, Mass.
NDA 2-624, Lady Ashton Foot Ease Cream.
Hoy, Salb & Co., Inc., 559 North Capitol Avenue, Indianapolis, Ind.
NDA's:
1-064, Epinephrine in Oil Injection.
1-065, Nidomil Tablets.
1-066, Sulfanilamide Tablets 2.5 gr.
1-067, Sulfanilamide Tablets 5 gr.
1-069, Kenene Solution.
1-070, Peptorex Elixir.
1-072, Bromokal Solution.
1-073, Sedone Elixir.
1-074 Pangene (Otalgia Drops).
1-075, Neatol Solution.
1-076, Vedos Liquid.
1-535, Hulgatone Liquid.
1-536, Genitex Liquid.
1-537, Nusomine Liquid.
1-538, Cadin Liquid.
Huber, C. J., D.D.S., 1105 Minor Avenue, Seattle, Wash.
NDA 2-661, Aleveobtundo Liquid.
Hudson Prod. Co., Jersey City, N.J.
NDA 10-570, Ointment-H Ointment.
Hufeland Products Co., 718 Harrison Street, San Francisco, Calif.
NDA 1-723, Hufeland Stomach Bitters.
Hughes Co., K. A., 22 Yeoman Street, Roxbury, Mass.
NDA 2-936, Tropikool Spray.
Humphreys Medicine Co., Inc., 63 Meadow Road, Rutherford, N.J.
NDA 7-751, Humphreys 60 Antihistamine Tablets.
Huntington Labs., Huntington, Ind.
NDA's:
3-189, Derma-San Powder.
3-532, Podi-San Solution.
6-797, Germa-Medica Antiseptic Soap.
9-240, Degrem w/actamer Liquid Soap.
9-297, Germa-Medica w/bithionol Soap.
Hurless Labs., 1117 Kammer Avenue, Cincinnati, Ohio.
NDA 0-886, Glyco-Thiamin Liquid.
Hutt Prod. Co., Lone Lack, Mo.
NDA 2-372, Zeft Antiseptic Mouthwash.
Hutton, George P., 2677 West Ninth Street, Los Angeles, Calif.
NDA 1-437, Bron-AS Tablets.
Hyma Chem Labs., Buckhannon, W. Va.
NDA 4-340, Paraform Procaine Paste.

Illinois Herb Co., 815 North Pulaski Road, Chicago, Ill.
NDA 2-491, #42 I.H.C. Rectal Ointment.
Imperial Foundation Corp., 235 West Galena Street, Milwaukee, Wis.
NDA 1-018, Sun-D.
Indian Labs., Corp., 601 Iturbide Street, Post Office Box 514, Loredo, Tex.
NDA's:
0-644, Prieto Tonic Liquid.
1-368, Mexican Indian Liniment Liquid.
1-369, Prieto Laxative Salts with Spearmint Flavor.
1-897, Prieto's Laxative Pills.
Ingersoll, William Brown, 1220 16th Street, NW., Washington, D.C.
NDA 1-135, T-20 Solution.
Injectables Research Corp., 2340 East Logan, Decatur, Ill.
NDA's:
6-253, Pennisol Injection.
6-487, Penni-Morph Injection.
Institute of Applied Biology, 144 East 90th Street, New York, N.Y.
NDA 8-946, Butadol Injection and Oral Solution.
Interchemical Corp., Route 17 and Berry Avenue, Carlstadt, N.J.
NDA 6-150, Elamine I. C. Lyophilized and Elamine with Dextrose.
Intermedico Corp., 21 Hudson Street, New York, N.Y.
NDA's:
8-514, Comison Tablets.
8-831, Hexamethonium Cl Tablets, 250 mg.
8-888, Pamison Tablets.
9-271, Rauwolfia Serpentina Tablets, 50 and 100 mg.
9-614, Rauwolfia-Veratrum Viride Tablets.
International Biochem Corp. (now known as Intro Biochemical Corp.), 6114 Seventh Avenue, Brooklyn, N.Y.
NDA 8-258, Biohepulin Injection.
International Hormones, Inc., 87 Bethpage Road, Hicksville, N.Y.
NDA 7-867, Adrenosal Injection.
International Latex Corp., Dover, Del.
NDA's:
6-350, Playtex Baby Oil & Kooleez Baby Oil.
6-351, Playtex Baby Powder & Kooleez Baby Powder.
6-352, Playtex Baby Cream & Kooleez Baby Cream.
International Mineral & Chemical Corp., 20 North Wacher Drive, Chicago, Ill.
NDA's:
8-378, TPN Tablets.
9-961, TPN Suspension.
10-242, Betasyamine Effervescent Powder.
International Pharm Co., 411 South Wells Street, Chicago, Ill.
NDA 12-661, Pyrilamine Maleate Capsules, 75 mg.
International Vitamin Corp. (Not in Drug Registration).
NDA 1-682, I.V.C. Ol-Vitamin Capsules.
Interstate Labs., 6490 Bay Street, Emeryville, Calif.
NDA's:
0-605, Oculine Dressing, Salve, Drops and Solution.
2-063, Thiabic Wafers.
4-427, Liquideze Liquid.
Intra Products, Inc., Post Office Box 14148, Northridge Station, Dayton, Ohio.
NDA's:
0-266, Van-Variz Injection.
3-900, Pyridoxine Injection.
Invenex Pharmaceuticals, 2176 Palou Avenue, San Francisco, Calif.
NDA's:
8-992, ACTH Injection.
8-834, Hydrocortisone Acetate Ophth. Susp.
Ions Exchange and Chemical Corp., 48 Leonard Street, New York, N.Y.
NDA's:
9-353, Agosan H-6 Liquid Disinfectant.
9-354, Agosan Y-4 Liquid Disinfectant.
9-355, Agosan H-6 Liquid Soap.
9-356, Agosan Y-4 Liquid Soap.
Irvin, Jess Wilson, 840 West Fourth Street, Winston-Salem, N.C.
NDA 4-086, Sulfan Ointment.
Irving Wise and Co., 47 Ann Street, New York, N.Y.
NDA 5-706, Alucet Syrup.
Italian Drug Importing Co., Inc., 225 Lafayette Street, New York, N.Y.
NDA 7-274, Pasidi Tablets.
Ivoryton Pharmacal Co., Ivoryton, Conn.
NDA 1-166, Sulfanilamide Tablets, 5 gr.
J. D. Pharmacal Co., Inc. (Name changed to Mid-Atlantic Pharmacal Co., Inc.), Post Office Box 117, 519 West Seventh Street, Richmond, Va.
NDA 10-480, Serpal Tablets.
J and R Chemical Co., Mr. O. K. Richardson, 339 Bridge Street, Elkin, N.C.
NDA 4-093, Pink Flag Liquid.
Jackson Mitchell Pharmaceuticals, 38-68 State Street, Santa Barbara, Calif.
NDA's:
7-742, Soldemul Solution.
8-246, Methanabol Tablets.
Jackson, Stephen, M.D., 43 Missouri Avenue, NW., Washington, D.C.
NDA 9-151, Orthomin Weidner.
Jamieson, C. E., Co., 1962-1980 Trombly Avenue, Detroit, Mich.
NDA's:
0-209, Magnephylline Tablets 100 mg.
0-401, Vitamin Tablets.
0-402, Mineral Tablets.
0-491, Phenobarbital and Hyosciamus Tablets.
0-540, Mosby's Compound Liquid.
0-907, Walter's Antacid Tablets.
1-163, Dellamo DAO Tablets.
1-195, Ferri-B-Compound Tablets.
1-196, Ephedrea w/chlorobutanol Solution.
1-197, Ephedrose Nasal Solution.
1-725, Aminophylline 1½ gr., and phenobarbital ¼ gr. Tablets.
2-095, Sulfanilamide and Sodium Bicarbonate Tablets.
2-458, KI-THEO-TAL Tablets.
2-787, Atropine Sulfate and Ephedrine HCl Tablets.
3-286, Phenobarbital and Atropine Sulfate Tablets.
3-503, Thenophen B Tablets.
3-899, Aminophylline (1½ gr.) and phenobarbital (½ gr.) (Rx #2) Tablets.
3-909, Aminophylline Compound "COR" Tablets.
4-000, Aminophylline Tablets 3 gr.
4-276, Sulfathiazole Tablets 0.5 gm.
Jamieson Pharm. Co., 7924 Riopelle Street, Detroit, Mich.
NDA's:
7-178, Jahist Capsules.
7-716, Jahist New Improved Capsules.
Janssen Labs, 1419 North Osage Street, Sedalia, Mo.
NDA 1-785, Janssen's Exposure Ointment.
Jason Pharm. Co., 114-144 Gifford Street, Syracuse, N.Y.
NDA 12-039, Jet Weydex Caps.
Jennings, Anne Stetler, Rural Delivery 1 Box 158, Clarks Summit, Pa.
NDA 1-617, Anne's Soothing Salve.
Jests Inc., TNF Ex-Lax, Inc., 423 Atlantic Avenue, Brooklyn, N.Y.
NDA 0-365, Jest Tablets.
Jettas Prod. Inc., 200 Maryland Avenue, Wilmington, Del.
NDA 0-242, Jettas Pile Relief Ointment.
Johnson and Co., J. A., 171 King Street East, Toronto, Ontario, Canada.
NDA 2-674, Absorbo Solution.
Johnston's Vitamin Products, 5105 York Boulevard, Los Angeles, Calif.
NDA 7-138, "J" Antihistamine Tablets (pyrilamine maleate, 25 mg.).
Jonas Corp., F., 50 West 44th Street, New York, N.Y.
NDA 1-814, Pancreotest Powder for Injection.
Jones, Jefferson Green, 1900 South 10th Street Boulevard, Dallas, Tex.
NDA 0-462, Wart Wrecker-Mole Mover Liquid.
Jones, Warren W., 508 Hastings Street, Pittsburgh, Pa.
NDA 1-347, Jones 1-Plus-1 Liquid.
Jordan, Rodrigo, M.D., San Julio 356 South Suarex, Habana, Cuba.
NDA 0-290, Cuajani Jordan Liquid.
Jordan Inc., Thomas, 404 St. Charles Street, New Orleans, La.
NDA 8-264, Triode Tablets 5, 20, 40 mg.
Josett Drug Co., 1 Okley Road, Wateroon, Mass.
NDA 2-609, Josette's Magic Deodorant Powder.
Jovan Labs., 95 Liberty Street, New York, N.Y.
NDA's:
2-497, Klotoleum Injection.
2-498, Klotochol Tablets.
3-434, DRB Emulsion Vials.
3-858, Klotone Tablets.
5-084, Kexovan Tablets.
Joy Products, 323 West Sixth Street, Los Angeles, Calif.
NDA 3-275, Banicet Tablets.
Justi and Sons Inc., H. D., 32d and Spring Garden Street, Philadelphia, Pa.
NDA 7-613, DMF Mouthwash.
K and S Remedy Co., 835 York Avenue SW., Atlanta, Ga.
NDA 1-006, A-1 Headache Powder.
Kald Products Co., 204 Euclid Avenue, Albert Lea, Minn.
NDA 4-299, KD Athlete's Foot Solution.
Kalusoff Ltd., Post Office Box 844, Springfield, Ill.
NDA 7-964, Hospital FGDS 10% Solution (Disinfectant).
Kanox Co., Post Office Box 244, Garden Grove, Calif.
NDA 1-571, Red Ball Poultice Plaster.
Kasar Manufacturing Co., 7313 North Harlem Avenue, Chicago, Ill.
NDA 9-855, Reserpine Tablets 0.1, 0.25, 0.5, 1, 2, 3, 4, 5 mg.
Katwalk Products, 310 Calhoun Building, Minneapolis, Minn.
NDA 2-348, Foot Sage Cream.
Kay Pharmacal Co., 1312 North Utica, Post Office Box 50375, Tulsa, Okla.
NDA's:
10-604, Theosyl Injection.
11-718, Rausertina, 50, 100, 150 mg. Tablets.
Kay Specialty Co., 77 Broadway, Denver, Colo.
NDA's:
0-253, Eugenol Compound.
0-254, Dental Glycerite Liquid.
0-255, Kay Ammoniacal Silver Nitrate Solution.
0-256, Kay Cleaning Paste PAS.
0-257, Cavoline-Solvent Liquid.
0-258, Cavoline.
0-259, Neo Paste PAS.
0-260, Surg-O-Cream.
0-261, Coag-O-Cream.
0-262, K-Tabs Tablets.
0-263, Topo-Theia Solution.
Kelco Co., Box 782, San Diego, Calif.
NDA 1-694, Kelgin Solution.
Kelgy Labs TNF Morgan Products Corp., 160 East 127th Street, New York, N.Y.
NDA 6-808, Tricholysin Powder.

Kelly's Labs., John W. Wheatley, Box 1125, Vernon, Tex.
NDA 1–258, Wheatley's Compound Liquid.
Kendall Co., Walpole, Mass.
NDA 4–474, Radiopaque Dressings.
Lewis Manufacturing Co., Division Kendall Co., Walpole, Mass.
NDA 0–698, Insultoic Membrane Dressing.
Kenndy Labs., 2200 North Colorado, Philadelphia, Pa.
NDA 1–823, Kenodone.
Kenosharx Lab., Kenosha Prescription Laboratory, 625 57th Street, Kenosha, Wis.
NDA 0–278, Dantol Capsules.
Kenton Pharmacal Co., Inc., 423–425 Greenup Street, Covington, Ky.
NDA's:
4–828, AM Solution.
8–140, Histeen Tablets.
Kerrigan, Sara, 3 Tyson Place, Bergenfield, N.J.
NDA 3–139, Car-Vas Ointment.
Ke-Vo Products, 707 Union Street, Terminal Sales Building, Seattle, Wash.
NDA's:
2–965, Korn-Ique Liquid.
2–966, Korn-Ique Cream.
Kilgore Co., Inc., Charles, Yonkers, N.Y.
NDA 6–966, Nosalt Granules.
Kimball Co., C. M., 131 State Street, Boston, Mass.
NDA 0–099, Red Cap Germicide Spray.
King, A. C., Route 3, Box 179, Benton, Ark.
NDA's:
2–548, King's Liniment Ointment.
2–549, King's 49 Salve.
King and Lang, Inc, Box 496, South Norwalk, Conn.
NDA 1–185, IVQ Poison Ivy Specific Liquid.
King Drug Co., Post Office Box 1925, Montgomery, Ala.
NDA 6–093, KNS Liquid.
King, Stanley M., 9 East Central, Miami, Okla.
NDA 2–782, Nox-A-Tone (King's Unique Ointment).
King's Goat Milk Labs. (Now King Organic Food Prods., Inc.), 415 Lexington Avenue, New York, N.Y.
NDA's:
1–248, King's Goat Milk Capsules.
1–250, King's Goat Milk, Garlic and Parsley Capsules.
Kinnison and Son Inc., 513 Felix Street, St. Joseph, Mo.
NDA 1–238, Lodo Tablets.
Kinosan Labs., Dr. Emilio Michelotti, 7221 17th Avenue, Brooklyn, N.Y.
NDA 3–243, Kinosan Solution.
Kirk Co., C. F. (Now Kirk Labs.), Worchester, Mass.
NDA's:
0–785, Rectocaine Suppositories.
7–196, Hemamin Tablets.
9–069, Cortisone Acetate Tablets 25 mg.
Kirk Co., C. F., New York, N.Y.
NDA 10–688, Hemomin-C.
Klee, O. W., 221 East 39th Street, Kansas City, Mo.
NDA 2–951, Foot-Rem Solution.
Klein, Samuel, 144 Hedden Terrace, Newark, N.J.
NDA 6–834, Subsalt Granules.
Klingensmith, James A., Marigold Products Co., Post Office Box A 75, Norvelt, Pa.
NDA 0–151, Mor-O-Gold Salve.
Knoll & Co., Inc., H. G., 511 East 72d Street, New York, N.Y.
NDA's:
3–285, Thiabrit Solution.
4–255, Complebarb Liquid.
3–979, Knollist Solution.
Knox Co., 1400 Cahuenga Boulevard, Los Angeles, Calif.
NDA 1–420, Amosan Powder.
Koch, Leo E. H., 519 Elm Street, Ontario, Calif.
NDA 2–448, El-Ko Powder.
Kohler, Ferdinand C., D.D.S., 216 North Union Avenue, Havre De Grace, Md.
NDA 5–354, Sorgos Dressing.
Koken Companies, Inc., 1932 North Broadway, St. Louis, Mo.
NDA 4–683, KDX Solution.
Krank Co., A. J., 1885 University Avenue, St. Paul, Minn.
NDA 2–001, Medicated Cream (camphor & sulfur).
Kreider, Jakob, 6408 Glenwood Avenue, Chicago, Ill.
NDA 2–042, Calum Solution (Swelstop Solution).
Kreis Labs., 158 South Rodeo Drive, Beverly Hills, Calif.
NDA 7–308, Pyrilamine Maleate Tablets 25 mg.
Kuhne Health Labs., Chicago, Ill.
NDA's:
0–546, Bio Food X (Kuhne X Powder).
0–621, Bio Food A (Kuhne's A Tonic).
0–622, Bio Food B (Kuhne's B Tonic).
0–623, Kuhne C Liquid.
Kunze and Beyersdorf Inc. (Now known as E. E. Kunze, Inc.), 1035 South Fifth Street, Milwaukee, Wis.
NDA 2–270, K-B Unction Ointment.
Kwell Co., 941 West Bay, Jacksonville, Fla.
NDA 0–744, Kwell Tablets.
L and H Labs., 1042 Holden Avenue, Detroit, Mich.
NDA 2–909, Circugen Ointment.
L and M Labs. Ltd., Sulton, Nebr.
NDA 0–550, Leak Oil Ointment.
Laboratories for Pharmaceutical Development, Inc., Yonkers, N.Y.
NDA 10–022, Reserpine Tablets.
Laboratorio Orlando Rango, Del Norte De Espana, S.A., Masnou, Barcelona, Spain, American agent: Thrift Drug Co., 16th and Mary Streets, Pittsburgh, Pa.
NDA 1–683, Boreno Liquid.
Labratest, Inc., 2302 49th Avenue, Long Island City, N.Y.
NDA 1–089, Sun Sooth Lotion.
Labs of Ojena, 7869 Melrose Avenue, Hollywood, Calif.
NDA 0–603, Holdit Cream.
Lackey, M. A., M.D., 507 North Main Street, High Point, N.C.
NDA 5–363, P-T-6 Solution.
Laclede Labs., Inc., St. Louis, Mo. (Bought out by: Peter, Strong and Co., 415 Lexington Avenue, New York, N.Y.)
NDA 6–511, Topi-Flur Cream.
Lafayette Pharmacal Inc., 15th and Ball Streets, Lafayette, Ind.
NDA 9–516, Pantopaque Injection.
Laisure, Victor, Dr., 3073 West Seventh Street, Los Angeles, Calif.
NDA 1–689, Leasurease Lotion.
Lake, Lloyd E., M.D., Kela Tooth Powder Co., Allen Building, Henderson, Tex.
NDA 0–663, Kela Tooth Powder.
Lamaunn, T. B., M.D., 105 East Third Street, Tulsa, Okla.
NDA 3–935, H-K Cones Suppositories.
Lambert, Frank A., The Sulfo-Styptic Co., 424½ Washington Street, Steubenville, Ohio.
NDA 6–058, Sulfo Styptic Powder.
Landon, Lewis C., c/o Landon and Co., Los Angeles, Calif.
NDA 5–143, Streptolin Tablets.
Lannett Co., 9000 State Road, Philadelphia, Pa.
NDA's:
7–014, Undecylenic Acid Capsules.
8–598, Laniazid Tablets 50 mg.
10–124, Serpalan Tablets 0.1, 0.25, 1.0 mg.
Lanteen Med Labs., Inc., (Bought out by Sterling Drug), 2020 Greenwood Street, Evanston, Ill.
NDA 8–045, Lanteen Antihistamine Cough Syrup.
Lanworth Co. (Now Kaldak Co.), Lansing, Mich.
NDA 0–230, Kaldak Powder.
Larre Labs., Inc./Division Gynecic Labs., Inc., 474 Nepperhan Avenue, Yonkers, N.Y.
NDA 6–089, Jellak Jel.
Larson, M. S., D.D.S. (Drexel Co.), 216 Strong Building, Beloit, Wis.
NDA 0–014, D-Rx-L Salve.
Lascoff and Son, J. Leon, 1209 Lexington Avenue, New York, N.Y.
NDA 2–299, Vinous Decoction of Bulgarian Belladonna Root Liquid.
Lathrop, Donald C., 2750 Reservoir Street, Los Angeles, Calif.
NDA 6–474, Ionex Capsules.
La Verne Chemical Co., 1328 Des Moines Boulevard, Des Moines, Iowa.
NDA's:
2–361, It 77 Liquid.
2–362, Citepsa.
Lavol Manufacturing Co., 552 Hayes Street, San Francisco, Calif.
NDA 2–751, Lavol Pine Oil Disinfectant Solution.
Lawrence Irwin, 341 13th Street South, Wisconsin Rapids, Wis.
NDA 1–467, Irwin Cough Syrup.
Laxa Fruit Co., 240 East 175th Street, New York, N.Y.
NDA 1–331, Laxation Paste.
Lederle Labs., Division American Cyanamid Co., Pearl River, N.Y.
NDA 6–123, VI-Ferrin with Folvite Folic Acid.
Lee-Bert, Inc., 900 Lapeer Street, Saginaw, Mich.
NDA's:
5–969, Lan Lip Pomade Cream.
5–697, Quench Liquid.
5–698, Quench Ointment.
Leeming, Thomas, Division Charles Pfizer, 235 East 42d Street, New York, N.Y.
NDA 4–311, Ethiomine Liquid.
Lee-Wood Inc., Post Office Box 453, South Norwalk, Conn.
NDA 3–090, Cofen Liquid.
Leger Labs., 8910 35th Avenue, New York, N.Y.
NDA 2–129, Edmond's Ointment.
Lehn & Fink Products Corp., 316 North Limit Street, Lincoln, Ill.
NDA 1–483, Tussy Deoderant Cream.
Lenitor Lab, 26 Burnet Street, Maplewood, N.J.
NDA 0–854, Derma-Toze Powder (Nu-Feet).
Leons Labs., Dr., 364 Eighth Avenue, New York, N.Y.
NDA 2–000, Sarkobium.
Leota Co., 1223 Pond Street, Memphis, Tenn.
NDA 2–028, Leota's Laxative Liquid.
Lesch, E., M.D., 201 Union Building, New Castle, Ind.
NDA's:
1–790, Nodor Liquid.
2–225, Rodon Douche.
Leslie Labs., 704 Market Street, Shawnee, Okla.
NDA's:
3–782, Air Flo Drops.
3–783, Res Toe Solution.
Levenson Jacob C., 25 East Main Street, Richmond, Va.
NDA 0–028, Lemisho Tablets.
Lewkens Labs., 127 Southwest 15th Street, Des Moines, Iowa.
NDA's:
0–601, Benosal Powder.
0–823, Epicaine-B Cream.
0–872, Epicaine-A Cream.
Lex Labs., 22 Linden Place, Flushing, N.Y.
NDA 4–400, Sulfathiazole Tablets and Sulfathiazole Monohydrate Powder Topical.
Liberson, Leon, Crescent Laboratories Inc., Shabakunk Parkway, Trenton, N.J.
NDA 7–070, Anathion Injection.
Liberty Vitamin Corp., 924 Rogers Avenue, Brooklyn, N.Y.
NDA 5–257, PABA Tablets 100 mg.

Lilly Dental Products Co., Welch, W. Va.
NDA 2–665, Armoriz Solution.
Limicol Products, 1014 Central Avenue, Cincinnati, Ohio.
NDA 7–799, Limicol Tablets.
Lincoln Labs., Hickory Point Road, Box 1139, Decatur, Ill.
NDA 10–123, Reserpine Tablets.
Lipton Drug Sales Co., 2023 Prospect Avenue, Cleveland, Ohio.
NDA 9–804, Rauwolfia Serpentina Tablets.
Liska and Sons, Inc., Rudolph, 4534 West Grand Avenue, Chicago, Ill.
NDA 4–030, Gem Bitters Liquid.
Litle, Inc., T. J., 8415 East Jefferson Avenue, Detroit, Mich.
NDA 0–676, K–4 powder.
Lloyd Bros., Inc., 1385 Tennessee Avenue, Cincinnati, Ohio.
NDA's:
7–720, Khelloyd Tablets.
8–182, Khelloyd with Phenobarbital Tablets.
10–235, Cobaloyd Tablets.
7–051, Histal (pyrilamine maleate) Tablets, 50 mg.
7–684, Co-Bromin Tablets.
Lockhart, P. O., Gary-Lockhart Drug Co., Perry, Fla.
NDA 1–036, Ben-Silic Compound Solution.
Loeb Dietetic Food Co., Inc., 4378 Broadway, New York, N.Y.
NDA 6–954, Stedasalt powder.
Logan Labs., Inc., 4256 North Crawford Avenue, Chicago, Ill.
NDA 0–364, Pellisan Powder.
Lord Baltimore Labs., 2821 East Fifth Street, Dayton, Ohio.
NDA 2–819, Taylor's Old Fashioned Cough Syrup.
Lor-Manza Inc., Berkeley, Calif.
NDA's:
4–530, Lor-Manza Lotion.
5–483, Manza-Tan Lotion (Lor-A-Li Lotion).
Loseff Lab, 310 South Michigan Boulevard, Chicago, Ill.
NDA 2–500, Cal-Coloid Ointment.
Louison's Pharm., 10 South 11th Avenue, Post Office Box 304, Evansville, Ind.
NDA's:
12–062, Loucarbate Tablets.
12–063, Loucarbate with SPC Capsules.
Loumen Drug Co., Division Saffran and Edelman Pharmacy, Brooklyn, N.Y.
NDA 11–943, Rx 553 Cold SRC (Pyrilamine maleate 75 mg.).
Lovins Labs (Julius Lovins), Denver, Colo.
NDA 0–454, Dencolo Mouth Wash.
Lowe, Charles W., 435 Columbia Road, Dorchester, Mass.
NDA 0–180, Tap Ointment.
Lubkin, Samuel, 5 North Wabash Avenue, Chicago, Ill.
NDA 5–090, Dr. Lubkin's Ideal Pocket Treatment.
Lucerne Labs., Salt Lake City, Utah.
NDA 1–657, Fungi Fiend Solution.
Luffy, Mathew, St. Louis, Mo.
NDA 2–954, Math Luffy's Pile Treatment Salve.
Luna Products, Mr. Andrew Sinatra, 2200 Fulton Street, Brooklyn, N.Y.
NDA 2–683, Sulphur Baths Powder.
Lura-Glo Labs., 1504 32d Street, Oakland, Calif.
NDA 5–612, Formula 4 Solution.
Lustgarten, Division of Wynn Pharmacal, Lancaster and 51st Street, Philadelphia, Pa.
NDA 9–840, Hexamethonium Chloride Tablets 125 and 250 mg.
Lutol Co., 7617 West State Street, Milwaukee, Wis.
NDA 0–726, Lutol Vaginal Suppositories.
McAleece, Rose, Mrs., 465 West Third Street, Dubuque, Iowa.
NDA 0–055, Herbal Ointment.
McBride Co., Columbus, Ohio.
NDA 3–627, Estrogenic Substances Injection.
McCarthy, J. J. and Ruskoski, John B., General Delivery, Orlando, Fla.
NDA 2–799, McCarthy's Cold Remedy Salve.
McClain Labs., Box 389, Morgantown, W. Va.
NDA 1–267, Theodore's Formula 48 Liquid.
McClure, E. L., 235 Kleberg Place, Corpus Christie, Tex.
NDA 2–025, Burnsol Solution.
McClusky Products, Dr., 106½ Cass Street, Woodstock, Ill.
NDA's:
0–249, Lip-Fix Ointment.
0–512, Ada-Burn Ointment.
McCollum Labs., 135 East 157th Street, Post Office Box 375, Gardena, Calif.
NDA's:
0–606, Vitamin B Complex Tablets.
3–057, Isotone Tablets.
3–059, A&D Tablets.
3–060, Garlic and Parsley with Vitamin D Tablets.
3–061, Isomar Tablets.
McCormick and Co., Inc., 414 Light Street, Baltimore, Md.
NDA 6–380, Scabicide McCormick Solution.
H. L. McCrary, M.D., Royston, Ga.
NDA 1–361, L. G. Laxative.
McDargh, Robert E., Rural Delivery 3, Box 33, Bellevue, Pa.
NDA's:
2–641, McDargh's Special Liquid.
2–643, Happy Lax Liquid.
2–989, Powdered Herbs Powder.
McGovern Products Co., 683 Berkeley Road, Columbus, Ohio.
NDA's:
2–998, Shur-Eze Foot Balm.
2–999, Shur-Eze Corn and Callous Remover Ointment.
3–000, Shur-Eze Foot Powder.
McIntyre Research Foundation (Canada), 25 King Street West, Toronto, Canada.
NDA 6–237, McIntyre Powder.
McKesson & Robbins, Inc., Bridgeport, Conn.
NDA's:
4–586, A–200 Pyrinate.
7–139, McKesson's Antihistamine Tablets.
McLintock Co., Duncan C., 591 Main Street, Hackensack, N.J.
NDA 7–006, Polyestol Bandage.
McMullen Products Co., 3503 West 58th Place, Los Angeles, Calif.
NDA 0–234, X-IT Liquid.
McNeil Labs., Camp Hill Road, Fort Washington, Pa.
NDA's:
1–906, Vitamin A Capsules 20,000 Units.
3–621, Butisol-Hyoscine Tablets.
8–626, Hesaline Chloride Inj. 50 mg./cc.
M and H Labs. Inc., 317 Commercial Building, Tulsa, Okla.
NDA 2–728, Derrick Throat Gargle and Mouthwash.
M S Prod. Inc., 1901 Southwest Ninth Street, Miami, Fla.
NDA 0–175, M S Antacid Tablets.
Macallister Labs., 9213 Wade Park Avenue, Cleveland, Ohio.
NDA's:
0–510, Al-U-CRM (aluminum hydroxide gel).
2–173, Phenedrine Solution.
3–202, Phenylmercuricnitrate Ointment.
4–718, Sulfathiazole Ointment.
Macdonald, C. E., 208 South Detroit Avenue, Tulsa, Okla.
NDA 2–218, Corn Doctor.
Macdonald, Eugene S., Palma Sola, Bradenton, Fla.
NDA 4–367, Chiggerun Ointment.
Macy & Co., Inc., R. H., 34th Street and Broadway, New York, N.Y.
NDA's:
1–718, Mineral Oil Emulsion.
1–719, Malt Extract with Extract Cascara Sagrada.
1–720, Chantrey Special Ointment for the Scalp.
2–867, Macy's Elixir Thiamine HCl.
2–868, Macy's Sulphur Cream.
2–869, Macy's Athletic Liniment Solution.
3–157, Mineral Oil Emulsion and Phenolphthalein.
4–430, Macy's Mint Flavored Oleo Vitamin A and D Liquid.
4–488, Clo Emulsion.
4–765, Macy's Antiseptic Exposure Cream.
4–766, Macy's Oleochondra Emulsion.
7–140, Macy's Antihistamine Tablets.
Maetone Distributors Inc., 1860 Broadway, New York, N.Y.
NDA 1–857, Maytone Liquid.
Magic Chemical Co., 370 Turk Street, San Francisco, Calif.
NDA 3–267, Magic Brand Fungicide Solution.
Makers of Kal, Inc., 256 North New Hampshire, Los Angeles, Calif.
NDA 6–890, Saltee Flavored Granules.
Makris and Son, Hartford, Conn.
NDA 4–431, Erysipelas Compound Solution.
Mands, Michael, 142 West 42d Street, New York, N.Y.
NDA 2–837, Florasol Powder.
Manhattan Drug Co., Inc./TNF Nyal Co., 155 Saw Mill River Road, Yonkers, N.Y.
NDA 7–169, Neohist Tablets.
Mann and Co., Frederick, 8123 Jones Road, Cleveland, Ohio.
NDA's:
6–262, Nes-Cystine Tabs.
6–336, Tyrocreme.
Mann and Co., Walter N., 811 Prospect Street, Indianapolis, Ind.
NDA 3–190, Tercol Liquid.
Manos Cosmetic Co., Seattle, Wash.
NDA 4–220, Manos Hair Oil.
Mansfield, Charles W., 2811 B Street, San Diego, Calif.
NDA 4–187, Old Timer Powder.
Mantos, Gust D., 936 Mission Street, San Francisco, Calif.
NDA 1–106, Mantos Liquid.
Marcellus, Ada, 241 West 103d Street, New York, N.Y.
NDA 4–207, Toplax.
Marlin Bitters Co., 916½ Third Avenue, Seattle, Wash.
NDA 2–228, Marlin's Laxative Bitters.
Marlo Products Co., Cleveland, Ohio, and Pittsburgh, Pa.
NDA's:
7–208, Maranhist Tablets.
7–761, APC-Pyrilamine Maleate Capsules.
Marsden Sales, c/o Mr. George C. Adams, Post Office Box 1364, Huntington, W. Va.
NDA 1–263, Marsden's Food Cap.
Marshall and Bell, 476 Peachtree Street, NE., Atlanta, Ga.
NDA 3–114, Elixir Quinthia M & B.
Marvan Products, 11 Park Avenue, Keansburg, N.J.
NDA 0–922, Marvan Salve.
Mar-Vena Medicine Co., Mack Building, Denver, Colo.
NDA 1–951, Mar-Vena Liquid.
Marxvach, A., Post Office Box 518, San Juan, P.R.
NDA's:
0–244, Norma-Nil Sup. (rectal).
1–445, Alfos-OM Injection.
1–466, Gripotilol Injection.

Masil Co., Shenandoah, Iowa.
NDA 0-987, Masil Tablets.
Mason Drug Co., 22 Thayer Street, Boston, Mass.
NDA 2-566, Kerodin.
Mason, Larry, 409 East 75th Terrace North, Kansas City, Mo.
NDA 9-508, Rauwolfia Serpentina Tablets.
Mason Medicine Co., W. J., Wesser, N.C.
NDA's:
2-151, Mason's Compound.
2-152, Pallagra Medicine.
Massachusetts Pharm. Corp., Lowell, Mass.
NDA 4-585, I-Pius-Peroxide Solution.
Master Products Co., Moorestown, N.J.
NDA 3-747, Foot Master Balm Ointment.
Mathis Chemical Co., 183 Chestnut Hill Avenue, Brighton, Mass.
NDA's:
2-149, Mathis Tablets.
2-501, Mg-Aspirin Tablets.
May, Thomas B., 5822 East Washington, Indianapolis, Ind.
NDA 1-999, Caperol Solution.
Mayrand, Inc., 1026 Oakmont Avenue, Drawer 3345, Greensboro, N.C.
NDA 4-424, Sulfathiazole Tablets and Powder 7.7 gr.
M Dee Products Inc., Los Angeles, Calif.
NDA 4-528, Nix Tablets.
M-Dex Corp., 3636 Beverly Boulevard, Los Angeles, Calif.
NDA 2-070, M-Dex Ointment.
Medical Arts Supply Co., 706-08-10 Fourth Avenue, Huntington, W. Va.
NDA's:
1-230, Coca-Brom Improved Liquid.
1-405, Fedramint Solution.
1-406, Vita Phos Liquid.
1-666, Yellow Sulfanilamide and Sod. Bicarbonate Tablets.
2-120, BBP Ointment.
2-710, Masco Revil Gelets Capsules (liver, iron and B_{12}).
2-711, Gelets Masco Vitamin Capsules.
2-743, Vitamin A and D Fish Liver Oil Capsules.
3-055, Sodium Phenobarbital Elixir.
3-512, Micosi A Ointment.
3-513, Micosi B Ointment.
9-178, Surginol Surgical Soap.
Medical Center Labs., 205 West Seventh Street, Coffeyville, Kans.
NDA 2-122, Chigs Dressing.
Medical Chemicals, Baltimore, Md.
NDA 4-959, Unguentum Iso-Par.
Medical Products Institute, Cincinnati, Ohio.
NDA 2-844, Filtovapor Cold Tablets.
Medical Research Labs, Raumain Building, Lake Charles, La.
NDA's:
3-277, Athletes' Foot Balm Ointment.
4-468, Dr. Ducotes Foot Lotion.
Medical Services Co., 2098 Warrensville Center Road, South Euclid, Ohio.
NDA 10-694, Reserpine Tablets 0.1, 0.25, 0.5, 1.0 mg.
Medical Specialties Co., 226 North 15th Street, Philadelphia, Pa.
NDA 10-692, Reserpine Tablets 0.1, 0.25, 0.5, 1.0 mg.
Medical Tea Co. of California, Los Angeles, Calif.
NDA's:
0-629, Cleo Tea Liquid.
0-630, Cento Tea (Aesculapius).
Medicao Chemical Corp. of America, 15 East 40th Street, New York, N.Y.
NDA's:
1-805, Effo-Brom Tablets.
1-806, Effo-Sal Tablets.
1-807, Effo-Barbibrom Tablets.
2-942, Effo-Conval Tablets.
5-801, Anthallan Capsules.
6-431, Anthaphylline Capsules.
6-631, Anthephedrine Capsules.
Medicus Distributors, 1926 Eye Street NW., Washington, D.C.
NDA 0-251, Medicus Tablets.
Medident Pharm., 108 East 79th Street, New York City, N.Y.
NDA 5-536, Calciflor Tablets.
Melinson Distributing Co., A. O., 923 North Franklin, Philadelphia, Pa.
NDA 0-694, A O Solution.
Melvin Co., Inc. (out of business), South Pasadena, Calif.
NDA 2-745, Dozets Tablets.
Mendez, Angel M., Post Office Box 1456, San Juan, P.R.
NDA 0-077, Quinarsine Injection.
Menlo Park Labs, Main Street, East Woodstock, Conn.
NDA 12-679, Cetril Aerosol Skin Antiseptic and Cleanser.
Menlo Pharms Inc., Palo Alto, Calif.
NDA 10-370, Cugilex sublingual pellets tab., 3 and 6 mg.
Merck Sharp & Dohme, Division Merck & Co., Inc., Attention: Charles E. Childs, Jr., Rahway, N.J.
NDA's:
90, Dagenan.
1-642, Dagenan Sodium.
Merck & Co., Inc., Rahway, N.J.
NDA 4-076, Stilbestrol.
Merit Labs Co. (Menit), 2122 Nicholas Street, Philadelphia, Pa.
NDA 7-328, Pyrilamine Maleate Syrup.
Mennen Co., Hanover Avenue, Morristown, N.J.
NDA 0-082, Quinsana Powder.
Methanthin Co. (out of business), 441 West Wondsor Road, Glendale, Calif.
NDA 2-521, Nuchart's Antacid Solution.
Metro Medicine Co., 2510 South Boulevard, Houston, Tex.
NDA 11-249, Serbio Capsules.
Metropolitan Labs., Division Michigan Chemical Corp., 500 North Bankson Street, St. Louis, Mich.
NDA's:
4-323, Diethylstilbestrol Tablets and Ampules.
11-350, Vitamin B_{12} Concentrate.
Meyer and Co. (Now known as: Meyer Laboratories), 16361 Black Avenue, Detroit, Mich.
NDA's:
10-457, Reserpina Tablets, 0.1, 0.25, 0.5, 1, 2, 3, 4, and 5 mg.
10-462 Rauwolfia Serpentina Tablets 50, 100, 150 mg.
Meyers, A. S., 217-02 Jamaic Avenue, Queens Village, N.Y.
NDA 3-289, ASM Antiseptic Solution.
Midgley & Co., Midgley J. Lawson, applicant, 220 South William Street, South Bend, Ind.
NDA 0-329, Athamis Vaginal Suppositories.
Midland Chemical Co., 207 Board of Education Building, St. Louis, Mo.
NDA 0-846, Nipp Solution.
Midwest Chemical Development Corp., Cleveland, Ohio.
NDA's:
7-573, Saltets Granules.
7-591, Histon Compound Tablets.
7-592, Histon Tablets.
7-811, A-P-C Pyrilamine Maleate Capsules.
Mifflin Chemical Co. (Now Mifflin, McCambridge Co.), 6400 Rhode Island Avenue, Riverdale, Md.
NDA 7-244, Pyrilamine Maleate Tabs., 25 mg.
Miley Medicine Co., John E. Miley, 714½ Barr Street, Fort Wayne, Ind.
NDA 0-373, Miley's Compound Treatment Capsules.
Milk Minerals Co., Inc., Chicago, Ill.
NDA 1-661, Milk Calcium Tablets.
Miller, Alice B., 1228 South Mariposa Avenue, Los Angeles, Calif.
NDA 2-721, Comfort Corn Salve.
Miller, C. C., Hydracon Products Co., 536 West Los Angeles Street, Baldwin Park, Calif.
NDA 2-590, Hydrocon Solution.
Miller, J. D., Route 3, Box 678, De Queen, Ark.
NDA 1-604, J. D. Miller Grand Salve.
Miller, Joseph W., Post Office Box 188, Skellytown, Tex.
NDA 2-826, Mewco Liquid.
Millers Products Co., Freemont, Nebr.
NDA 3-585, Millers Tablets (Mag. Oxide).
Mills Pharm. Co., 865 South East Street, Anaheim, Calif. (Also: St. Louis, Mo.).
NDA 11-611, Thyrobrom Tablets.
Mims Medicine Co., 525 Dillingham Street, Phenix City, Ala.
NDA 3-733, Mikosol Tincture.
Min-A-Rex, 383 Santa Ana, San Francisco, Calif.
NDA 3-469, Min-A-Rex Liquid.
Mineral Specialties, Inc., 3248 Mission Street, San Francisco, Calif.
NDA 1-789, Invigo Mis.
Min-Ral-Par Distributing Co., Denver, Colo.
NDA 4-107, Nature's Mineral Supplement Capsule.
Minson, Inc., Atlanta, Ga.
NDA 1-763, Tempo Tablets.
Miracle Mineral Baths, Title & Trust Building, Phoenix, Ariz.
NDA 4-343, Texas Mineral Crystals.
Mistretta and Co., Inc. (Out of business), 3340 M Street NW., Washington, D.C.
NDA 11-223, Sleek Timed Disintegrated Capsules.
Mitchell, Joseph F., Excel Manufacturing Co., 5414 West Huron Street, Chicago, Ill.
NDA 0-328, Fire Water Liquid.
Mitchum Co., The, 206 West Blythe Street, Paris, Tenn.
NDA's:
8-272, Pyril Tablets 25 mg.
8-300, Pyrilaca Tablets.
Mizzy, Inc., Clifton Forge, Va.
NDA's:
2-090, Hemodine solution.
9-348, Oracaine HCl Injection.
Modern Drugs, Inc., 4204-04 East New York Street, Indianapolis, Ind.
NDA's:
0-022, Efedrops.
0-044, Tannic Acid.
0-187, Sassafras Oil.
0-195, Ginger F. E.
0-196, Aloin.
0-197, Modern Tonic Tablets Capsicum.
0-199, Alkaline Laxative Rhubarb Elixir.
0-200, Waferlax.
0-201, Medicated Disc Lozenges.
0-202, Pepsin Lacated Elixir.
0-203, H & P Powders.
0-204, Astringent Powder.
0-205, Modern Steam Inhalant with Menthol.
0-206, Modern Cold Tablets.
0-207, Isopropyl Alcohol.
0-028, Vermifuge for Large Round Worms.
0-222, Cafo-Phenol Liquid.
0-224, Anti-R-Co.
0-225, Prescription A Compound.
0-226, Composition Powder.
0-227, No-Ko Tablets.
0-228, Expectorant for Coughs.
0-229, Cascaralax.
0-286, Altraco.
0-287, Irene (Liquid).
0-288, Modern Iodal Tablets.
0-298, Tablets for Nasal Douche.
0-299, M. D. Powders.
0-300, R. O. Salve.
0-301, Uno.
0-302, Pet-Lax.
0-303, Relevo (Ointment).
0-330, Footex.
0-331, Modern Antacid Tablets.
0-332, Vaginal Wafers.
0-333, Modern Liquid Tonic Compound.
2-219, Camphorated Oil with Eucalyptol and Guaiacol.
2-971, M-D Cold Tablets (without Laxative).
2-972, M-D Cold Tablets with Laxative.
4-194, Canfo-Phenyl.

Modern Drugs, Inc., Philippi, W. Va.
NDA's:
0–963, Modern Diuretic and Analgesic Tablets.
0–975, Modern Aspirin with Caffeine.
Modern Necessities Co., 737 West Randolph Street, Chicago, Ill.
NDA 4–260, Gaustape Dressing.
Moe-Nade Labs, 1545 Glenarm Street, Denver, Colo.
NDA 3–996, Moe-Nade Massage Bar D. F.
Monsanto Chemical Co., 1700 South Second Street, St. Louis, Mo.
NDA 4–719, Sulfathiazole (tablets?).
Mor Labs, Ltd., Paramount Building, Cedar Rapids, Iowa.
NDA 0–089, Mor Concentrated Mouthwash.
Moran Co., R. J., 9 Columbia Street, Cambridge, Mass.
NDA 10–083, Reserpine Tablets 0.25 mg.
Morgan, Adam, 172 South Boulevard, Pontiac, Mich.
NDA 2–564, Adam and Eve.
Morgan, Tom (Mrs.), Rockmart, Ga.
NDA 2–253, Kamson Liquid.
Morning Glory Co., 519 Maple Avenue, Takoma Park, Md.
NDA 0–397, Beechwood Creosote and Menthol Inhalant.
Morse Labs., 155 Waverly Place, New York, N.Y.
NDA's:
7–170, Pyranisamine Maleate Tablets.
10–384, Hydrocortisone Acetate Ointment.
0.5%, 0.1%, 0.25%.
Morten Labs., 9530 Alta Mira Drive, Dallas, Tex.
NDA's:
0–869, Chlo-Thanol Nose and Throat Drops.
0–870, Bell-Aspadrin Capsules.
Morton Manufacturing Corp., Lynchburg, Va.
NDA 6–278, Blair's Athlete's Foot Aid.
Mosher, Inc., L. A., 268 Spring Street, NW., Atlanta, Ga.
NDA 0–217, Lantagen Liquid.
Mosley, Joseph G., Monette, Ark.
NDA 2–962, Mosley's Compound Elixir.
Muclavo Chemical Co., Los Angeles, Calif.
NDA 2–634, Muclavo Mouthwash and Gargle.
Multiproducts Drug Co., Inc., 3903 Jenifer Street, NW., Washington, D.C.
NDA 5–986, Hysine Gum.
Murrell Labs, Norman, Okla.
NDA 6–163, Rx 7–11 Solution.
Mutual Pharmacal Co., 107 North Franklin Street, Syracuse, N.Y.
NDA's:
4–085, Sulfathiazole Tablets.
4–365, Estrogenic Substances Injection.
4–777, Stilbestrol Tablets.
Myers Drug Co., 5303 Hastings Street, Detroit, Mich.
NDA 4–036, Nyer's Laxative Liquid.
Myron Puff, Millerton, Dutchess County, N.Y.
NDA 0–132, Puff's Alkaline Pastilles.
Mysan Co., 2352 Ingleside Avenue, Post Office Box 2111, Macon, Ga.
NDA 7–216, Hista-Mysan Tablets.
Nadin Co., 1815 Flower Street, Glendale, Calif.
NDA 10–013, Bio-Fla Tablets.
Narodetzki, Andre N., Paris, France.
NDA 1–572, Spark (Elixir).
National Biochem. Co., 612 North Vermont Avenue, Los Angeles, Calif.
NDA 0–272, VI-KA-MIN Compound Tablets.
The National Drug Co., Haines and McCallum Streets, Philadelphia, Pa.
NDA 6–223, Resinat Capsules.
The National Drug Co., 4663 Stenton Avenue, Philadelphia, Pa.
NDA 8–166, Ammivin Injectable.
National Drug Laboratories, Inc., Chicago, Ill.
NDA 11–634, Silhouettes Timed Disintegration Capsules.
National Oil Products Co., Harrison, N.J.
NDA 4–334, Calcium Pantothenate Dextrotatory.
National Synthetics Inc. (Now Bell-Craig Inc.), 270 Lafayette Street, New York, N.Y.
NDA's:
5–395, Dikol Tablets.
5–853, Neodikol Capsules.
6–016, Monophen Tablets.
7–107, Monophen Capsules.
National Titanium Alloy Mfg., Division National Lead Co., Bridge Station, Niagara Falls, N.Y.
NDA 7–467, T A M Poison Ivy Salve.
Natural Health Products, Baltimore, Md.
NDA 0–810, Garlic and Parsley Pellets ECT.
Naysol Co., 29 Sassafras Street, Providence, R.I.
NDA's:
0–804, Snifol Nose Aid Drops.
1–555, Snifol Nose Drops.
Neiwert, Albert, 194 Avon Avenue, Newark, N.J.
NDA 3–301, Scalp Conditioner Ointment.
Neoco Corp., 1000 North Highland Avenue, Los Angeles, Calif.
NDA 9–541, Vertigon Tablets.
Neolene Co., Ferndale, Mich.
NDA 1–372, Neolene Drops.
The Nevlo Co., San Antonio, Tex.
NDA 0–910, Nevlo Tablets.
Nicholas Products Labs., Ltd., A & G Nicholas Inc., 1 Park Avenue, New York, N.Y.
NDA 10–273, Megimide Injection.
Nicolar, Joseph F., 5812 Lexington Avenue, Hollywood, Calif.
NDA's:
1–094, WA-LE-GU Balm (Iroquois Indian Balm for Athletes Foot).
1–095, WA-LE-GU Balm (Iroquois Indian Balm for Hemorrhoids).
Nikander, Werner, 411 Holland Street, Hancock, Mich.
NDA 2–567, Nikander's Cough Medicine Syrup (Nikander's Cough Balsam Syrup).
Ni-Late Manufacturing Co., Inc., Post Office Box 1518 Northwest, Atlanta, Ga.
NDA 0–039, Epsom Salt Soda Tablets (Mag. Sufate, Sodium Bicarb.)
Nisbet Co., W. B., Los Angeles, Calif.
NDA's:
2–008, Tebsin Powder.
2–708, Tebsin Tablets.
Nixon's Labs., 1801 Old Shell Road, Mobile, Ala.
NDA 0–038, Hak Liquid.
Nonspi Co., Standard Labs, Division Warner Lambert, 201 Tabor Road, Morris Plains, N.J.
NDA 0–614, Nonspi Cream.
Normal Pharmacal Co., 1101 Broadway, Oakland, Calif.
NDA 11–473, Reserp-Sules Capsules.
North Coast Chemical and Soap Works, Seattle, Wash.
NDA 9–287, Cocoa-Borax Powdered Hand Soap with Bithionol.
North Highlands Drug Co., 1433 18th Street, Birmingham, Ala.
NDA 1433, Postman's Joy Solution.
Norwich Pharmacal Co., 17 Eaton Avenue, Norwich, N.Y.
NDA 8–549, Butazolidin Tablets 100 and 200 mg.
Novo Pharmacal Corp., 559 North Capital Avenue, Indianapolis, Ind.
NDA's:
2–647, Salikol (Napikol) Liquid.
2–648, Novodine Liquid.
2–649, Sedacol (Aprikol) Liquid.
2–650, Novosol Liquid.
2–651, Cherazine Liquid.
2–652, Novine (Elixir).
2–653, Amorex Liquid.
Novy, Frank, 3935 West 26th Street, Chicago, Ill.
NDA's:
5–476, Petrolin Drops.
5–477, Petrolin Salve.
Nowland Co., George H., 23 West Pearl Street, Cincinnati, Ohio.
NDA's:
5–476, Petrolin Drops.
5–477, Petrolin Salve.
Noyes Co., P. J., 101 Main Street, Lancaster, N.H.
NDA's:
0–319, Aspirin Tablets 10 gr.
0–519, Ipecac Tablets ½ gr.
1–260, Potassium Chloride Tablets.
1–489, Special Formula Tablets for Norman E. Cobb, M.D. containing: Phenobarbital ¼ gr., Veratrum Virides, Nitroglycerin.
1–490, Same as 1–489 except Phenobarbital content is ½ gr.
2–413, Sodium Phenobarbital and Sodium Bromide Elixir.
2–733, Magnesium Trisilicate Tablets 7.5 gr.
4–396, Beta-Prime Tablets 1, 5, 10 mg.
4–397, Beta-Prime Elixir.
8–230, Alayans Suspension.
9–954, Reserpine Tablets 0.1, 0.25, 1.0 mg.
Nuclear Corporation of America, St. Louis, Mo.
NDA 11–428, Sodium Iodid 131 Therapy Capsule.
Nu-Life Products Co., St. Joseph, Mo.
NDA's:
4–175, Nu-Life Foot Rub Liquid.
4–176, Smith's Scalp Rub or Shampoo.
Nupres Laboratories, Dayton, Ohio.
NDA 1–138, Nupres Topical Liquid.
Nutrition Research Labs., Inc., 332 South Michigan Avenue, Chicago, Ill.
NDA's:
2–873, Bezon Capsules.
3–035, Quintrex VX Vitamins with Liver, Tablets.
5–450, Pendarvon Wafers.
Nyal Co., 155 Saw Mill River Road, Yonkers, N.Y.
NDA's:
0–477, CP Solution.
0–479, Nyrub Ointment.
0–551, Baby Oil by Dalon Liquid.
1–448, Vita-Vim Fortified Globules (capsules).
1–693, Nygar Emulsion of Mineral Oil.
1–955, Nyal Eyemaster Drops.
1–977, Nyal Soothing Lotion.
2–137, Manacea (laxative-expectorant).
2–319, Nova-tonic (fortonic) Liquid.
3–087, Before and After Digestive Treatment Tablets and Capsules.
Nysco Laboratories, Inc., 34–24 Vernon Boulevard, Long Island City, N.Y.
NDA's:
11–507, Hydrocortisone Acetate Spray Caps.
11–508, Hydrocortisone Acetate with Antihistamone Spray Caps.
Oca Medicine Co., Inc., 233 West 14th Street, New York, N.Y.
NDA 0–040, Pinkovels Tablets.
O'Camp, Horner and Co., 534 West 152d Street, New York, N.Y.
NDA 2–365, Biocervin Ointment.
O-Cel-O, Division General Mills, Inc., Buffalo, N.Y.
NDA 9–209, Cel-O-Sorb.
Od Peacock Sultan Co., Lexington Avenue, Bethpage, N.Y.
NDA 1–742, Thi-Amino Liquid.
O'Dara Products Co., St. Louis, Mo.
NDA 3–415, O'Dara Mouthwash.
O'Dell Hot Springs Hotel and Bathhouse, Radium Springs, N. Mex.
NDA 3–937, Mineral Water Solution.

OK Solution Co., P. E. Hutchinson, City Cash Drug Store, Natoma, Kans.
NDA 1–766, OK Solution.
Oktul Specialty Co., 1635 South Evanston Street, Tulsa, Okla.
NDA 5–459, Vitapulp Sedative Cement and Pulp Capper.
Old Homestead Clay Co., 1222 Bank of America Building, San Diego, Calif.
NDA 3–142, Old Homestead Clay Ointment.
Old Man Frantz Co., Pittsburgh, Pa.
NDA 0–448, Old Man Frantz Mountain Tonic Liquid.
Onalim Co., Inc., 2295 Second Avenue, New York, N.Y.
NDA 5–223, Onalim Antiseptic Lotion.
Onyx Oil & Chemical Co., Division Millmaster-Onyx Corp., 1900 Warren Street, Jersey City, N.J.
NDA 5–384, Onyxsan Solution.
Optine Co., 303 Altman Building, Kansas City, Mo.
NDA 0–755, Optine Drops.
Optol Co., Adams, N.Y.
NDA 2–964, Bon-Derma Powder.
Oradent Chemical Co., Division Mizzy Inc., 105 East 16th Street, New York, N.Y.
NDA 11–285, Kincaine HCl Injection.
Oral Prophylactic Assoc., Inc., 1915 East Eighth Street, Duluth, Minn.
NDA 0–549, Denture-Aid Liquid.
Organic Chemicals, Inc., 30 North Raymond Street, Pasadena, Calif.
NDA's:
6–411, Histex Tablets.
7–133, Tyral Solution.
Organics, Inc., Chicago, Ill.
NDA 10–752, Cobalamine Concentrate Injection.
Oro Drug Co., 718 Harrison Street, San Francisco, Calif.
NDA 1–722, T-A-S Elixir.
Oro Pharmacal Co., 257 Kearney Street, San Francisco, Calif.
NDA 3–927, Orovin Liquid.
Orr, Thomas and Balmer, John, Orba Sales Co., 600 South Broadway, Box 67, New Philadelphia, Ohio.
NDA 3–100, Orba Powder.
Ortho Labs., 1037 Madison Avenue, New York, N.Y.
NDA 3–654, Emulsio Olei Picis.
Otis Labs., New York, N.Y.
NDA 7–725, Otisamin (Khellin) Tablets.
Overfield, Sneldon, and Paul M., Stroudsberg, Pa.
NDA 1–349, Sativa Ointment.
Owens, E. J., 1400 Larimer Street, Denver, Colo.
NDA 1–332, Analgedine Liquid.
Owing Bros. of York, Seitzville, Glen Rock, Violet Hill, Pa.
NDA 7–494, Sulfaquinoxaline.
Oxford Prod. Inc., 2108 Payne Avenue, Cleveland, Ohio.
NDA's:
2–121, Creme-A-Tonic.
2–205, Lorisol Mouthwash.
2–206, Halitol Mouthwash.
2–207, Thycal Antiseptic and Hi-test Mouthwash.
6–933, Saltase Powder.
Oza Compound Products, 1221 Production Road, Fort Wayne, Ind.
NDA's:
2–874, Lenene Liquid.
2–875, Ozine Gargle Mouthwash.
3–322, Senene Syrup.
3–332, Senene.
3–418, Pervo Suspension.
P-B Manufacturing Co., Paris, Tenn.
NDA 3–123, Fev-O-Blis Liquid.
P and O Products Co., Ozark, Mo.
NDA 1–899, P and O Foot Powder.
Pacific Isotopes Inc. (Out of business), 511 Southwest 10th Avenue, Portland, Oreg.
NDA 9–902, Radioactive Iodine-131 Solution.
Pacific Labs Inc., Richmond, Calif.
NDA 8–242, ACTH Pacific Injection.
Pacific States Labs Inc., San Francisco, Calif.
NDA's:
9–549, Isotinic Acid Hydrazide (Pacrizid) Tablets.
9–917, Reserpine Tablets.
Palm Pharmacal Co., 2647 Sedgwick Avenue, Bronx, N.Y.
NDA 4–729, Vischolinal Tablets.
Paradise Pharmaceutical Labs., 41–19 31st Avenue, Long Island City, N.Y.
NDA 1–557, Aspirlik Tablets 3 gr.
Paramino Corp., New York, N.Y.
NDA 5–059, Indrazide Tablets.
Parfums Duvee, 103 Fifth Avenue, New York, N.Y.
NDA 0–653, Sinazol Inhalant and Ointment.
Parfums Schiaparelli, 597 Fifth Avenue, New York, N.Y.
NDA 3–382, Secret De Schiaparelli douche.
Park Drug Co., Inc., 147–151 West 15th Street, New York, N.Y.
NDA's:
7–120, Ridahist (Histasan) Antihistamine Tablets.
9–293, Rauwolfia Serpentina Tablets 50 and 100 mg.
9–913, Reserpine Tablets 0.1, 0.25, 0.5, 1.0 mg.
10–202, Reserpine Elixir 0.25 mg./0.5 cc.
10–451, Hydrocortisone Ointment 0.5%, 1.0%, 2.5%. Hydrocortisone Acetate Ointment, same strength as above.
A. J. Parker Co., Philadelphia, Pa.
NDA 9–805, Purital R.S.
Pasadena Research Labs., 2107 East Villa Street, Pasadena, Calif.
NDA's:
8–666, Redema Tablets 50 mg.
10–605, Hydrocortisone Acetate Injection 25 mg./cc
11–257, Genten Tablets 0.25 mg. and 0.5 mg.
11–259, Manaten Tab.
11–260, Wolfina Tablets 50 and 100 mg.
Paul-Lewis Labs. Inc., Milwaukee, Wis.
NDA 6–981, Atrochol Capsules.
Pauze Products Co., 1500 Echo Park Avenue, Los Angeles, Calif.
NDA 2–688, Pauze Foot Powder.
Peanut Products Co., Tuskegee, Ala.
NDA 0–800, Miracle Massaging Oil Liquid.
Pearl, Irwin A., University of Washington, Seattle, Wash.
NDA's:
3–412, Metaldehyde Tablets, 4 gr.
3–413, Acid Metaldehyde Tablets.
Pediatric Drug Co., 305 Market Street, Lawrence, Mass.
NDA 11–546, Serenoid Tablets 0.25 mg.
Peerless White Lime Co., Mosher Station, Ste. Genevieve, Mo.
NDA's:
1–044, Water-Repellant Precipitated Calcium Carbonate # 1.
1–045, Water-Repellant Precipitated Calcium Carbonate #2.
Pelican State Lab, 423 Poydras Street, New Orleans, La.
NDA 1–412, Xlent Pine Oil Liquid.
S. B. Penick & Co., 258 Brunswick Street, Jersey City, N.J.
NDA 4–569, Diethylstilbestrol.
Peps Corp., 4660 Maryland Avenue, St. Louis, Mo.
NDA 2–406, Alka-Peps Tablets.
Peptone Medicine Co. (Nu-Tine Med. Co.), 1104 Topping Avenue, Kansas City, Mo.
NDA 2–997, Peptone (Nu-Tine) Solution.
Perfecto Labs, 822 East Seventh Street, Pueblo, Colo.
NDA's:
3–630, Perfecto Aseptic Liquid.
3–631, Lypto-Mento-Perfecto Ointment.
3–632, Perfecto Nose Drops.
3–633, Perfecto Rubbing Oil Liquid.
Perrigo Co., L., 100 Brady Street, Allegan, Mich.
NDA's:
2–698, Concentrated Cough Syrup.
7–187, Antihistamine tablets (Pyrilamine maleate 25 mg.).
7–797, Antihistamine tablets Fortified (antihistamine plus APC).
7–824, Histagesic Capsules.
9–351, Cal-Hist Lotion.
Personeni, Inc., Joseph, 70 Spring Street, New York, N.Y.
NDA's:
0–414, Metranodina solution.
0–478, Treponyl injection.
Pescett Pharm. Co., Inc., Room 1111, 299 Broadway, New York, N.Y.
NDA 3–051, Mar Ointment.
Peterson, John H., 1152 15th Street, Santa Monica, Calif.
NDA 0–137, XILOR Lotion.
Peterson, M. C., Box 68, Allen County, Lafayette, Ohio.
NDA's:
1–749, Peterson's Black Salve.
1–750, Peterson's White Salve.
1–751, Peterson's Cough Remedy Liquid.
Pfeiffer Manufacturing Co., S., 3949 Laclede Avenue, St. Louis, Mo.
NDA's:
3–311, Fungusine and Fungusine concentrate liquid.
3–685, Gold Medal Purgees, ECT.
3–700, Fungusine powder.
7–179, Novahist antihistamine tablets.
7–338, Histilles capsules (Pyrilamine maleate).
7–339, Koldets capsules.
Pfizer & Co., Inc., Chas., 235 East 42d Street, New York, N.Y.
NDA's:
5–137, Magnesium, calcium, and sodium fumarate bulk.
6–949, Vibalt injection.
11–607, Cor-Tyzine 0.1% Nasal Solution.
Pharmacal Products Corp., 1317 North Kingshighway, St. Louis, Mo.
NDA 4–071, Ped-I-Septic for athletes foot liquid.
Pharmaceutical Products Labs (Also known as Pharm-A-Lab(s)), 21661 Sussex Avenue, Oak Park, Mich.
NDA 11–991, Diet-Aid Cap (Diet-A-Way Cap).
Pharmakon, Ltd., Hardturmatr, 173, Zurich 37, Switzerland.
NDA 4–651, LTD Ointment.
Phar-Med, Inc., 14614 East Nine Mile Road, East Detroit, Mich.
NDA 8–022, Histagesic.
Pharmex, Inc., 2113 Lincoln Street, Hollywood, Fla.
NDA 11–995, Inhibi-Tussin.
PHD Lab, Inc., 3839 Washington Avenue, New Orleans, La. or 2337 Tchoupitoulas Street, New Orleans, La.
NDA's:
3–056, Oto-Algos Drops.
3–167, Dex-O-Fed Drops.
3–247, Nosotol solution.
3–584, Prinikol syrup.
Philadelphia Quartz Co., Chester, Pa.
NDA 1–375, Magnesium Trisilicate Batch.
Phillips, Hiram A., M.D., 1802 Colorado, Austin, Tex.
NDA 0–747, Renovo Cream.
Phymel Co. (Out of business), 403 West Eighth Street, Los Angeles, Calif.
NDA 7–954, Phymel tablets.
Physicians Drug & Supply Co., 408 North Third Street, Philadelphia, Pa. or 1458 Chestnut Avenue, Hillside, N.J.
NDA's:
4–614, Diethylstilbestrol tablets 0.2, 1, 25 mg/tab, and 0.2, 0.5, 1.0 mg/cc/inj.
5–981, Amphetamine tablets 5 & 10 mg.
6–679, Thimecil tablets.

NDA's—Continued
7–583, Methafrone brand Vitamin tablets.
7–896, Sodium Gentisate tablets 0.5 gm.
8–038, Okellol ECT (Corotrol ECT).
8–040, Mefurone tablets 50 mg.
8–293, Cortisone acetate tablets 25 mg.
8–513, Idrozide (INH) tablets 50 & 100 mg.
8–517, Hexamethonium Chloride tablets 125 and 250 mg.
9–156, Procadil tablets 250 and 500 mg.
9–275, Rautena 50 and 100 mg.
9–613, Rauwolfia-Veratrum Virides ECT.
9–625, Reserpine tablets 0.1, 0.25, 0.5, 1, 2, 3, 4, 5 mg.
9–656, Hydrocortisone tablets 10 and 20 mg.
9–657, Hydrocortisone topical ointment 1 and 2½%.
9–704, Protoveratrines A & B tablets 0.2 and 0.5 mg.
10–136, Rautenal tablets.
10–190, Reserpine elixir.

Physicians Pharmacal Co., 5942 Northwest 39th, Oklahoma City, Okla.
NDA 3–313, Sedadyne tablets.

Physicians & Surgeons Pharmacal Co., 710 North Sixth Street, Kansas City, Kans.
NDA 10–618, Reserpine Capsules.

Physiological Chemical Co., Inc., 20 Everett Street, New Rochelle, N.Y.
NDA 7–792, Procaine Ascorbate injection.

Picker X-Ray Corp., White Plains, N.Y.
NDA 12–643, Vesipaque tablets.

Pidge, Elmer D., 333 South Hope Street, Los Angeles, Calif.
NDA 0–659, Pidge's Ointment.

Pile Chemical Co., Post Office Box 145, Berwick, Pa.
NDA 0–129, 13 Ointment.

Pilot Labs, 1528 Brandywine Street, Philadelphia, Pa.
NDA 7–301, Pyrilamine maleate syrup 2.5 mg/cc.

Pinex Co., 41 East 57th Street, New York, N.Y.
NDA's:
2–714, Pinex Cough Drops.
7–201, Pinex Antihistamine tablets (pyrilamine maleate) 25 mg.

Pinkham Medicine Co., Lydia E., 271 Western Avenue, Lynn, Mass.
NDA 1–600, Tyzer Syrup (Tang).

Pippinger, Edwin B., 950 Dierks Building, Kansas City, Mo.
NDA 1–493, Pippinger's Preparation Liquid.

Pitman-Moore Co., Division Dow Chemical Co., 1200 Madison Avenue, Indianapolis, Ind.
NDA 5–688, Di-Sulfalac.

Pixacol Co., Dept. Post Office Box 38, Westlake, Ohio.
NDA 3–141, Pixacol Liquid.

Plastic Research Labs, 118 Classon Avenue, Brooklyn, N.Y.
NDA 3–120, Plastic I Liquid.

Plessner Co., Paul, 635 30th Avenue North, Post Office Box 7087, St. Petersburg, Fla.
NDA's:
3–164, Plibital tablets.
10–046, Capilon tablets.

Plough, Inc., 121 South Second Street, Memphis, Tenn.
NDA 10–519, St. Joseph Buffered Aspirin tablets.

Polamer Drug Co., Inc., Post Office Box 222, South River, N.J.
NDA 0–518, Shur-Stop Syrup.

Poole Chemical Co., R. E., Harlan, Iowa.
NDA 4–649, Dermol Solution.

Porter Labs, 245 Fifth Avenue, New York, N.Y.
NDA 2–533, Ornal Nose Drops.

Portia Labs, 4328 McRee Avenue, St. Louis, Mo.
NDA 0–463, Mal-Caps.

Potter and Clark, Ltd., Soothwood High Cliff, Christchurch, Hants, England.
NDA 1–262, Nurvlyfe Cachets Powder.

Premier Dental Products Co., Philadelphia, Pa.
NDA 11–739, Diaket Powder.

Premo Pharmaceutical Labs, Inc., New York, N.Y.
NDA's:
6–099, Aminophylline Suppositories.
6–477, Propylthiouracil Tabs 50 mg.
7–083, Pyranisamine Maleate Tabs.

Blackman & Blackman on NDA, Premo Pharmaceutical Labs. Inc., 608 South Dearborn Street, Room 825, Chicago, Ill.
NDA's:
1–168, Morphine Sulfate Tablets.
1–169, Codeine Sulfate Tables.

Premo Pharmaceutical Labs, Inc., 111 Leuning Street, South Hackensack, N.J.
NDA's:
8–534, Isonicotinic Acid, Hydrazide Tabs. also Nicozide.
9–497, Cortisone Acetate Tabs.
9–558, Hydrocortisone Tabs.
9–676, Respital Tables.
9–723, Cortisone Acetate Ophthalmic Suspension.
9–791, Hycortole Acetate.
10–183, Respital Elixir.
12–678, Tolbutamide Tablets.

Prescription Products Co., 707 East Lincoln Street, Bloomington, Ill.
NDA 0–580, Alphega Salve.

Preston National Drug Co. (Now known as Preston Franklin Pharmacal Co.), Dallas, Tex.
NDA 11–655, Trim Time Caps.

Price, Jesse David, M.D., Room 2, Kresge Building, Michigan City, Ind.
NDA 0–252, Whoopeasy Syrup.

Princeton Lab Products Co., 1 Cherry Hill Road, Princeton, N.J.
NDA 8–577, Adrenocorticotropic Injection.

Prins, Benjamin, 230 East 51st Street, New York, N.Y.
NDA 1–936, Sesa-Creme A–1.

Proco-Sol Chemical Co., 1209 Arch Street, Philadelphia, Pa.
NDA 12–645, EDTAC.

Products Development Co., Inc., Post Office Box 507, La Crosse, Wis.
NDA 1–676, Athex Solution.

Professional Drugs Inc., 76 Ninth Avenue, New York, N.Y.
NDA 6–062, Brevosol Ointment.

Professional Pharm. Co., Petersburg, Va.
NDA's:
0–108, Sal-Boride solution.
0–109, Cherapyne Syrup.
0–110, FerroVita Elixir.
0–118, Padiene capsules.
0–119, Vita-B elixir.
0–120, Bellatal tablets.
0–121, Ferrofate tablets.
0–122, Epso Phos Solution.
0–163, Calcilate Wafers.
0–164, Sulfanil-A-Carb tablets.

Professional Products Co., 1601 Calhoun, Post Office Box 22404, Houston, Tex.
NDA's:
9–384, Raupentina tablets 50 and 100 mg.
9–727, Reserpine tablets 0.1, 0.25 mg.

Pro-Medico Pharmaceutical Co., Inc., 778 Bergen Street, Brooklyn, N.Y.
NDA's:
4–481, Stilbestrol inj. 0.5, 1, 2, 5 mg/cc.
4–867, Stilbestrol in oil inj.

Pronovost, Malvina, 75 Birch Street, Lewiston, Maine.
NDA 0–809, Pronto Ointment.

Prote, Joseph C., Jr., Prote's Laboratory, 155–93 Sanford Avenue, Flushing, N.Y.
NDA 0–466, Herbs Powder for Athlete's Foot.

Prouty, R. L., 601 San Mateo Avenue, San Bruno, Calif.
NDA 2–038, Prouty's Tightener.

Pruden, Albert F., 700 West Main Street, Hartford City, Ind.
NDA 4–403, Prudo Ointment.

Prussin & Co., S., 129 Dupont Street, Brooklyn, N.Y.
NDA 6–028, Woodman Hair Cream Lotion.

Purepac Corp., 200 Elmora Avenue, Elizabeth, N.J.
NDA's:
7–081, Histacol tablets.
7–908, Histacol compound tablets.
9–315, Hist-A-Cal Lotion.
9–467, Kalahist Ointment.

Purity Drug Co., Passaic, N.J.
NDA's:
3–501, Sulfathiazole tablets.
3–502, Sulfapyridine tablets.
4–922, Stilbestrol tablets.
5–990, Methamphetamine HCl tablets.

Quarles Sales Co., Paris, Ill.
NDA 1–186, Maple Leaf Stainless Salve.

Queen City Pharmacal Co., 1040 Marshall Avenue, Cincinnati, Ohio.
NDA's:
6–105, dl-Desoxyephedrine HCl tablets 10 mg.
9–701, Rawtina tablets 50 and 100 mg.
10–403, Rawserp tablets 0.25 mg.

Quincy Labs, 3831 West Lake Street, Chicago, Ill.
NDA 5–613, Orasept Mouthwash.

R and J Chemical Co., 4554 Broadway Avenue, Chicago, Ill.
NDA 1–791, Nogerm Mouthwash and Gargle.

Rainbow Manufacturing Co., 3819 Walnut Street, Kansas City, Mo.
NDA 2–397, Uncle John's Ointment.

Ra-Lo Jr. Manufacturing Co., 1548 North Miro Street, New Orleans, La.
NDA 3–047, Ralojr Liquid.

Rand Pharmaceutical Co., 333 Columbia Street, Rensselaer, N.Y.
NDA 9–284, Pruraine (Domine) ointment.

Rapsol Process Inc., New York, N.Y.
NDA 5–910, Rapsolized Gum Tragacanth, Acacia, Karaya.

Rational Medicines Inc., 185 Madison Avenue, New York, N.Y.
NDA 0–413, Sunscreen 99 Cream.

Rawleigh Co., W. T., 223–225 East Main Street, Freeport, Ill.
NDA 12–130, Throat Balm Syrup.

Ray Drug Co., 3335 Grand Avenue, Oakland, Calif.
NDA 12–214, Leen Timed Disintegration capsules.

Raymer Pharmacal Co., Jasper and Willard Streets, Philadelphia, Pa.
NDA's:
3–687, Estrogenic substance inj. 2M, 10M, 20M IU/cc.
4–426, Stilbestrol tablets 0.1, 0.5, 1.0 mg., inj. 0.2, 0.5, 1.0 mg/cc.
4–833, Sulfanilamide injection.
6–401, Methadon inj. 5 and 10 mg/cc; tablets 2.5, 5.0, 7.5 mg.
7–826, Gentarth ECT.
10–001, Reserpine tablets 0.25, 1, 2, 3, 4, 5 mg.
10–561, Hydrocortisone acetate ointment 1 and 2.5%.

Reape, John E., 525 East Avondale Avenue, Youngstown, Ohio.
NDA 0–717, Hydro S Shampoo.

Red River Medicine Co., Minneapolis, Minn.
NDA 1–934, Tonestom Elixir.

Red Rose Products Co., 139 Fayetteville, Decatur, Ga.
NDA 3–235, Red Rose Headache Powder.

Red Star Chemical Co., Inc., 17–21 East 22d Street, New York, N.Y.
NDA 8–495, ACTH Injection.

Byrd Redd, Martinsville, Va.
NDA 4–021, Red Bird Corn Remedy Salve.

Redman, Orrin A., 7403 South Euclid Avenue, Chicago, Ill.
NDA 4–037, Moccasin Foot Powder.

Redwood Zone Inhalant Co., Santa Rosa, Calif.
NDA 0-427, Essence of Redwood with Eucalyptol Compound—Inhalant and spray.
Redyns Co., Inc., 2114 Coplin Avenue, Detroit, Mich.
NDA 9-438, Aqua-Dent Liquid.
Redzisz, Andrew, 301 Halladay Street, Jersey City, N.J.
NDA 0-155, AR Radical Ointment.
Reed Labs, San Mateo, Calif.
NDA's:
1-211, Gypsolene skin lotion.
1-213, Pineolene liquid.
1-214, Plaster-Off liquid.
Reese Chemical Co., 10617 Frank Avenue, Cleveland, Ohio.
NDA's:
0-029, Blue tablets.
2-147, Red Hearts tablets.
3-514, Thoxine solution.
5-648, Doughboy Prophylactic kit ointment.
7-163, Pyranisamine Maleate (Rehistin).
7-624, Rehistco tablets.
Reeve Chemical Co., Inc., 148 Chambers Street, New York, N.Y.
NDA 10-582, Ambratal-Reserpine tablets.
Reinhardt, L. F., La Center, Minn.
NDA 2-593, Reinhardt's Foot Powder.
Reins Star Tea Co., 307 East 89th Street, New York, N.Y.
NDA 0-610, Rein's Star Tea.
Reinsch, Charles, 109 West 84th Street, New York, N.Y.
NDA 3-851, Urex Granules (Salurmed Granules).
Reinschild Chemical Co., Subsidiary of Reguiin Inc., New Rochelle, N.Y.
NDA 0-899, Ferma liquid.
Rek On So Products Inc., 808 Southwest 19th Street, Miami, Fla.
NDA 1-341, Rekonso Cough Drops.
Ramin Pharm. Co., 804 Hudson Avenue, Rochester, N.Y.
NDA 0-091, Pro-Vita Solution.
Renlow Chemical Co., 112 North Eighth Street, Easton, Pa.
NDA 0-138, O-B Powder.
Republic Drug Co., Inc., 30 Pannell Street, Buffalo, N.Y.
NDA 11-180, Super-Hist capsules.
Republic Drug & Sundry Co., Buffalo, N.Y.
NDA 11-605, Unitrol capsules.
Reserve Research Co., 960 St. Clair West, Cleveland, Ohio.
NDA's:
2-450, Aloloid suspension and drops.
2-451, Colloidal aluminum hydroxide suspension and drops.
4-060, Sulfonacreme ointment.
Revere Chemical Co., 39 Broadway, New York, N.Y.
NDA 7-132, Tolergen tablets, 10 mg.
Rexar Pharmacal Corp., 382 Schenck Avenue, Brooklyn, N.Y.
NDA 9-615, Rauwolfia-Veratrum virides tablets.
Rhinopto Co., 308 South Harwood Avenue, Dallas, Tex.
NDA's:
4-267, Rhinafedrin drops 1%.
4-284, Rhinall capsules.
Rhodes Pharmacal Co., Inc., 41 East Oak Street, Chicago, Ill.
NDA's:
7-777, Antussamine syrup (antihistamine).
10-310, Prevoides tablets and capsules.
Rhodia, Inc., 297 Jersey Avenue, New Brunswick, N.J.
NDA 13-048, Sultirene (sulfamethoxypyridazine) tablets for export to Vietnam.
Richlyn Labs, 3725 Castor Avenue, Philadelphia, Pa.
NDA 10-228, APAP tablets.
Ridco Lab., 2013 Spruce Street, Boulder, Colo.
NDA 0-989, Ridco Corn and Callus Remover Cream.
Riesen, Walter P., Box 146, Elm Grove, Wis.
NDA 0-386, Riesen's Antiseptic Foot Powder.
Rigidtest Products, Inc., c/o Becker Professional Pharmacy, 4744 North Western Avenue, Chicago, Ill.
NDA 3-730, Rigitest Surgical Dressing.
Rin, Inc., 38 Pearl Street, New York, N.Y.
NDA 0-112, Rin for Men Only Under Arm Lotion.
Ritz Bitters Co., 3123 North Ashland Avenue, Chicago, Ill.
NDA 3-679, Ritz Bitters Solution.
Ri-Zo Corp., 742 Market Street, San Francisco, Calif.
NDA 4-320, Ri-Zo Powder.
Robbins, Williams and Co., 8006 Oakland Avenue, Detroit, Mich.
NDA 0-692, Trihygenol Mouthwash and gargle.
Roberts Biological Lab, Buffalo, N.Y.
NDA 5-277, Aller-Tabs and Allergi-Tabs.
Robertson's Drug Co., Frederick, 1001 Fourth Avenue, Huntington, W. Va.
NDA 3-178, Robertson's Balm.
Robertson Products Co., Inc., Theo. B., 700-704, West Division Street, Chicago, Ill.
NDA 0-711, Sept-O-Soap Liquid.
Robin Pharmacal Co., 480 Broome Street, New York, N.Y.
NDA's:
7-240, PASA and Sodium PASA tablets.
7-241, Pyranissamine maleate.
8-006, Wards formula antihistamine tablets.
8-896, Iso-nicotinic hydrazide tablets.
9-361, Rauwolfia serpentina tablets 50 and 100 mg.
9-628, Reserpine tablets.
9-685, Rauwolfia Serpentina, Mannitol hexanitrate, rutin tablets.
9-883, Rauwolfia Serpentina-Veratrum virides tablets.
Robinson Laboratories, Inc., 355 Brannan Street, San Francisco, Calif.
NDA 12-340, Protrim Timedcaps.
Roch, Joseph Conrad, 496 Pine Street, Providence, R.I.
NDA 3-396, Roch's syrup.
Rogers Diesel and Aircraft Corp., 1120 Leggett Avenue, New York, N.Y.
NDA 5-894, Triethylene Glycol liquid.
Rogers Products Co., 124 West Jackson Street, Ripley, Tenn.
NDA 1-184, Foot Bath Powder.
Rona Drug, Inc., TNF Pace Pharmacal Co., Inc., 457 North Third Street, Philadelphia, Pa.
NDA's:
7-223, Ronamine tablets.
10-528, Reserpine tablets 0.1, 0.25, 0.5, 1, 2, 3, 4, 5 mg.
Rootone Products, Inc., 6801 South Broadway, St. Louis, Mo.
NDA 1-797, Rootone Scalp Massage Shampoo.
Rorer, Inc., William H., 500 Virginia Drive, Fort Washington, Pa.
NDA 4-114, Special formula powder for Slaw Adam, M.D. containing: Salicylic acid, menthol, camphor, boric acid, starch.
Rosen, Maurice, 1218 West State Street, Milwaukee, Wis.
NDA 0-612, Pile-O-Tors.
Rossmar Labs, 1806 East Venango, Philadelphia, Pa.
NDA's:
0-374, Hepron tablets with liver fraction.
2-330, Hepron tablets.
3-144, Tri-Alum-Alac liquid.
4-378, Hep-Iron liquid.
Roswill Co., Attention: John A. Ross, Plymouth, Mich.
NDA 2-587, Rightway Ointment.
Rouche-Renaud Pharm. Co., Fairhaven, Mass.
NDA 4-444, Adheron liquid.
Round Corner Drug Co., 801 Massachusetts Street, Lawrence, Kans.
NDA 2-482, Dr. Gowdy's Rx for Acid Stomach Powder.
Roussel Corp., 155 East 44th Street, New York, N.Y.
NDA's:
7-429, Sterogyl injection.
9-972, Hydrocortisone tablets 10 and 20 mg.
Rowell Labs, Baudette, Minn.
NDA 10-044, Hydrocortisone tablets 10 and 20 mg.
Royal Drug Co. of Batlimore Maryland, 517 West Lombard Street, Baltimore, Md.
NDA 0-731, Royal Headache tablets.
Royal Oak Product Co., Royal Oak, Mich.
NDA 4-199, Polle No Liquid.
Rubel and Co., J. R., Okolono, Miss.
NDA 1-765, Salvacam Salve.
Rubenstein, Helena, 655 Fifth Avenue, New York, N.Y.
NDA 4-147, Gourielli Estrogen Cream.
Rubin, Louis, 3466 Jackson Boulevard, Jackson Heights, Long Island, N.Y.
NDA 1-962, Poditats Wafers.
Runner Co., Inc., E. I., Wheeling, W. Va.
NDA 7-228, Earle's Antihistamine tablet.
Ryback, Joseph W., 75 West Jackson, Chicago, Ill.
NDA 4-014, Herbaco Liquid.
Ryco Labs Inc., 79 Northwest 40th Court, Miami, Fla.
NDA 4-643, Para-Pads Dressing.
Sage Co., 325 East Young Street, Tulsa, Okla.
NDA 8-035, Sayko ointment (Sayko Pile Ointment).
Sahyun Labs, Santa Barbara, Calif.
NDA 7-406, Methocine tablets.
Salander, Abraham B., 168 North 170th Street, Bronx, N.Y.
NDA 2-146, ABS Foot Powder.
Sales Co., J. S., Joseph Spevock, 4072 Olive Street, St. Louis, Mo.
NDA 0-198, Punkin-Seds tablets (P.S. Laxative) (Pompon Sade).
Salvgene Laboratories, 222 East Front Street, Youngstown, Ohio.
NDA's:
0-724, Toka-Sana Oral Solution.
1-395, Tonka-Sana Tonic Solution.
Sandoz Chemical Works, Inc., Route 10, Hanover, N.J.
NDA 5-267, Ipesandrine Syrup.
Sa-Tan-Ic Medicine and Manufacturing Co., Wichita, Kans.
NDA 0-944, Sa-Tan-Ic Laxative liquid.
Saul Co., Richard F., 2500 North 25th Street, Philadelphia, Pa.
NDA 1-322, Pruniform Syrup.
Savoy Drug & Chemical Co., 16 South Peoria Street, Chicago, Ill.
NDA's:
3-936, Vitamar tablets.
7-158, Nutro tablets.
9-482, Rauwolfia Serpentina tablets 50 mg.
Sayman Products Co., 2101 Locust Street, St. Louis, Mo.
NDA 7-313, Pyrilamine maleate tablets 25 mg.
Schaffer, C. F., 1126 Lakewood, Detroit, Mich.
NDA 5-089, Silver Allantoinate Vaginal powder.
Scheidemann Remedy Co., Inc., Milwaukee, Wis.
NDA 0-577, Scheidemann's Herbal Tea.
Schenley Laboratories, Inc., New York, N.Y.
NDA 10-621, Dorbantyl Capsules.
Scherer Corp., R. P., 9425 Ginnel Avenue, Detroit, Mich.
NDA's:
6-881, Undecylenic acid capsules—made for Schering Corp.
6-900, Tween-80 capsules 500 mg.
6-915, Undecylenic capsules—made for Sharp & Dohme.

Schering and Glatz, Inc., 113 West 18th Street, New York, N.Y.
NDA's:
0–893, Urotropin and Sodium Acid Phosphate tablets.
2–403, Peralga tablets.
3–734, Ampules Sodium Citrate Injection, 3.8%.
3–735, Ampules Sodium Citrate injection, 5%.
4–163, Ampules Ascorbic Acid injection, 100 mg./2 cc.
4–164, Ampules Thiamine HCl injection.

Schlicksup Drug Co., Inc., 420–22 Southwest Washington Street, Peoria, Ill.
NDA 10–246, Repoid Tablets.

Schlueter Medicine Co., C. O., 733 South Norman Avenue, Evansville, Ind.
NDA 2–780, Schlueter's Pink Ointment.

Julius Schmid, Inc., Lackawanna Avenue, West Paterson, N.J.
NDA 8–161, Ramses Vaginal Cream.

Schneiderwirth, Herman J., 445 Gramatan Avenue, Mount Vernon, N.Y.
NDA's:
2–211, Mucargol Powder.
2–212, Mucargol Ointment.
2–213, Musil Suppositories with Benzocaine.
3–128, Lubricaine Jel.

School Manufacturing Co., Inc., 213 West Schiller Street, Chicago, Ill.
NDA's:
0–857, Dr. Scholl's Foot Balm Lotion.
5–432, Sulfa-Solvex powder.

Schumann-Sumner Products, 858 North Alexandria Avenue, Los Angeles, Calif.
NDA's:
0–380, Teef Powder.
0–381, Teef Solution.

Schuylkill Chemical Co., 2436 West Sedgley Avenue, Philadelphia, Pa.
NDA 3–756, Sulfallantoin powder and ointment.

Schwartz Labs, Inc., 202 East 44th Street, New York, N.Y.
NDA 6–296, Methiacil tablets, 50 mg.

Schweickard(t), Karl W., 87 Georgetown Avenue, West View, Pa.
NDA's:
4–077, Chorasto liquid.
4–121, Campho capsules.

Scientific Nutrition Corp., 60 East 42d Street, New York, N.Y.
NDA's:
3–845, Foodex.
4–419, Vitadiet w/minerals wafers.

Scott and Bowne Vitamin Corp., Bloomfield, N.J.
NDA's:
0–658, Emulsion of Natural A and C Concentrate, batch.
3–696, Calcium compound wafers.
6–442, Browne antiseptic baby oil liquid.

Scott Gallan and Co., Inc., 16818 Vaughan Avenue, Detroit, Mich.
NDA 2–738, Bruce's Formula SG 12 lotion.

Seaboard Drug Co., 21 West 45th Street, New York, N.Y.
NDA 9–308, Mericin tablets.

Seal-Ins Labs., Inc., 4021 East Florence Avenue, Bell, Calif.
NDA's:
0–289, Seal-Ins of Gentian Violet ECT.
2–034, Seal-Ins Sodium Salicylate ECT.
2–130, Seal-Ins tablets containing: Belladonna, thyroid, pituitary sodium glycolate and others.
2–131, Seal-Ins tablets containing: Belladona, thyroid, pituitary and others.
2–524, Seal-Ins tablets and ECT of phenobarbital and Ephedrine.
2–737, Phenoparbital tablets and Sustained release tablets both ½ gr.

Seamless Rubber Co., 253 Hallock Avenue, New Haven, Conn.
NDA's:
5–486, Synthetic Rubber Adhesive Plaster Dressing.
6–407, Seamless Pro-Cap dressing.

Sears Roebuck & Co., Chicago, Ill.
NDA 7–224, Contra-Hist tablets.

Seaver and Co., S. R., North Kansas City, Mo.
NDA's:
0–355, Aspirin tablets, 1 gr.
0–356, Aspirin tablets, 5 gr.
0–357, Aspirin tablets, 1 gr.
0–358, Aspirin tablets, 5 gr.
0–359, Fenital tablets.
0–360, Alkavan tablets.
0–377, Tri-Sili-Carb powder.
0–378, Cala-Derma lotion.
0–419, Vapocol ointment.
0–420, Birnasan ointment.
0–421, Opti-Lave lotion.
0–523, Imo ointment.
0–527, Mineral oil emulsion.
0–528, Lubri-Mul with Phenolphthalein.
0–553, Sulfosol solution.
0–554, Sodium Salicylate ECT 5 gr.
0–572, Pabico tablets.
0–573, Scabisul ointment.
0–574, Ryzalen tablets.
0–575, Algesan ECT.
0–645, Nasarex drops.
0–646, Cophycl ointment.
0–647, Triti-Flex liquid.
0–648, Cremalgin cream and ointment.
0–649, Impetex ointment.
0–650, Lavagene douche.
0–688, Calazox ointment.
0–689, B–E–Z ointment.
0–690, Entotab Mon-HEX tablets.
0–745, Enzonan liquid.
0–858, Isojell Jel.
0–859, Oxy-Tan Jel.
0–860, Stafenol ointment.
0–952, Nasarex with Ephedrine drops.
0–953, Emeralgin solution.
0–954, Barbicyl ECT.
0–972, Ferrous sulfate tablets, 5 gr.
0–973, Sulfanilamide tablets.
1–010, Vitonal liquid.
1–011, Entotab Amino Phen ECT.
1–012, Sedazane tablets.
1–026, Ogiene Mouthwash.
1–027, Diurex tablets.
1–109, Pyroferrin liquid.
1–110, Sodium Salicylate ECT 10 gr.
1–159, ABC Concentrate solution.
1–202, K-B Granules.
1–269, Fedriphen tablets.
1–274, Tamporex liquid.
1–278, Agapectin Jel.
1–279, Homann's Astrigent lotion.
1–380, Cholaphen with Aloin and Cascara tablets.
1–451, Infacol liquid.
1–462, Pectolin syrup.
1–539, Dilanol ECT.
1–544, Alka-Zyme tablets.
1–545, Brewer's Yeast tablets, 6 gr.
1–758, Entotab Magnesium sulfate 10 gr.
1–775, Pectolin with Morphine liquid.
1–896, Modifen tablets.
1–950, Copper Sulfate and aluminum sol. and douche.
1–966, Lubri-Mul No. 2.
1–967, Lubri-Mul No. 2 with Phenophthalein.
2–148, Lactrisil tablets.
2–392, Lactripectal tablets.
2–443, Phenobarbital and Belladonna tablets.
2–459, Methenamine and Acid Phosphate tablets.
2–460, Methenamine tablets, 5 gr.
2–525, Lac-D-Cal tablets.
2–639, CT Sedaco tablets.
2–667, Benzo Mul Emulsion.
2–886, Phenobarbital tablets, 1.5 gr.
2–887, Phenobarbital tablets, ½ gr.
2–888, Phenobarbital tablets, ¼ gr.
2–952, Theobromine with sodium salicylate ECT.
4–577, Dica-Phos with vitamin D tablets.

Sed-A-Dent Co., 336 Palace Building, Minneapolis, Minn.
NDA 2–723, Sed-A-Dent Dressing.

Seeqit, Inc., 150 West 55th Street, New York, N.Y.
NDA 1–129, Seeqit tablets.

Sheldon Labs., Los Angeles, Calif.
NDA 10–938, Vibelve 1000 Concentrate injection.

Selig Co., 342 Marietta Street, Atlanta, Ga.
NDA 6–075, Showertol solution.

Sencerbox, Robert W., 2704 Hollister Avenue, Santa Barbara, Calif.
NDA 1–841, Vitamin B_1 and B_2 complex with vitamin C caps.

Senna Products Co., 701 Ramsay-McCormack Building, Birmingham, Ala.
NDA's:
3–309, Senna-Phen wafers.
3–310, Senna Mint wafers.

Service Drug Co., Plaquemine, La.
NDA 0–675, Ben-Sal ointment.

Sesol Co., 1668 Union Commerce Building, Cleveland, Ohio
NDA 7–388, Sesol shampoo.

Seydel Products Co., N.J.
NDA 0–092, Seydel Salve Ointment.

S. F. Labs, 509 Morse Street, NE., Washington, D.C.
NDA 2–983, 3-Way solution.

Sfregos Products Co., 2819 23d Avenue, Astoria, Long Island, N.Y.
NDA 1–542, S Fregos Powder.

Shadowen and Medicine Co., 3515 Buck Street, Houston, Tex.
NDA 1–306, Shad-O-Lax Powder.

Shaw, Frank M., 135 West 20th Street, New York, N.Y.
NDA 0–346, Dr. Jones' capsules.

Shellmar Products Co., Mount Vernon, Ohio.
NDA 5–762, Sterilite Alpha Powder.

Sheperd, John, Stearns, Ky.
NDA 2–703, Sheperd's ointment.

Sheridan Co., Inc., F., 452 Bagley Avenue, Detroit, Mich.
NDA 1–241, Sheridans Foot Lotion Liquid.

Sherman Labs., 5031 Grandy Avenue, Detroit, Mich.
NDA's:
1–486, Acarosil liquid.
1–487, Acaralum liquid.
2–046, Fenatrate (tetraferrate) B_1 syrup.
2–047, Fenatrate tablets.
2–048, Iron, Arsenic, and vitamin B_1.
4–106, Primacol injection.
3–874, Fenatrate B_1 w/copper tablets.
3–875, Fenatrate B_1 w/copper syrup.
4–640, Stilbestrol tablets.
4–641, Stilbestrol injection.
7–153, Histavac tablets.

Shom Drug Co., 163 North Concord Street, St. Paul, Minn.
NDA 4–711, Ivol solution.

Shores Co., Inc., Cedar Rapids, Iowa.
NDA's:
0–424, Eye lotion.
0–581, Liver Ron tablets.
1–574, Dicalcium phosphate with vitamin B and D tablets.
4–428, Sulfathiazole tablets.
4–465, Sulfapyridine tablets.
4–676, Stilbestrol tablets.
5–094, Sulfathiazole ointment 10%.

Shulton, Inc., 697 Route 46, Clifton, N.J.
NDA 9–233, Thylox sulphur w/actamer cream and soap.

Siegler, Carl, 871 Lakeview Road, Cleveland, Ohio.
NDA 2–645, Meldol liquid.

Silkoloid Corp., 5140 West Lisbon Avenue, Milwaukee, Wis.
NDA 9–651, Sil-kol-oid liquid.

Silverman, David, and Edith, 3402 West Carmen Avenue, Chicago, Ill.
NDA's:
2–686, Evrons Rectal ointment.
2–687, Evrons Rectal suppositories.

Simmy Labs, Inc., 116 East 58th Street, New York, N.Y.
NDA 2–289, Schwarz Tea.

Singleton and Sons, 108 Dallas Street, Wichita Falls, Tex.
NDA 0–383, Royal Corn Remover solution.

Siol Co., J. C. Milner, 2221 Pearl Street, Fort Worth, Tex.
NDA 1-040, Lotio Cherne Lotion.
Sisom Clinical Lab, Cold Springs and Collingswood Avenues, Oaklyn, N.J.
NDA 3-947, Gemma liquid.
Sisreau Co., 363 Rice Street, St. Paul, Minn.
NDA 0-988, T and T Foot lotion.
Skat Labs (Skat Sales Co.), 3 Green Street, Woburn, Mass.
NDA 1-442, Skat ointment.
Skepner, Harry, Hollywood, Calif.
NDA 1-029, Private formula tablets #415969.
Skol Co., Inc., 304 East 23d Street, New York, N.Y.
NDA 0-361, Skol antiseptic cream.
Smith, Kline, and French Labs., 1500 Spring Garden Street, Philadelphia, Pa.
NDA's:
5-171, Microform Sulfathiazole suspension 20% and microcrystalline powder.
5-692, Pervitin HCl tablets, 5 mg. (desoxyephedrine).
6-688 Paredrine HCl ampules, 10 mg.
Smith Drug Store, C. E., 90 Front Street, West Springfield, Mass.
NDA 2-235, White's powder.
Smith, Charles H., 2449 West Sargent Street, Philadelphia, Pa.
NDA 0-030, CHS Ointment.
Smith, Clifford, 4847 North Winchester Avenue, Chicago, Ill.
NDA 0-351, Smith's Liniment ointment.
Smith, Curtis, Oza Compound Products, Fort Wayne, Ind.
NDA 1-303, OZA compound emulsion.
Smith, James A., M.D., 233 South 45th Street, Philadelphia, Pa.
NDA 0-904, Fawn Soap.
Smith, J. Henry, M.D., 1207 North Seventh Street, Longview, Tex.
NDA 2-009, Dr. Smith's Sweet Euquinine and iron tonic syrup.
Smith, L. A., 1 Montgomery Street, San Francisco, Calif.
NDA 5-662, OKUR liquid.
Smith, Nathan, 47 Ann Street, New York, N.Y.
NDA 4-401, Neutradent Mouthwash.
S.N.J. Products Co., 4757 South Broadway, Los Angeles, Calif.
NDA 5-263, Sulfathiazole Nasal Jel.
Snoddy, Robert C., 1206 Central Avenue, Indianapolis, Ind.
NDA 0-408, Pepto Magna tables.
Sodasal Co., South Bend, Ind.
NDA 2-334, Enkasal liquid.
Solon Parker, Pearl County, Ratcliff, Ark.
NDA's:
0-008, Mer Ton solution (Ty-Tan).
1-548, Creo Nips syrup.
Sonoral Labs., TNF Sonoral Products Corp., 1910 Webster Avenue, New York, N.Y.
NDA 10-932, Ret-O-Gen injection.
Southern Products Co., St. Louis, Mo.
NDA 0-504, Vita-Jel Gel.
Southern Remedies Inc., 219 East Savannah Avenue, Valdosta, Ga.
NDA's:
1-646, Soreco Laxative compound liquid.
1-647, Ido Rub liniment.
Spandy Inc., 19 Spring Street, West Orange, N.J.
NDA 8-224, Spandy liquid.
Spa-Rex Co., Box 501, St. Louis, Mo.
NDA 1-607, Spa-Rex liquid.
Spartan Pharmacal Co., 354 Mercer Street, Jersey City, N.J.
NDA's:
7-197, Nehistagen tablets (antagonhist tablets).
7-760, Phenacetin & caffeine tablets.
S.P.D. Products Co., Now known as Sulfadent Co., Kansas City, Mo.
NDA 5-429, Sulfa-Dent Toothpowder.
Specialty Products Co., 433 Bourbon Street, New Orleans, La.
NDA's:
1-370, Holmes Aromatic Mouthwash.
1-371, Maison Blanche Mouthwash.
Specific Pharm. Co., 331 Fourth Avenue, New York, N.Y.
NDA's:
5-124, Analbis.
5-652, Soluazole injection 1 gm./5cc.
Speetzen, G. C., 1603 West Ninth Street, Davenport, Iowa.
NDA's:
0-909, Byteze lotion.
1-673, Speetzen's capsules.
Spicer-Gerhart Co., 8350 Foothill Boulevard, Sunland, Calif.
NDA 2-718, Thiamine chloride solution.
Sporex Products Co., 2017 South Michigan Avenue, Chicago, Ill.
NDA 5-494, Sporex powder.
Sta-Dri Products Co., 147-47 Sixth Avenue, Whitestone, N.Y.
NDA 2-547, Sta-Dri lotion.
Standard Chemical Co., 1013-1017 High Street, Des Moines, Iowa.
NDA's:
0-433, Magnesium hydroxide tablets.
0-434, Carminative solution containing: cinnamon oil, clove oil, peppermint oil, and anise oil.
0-559, Stanex Balm ointment.
0-582, Nicotinic acid tablets 25 mg.
0-794, Allantocaine ointment.
0-795, Bile Salts compound tablets.
1-388, Carbromal #602 tablets.
1-880, Pep-Skin solution.
2-166, Sulfapyridine tablets 7.5 gr.
2-167, Thiamine chloride elixir.
2-305, Pectos Rx 3 liquid.
2-306, Aminophylline tablets 1.5 gr.
2-307, Phena-Stan (Stanodyne Rx 1).
2-308, Phena-Stan w/codeine.
2-393, Beta-Stan Syrup.
2-394, Vita-Stan liquid.
2-461, Digitalis powder capsules 1.5 gr.
3-118, Pentibarbital sodium capsules ¾ & 1½ gr.
3-209, Aquadrine wafers.
3-539, Sulfathiazole tablets 7.5 gr.
3-688, B-G tablets.
3-689, Mercaseptic solution.
3-762, Estrogenic substance inj. 1000, 2000, 10000 IU/cc.
4-639, Sulfathiazole ointment 5%.
5-101, Sulfanilamide ointment 5%.
3-117, Bellaphen tablets.
3-592, B-Complex elixir.
3-593, B-Complex syrup.
Standard Chemical & Mineral Corp., 332 South Michigan Avenue, Chicago, Ill.
NDA's:
0-429, Prolarmon rectal jel.
0-430, Jeltone Jel.
0-431, Prolarmon liquid.
0-432, Prolarmon jel.
Standard Drug Co., Cleveland, Ohio.
NDA 7-160, Antihistamine tablets 25 mg.
Standard Pharmacal Co., 847 West Jackson Boulevard, Chicago, Ill.
NDA's:
1-426, Calsamate solution.
7-106, Somnite Relaxant tablets.
Standard Pharmacal Co., 1300 Abbott Drive, Elgin, Ill.
NDA 9-896, Reserpine Alkaloid tablets, 0.25 mg.
Standard Products Co., Charleston, W. Va.
NDA's:
1-268, Silatrobarb tablets.
1-431, Tonik Tyme elixir.
Stansbury Chemical Co., 1929 Aurora Avenue, Seattle, Wash.
NDA 7-209, Selrodo antihistamine tablets 25 mg.
Starer, Betty G., 1730 E Street, Washington, D.C.
NDA's:
2-432, Betty Tusts Goodwill compound liquid.
4-247, Betty and Leon Goodwill compound syrup.
Starr Manufacturing Co., Petersburg, Va.
NDA 7-715, Histab tablets.
State Sales Co., 145 Weber Avenue, North Canton, Ohio.
NDA's:
1-876, Kozak medicines special formula A tablets.
1-877, Kozak medicines special formula B tablets.
1-878, Kozak medicines special formula C tablets.
1-879, Kozak medicines special formula D tablets.
Stayner Corp., 2531, Ninth Street, Berkeley, Calif.
NDA 7-257, Pyranisamine maleate tablets 25 mg.
Steifel Labs., Inc., Route 145, Durham, N.Y.
NDA 10-777, Metashal (Colorado Shale oil) ointment and lotion.
Stein & Co., Carlos, 806 Augusta Street, San Antonio, Tex.
NDA's:
1-508, Syrup of garlic Stein.
1-510, Urolizine granules.
1-511, Stein stomachal elixir.
1-512, Neodumol Stein Syrup (Neopulmol).
1-513, Analgesic Balm Stein ointment.
1-514, Stein Hemoglobin & Iron peptonate syrup.
1-515, Stein Vaginal ovules 2 strengths.
1-516, Vaginal ovules Stein suppositories 2 strengths.
1-517, Vaginal ovules Belladonna suppositories.
1-520, Lubricol liquid.
1-522, Malcodon liquid.
1-523, Malcodon w/Creosoye & Guaiacol liquid.
1-525, Yodosalicol injection.
1-527, Ergovitam drops.
1-528, Ergovitam capsules.
1-529, Collyrium drops.
Steinecke, Henry Louis, 3626 Woodland Avenue, Kansas City, Mo.
NDA 1-595, Apex Salve.
Stevens, F. B., 2777 Lancashire Road, Cleveland Heights, Ohio.
NDA 1-254, Sani-Soles.
Stewart Co., A. Collins, 251 Mill Street, Newtonville, Mass.
NDA 0-295, Claranol ointment and soap.
Stillco Labs., 1677 10th Way, Post Office Box 991, Sarasota, Fla.
NDA 9-811, Tensin 0.1 and Tensin 0.25 tablets.
Stolberg Labs., 667 Madison Avenue, New York, N.Y.
NDA's:
1-631, Apydol capsules.
1-853, Senafol.
Straub and Co., W. F., Chicago, Ill.
NDA's:
4-774, Diethylstilbestrol powder batch.
5-187, Water soluble vitamin K3 batch.
5-622, Forbestrin injection.
Strax Manufacturing Co., 168 Fifth Street, Oakland, Calif.
NDA 2-193, Strax liquid.
Stuart Co./Division Atlas Chemical Industries, Inc., 3360 East Foothill Boulevard, Pasadena, Calif.
NDA 9-019, Achlorohydria Diagnostic Aid.
Studebaker Labs., Inc., L. H., 301-303 East 11th Street, Erie, Pa.
NDA 10-196, Serexal tablets #0.1, 0.25, 0.5, 1, 2, 3, 4, 5.
Success Chemical Co., Inc., 800 Hinsdale Street, Brooklyn, N.Y.
NDA's:
9-279, Rauwolfia Serpentina tablets 50 and 100 mg.
9-403, Cortisone acetate tablets.
9-578, Hydrocortisone ointment 1 and 2½%.
9-611, Rauwolfia-Veratrum virides tablets.
9-629, Reserpine tablets.
10-192, Reserpine elixir 0.25 mg/5cc.
11-479, Trim-N-Slim capsules.

Sulfazole, Inc., North Avenue and Washington Street, Baltimore, Md.
NDA 4–248, Sulfazole ointment, 5%.
Supreme Labs. (Knox All Labs.), Kansas City, Mo.
NDA 1–608, Supreme formula liquid (Knox All Liquid).
Surface Chemicals Inc., McKee's Rocks, Pa.
NDA 6–612, Surfacide lotion.
Sutliff & Case Co., Inc., 291 Spring Street, Post Office Box 838, Peoria, Ill.
NDA's:
0–368, Private formula #6641 tablets containing: Belladonna, mag. oxide, calcium carbonate and others.
0–856, Iron Sulfate, thiamine compound tablets.
0–916, Private formula #6647 tablets containing: phenobarbital, hyosciamus, valerian and others.
1–165, Potassium chloride tablets 5 gr.
1–975, Quinidine sulfate tablets 3 gr.
2–134, Elixir Thiamine chloride.
2–164, Solution morphine sulfate inj. ¼ gr./cc.
2–165, Phenylmercuric nitrate ointment.
2–190, Sulpyride tablets 7.7 gr.
2–312, Terpin Hydrate-Codeine-Creosote elixir.
2–486, Lixir-B elixir.
2–801, Cervo Syrup.
3–116, Wintergreen-Camphor compound liquid.
3–171, Cervo with morphine liquid.
3–172, Cervo with codeine liquid.
3–250, Cero Green solution.
3–292, Aspirin-Dover-Phenacetin compound tablets.
3–348, Cervo/Codeine liquid.
3–349, Cervo/morphine liquid.
3–698, Blood Thiocyanate test set solution.
3–797, Vitamin B complex w/thiamine and riboflavin syrup.
3–828, Dicalate compound powder.
3–898, Potassium thiocyanate tablets 1½ gr.
3–923, Salicylate-Iodide compound w/ gelsemium-cimicifugh tablets.
3–940, Potassium thiocyanate ECT 3 gr.
4–002, Sulfathiazole tablets 7.7 gr. (sugar coated).
4–110, Sulfanilamide powder.
3–365, Sodium Pentobarbital capsules 1½ gr.
3–541, Maginal tablets.
Swamp and Dixie Labs, Fort Smith, Ark., or Tulsa, Okla.
NDA 0–971, Dixie Powder.
Swann and Co., Birmingham, Ala.
NDA's:
0–714, Acet-Phenetidin batch.
0–715, Acetanilide batch.
0–966, Acetylsalicylic Acid USP batch.
Syntam Labs, 46–30 27th Street, Long Island City, N.Y.
NDA 6–451, Chlorguanide HCl tablets.
Syntex Chemical Co. (Labs), 701 Welch Road, Palo Alto, Calif.
NDA 10–125, Reserpine tablets 0.1, 0.25, 0.5, 1.0, 5.0 mg.
Taco Products (Out of business), Wichita, Kans.
NDA's:
1–495, Tacorub Ointment.
2–196, NOVE PAS.
2–570, Noral Drops.
2–571, Aurevin liquid.
2–572, Sevital liquid.
Taiber, Edwin E., Taiber's Retail Drug Store, 152 Main Street, Freeport, N.Y.
NDA 0–304, Ammonipica liquid.
Tailby-Nason Co., 49 Amherst Street, Boston, Mass. (NOTE: Address listed also as 49 Amherst Street, Cambridge, Mass.).
NDA's:
2–772, Bilagog Tablets.
3–477, Calbital Tablets.
3–894, Tablets Vitaliv.
4–031, Tablets Sulfanilamide & Sodium Bicarbonate.
4–399, Tablets Vits (Listed Under Cambridge Address).
Takamine Labs., 192 Arlington Avenue, Clifton, N.J.
NDA's:
1–455, Incotin ointment.
1–811, Olithol capsules.
3–784, Carbocaine cream.
Takoma Drug Co., 7113 Poplar Avenue, Takoma Park, Md.
NDA 12–079, Pyrilamine Maleate capsules, 75 mg.
Taylor, James B., 814 Chandler Street, Danville, Ill.
NDA 4–307, Taylor's Diabetic Vegetables and Herbs powder.
Taylor, W. D., & Co., 1627 Carolina Avenue, Bessemer, Ala.
NDA's:
2–019, Kolex liquid.
2–020, Kolex Penetrating salve.
Teeple and Hofferbert Inc., Baltimore, Md.
NDA 1–581, Meredyne liquid.
Tepee Herb Co., Post Office Box 2284, Baton Rouge, La.
NDA 1–831, Cleansing Tea 3X (HART's 3X Tea).
Terris Co., Inc., E. S., 1225 Park Avenue, New York, N.Y.
NDA 3–043, Drizon Ointment.
Testagar Labs, Fellows Medical Manufacturing Co., 1354 West Lafayette Boulevard, Detroit, Mich.
NDA 2–051, Sulfanilamide tablets.
Tested Products Co., TNF Rexall Drug Co., 8480 Beverly Boulevard, Los Angeles, Calif.
NDA 4–370, Salitex ECT.
Tetley-Wessinger Co., 623 F Street NW., Washington, D.C.
NDA 4–566, Vita-Port Liquid.
Thayer Chemical Co., 302 Main Street, Greenwood, S.C.
NDA's:
2–757, Thayer's External lotion.
2–758, Calcium Gluconate solution.
2–759, Thayer's Gargle.
2–760, Thayer's Antiseptic dressing.
Therapy Ltd., Pasadena, Calif.
NDA 1–116, Theracol Wafers.
Thilo and Co., Dr., Mainz, Germany.
NDA 0–786, Eupragin injection.
Thomas, W. J. (M.D.), 1140 Lake Street, Oak Park, Ill.
NDA 3–163, Namron Inhaler.
Thomason Co., J. I., 612 Park Avenue, Greensboro, N.C.
NDA 4–053, Foot-Sarge Cream.
Thompson, Basil (M.D.), 5275 Lee Highway, Arlington, Va.
NDA 5–758, Thricidiazole liquid.
Thompson, I. S., 835 Poplar Avenue, Memphis, Tenn.
NDA 3–985, Ferogran Syrup.
Thompson, Wm. T., 2727 Hyperion Avenue, Los Angeles, Calif.
NDA 5–188, PABA tablets 100 mg.
Thorenson, Carroll A., 1148 Commonwealth Avenue, Boston, Mass.
NDA 3–667, Tronisidine liquid.
Thrasa Oil Co., 1210 C Street, Bellingham, Wash.
NDA 0–065, Thrasa Oil liquid.
Toivonen Suloe, 5 South 63d Avenue West, Duluth, Minn.
NDA 0–348, Ver-Pu Salts Solution.
Tonalex Co., Attention: C. P. Porter, Stella, Mo.
NDA 1–193, Tonalex liquid.
Toto-Seltzer Co., 708 South Lorraine Road, Los Angeles, Calif.
NDA 1–465, Toto-Seltzer tablets.
Tracerlab Inc., Boston, Mass. or Berkeley, Calif.
NDA 10–103, Radioactive Iodine-131 liquid.
Tracy, Ella, Route 1, Bismarck, Mo.
NDA 0–608, Tracy's Cough and Cold Remedy.
Trade Labs., Inc., 320 Market Street, Newark, N.J.
NDA's:
0–494, Tween Toes Powder.
1–204, TL Ointment for Superficial burns.
Treemond Co., 180 Montague Street, Brooklyn, N.Y.
NDA's:
2–715, Estrogenic substance.
2–949, Nicotinic Acid Dietamide batch.
Tri-Mee Labs, 2525 West Wilcox Street, Chicago, Ill.
NDA 2–637, Tri-Mee Ointment.
Trinity Pharmacal, 301 North Market Street, Dallas, Tex.
NDA 3–341, Trinsix liquid.
Tri-Noid Co., 161 East Utica Street, Buffalo, N.Y.
NDA 3–776, Tri-Noid's Syrup.
Tropical Products, Inc., Colton, Calif. or Chicago, Ill.
NDA 1–982, Sinalga liniment ointment.
True Aloe Products Co., 5700 Southwest Red Road, Miami, Fla.
NDA's:
5–752, True Aloe liquid lotion.
6–066, Aloe Vera Ointment.
Truesdale Co., Inc., 160 East 56th Street, New York, N.Y.
NDA 0–096, BA–AL suspension (Diagnostic Barium suspension).
Tulane Labs, Inc., Balter Building, New Orleans, La.
NDA 3–107, Tulane's Alkaline Gargle Mouthwash.
Turner Pharmacal Co., 6 Renuart Arcade, Coral Gables, Fla.
NDA 0–457, No-Tanl tablets.
Tutag & Co., S. J., 19180 Mount Elliott Avenue, Detroit, Mich.
NDA's:
9–407, Rauserpa tables 50 and 100 mg.
10–411, Rauloydin Reserpine inj. 5 mg/cc.
Tiebolaget Kabi, A.K. (Sweden)/Tuteur Biochems, Inc., Agent, 60 Wall Street, New York, N.Y.
NDA 12–781, Meprobamate tablets 400 mg.
Tyson & Co., Inc., 133 North Poplar Street, Paris, Tenn.
NDA's:
3–078, Tyson's Best Medicated Mutton Suet Compound Salve.
3–080, Clearo vaporizing nose and throat drops.
3–082, Rubease Senior Liniment liquid.
3–084, Ladainty Medicated Pomade and and Scalp massage ointment.
4–329, On The Spot Household Salve.
Ulmer Pharmacal Co., 1400 Harmon Place, Minneapolis, Minn.
NDA's:
0–497, Ulmer Antiseptic baby oil.
0–498, Vita-Sol-E capsules.
0–974, Nyrel cream.
0–980, Mamlene ointment.
2–453, Novak's solution.
3–075, Sulfanilamide and sodium bicarbonate tablets.
9–003, Neo-Pyraper.
10–161 Banasil tablets 0.25 and 1.0 mg.
Ulrich, W. E., 16 Cleveburn Place, Buffalo, N.Y.
NDA 1–755, Double-Tee athletes foot remedy liquid.
The Ulrici Medicine Co., Inc., New York, N.Y.
NDA 679, Cregen.

Union Pharmaceutical Co., Inc.—Division Schering Corp., 60 Orange Street, Bloomfield, N.J.
NDA 7–631, Inhiston lotion with prepared neocalamine.

Union Starch & Refining Co., Edinburg, Ind.
or
Granite City, Ill.
or
St. Louis, Mo.
or
Columbus, Ind.
NDA 2–554, Beheparon capsules.

United Drug Co., Boston, Mass.
or
St. Louis, Mo.
NDA's:
0–157, Synthetic Vitamin B, tablets 100, 300, 1,000 IU/tab.
2–144, Sulfapyridine tablets 7.7 gr.
3–399, Sulfathiazole tablets 3.85 and 7.7 gr.
3–790, U.D. Estrogenic substance 1*M*, 2*M*, 4*M* IU/Cap and 2*M*, 10*M* IU/cc inj.
4–598, Menadione tablets 1 mg.
4–609, Stilbestrol tablets 0.1, 0.25, 0.5, 1.0 mg./tab.

United Labs., 333 South Fair Oaks Avenue, Pasadena, Calif.
NDA's:
1–117, Dicalcium phosphate w/vitamins A and D, and dextrose, tablets.
2–633, Vitamin-Mineral compound tablets.
7–932, Actrope tablets.
7–344, Paramicylate tablets 0.5 Gm.

United Research Labs., Inc., 4629 Adams Avenue, Philadelphia, Pa.
NDA 8–265, ACTH inj. 20 U/cc and 25, 40, 50 U/vial.

Universal Distributors, 1521 Hedding Street, San Jose, Calif.
NDA 1–746, Vitona.

University of Rochester Isotope Center, 260 Crittenden Boulevard, Rochester, N.Y.
NDA 9–724, Iodine-131 Oral Solution.

The Upjohn Co., 7171 Portage Road, Kalamazoo, Mich.
NDA 11–084, Compressed tablets Prodox 25 mg. and 50 mg.

Urban, Bertha M., Ewing, Nebr.
NDA 3–086, Lakota liquid.

Uz-It, Inc. (R. A. Jackson), 400 Edmunds Building, Washington, D.C.
NDA 0–816, Uz-It ointment.

Uz-One Chemical Corp., Burlington Hotel, Washington, D.C.
NDA 2–350, Uz-One ointment.

Vad Corp., 225 Broadway, New York, N.Y.
NDA 4–792, Vad Cream.

Valley Labs., 291 North Main Street, Spring Valley, N.Y.
NDA 0–190, Salicylic acid, potassium hydroxide, benzocaine, salve.

Vandi, Jon, Box 1, Station B, Dayton, Ohio.
NDA's:
1–757, Weno.
2–984, Chec-O-Phan solution.

Van Pattern Pharmaceutical Co., 4450 Ravenswood Avenue, Chicago, Ill.
NDA's:
4–712, Stilbestrol ECT 0.1, 0.5, 1.0 mg.
5–727, Thyrobrom tablets.

Van-Tage Medicine Co., Inc., 1265 North Vermont Avenue, Los Angeles, Calif.
NDA 0–012, Van-Tage Medicine liquid.

Van Vlack, E. H., 1104 Eye Street, Eureka, Calif.
NDA 2–481, Van's Gas Go Powder.

Vecar Products, Carl Patting, 124 East Grantley Avenue, Elmhurst, Ill.
NDA 2–893, Vecar-Lax tablets.

Veltex Inc., 1811 First Avenue North, Birmingham, Ala.
NDA's:
3–143, Zulies toothache drops.
8–756, Zynafon tablets 50 and 100 mg.
9–736, Reserpine tablets 0.1, 0.25, 0.5, 1.0 mg.
9–867, Sirpinal brand of reserpine tablets 0.1, 0.25, 1.0 mg.
9–934, Rawpentina tablets 50 and 100 mg.

Verard Co., 119 West 227th Street, New York, N.Y.
NDA 1–504, Verard solution.

Verax Products Co., 116 Fourth Avenue, New York, N.Y.
NDA 5–251, Stilbestrol inj. 0.5 mg./cc.

Vestal Chemical Co., Division W. R. Grace, 4963 Manchester Avenue, St. Louis, Mo.
NDA 3–208, Vestal F-O Topical solution.

Veterans Chemical Co., 18 Joy Terrace, Methuen, Mass.
NDA 6–287, Licide Cream.

Vice Products Co., 415 West Scott Street, Chicago, Ill.
NDA's:
3–910, Mykron (good morning) Syrup.
4–118, VI-CO injection.
8–148, Ribolactin Vico solution.

Victor, Audrey (Miss), 12434 Cedar Road, Cleveland Heights, Ohio.
NDA's:
0–837, Victorub liquid compresses.
0–838, Victorub ointment.

Victoria Chemical Co., 1045 Stuyvesant Avenue, Union, N.J.
NDA's:
0–453, PAP tablets.
1–460, Ribe liquid.
1–762, Bret (Erb-Tonol).

Viniron Products Co., 237 Nassau Avenue, Brooklyn, N.Y.
NDA 2–316, Viniron w/manganese citrate elixir.

Virginia Medicine Co., 922 East 26th Street, Norfolk, Va.
NDA's:
0–534, Moses Tonic liquid.
0–535, Moses Expectorant syrup.

Vita-Fore Products Co., Inc., 9507 98th Street, Ozone Park, N.Y.
NDA 11–606, Slenda-Kaps.

Vitable Powder Co., Frank Suchanek, 1929 Blue Island Avenue, Chicago, Ill.
NDA 1–285, Vitable Powder.

Vita-Life Co., 2525 Southeast 41st Street, Portland, Oreg.
NDA 1–547, Crystal Springs Mineral Water Liquid.

Vitamin B Co., Munsey Building, Baltimore, Md.
NDA 3–921, B-Natural Vitamin B complex syrup (2 strengths).

Vitamin Beverage Corp., Foot of Van Dyke Street, Brooklyn, N.Y.
NDA 2–111, VV Concentrate solution.

Vita-Phates Inc., 2770 Broadway, New York, N.Y.
NDA 3–951, Vita-Phates Capsules.

Vodine Co., Chicago, Ill.
NDA's:
5–926, Solubase Ointment.
5–927, Vodine Iodine solubase ointment.
5–996, Vodust powder.
5–998, Vodisan Brand Hyclomane solusalve.

Voelker, Henry, 4430 North Washington Boulevard, Chicago, Ill.
NDA 1–483, Perfecto Rub ointment.

Vogel Labs., Main Street, Mohegan Lake, N.Y.
NDA's:
4–855, Sulfanila ointment, 5%.
4–856, Sulfathia ointment, 5%.
5–030, Emulsion sulfathiazole 5% sterilized.
5–031, Emulsion sulfathiazole 10% sterilized.
5–463, Phenyl cellosolve lotion.
8–367, Zirocarb lotion.

Wade Pharmacal—Division Van Sickle, 2115 59th Street, St. Louis, Mo.
NDA 1–056, Kool-Foot Cream and lotion.

Wagner, W. S., 6577 Orange Avenue, Long Beach, Calif.
NDA 0–548, W-Z Ear drops.

Walker Corp. & Co., Easthampton Place and Collingwood Avenue, Post Office Drawer 1320, Syracuse, N.Y.
NDA's:
0–700, Walcotone No. 2 liquid.
0–752, Walcosol liquid.
1–161, Walco-Jel Jel.
1–627, Chlorodrin solution.
2–476, Medex ointment.
2–487, C-B-O tablets.
2–657, Sedakof liquid.
3–755, Cebrogen tablets.
3–870, A-Dans tablets.

Walker-Hill Co., 665 West Washington Street, Chicago, Ill.
NDA's:
3–671, Walker-Hill Three Star Laxative solution.
3–681, Brandy Egg Tonic liquid.

O. W. Wall, Greensboro, N.C.
NDA 957, Wall's External Rub.

Wallace Labs./Carter Products, Half Acre Road, Cranburry, N.J.
NDA's:
0–751, Nair Depilatory.
0–604, Nair depilatory.
4–759, Bactrazole ointment.
5–768, TCAP Fungicidal ointment.
5–770, TCAP Fungicidal Shampoo.
5–779, Intraderm TCAP solution.

Wallace & Tiernan Products, Inc., Belleville, N.J.
NDA's:
5–105, Sodium Tetradecyl.
5–584, Azochlorasul Suspension.
8–494, Malcotran tablets.

Waltman, Walter, 418 Cohannet Street, Taunton, Mass.
NDA 2–977, Senusol liquid.

Wampole, Henry K., 440 Fairmount Avenue, Philadelphia, Pa.
NDA 1–737, Wampole's laxative tablets.

Warner, William R., New York, N.Y.
NDA 3–500, Omni-Beta capsules.

Warren-Teed Products Co., 582 West Goodale Street, Columbus, Ohio.
NDA's:
3–517, Sulfathiazole tablets.
4–197, Stilbestrol compressed tablets, ECT, inj.
4–763, Epsilan tablets.
4–764, Epsilan inj.
4–821, Sulfathiazole ointment 5%.
4–822, Sulfathiazole ointment 10%.
5–830, Indosil solutions #248, 249, 250, 420.
3–393, Nico-Thian inj.
3–394, Nico-Beta tablets.

Warren, A. R., 1441 West Main Street, Oklahoma City, Okla.
NDA 1–352, Warren Red Dot lotion.

Watchung Labs., Bound Brook, N.J.
NDA's:
1–039, Time tablets.
1–387, Chex powder and tablets.

Wattman, Gussie, 187 Blake Avenue, Brooklyn, N.J.
NDA 4–596, Noble scalp lotion.

Wean, John I., Eustis, Fla.
NDA 0–043, Aldorine solution.

Weaver, R. Thor (M.D.), Dade City, Fla.
NDA 0–003, Result Antiseptic healing powder.

Weber, H. R., Route No. 3, Chambersburg, Pa.
NDA 0–032, Old Dr. Weber's cough syrup.

Webster, William A., 3580 Air Park Street, Post Office Box 18358, Memphis, Tenn.
NDA's:
7–214, Bonded brand antihistamine tablets.
7–701, Antihistamine compound tablets.

Weeks & Leo Co., 4000 100th Street NW., Des Moines, Iowa.
NDA's:
1–453, Aqueous nose drops (ephedrine sulfate).
2–300, Cold sore lotion.
Wells and Co., S. C., LeRoy, N.Y.
NDA 7–284, Covac tablets.
Wendt Bristol Co., 1159 Dublin Road, Columbus, Ohio.
NDA 10–745, Wendatinic (Ferrous Fumarate) tablets.
Wertheim, Charles, Post Office Building, Denville, N.J.
NDA 5–165, Verex powder.
Wescott Labs (Synal Co.), Chicago, Ill.
NDA's:
0–465, Synal drops.
1–137, Vegalose.
West Disinfecting Co., Long Island City, N.Y.
NDA 9–254, Lan-O-Kleen soap.
Westbury Chemical Co., Inc., 405 Lexington Avenue, New York, N.Y.
NDA 6–056, Cerbolate solution.
Western Chemical Co., TNF Chase Chemical Co., 280 Chestnut Street, Newark, N.J.
NDA 3–147, Pedatox solution.
Western Pharmacal Co., 121 West Commonwealth Avenue, Salt Lake City, Utah.
NDA's:
0–926, Fedrolin isotonic solution.
3–296, Potency B-Comp liquid.
Westgardes, Frank, 1326 Linden Avenue, Dayton, Ohio.
NDA 2–243, Wonder salve.
Weston Labs., 1003 Blanchard Street, Post Office Box 218, Ottawa, Ill.
NDA 0–927, Tob liquid.
West-Ward, Inc., 745 Eagle Avenue, New York, N.Y.
NDA's:
9–650 Rauwolfia Serpentina tablets 50 and 100 mg.
10–166, Rauwolverate tablets.
11–697, Reserpine alkaloid tablets 0.10, 0.25, 0.5, 1.0 mg.
Westwood Pharmaceuticals, 468 De Witt Street, Buffalo, N.Y.
NDA's:
5–325, Westhiazole solution.
5–326, Westhiazole-ENT solution.
5–327, Westanilamide solution.
5–513, Westhiazole solution oph.
8–825, Proderma cream.
Wetzel, N. M. (Mrs.), 1717 Overton, Independence, Mo.
NDA 1–164, Nolafene ointment.
Wetzel and Co., O. E., 1217 South Denver, Tulsa, Okla.
NDA 1–016, Athletoe solution.
White, S. M., 2909 Gordon Road, Atlanta, Ga.
NDA 3–134, White's Foot comfort powder.
Whitecliff Labs., 211 First Street, Post Office Box C, Los Altos, Calif.
NDA 12–022, Formula #117 (propanolamine HCl 75 mg. capsules).
Whitmire Research Labs., 339 South Vandeventer, St. Louis, Mo.
NDA 6–468, Litoid lotion.
Whitney Co., 3240 Ellenda Avenue, Los Angeles, Calif.
NDA 4–472 Whitney's corn and callous salve.
Wiel Labs Inc., 5514 Myrtle Avenue, Ridgewood, New York City, N.Y.
NDA 1–326, Dr. Wiel's Garlic pills.
Will Equipment Co., 1443 Stanford Avenue, St. Paul, Minn.
NDA 4–406, Colon Motility test (carmine capsules, 5 gr.).
Wilco Labs., 800 Clark Street, Chicago, Ill.
NDA 1–210, Purity brand prophylactic ointment (Saf-T-Way prophylactic ointment).
Wilhelmina Hemrich, 503 Melrose Avenue North, Seattle, Wash.
NDA 0–218, Wilhelmina's skin cream.
Wilkins, C. C. (M.D.), Tarpon Springs, Fla.
NDA 1–696, Dr. Wilkins Exodus liniment emulsion.
Williams, Allison W. (Deceased), Route 1, Columbus, Ga.
NDA 4–510, Best Buddy Foot powder.
Wilson Labs., Gilbert C., Post Office Box 818, Denton, Tex.
NDA 5–453, Nil A Medicated foot powder.
Wilson, G. W. (M.D.), 26 Dennison Avenue, Dayton, Ohio.
NDA 0–660, Wilson's King of All salves.
Windsor Chem Labs. Corp., Philadelphia, Pa.
NDA's:
0–308, Burdocol drops.
6–387, Mede-X antiseptic cream.
Wink Labs., 309 Elm Street, Lumberton, N.C.
NDA 3–673, Wink Headache powder.
Wintersmith Chemical Co., 649 West Hill Street, Louisville, Ky.
NDA 7–304, Pyrilamine maleate tablets, 25 mg.
Wisconsin Pharm. Co., 217 North Water Street, Milwaukee, Wis.
NDA 12–143, Consin tablets (carbetapentane citrate).
Wood Co., W. H., 16 Main Street, South Hadley Falls, Mass.
NDA 0–722, Fleet Foot powder.
Woodruff, J. E., 8 West Lincoln Street, Buckhannon, W. Va.
NDA 3–149, KI liquid.
World's Products Co., 1100 Waterway Boulevard, Indianapolis, Ind.
NDA 7–167, Laymons Antihistamine tablets.
Wray, Everest, 115 West Minneapolis, Salina, Kans.
NDA 1–167, Wray's liniment liquid.
Wright & Lawrence, (Peau Seche Sales, Inc.), 14 North Michigan Avenue, Chicago, Ill.
NDA 6–088, Hyanilid ointment.
Wyoming Herb Lab, Casper, Wyo.
NDA 1–217, Special M liquid.
X B A Chem Co., Lexington, N.C.
NDA 3–260, XBA Foot and body powder.
Yanceys Lab., 301 Wheat Building, Fort Worth, Tex.
NDA's:
1–843, HBP solution.
1–844, Dr. Yancey's compound solution.
1–845, Six-X solution.
1–846, Dr. Yancey's nose drops.
Yarbrough Drug Co., Post Office Box 1987, Dallas, Tex.
NDA 2–347, Yarkreme.
Yellow Pine Products Co., Montgomery, Ala.
NDA 3–419, Pinolene liquid.
Yordon, Reginal A., G.P.O. Box 574, New York, N.Y.
NDA 0–833, Anal ointment.
Yorktown Products Corp., 420 Lexington Avenue, c/o Box 272, Grand Central Station, New York, N.Y.
NDA 9–575, Exul tablets.
Youngs Rubber Corp., 145 Hudson Street, New York, N.Y.
NDA's:
0–712, NU-Venol ointment.
1–575, NU-Veen ointment.
2–682, Trojan lubricant jel.
Zeller, Joseph, Bronx, N.Y.
NDA 2–240, Mas solution.
Zemmer Co., 231 Hulton Road, Oakmont, Pa.
NDA's:
0–529, Potachlori-Zem tablets.
3–680, Zem-Strogen inj. 2,000, 5,000, 10,000 IU/cc.
Zerbst Pharm Co., St. Joseph, Mo.
NDA 8–123, Zerb-O-Hist tablets.
Ziegler Pharmacal Co., 484 Delaware Avenue, Buffalo, N.Y.
NDA's:
3–417, Kavita tablets 1 mg.
3–609, Sulfapyridine tablets 7.7 gr.
3–610, Sulfathiazole tablets 7.7 gr.
4–558, Stilbestrol tablets 1 mg.
10–266, Rauwolfia Serpentina tablets 50 mg.
10–587, Cowlserpa tablets 0.25 mg.
Zin-O-Pix Co., Box 204, Lees Summit, Mo.
NDA 2–493, Quitz ointment.

Within 30 days after the date of publication hereof in the FEDERAL REGISTER, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Office of the General Counsel, Food, Drug, and Environmental Health Division, Room 5440, 330 Independence Avenue SW., Washington, D.C. 20201, a written appearance electing whether:

1. To avail themselves of the opportunity for a hearing; or

2. Not to avail themselves of the opportunity for a hearing.

If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within such 30 days will be construed as an election by such persons not to avail themselves of the opportunity for a hearing.

If such persons elect to avail themselves of the opportunity for a hearing, they are required to state the reasons why the new-drug applications should not be withdrawn, together with a full, factual analysis. If a hearing is requested and justified, a hearing examiner will be named by the Commissioner and he shall issue a written notice of the time and place for the hearing.

The hearing contemplated by this notice will be open to the public, except that any portion of the hearing that concerns a method or process which the Commissioner finds is entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050–53, as amended; 21 U.S.C. 352, 355) and under authority delegated to the Commissioner (21 CFR 2.120).

Dated: January 29, 1970.

CHARLES C. EDWARDS,
Acting Commissioner of Food and Drugs.

[F.R. Doc. 70–1341; Filed, Feb. 5, 1970; 8:45 a.m.]

PILLSBURY CO.

Notice of Withdrawal of Food Additive Glucan Polysaccharide

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409 (b), 72 Stat. 1786; 21 U.S.C. 348(b)), the following notice is issued:

In accordance with § 121.52 *Withdrawal of petitions without prejudice* of the procedural food additive regulations (21 CFR 121.52), The Pillsbury Co., 608 Second Avenue South, Minneapolis, Minn. 55402, has withdrawn its petition

(MF 3421V), notice of which was published in the FEDERAL REGISTER of August 14, 1969 (34 F.R. 13162), proposing the issuance of a food additive regulation (21 CFR Part 121) to provide for the safe use of a whole spray-dried fermentation product produced by fermentation of carbohydrate substrates by the fungus *Sclerotium rolfsii* and related species where the fermentation is carried out under conditions that produce glucan polysaccharide. The whole spray-dried product is for use as a suspending and emulsifying agent in liquid feed concentrates to be used in feed for ruminants.

Dated: January 29, 1970.

R. E. DUGGAN,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1498; Filed, Feb. 5, 1970; 8:46 a.m.]

STAUFFER CHEMICAL CO.

Notice of Filing of Petition Regarding Pesticides

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 408 (d)(1), 68 Stat. 512; 21 U.S.C. 346a(d)(1)), notice is given that a petition (PP 0F0937) has been filed by Stauffer Chemical Co., 1200 South 47th Street, Richmond, Calif. 94804, proposing the establishment of tolerances (21 CFR Part 120) for the combined residues of the insecticide *N*-(mercaptomethyl) phthalimide *S*-(*O,O*-dimethyl phosphorodithioate) and its oxygen analog *N*-(mercaptomethyl) phthalimide *S*-(*O,O*-dimethyl phosphorothioate) in or on the raw agricultural commodities apricots and nectarines at 5 parts per million; cherries, plums, and prunes at 7 parts per million; and grapes at 10 parts per million.

The analytical method proposed in the petition for determining residues of the insecticide is a gas-liquid chromatographic technique using a phosphorus-specific thermionic detector.

Dated: January 29, 1970.

R. E. DUGGAN,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1499; Filed, Feb. 5, 1970; 8:46 a.m.]

[DESI 9947]

MEGLUMINE DIATRIZOATE AND MEGLUMINE IODIPAMIDE; RESERPINE AND ETHINYL ESTRADIOL; METAXALONE; MEPROBAMATE AND HYDROCHOLOROTHIAZIDE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drugs:

1. Duografin Injection; 40 percent meglumine diatrizoate and 20 percent meglumine iodipamide; marketed by E. R. Squibb & Sons, Inc., Georges Road, New Brunswick, N.J. 08903 (NDA 11-324).

2. Estrosed Tablets; 0.1 milligram reserpine and 0.01 milligram ethinyl estradiol; marketed by Conal Pharmaceuticals, Inc., 5547 North Ravenswood, Chicago, Ill. 60640 (NDA 10-465).

3. Sergynol Tablets; 0.167 milligram reserpine and 0.02 milligram ethinyl estradiol; marketed by B. F. Ascher and Co., Inc., 5100 East 59th Street, Kansas City, Mo. 64130 (NDA 9-947).

4. Skelaxin Tablets; 400 milligrams metaxalone; marketed by A. H. Robins Co., Inc., 1407 Cummings Drive, Richmond, Va. 23220 (NDA 13-217).

5. Pree MT Tablets; 200 milligrams meprobamate and 25 milligrams hydrochlorothiazide; marketed by Wallace Pharmaceuticals, Half Acre Road, Cranbury, N.J. 08512 (NDA 12-404).

6. Cyclex Tablets; 200 milligrams meprobamate and 25 milligrams hydrochlorothiazide; marketed by Merck Sharp and Dohme, Division of Merck and Co., Inc., Rahway, N.J. 07065 (NDA 12-341).

The Food and Drug Administration has considered the reports of the Academy and concludes that there is a lack of substantial evidence that the drugs are effective or effective as fixed combinations for the following claims:

(1) Meglumine diatrizoate and meglumine iodipamide solution for injection for simultaneous visualization of the biliary and urinary tracts.

(2) Reserpine and ethinyl estradiol tablets for the menopausal syndrome; for disturbances of the menopause and postmenopausal period.

(3) Metaxalone tablets for the initial phase of acute skeletal-muscle spasm related to sprains and strains, fractures, dislocations, and trauma to tendons and ligaments.

(4) Meprobamate and hydrochlorothiazide tablets for use in all types and grades of severity of congestive heart failure; premenstrual tension; premenstrual syndrome; treatment of hypertension with or without complicating congestive heart failure; enhancement of the action of other antihypertensive agents; relief of headache, irritability, nervousness, depression, malaise, anxiety, nausea, insomnia, and tachycardia in hypertensive patients; postcoronary thrombosis, coronary insufficiency, paroxysmal sinus tachycardia, and premature contractions; and angina and the anginal syndrome accompanying congestive failure or high blood pressure.

The Commissioner of Food and Drugs intends to initiate proceedings to withdraw approval of the new-drug applications for these drugs. Prior to initiating such action, however, the Commissioner invites the holders of new-drug applications for these drugs, and any interested person who may be adversely affected by removal of these drugs from the market, to submit any pertinent data bearing on the proposal not later than 30 days following the date of publication of this notice in the FEDERAL REGISTER. The only material which will be considered acceptable for review must be well-organized and consist of adequate and well-controlled studies bearing on the efficacy of the products, and not previously submitted.

This announcement of the proposed action and implementation of the NAS-NRC report for the above drugs is made to give notice to persons who might be adversely affected by withdrawal of these drugs from the market. Promulgation of an order withdrawing approval of the new-drug applications will cause any such drug on the market offered for these uses to be a new drug for which an approved new-drug application is not in effect, and will make it subject to regulatory action.

A copy of the NAS-NRC report has been furnished to each firm referred to above. Any other interested person may obtain a copy by request to the appropriate office named below.

Communications forwarded in response to this announcement should be identified with the reference number DESI 9947 and should be directed to the attention of the following appropriate office and addressed to the Food and Drug Administration, 200 C Street SW., Washington, D.C. 20204:

Requests for NAS-NRC report: Press Relations Office (CE-300).

All other communications regarding this announcement: Special Assistant for Drug Efficacy Study Implementation (MD-16), Bureau of Medicine.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: January 29, 1970.

SAM D. FINE,
Acting Associate Commissioner for Compliance.

[F.R. Doc. 70-1500; Filed, Feb. 5, 1970; 8:46 a.m.]

CIVIL AERONAUTICS BOARD

[Docket No. 21866, etc.]

DOMESTIC PASSENGER-FARE INVESTIGATION

Notice of Second Supplemental Prehearing Conference

Standby Youth Fares, "Young Adult" Reservation Fares, Family Fares, Discover America Fares.

In view of the action taken by the Board in Order 70-1-147, January 29, 1970, which, among other things, consolidated the Youth Fares case, Docket 18936 et al., into the investigation instituted by the Board's order and also expanded the scope of the investigation in Docket 18936 to include the Discover America roundtrip excursion fares, a second supplemental prehearing conference will be held on February 11, 1970, at 10 a.m., e.s.t., in Room 911, Universal

Building, 1825 Connecticut Avenue NW., Washington, D.C., before the undersigned Examiner.

The second supplemental prehearing conference will be limited to discussion of measures to supplement the results of the prehearing conference held on January 22, 1970. In order to facilitate the conduct of the conference, interested parties are instructed to be prepared to submit at the conference (1) proposed statements of issues; (2) proposed stipulations; (3) requests for information; (4) statements of position; and (5) proposed procedural dates. It should be noted, however, that a compelling showing will be necessary to justify any deviation from the procedural dates established at the January 22 prehearing conference.

Dated at Washington, D.C., February 3, 1970.

[SEAL] ARTHUR S. PRESENT,
Hearing Examiner.

[F.R. Doc. 70-1527; Filed, Feb. 5, 1970; 8:49 a.m.]

FEDERAL COMMUNICATIONS COMMISSION

[Report 477]

COMMON CARRIER SERVICES INFORMATION [1]

Domestic Public Radio Services Applications Accepted for Filing [2]

FEBRUARY 2, 1970.

Pursuant to §§ 1.227(b)(3) and 21.26 (b) of the Commission's rules, an application, in order to be considered with any domestic public radio services application appearing on the attached list, must be substantially complete and tendered for filing by whichever date is earlier: (a) The close of business 1 business day preceding the day on which the Commission takes action on the previously filed application; or (b) within 60 days after the date of the public notice listing the first prior filed application (with which subsequent applications are in conflict) as having been accepted for filing. An application which is susbequently amended by a major change will be considered to be a newly filed application. It is to be noted that the cutoff dates are set forth in the alternative—applications will be entitled to consideration with those listed in the appendix if filed by the end of the 60-day period, only if the Commission has not acted upon the application by that time pursuant to the first alternative earlier date. The mutual exclusivity rights of a new application are governed by the earliest action with respect to any one of the earlier filed conflicting applications.

The attention of any party in interest desiring to file pleadings pursuant to section 309 of the Communications Act of 1934, as amended, concerning any domestic public radio services application accepted for filing, is directed to § 21.27 of the Commission's rules for provisions governing the time for filing and other requirements relating to such pleadings.

FEDERAL COMMUNICATIONS COMMISSION,
BEN F. WAPLE,
Secretary.

APPLICATIONS ACCEPTED FOR FILING

DOMESTIC PUBLIC LAND MOBILE RADIO SERVICE

File No., applicant, call sign, and nature of application

4016-C2-P/L-70—Paul A. Pauley, doing business as Midwest Mobil Telephone Co. (KAQ644), C.P. and license to reinstate facilities to operate on base frequency 152.21 MHz to be located at northwest edge of Harlan, Iowa.

4015-C2-AL-70—Mary E. Anstead, doing business as Boston Two-Way Radio Service (KCC263), Consent to assignment of license from: Mary E. Anstead, doing business as Boston Two-Way Radio Service Assignor to: Ram Broadcasting of Massachusetts, Inc. Assignee.

4018-C2-P-70—Central Mobilphone, Inc. (KBM516), C.P. to replace transmitter operating on base frequency 152.03 MHz at location No. 1: Old Highway No. 54, Jefferson City, Mo.

4022-C2-TC-(2)-70—Colgan Communications, Inc. doing business as Mobilfone of Boston (KCA240), (KLF585), Consent to transfer of control from: James F. and Kathryn G. Colgan Transferor to: Edward A. Gargone, Transferee.

4023-C2-P-(2)-70—Dee Wetmore, doing business as Westside Answering Service (KFL877), C.P. for additional facilities to operate on base frequencies 454.025 and 454.050 MHz at station located at 3717 Spruce Street, Tampa, Fla.

4024-C2-P-70—General Telephone Co. of Michigan (New), C.P. for a new 1-way station to be located at 1131 Barlow Street, Muskegon Township, Mich., to operate on base frequency 152.84 MHz.

4032-C2-P-70—Curtin Call Communications, Inc. (New), C.P. for a new 1-way station to be located on Skyline Road, 1,200 feet south of Linn Avenue, Council Bluffs, Iowa, to operate on frequency 158.70 MHz.

4033-C2-P-(3)-70—ATS Mobile Telephone, Inc. (KBM512), C.P. for additional facilities to be located at a new site to be identified as location No. 2: Woodmen Tower Building, 1700 Farnam Street, Omaha, Nebr., to operate on frequencies 152.18, 454.050, 454.300 MHz.

4034-C2-P-70—ATS Mobile Telephone, Inc. (New), C.P. for a new 1-way station to be located at 900 feet south of junction of Lynn and Skyline, Council Bluffs, Iowa, to operate on base frequency 158.70 MHz.

4035-C2-P-70—ATS Mobile Telephone, Inc. (New), C.P. for a new 2-way station to be located at 900 feet south of junction of Lynn and Skyline, Council Bluffs, Iowa, to operate on base frequency 152.15 MHz.

3846-C2-P-(3)-70—The Mountain States Telephone & Telegraph Co. (KOK416), C.P. to replace two existing base station transmitters operating on frequencies 152.63 and 152.69 MHz at station located at 9 miles northeast of Idaho Falls, Idaho. Also add auxiliary test transmitter to operate on frequencies 157.89 and 157.95 MHz to be located at 299 C Street, Idaho Falls, Idaho.

2281-C2-R-70—Maine Telephone Co. (KCC489), Renewal of License expiring Feb. 1, 1970. Term: Feb. 1, 1970 to July 1, 1973.

2282-C2-R-70—Maine Telephone Co. (KCC795), Renewal of License expiring Feb. 1, 1970. Term: Feb. 1, 1970 to July 1, 1973.

2283-C2-R-70—Maine Telephone Co. (KCC794), Renewal of License expiring Feb. 1, 1970. Term: Feb. 1, 1970 to July 1, 1973.

4047-C2-P-70—General Telephone Co. of Wisconsin (New), Resubmitted: C.P. for a new 1-way station to be located at 0.4 mile south-southwest from Dodgeville, Wis., to operate on base frequency 152.840 MHz.

4048-C2-P-70—General Telephone Co. of the Southwest (New), C.P. for a new 2-way station to be located at 602 Highway 79 North, Henderson, Tex., to operate on base frequency 152.81 MHz.

4049-C2-MP-70—E. B. and D. W. Brownell (KOP254), Modification of C.P. to relocate the control station at location No. 5 to: Billings Municipal Airport, Hangars 13 and 14, Billings, Mont., operating on frequency 454.05 MHz.

4050-C2-P-(2)-70—General Telephone Co., of the Northwest, Inc. (KON912), C.P. to replace transmtter for base frequencies 152.78 and 152.69 MHz at station located at 426 Casino Road, Everett, Wash.

4051-C2-P-(2)-70—South Central Bell Telephone Co. (KIG287), C.P. to replace transmitter for base frequencies 152.60 and 152.75 MHz at station located at 100 North Franklin Street, Mobile, Ala.

4052-C2-P-(2)-70—The Mountain States Telephone & Telegraph Co. (KOP308), C.P. to add additional channel to operate on base frequency 152.72 MHz at station located at 6 miles east of Conrad, Mont. Also change antenna system and replace transmitter for existing frequency 152.66 MHz.

4054-C2-P-70—General Telephone Co. of the Southwest (New), C.P. for a new 2-way station to be located at 915 Avenue G, Ralls, Tex., to operate on base frequency 152.72 MHz.

4055-C2-P-70—Great Eastern Communications Co. (New), C.P. for a new 2-way station to be located at 546 County Street, New Bedford, Mass., to operate on base frequency 152.06 MHz.

4053-C2-P-(2)-70—South Central Bell Telephone Co. (KKI454), C.P. to correct antenna height and coordinates to read lat. 29°34'29" N., long. 90°42'56" W. at its station located at intersection of Boundary Road and Intracoastal Canal, Houma, La. Base frequencies: 152.69 and 152.75 MHz.

[1] All applications listed in the appendix are subject to further consideration and review and may be returned and/or dismissed if not found to be in accordance with the Commission's rules, regulations, and other requirements.

[2] The above alternative cutoff rules apply to those applications listed in the appendix as having been accepted in Domestic Public Land Mobile Radio, Rural Radio, Point-to-Point Microwave Radio, and Local Television Transmission Services (Part 21 of the rules).

DOMESTIC PUBLIC LAND MOBILE RADIO SERVICE—continued

4072–C2–P–(2)–70—Curry County Communications (KOK348), C.P. to replace transmitters for frequencies 152.15 and 152.18 MHz. Location: Bosley Butte, Oreg.

4073–C2–TC–70—Stillwell Telephone Corp. (KLB620), Consent to transfer of control from Jack K. Holt, Ross J. Holt, Mary Holt Taylor, Ethel Holt Worsham, William L. Holt, Robert G. Holt, Transferors to Allied Telephone Co., Transferee. (Stillwell, Okla.)

4074–C2–TC–70—Holt Telephone Co., Inc. (KLB675), Consent to transfer of control from Jack K. Holt, Ross J. Holt, Mary Holt Taylor, Ethel Holt Worsham, William L. Holt, Robert C. Holt, Transferors to Allied Telephone Co., Transferee. (Poteau, Okla.)

4071–C2–AP/AL–(2)–70—Radio Mobile Phones, Inc., Consent to assignment from Radio Mobile Phones, Inc., Assignor to Mobilephones of Texas, Inc., Assignee. Stations: (KLB 322), Beaumont, Tex. (2-way), (KQZ708), Beaumont, Tex. (1-way-signaling).

Corrections

3532–C2–P–70—McLean County Telephone Co. (New), Correct applicant's name to read: McLean County Telephone Answering Service. All other particulars remain the same as reported on public notice dated Jan. 5, 1970, Report No. 473.

3526–C2–P–70—Communications Industries, Inc., doing business as New Orleans Mobilfone KLB759), Correct entry to read to operate on frequencies 152.06 and 152.12 MHz. All other particulars same as reported on public notice dated Jan. 5, 1970, Report No. 473.

RURAL RADIO SERVICE

3936–C1–P/L–70—The Mountain States Telephone & Telegraph Co. (New), C.P. and license for a new fixed station to be located at 17 miles east-southeast of Billings, Mont., to operate on frequency 157.80 MHz.

4056–C1–P/L–70—The Mountain States Telephone & Telegraph Co. (New), C.P. and license for a new rural subscriber station. Subscriber: Sigma-Teton Mining Ltd. Location: 27.8 miles northeast of Jeffrey City, Wyo. Frequency: 157.98 MHz.

POINT-TO-POINT MICROWAVE RADIO SERVICE (TELEPHONE CARRIER)

4009–C1–P–70—American Telephone & Telegraph Co. (KQE91), C.P. to add frequencies 3890, 3970, and 4050 MHz toward Plymouth Junction, Mich. Station location: 4.5 miles southwest of Milford, Mich.

4010–C1–P–70—American Telephone & Telegraph Co. (KVU74), C.P. to add frequencies 3930, 4010, and 4090 MHz toward Milford, Mich. Station location: 4 miles west of Plymouth Junction, Mich.

4011–C1–P–70—Hawaiian Telephone Co. (New), C.P. for a new fixed station to be located at Halai Triangulation Station, Hilo, Hawaii, to operate on frequency 2123.6 MHz toward Pahoa, Hawaii.

4012–C1–P–70—Hawaiian Telephone Co. (New), C.P. for a new fixed station to be located near the Pahoa Postoffice, Pahoa, Hawaii, to operate on frequency 2173.6 MHz toward Halai, Hawaii.

4013–C1–P–70—Illinois Bell Telephone Co. (New), C.P. for a new fixed station to be located at 2.3 miles southeast of Manhattan, Ill., to operate on frequency 2128.0 MHz toward Rockdale, Ill.

4014–C1–P–70—Illinois Bell Telephone Co. (KYC68), C.P. to add frequency 2178.0 MHz toward Manhattan, Ill. Station location: 1 mile southwest of Rockdale, Ill.

4019–C1–P–70—Bell Telephone Co. of Nevada (KPF96), C.P. to add frequency 2178.0 MHz toward Quinn River, Nev. Station location: Winnemucca Mountain, 3.8 miles northwest of Winnemucca, Nev.

4020–C1–P–70—Bell Telephone Co. of Nevada (New), C.P. for a new fixed station to be located at 3 miles north of Quinn River Crossing, Nev., to operate on frequency 2128.0 MHz toward Winnemucca Mountain, Nev., and 2115.2 MHz toward Denio Summit, Nev.

4021–C1–P–70—Bell Telephone Co. of Nevada (New), C.P. for a new fixed station to be located at Denio Summit, 9 miles south of Denio, Nev., to operate on frequency 2165.2 MHz toward Quinn River, Nev.

POINT-TO-POINT MICROWAVE RADIO SERVICE (TELEPHONE CARRIER)—continued

4026–C1–P–70—South Central Bell Telephone Co. (KIV60), C.P. to add frequency 3910 MHz toward Lebanon, Tenn. Station location: 215 Church Street, Nashville, Tenn.

4027–C1–P–70—South Central Bell Telephone Co. (KRW74), C.P. to add frequencies 3710 and 3870 MHz toward Short Mountain, Tenn., and 3870 MHz toward Nashville, Tenn. Station location: 7 miles southwest of Lebanon, Tenn.

4028–C1–P–70—South Central Bell Telephone Co. (KRW75), C.P. to add frequencies 3730 and 3810 MHz toward Cookeville, Tenn.; add frequencies 3750 and 3910 MHz toward Lebanon, Tenn., and change the antenna system. Station location: 6 miles northeast of Woodbury, Tenn.

4029–C1–P–70—New England Telephone & Telegraph Co. (KTF43), C.P. to add frequencies 6352.9 and 11,075.0 MHz toward Putney, Vt. Station location: 3.4 miles east-northeast of Springfield, Vt.

4030–C1–P–70—New England Telephone & Telegraph Co. (KTF42), C.P. to add frequencies 6100.9 and 11,525.0 MHz toward Springfield, Vt., and 11,665.0 and 11,425.0 MHz toward Brattleboro, Vt. Station location: Hannum Hill, 4.1 miles west of Putney, Vt.

4031–C1–P–70—New England Telephone & Telegraph Co. (New), C.P. for a new fixed station to be located at Lawrence Street, 0.37 mile south of Brattleboro Central Office, Brattleboro, Vt., to operate on frequencies 10,775.0 and 11,015.0 MHz toward Putney, Vt.

4058–C1–MP–70—American Telephone & Telegraph Co. (WAD35), Modification of C.P. to correct the station coordinates to read: Lat. 34°23′44″ N., long. 107°00′42″ W. All other particulars same as reported in public notice dated Mar. 31, 1969.

4059–C1–P–70—Illinois Bell Telephone Co. (KSO76), C.P. to add frequencies 6390.0 and 6271.4 MHz toward Sunnyland, Ill. Station location: 320 Fulton Street, Peoria, Ill.

4060–C1–P–70—Illinois Bell Telephone Co. (KSO78), C.P. to add frequencies 6108.3 and 5989.7 MHz toward Peoria, Ill., and add frequencies 6137.9 and 6019.3 MHz toward Princeville, Ill. Station location: 1.8 miles north-northeast of Sunnyland, Ill.

4061–C1–P–70—Illinois Bell Telephone Co. (New), C.P. for a new fixed station to be located 1 mile southwest of Princeville, Ill., to operate on frequencies 6360.3 and 6241.7 MHz toward Sunnyland, Ill., and frequencies 6390.0 and 6271.4 MHz toward Victoria, Ill.

4062–C1–P–70—Illinois Bell Telephone Co. (New), C.P. for a new fixed station to be located 2 miles west of Victoria, Ill., to operate on frequencies 6108.3 and 5989.7 MHz toward Princeville, Ill., and frequencies 6137.9 and 6019.3 MHz toward Alpha, Ill.

4063–C1–P–70—Illinois Bell Telephone Co. (New), C.P. for a new fixed station to be located at 3.5 miles northeast of Alpha, Ill., to operate on frequencies 6360.3 and 6241.7 MHz toward Victoria, Ill., and frequencies 6345.5 and 6226.9 MHz toward Moline, Ill.

4064–C1–P–70—Illinois Bell Telephone Co. (KYS94), C.P. to add frequencies 6063.8 and 5945.2 MHz toward Alpha, Ill., and frequencies 6093.5 and 5974.8 MHz toward Rock Island, Ill. Station location: Seventh Street and 28th Avenue, Moline, Ill.

4065–C1–P–70—Illinois Bell Telephone Co. (KYS95), C.P. to add frequencies 6315.9 and 6197.2 MHz toward Moline, Ill. Station location: 635 18th Street, Rock Island, Ill.

4075–C1–P–70—Indiana Bell Telephone Co. (New), C.P. for a new fixed station to be located at 2 miles east-northeast of Bruceville, Ind., to operate on frequency 10,755 MHz toward Vincennes, Ind.

4077–C1–TC–(3)–70—Vian Telephone Co., Stilwell, Okla. Consent to transfer of control from Jack K. Holt, Ross H. Holt, Mary Holt Taylor, Ethel Holt Worsham, William L. Holt, and Robert G. Holt, Transferors, to: Allied Telephone Co., Transferee. Stations: KPP33, KPP34, and KPP35.

Maine Telephone Co. Renewal of licenses expiring Feb. 1, 1970. Term: Feb. 1, 1970 to Feb. 1, 1971. Stations: KCK68, Benner Hill, Maine; KCK69, Matinicus Island, Maine; KTQ60, Swans Island, Maine; KTQ61, East Surry, Maine.

POINT-TO-POINT MICROWAVE RADIO SERVICE (NONTELEPHONE)

Correction

3686–C1–P–70—American Television Relay, Inc. (KGC90), Correct latitude to read: Lat. 32°11′15″ N. All other particulars same as reported on public notice dated Jan. 12, 1970.

[F.R. Doc. 70–1512; Filed, Feb. 5, 1970; 8:47 a.m.]

FEDERAL MARITIME COMMISSION

INDEPENDENT OCEAN FREIGHT FORWARDER LICENSES

Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as independent ocean freight forwarders, pursuant to section 44(a) of the Shipping Act, 1916 (75 Stat. 522 and 46 U.S.C. 841(b)).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to communicate with the Director, Bureau of Domestic Regulation, Federal Maritime Commission, Washington, D.C. 20573.

James Joseph McGrath, Sr., 700 Crawford Parkway, Apt. 6, Portsmouth, Va. 23704, James Joseph McGrath, Sr., Owner.

Midland Pacific Shipping Co. Inc., 38 Pearl Street, Room 602, New York, N.Y. 10004.
Officers:
Bernard Leyden, President.
Helen Leyden, Treasurer.
Walter Katzman, Vice President/Secretary.

Nak Hyun Sohn, doing business as Korean Express Co., 11 Broadway, Room 433, New York, N.Y. 10004, Mr. Nak Hyun Sohn, Owner.

Profit By Air, Inc., 148–11 New York Boulevard, Jamaica, N.Y. 11434.
Officers:
Harvey E. Pittluck, President/Treasurer/Director.
Americo J. Focacci, Vice President/Director/Assistant Secretary.
Silas Spengler, Secretary/Director.
Morris Kritz, Director.
Jerry LeWine, Assistant Secretary.
Stuart S. Brown, Director.

Ejec Associates, Inc., 228 Franklin Street, Ogdensburg, N.Y. 13669.
Officers:
Edward J. Keenan, President.
Erika C. Keenan, Vice President.

Wolf D. Barth, Lafayette Building, Room 516, 437 Chestnut Street, Philadelphia, Pa. 19106.

Howard C. Sharrott, 8 Brooks Avenue, Venice, Calif. 90291, Howard C. Sharrott, Owner.

Imperial Air Freight Service, Inc., 151 Oliver Street, Newark, N.J. 07105.
Officers:
Irving A. Levine, Chairman.
Henry Jerum, President.
Carol Schlanger, Director.
Billye Levine, Director.
David Schlanger, Vice President.
Richard R. Levine, Treasurer.
Martin Krugman, Director.

Dated: February 2, 1970.

FRANCIS C. HURNEY,
Secretary.

[F.R. Doc. 70–1540; Filed, Feb. 5, 1970; 8:50 a.m.]

TRANS-ATLANTIC PASSENGER STEAMSHIP CONFERENCE

Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202, or may inspect the agreement at the offices of the District Managers, New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, 1405 I Street NW., Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed for approval by:

Mr. William J. Armstrong, Secretary, Trans-Atlantic Passenger Steamship Conference, 17 Battery Place, New York, N.Y. 10004.

Agreement No. 120–90 between the member lines of the Trans-Atlantic Passenger Steamship Conference modifies the General Agreement and the Regulations Governing Subagencies:

(1) Article A(d) of the General Agreement concerning the Managing Committee, which consists of managerial representatives selected from four designated regional groups of the Conference, is amended to provide that if membership in a group is reduced to one Line, the prohibition against reelection for a successive term shall not apply and that if the membership in a group is reduced to zero, the other three members of the Managing Committee will unanimously select a representative at large. No one line shall have more than one representative on the Committee. The authority of one Committee member may be delegated in his absence to another member of the Committee.

(2) Annex 2 to Article E(4) of the Regulations Governing Subagencies providing for a Trustee Bank Account is deleted.

Dated: February 3, 1970.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY,
Secretary.

[F.R. Doc. 70–1541; Filed, Feb. 5, 1970; 8:50 a.m.]

FEDERAL POWER COMMISSION

[Project 2145]

CHELAN COUNTY, WASH., PUBLIC UTILITY DISTRICT NO. 1

Notice of Application for Approval of Exhibit R (Recreation Use Plan) for Project

JANUARY 29, 1970.

Public notice is hereby given that application for approval of Exhibit R has been filed under the Regulations under the Federal Power Act (16 U.S.C. 791a–825r) by Public Utility District No. 1 of Chelan County, Wash. (correspondence to: Howard C. Elmore, Manager, PUD No. 1 of Chelan County, Wash. 98801) for constructed Project No. 2145, known as Rocky Reach Project, located on the Columbia River in Chelan and Douglas Counties, Wash., in the vicinity of Wenatchee.

According to the application: (a) The existing recreational facilities at the project consist of: (1) Vista site; (2) historical museum; (3) art and exhibition galleries; (4) industrial display area; (5) aquarium; (6) fish viewing room; (7) sanitary facilities; (8) public gardens; (9) visitor parking areas; (10) information center with concessions and comfort accommodations; (11) observatories; (1) playgrounds; (13) swimming beach; (14) boat ramps and provisions for water sports; (15) picnic area; and (16) dramatic lighting at the powerhouse; and (b) the planned recreational developments will consist of: (1) Another vista site at Rocky Reach; (2) an outdoor theater; (3) public water wells; (4) sanitary facilities at Turtle Rock, Twin Rocks, and Chelan Falls; (5) Concessions and comfort accommodations at Twin Rocks; (6) a playground at Chelan Falls; (7) athletic fields at Rocky Reach site and Chelan Falls; (8) a golf course at Rocky Reach; (9) swimming beaches at Twin Rocks and Turtle Rock; (10) picnic areas at Rocky Reach, Turtle Rock, and Chelan Falls; (12) camping sites at Twin Rocks, Turtle Rock, and Chelan Falls; (13) a fishing site at Rocky Reach; (14) a water garden at Twin Rocks; (15) riding trails at Swakane Canyon, and Entiat Range; (16) nature trails at Turtle Rock and Twin Rocks; and (17) a landing strip for light planes at Twin Rocks.

Any person desiring to be heard or to make any protest with reference to said application should on or before March 23, 1970, file with the Federal Power Commission, Washington, D.C. 20426, petitions to intervene or protests in accordance with the requirements of the Commission's rules of practice and procedure (18 CFR 1.8 or 1.10). All protests filed with the Commission will be considered by it in determining the appropriate action to be taken but will not serve to make the protestants parties to the proceeding. Persons wishing to become parties to a proceeding or to participate as a party in any hearing therein must file petitions to intervene in accordance

with the Commission's rules. The application is on file with the Commission and available for public inspection.

GORDON M. GRANT,
Secretary.

[F.R. Doc. 70-1517; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket No. RI70-1090]

CONSOLIDATED GAS SUPPLY CORP.

Order Making Initial Rates Effective and Providing for Hearing on and Suspension of Proposed Changes in Rates and Allowing Rate Changes To Become Effective Subject to Refund

JANUARY 29, 1970.

Consolidated Gas Supply Corp. (Consolidated) filed initial tariff sheets [1] comprising a new Rate Schedule F-19 applicable to sales to Texas Gas Transmission Corp. (Texas Gas) at 18.5 cents per Mcf of gas produced in Blocks 272 and 292 Fields, Eugene Island Area, Offshore Zone 4, Louisiana. In addition Consolidated filed certain revised tariff sheets [2] to increase the initial rate from 18.5 cents per Mcf to 20 cents.

Consolidated was granted temporary authority to make the sale to Texas Gas in Docket No. CP69-235, on condition that third vintage prices established in Opinion No. 546 [3] be charged for the initial service (18.5 cents for offshore gas well gas and 17 cents for casinghead gas). The Opinion also imposed an indefinite moratorium on the filing of increased rates. Opinion No. 546-A [4] issued on Petition for Reconsideration, lifted the moratorium on the filing of rates above 18.5 cents per Mcf, and permitted producers to file for increases contractually provided for "subject to suspension and possible refund, depending upon the outcome of the new proceeding." [5] Consolidated requests that notice requirements be waived and permit the tendered sheets to become effective on the date of initial delivery subject to such suspension period deemed appropriate for the tariff sheets reflecting the rate increase, but requests that the Commission limit such suspension to a 1-day period.

The Commission finds:

(1) Good cause exists for waiving the 30-day notice requirement provided in the Commission's regulations with respect to the filing of the tariff sheets applicable to the aforementioned sale of natural gas.

(2) It is in the public interest and consistent with the Natural Gas Act, that the Commission enter upon hearings regarding the lawfulness of the proposed changes in rates set out in First Revised Sheet Nos. 498 and 499, and that such sheets be suspended and their use deferred as hereinafter ordered.

The Commission orders:

(A) The 30-day notice requirements provided in the Natural Gas Act and the Commission's regulations are hereby waived and the Original Tariff Sheet Nos. 496 through 523 to Consolidated's FPC Gas Tariff, Original Volume No. 3 are hereby permitted to become effective upon date of initial delivery of the natural gas to Texas Gas under the authorization hereinbefore described.

(B) Under the Natural Gas Act, particularly sections 4 and 15, the regulations pertaining thereto (18 CFR Ch. I), and the Commission's rules of practice and procedure, public hearings shall be held concerning the lawfulness of the changes in rates proposed in First Revised Sheet Nos. 498 and 499.

(C) Pending hearings and decisions thereon, First Revised Sheet Nos. 498 and 499 are hereby suspended and their use deferred until 1 day following the date of initial delivery, and thereafter until made effective as prescribed in the Natural Gas Act: *Provided, however,* That the First Revised Sheet Nos. 498 and 499 shall become effective subject to refund on the date and in the manner hereinbefore set forth if within 20 days from the date of the issuance of this order Consolidated shall execute and file under the above designated docket with the Secretary of the Commission its agreement and undertaking to comply with the refunding and reporting procedures required by the Natural Gas Act and § 154.102 of the regulations thereunder, accompanied by a certificate showing service of a copy thereof upon Texas Gas. Unless Consolidated is advised to the contrary within 15 days after the filing of the aforementioned agreement and undertaking, such agreement and undertaking shall be deemed to have been accepted.

(D) Until otherwise ordered by the Commission, neither the aforementioned suspended tariff sheets, nor the tariff sheets sought to be superseded, shall be changed until the disposition of these proceedings or the expiration of the suspension period.

(E) Notices of intervention or petitions to intervene may be filed with the Federal Power Commission, Washington, D.C. 20426, in accordance with the rules of practice and procedure (18 CFR 1.8 and 1.37) on or before February 16, 1970.

By the Commission.

[SEAL] GORDON M. GRANT,
Secretary.

[F.R. Doc. 70-1518; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket No. CP70-176]

FLORIDA GAS TRANSMISSION CO.

Notice of Application

JANUARY 30, 1970.

Take notice that on January 21, 1970, Florida Gas Transmission Co. (applicant), Post Office Box 44, Winter Park, Fla. 32789, filed in Docket No. CP70-176 an application pursuant to section 7(c) of the Natural Gas Act for a certificate of public convenience and necessity authorizing the construction and operation of certain natural gas facilities and for the sale and delivery of natural gas to the Indiantown Gas Co., Inc. (Indiantown Gas), for resale and distribution in the communities of Indiantown and Booker Park in Martin County, Fla., and for resale and delivery to Florida Steel Corp. for use in their plant which is presently under construction near Indiantown, all as more fully set forth in the application which is on file with the Commission and open to public inspection.

Applicant proposes to construct and operate approximately 9 miles of 6-inch lateral extending from a point in its existing 6-inch transmission pipeline in Palm Beach County, Fla., to a point near Indiantown, where delivery of gas will be made to Indiantown Gas. Applicant also proposes to construct and operate meter stations and other appurtenant facilities for the delivery of gas for resale.

Indiantown Gas estimates that its third year annual and peak day requirements will be 389,689 MMBtu and 3,461 MMBtu, respectively.

The total estimated cost of the facilities to be constructed by applicant is $282,000, of which $201,492 will be paid by Indiantown Gas and the remaining $80,508 will be paid by applicant out of cash on hand.

Any person desiring to be heard or to make any protest with reference to said application should on or before February 24, 1970, file with the Federal Power Commission, Washington, D.C. 20426, a petition to intervene or a protest in accordance with the requirements of the Commission's rules of practice and procedure (18 CFR 1.8 or 1.10) and the regulations under the Natural Gas Act (18 CFR 157.10). All protests filed with the Commission will be considered by it in determining the appropriate action to be taken but will not serve to make the protestants parties to the proceeding. Any person wishing to become a party to a proceeding or to participate as a party in any hearing therein must file a petition to intervene in accordance with the Commission's rules.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Federal Power Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition to intervene is filed within the time required herein, if the Commission on its own review of the matter finds that a grant of the certificate is required by the public convenience and necessity. If a petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given.

Under the procedure herein provided for, unless otherwise advised, it will be

[1] Original Sheets Nos. 496 through 523 to FPC Gas Tariff, Original Volume No. 3.
[2] First Revised Sheets Nos. 498 and 499 to FPC Gas Tariff, Original Volume No. 3.
[3] Area Rate Proceeding (Southern Louisiana Area) 40 FPC 530, petition for review pending sub nom. Austral Oil Co. et al. v. FPC, CA5 No. 27492.
[4] Issued Mar. 20, 1969, 41 FPC 301.
[5] 41 FPC 301, 307.

unnecessary for applicant to appear or be represented at the hearing.

GORDON M. GRANT,
Secretary.

[F.R. Doc. 70-1526; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket No. RP69-16 etc.]

MANUFACTURERS LIGHT AND HEAT CO. ET AL.

Order Consolidating Proceedings for Determination of Severed Rate Issues

JANUARY 30, 1970.

The Manufacturers Light and Heat Co. et al., Pennsylvania Gas and Water Co., applicant, Docket No. RP69-16 et al., v. the Manufacturers Light and Heat Co., respondent, Docket No. CP69-100.

On October 9, 1968, Pennsylvania Gas and Water Co. (Penn Gas) filed an application in Docket No. CP69-100,[1] pursuant to sections 5(a) and 7(a) of the Natural Gas Act, asking the Commission to find that the rates at which it purchases gas from The Manufacturers Light and Heat Co. (Manufacturers) are unlawful under the circumstances described in its application and requesting that the Commission order Transcontinental Gas Pipe Line Corp. (Transco) to deliver and sell gas to it directly instead of delivering gas to it at two delivery points for the account of Manufacturers.

By order issued September 16, 1969, in Docket No. RP69-16 et al., Penn Gas was permitted to intervene in Manufacturers rate proceeding. Examination of the testimony which was submitted by Penn Gas in Docket No. RP69-16 et al., shows that all the rate issues raised by Penn Gas' application in Docket No. CP69-100 have already been interjected into the proceeding in Docket No. RP69-16 et al., in addition to many other issues not specifically related to Penn Gas' claim that deliveries to it by Transco for Manufacturers' account are unduly discriminatory.

In other words, Penn Gas' application in Docket No. CP69-100 does not bring before the Commission any rate issues which have not already been the subject of direct and rebuttal testimony submitted in Manufacturers' rate proceeding. Consequently, the severance of the rate issues from Docket No. RP69-16 et al., will not enlarge the issues already presented for determination in the rate proceeding. Severance and consolidation of issues will eliminate the duplication of effort which would otherwise occur if Penn Gas were not precluded from raising identical issues and pursuing them to decision in two different proceedings.

The Commission finds: It is necessary and appropriate in the administration of the Natural Gas Act to sever all rate issues raised by the application filed in Docket No. CP69-100 from that application and consolidate them with the rate proceeding in Docket No. RP69-16 et al.

The Commission orders: All rate issues raised by Penn Gas' application in Docket No. CP69-100 are severed from the certificate proceeding in Docket No. CP69-100 and consolidated with the rate proceeding in Docket No. RP69-16 et al., for purposes of hearing and decision.

By the Commission.

[SEAL] GORDON M. GRANT,
Secretary.

[F.R. Doc. 70-1522; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket No. G-7517 etc.]

PAN AMERICAN PETROLEUM CORP. ET AL.

Findings and Order

JANUARY 30, 1970.

Findings and order after statutory hearing issuing certificates of public convenience and necessity, amending orders issuing certificates, permitting and approving abandonment, terminating certificate, redesignating FPC gas rate schedule, accepting FPC gas rate schedules and supplements for filing, making successor co-respondent, redesignating proceedings, and requiring filing of agreement and undertaking.

Lone Star Producing Co. (Lone Star) filed in Docket No. CI70-327, as successor to Placid Oil Co. (Operator), et al. (Placid), certificate holder in Docket No. G-14679, an application pursuant to section 7(b) of the Natural Gas Act for permission and approval to abandon the sale of natural gas to H. L. Hunt, et al., from the Whelan Field, Harrison County, Tex., all as more fully set forth in the application. On October 27, 1969, Pan American Petroleum Corp. (Pan American) filed in Docket No. G-7517 a petition to amend the order issuing a certificate of public convenience and necessity in said docket by deleting therefrom authorization to sell natural gas to Hunt from the same field, all as more fully set forth in the petition to amend. Concurrently with the aforementioned application and petition to amend Lone Star and Pan American filed in Dockets Nos. CI70-326 and CI70-403, respectively, applications pursuant to section 7(c) of the Natural Gas Act for certificates of public convenience and necessity authorizing the sales of natural gas to Texas Eastern Transmission Corp. (Texas Eastern) from the same field, all as more fully set forth in the applications.

Applicants' low pressure wells connected to Hunt's gathering system are depleted to the extent that they are no longer economical to operate. Hunt resells applicants' gas after gathering and compression to Texas Eastern. Under a new and separate drilling program, applicants have completed new wells to deeper horizons found to be productive of large volumes of high pressure gas. Hunt has declined applicants' offer of the high pressure gas because Hunt deems its existing gathering system inadequate to accommodate these volumes, and it would not be economical for Hunt to install additional facilities to purchase this gas. Applicants propose to connect the new high pressure wells to Lone Star's existing high pressure gathering system from which deliveries are currently being made to Texas Eastern from other leases in the area.

Placid, Lone Star's predecessor in interest, is authorized to make the low pressure sales to Hunt pursuant to its FPC Gas Rate Schedule No. 29 at the rate of 13.9 cents per Mcf at 14.65 p.s.i.a., subject to refund in Docket No. RI68-187. Placid collected prior increased rates for locked-in periods subject to refund in Dockets Nos. G-15370, G-17423, G-19767, RI61-213, RI62-104, RI63-132, RI64-202, RI65-259, RI66-132, and RI67-91. Placid filed a notice of change under the subject rate schedule, which change is suspended in Docket No. RI69-161. Pan American is authorized to make the low pressure sale to Hunt pursuant to its FPC Gas Rate Schedule No. 275 at the rate of 14.1 cents per Mcf at 14.65 p.s.i.a., subject to refund in Docket No. RI69-163. Pan American collected prior increased rates for locked-in periods subject to refund in Dockets Nos. RI61-192, RI62-121, RI63-81, RI64-222, RI65-178, RI66-129, and RI68-186. Hunt resells applicants' gas to Texas Eastern at the rate of 16.67263 cents per Mcf. Applicants propose to sell gas to Texas Eastern under contracts which provide for the rate of 17.5 cents per Mcf, but applicants agree to accept certificates conditioned to the rate of 15 cents per Mcf.

Lone Star filed in Docket No. G-14679 a petition to amend the order issuing a certificate of public convenience and necessity in said docket to Placid by authorizing Lone Star to continue the sales of natural gas therein authorized, all as more fully set forth in the petition to amend. Lone Star also acquired the interest of R. Lacy, Inc., which is covered by the Placid certificate and rate schedule. In addition to sales from the interests acquired from Placid and Lacy, Lone Star proposes to sell natural gas to Texas Eastern from the interests of Gulf Oil Corp., presently authorized in Docket No. G-7148 to sell gas to Hunt pursuant to its FPC Gas Rate Schedule No. 182.

Lone Star has filed in Dockets Nos. RI68-187 and RI69-161 a motion to be made co-respondent in said proceedings. Therefore, Lone Star will be made co-respondent; the proceedings will be redesignated accordingly; and Lone Star will be required to file an agreement and undertaking in Docket No. RI68-187 to assure the refund of any amounts collected by it in excess of the amounts determined to be just and reasonable in said proceeding.

Applicants have submitted FPC gas rate schedules and rate schedule supplements, which will be accepted for filing, for the sales proposed to be continued, abandoned, and initiated. Placid's rate schedule will be redesignated as that of Lone Star.

[1] Notice of the application was issued Oct. 17, 1968, and published in the FEDERAL REGISTER on Oct. 24, 1968 (33 F.R. 15719).

The Commission's staff has reviewed the applications and petitions to amend and recommends each action ordered as consistent with all substantive Commission policies and required by the public convenience and necessity.

After due notice by publication in the FEDERAL REGISTER, no petition to intervene, notice of intervention, or protest to the granting of the applications has been filed.

At a hearing held on January 22, 1970, the Commission on its own motion received and made a part of the record in this proceeding all evidence, including the applications and petitions to amend and exhibits thereto, submitted in support of the authorization sought herein, and upon consideration of the record,

The Commission finds:

(1) Applicants, Lone Star Producing Co. and Pan American Petroleum Corp., are engaged in the sale for resale of natural gas in interstate commerce for ultimate public consumption and each is a "natural-gas company" within the meaning of the Natural Gas Act as heretofore found by the Commission.

(2) The sales of natural gas proposed to be abandoned and initiated, as hereinbefore described and as more fully described in the applications and petitions to amend in this proceeding, are or will be made in interstate commerce subject to the jurisdiction of the Commission. The abandonment of current sales is subject to the requirements of subsection (b) of section 7 of the Natural Gas Act; and the proposed new sales, together with the construction and operation of any facilities subject to the jurisdiction of the Commission necessary therefor, are subject to the requirements of subsections (c) and (e) of section 7 of the Natural Gas Act.

(3) Applicants are able and willing properly to do the acts and to perform the service proposed and to conform to the provisions of the Natural Gas Act and the requirements, rules, and regulations of the Commission thereunder.

(4) The sales of natural gas proposed in Dockets Nos. CI70–326 and CI70–403 are required by the public convenience and necessity, and certificates therefor should be issued as hereinafter ordered and conditioned.

(5) The abandonments proposed in Dockets Nos. G–7517 and CI70–327 are permitted by the public convenience and necessity, and an order approving same should be issued as hereinafter ordered.

(6) It is necessary and appropriate in carrying out the provisions of the Natural Gas Act and the public convenience and necessity require that the orders issuing certificates in Dockets Nos. G–7517 and G–14679 should be amended as hereinafter ordered.

(7) It is necessary and appropriate in carrying out the provisions of the Natural Gas Act that Lone Star Producing Co. should be made a co-respondent in the proceedings pending in Dockets Nos. RI68–187 and RI69–161, that said proceedings should be redesignated accordingly, and that Lone Star should be required to file an agreement and undertaking in Docket No. RI68–187.

(8) It is necessary and appropriate in carrying out the provisions of the Natural Gas Act that the FPC gas rate schedules and supplements submitted by Applicants should be accepted for filing and that Placid's rate schedule should be redesignated as that of Lone Star.

The Commission orders:

(A) Certificates of public convenience and necessity are issued in Dockets Nos. CI70–326 and CI70–403 upon the terms and conditions of this order authorizing the sales by applicants of natural gas in interstate commerce for resale for ultimate public consumption, together with the construction and operation of any facilities subject to the jurisdiction of the Commission necessary therefor, all as hereinbefore described and as more fully described in the applications in said dockets. The sales shall be made at the rate of 15.0 cents per Mcf at 14.65 p.s.i.a.

(B) The certificates issued in paragraph (A) above are not transferable and shall be effective only so long as applicants continue the acts or operations hereby authorized in accordance with the provisions of the Natural Gas Act and the applicable rules, regulations, and orders of the Commission.

(C) The grant of the certificates issued in paragraph (A) above shall not be construed as a waiver of the requirements of section 4 of the Natural Gas Act or of Part 154 or Part 157 of the regulations thereunder and is without prejudice to any findings or orders which have been or which hereafter may be made by the Commission in any proceedings now pending or hereafter instituted by or against applicants. Further, our action in this proceeding shall not foreclose nor prejudice any future proceedings or objections relating to the operation of any price or related provisions in the gas purchase contracts herein involved. The grant of the certificates herein for service to the particular customer involved shall not imply approval of all of the terms of the contracts, particularly as to the cessation of service upon termination of said contracts, as provided by section 7(b) of the Natural Gas Act. The grant of the certificates herein shall not be construed to preclude the imposition of any sanctions pursuant to the provisions of the Natural Gas Act for the unauthorized commencement of any sale of natural gas subject to said certificates.

(D) Permission for and approval of the abandonments proposed in Dockets Nos. G–7517 and CI70–326 are granted. The order issuing a certificate in Docket No. G–7517 is amended by deleting therefrom authorization to sell natural gas to Hunt from the acreage from which sales are authorized to be abandoned, and in all other respects said order shall remain in full force and effect.

(E) The order issuing a certificate of public convenience and necessity to Placid in Docket No. G–14679 is amended by substituting Lone Star in lieu of Placid as certificate holder, and in all other respects said order shall remain in full force and effect. The certificate issued in Docket No. G–14679 shall terminate at the time of the initial delivery of the sale authorized in Docket No. CI70–326.

(F) The abandonment permitted and approved in Docket No. G–7517 and the partial cancellation of the related rate schedule do not relieve Pan American of any refund obligation in Dockets Nos. RI61–192, RI62–121, RI63–81, RI64–222, RI65–178, RI66–129, RI68–186, and RI 69–163. The abandonment permitted and approved in Docket No. CI70–327 and the cancellation of the related rate schedule do not relieve Placid and Lone Star of any refund obligation in Dockets Nos. G–15370, G–17423, G–19767, RI61–213, RI62–104, RI63–132, RI64–202, RI 65–259, RI66–132, RI67–91, and RI68–187.

(G) Lone Star is made a co-respondent in the proceedings pending in Dockets Nos. RI68–187 and RI69–161 and the proceedings are redesignated accordingly. Lone Star shall comply with the refunding and reporting procedure required by the Natural Gas Act and § 154.102 of the regulations thereunder.

(H) Within 30 days from the issuance of this order, Lone Star shall execute, in the form set out below, and shall file with the Secretary of the Commission an acceptable agreement and undertaking in Docket No. RI69–161 to assure the refund of any amounts collected by it, together with interest at the rate of 7 percent per annum, in excess of the amount determined to be just and reasonable in said proceeding. Unless notified to the contrary by the Secretary within 30 days from the date of submission, such agreement and undertaking shall be deemed to have been accepted for filing. The agreement and undertaking shall remain in full force and effect until discharged by the Commission.

(I) The FPC gas rate schedules and supplements submitted by Applicants are accepted for filing and Placid's rate schedule is redesignated as set forth below.

By the Commission.

[SEAL] GORDON M. GRANT,
Secretary.

Docket No. and date filed	Applicant	Purchaser, field, and location	FPC rate schedule to be accepted: Description and date of document	No.	Supp.
G-7517..... D 10-27-69	Pan American Petroleum Corp.	H. L. Hunt et al., Whelan Field, Harrison County, Tex.	Release agreement 6-19-69.[1 2 3]	275	11
G-14679..... E 10-2-69	Lone Star Producing Co. (successor to Placid Oil Co. (Operator)).	....do.....	Placid Oil Co. (Operator), FPC GRS No. 29.	89	.....
			Supplemental Nos. 1-9.....	89	1-9
			Notice of succession 9-30-69.	.....	.....
			Assignment 10-2-68[4].....	89	10
			Effective date: 10-1-68.....	.....	.....
			Assignment 5-22-69[5].....	89	11
			Effective date: 6-1-69.....	.....	.....
CI70-326..... A 10-2-69	Lone Star Producing Co. (Operator) et al.	Texas Eastern Transmission Corp., Whelan Field, Harrison County, Tex.	Contract 5-1-69.....	90	.....
			Ratified 5-26-69[6].....	90	1
			Amended 6-17-69[7 8].....	90	2
CI70-327..... (G-14679) B 10-2-69	Lone Star Producing Co.	H. L. Hunt et al., Whelan Field, Harrison County, Tex.	Notice of cancellation 9-30-69.[2]	89	12
CI70-403..... A 10-27-69	Pan American Petroleum Corp.	Texas Eastern Transmission Corp., Whelan Field, Harrison County, Tex.	Ratified 6-19-69[10].....	541	.....
			Contract 5-1-69[9].....	541	1

Filing code: A—Initial service.
B—Abandonment.
C—Amendment to add acreage.
D—Amendment to delete acreage.
E—Succession.
F—Partial succession.

[1] Cancels FPC GRS No. 275 insofar as it pertains to Dee Knox Unit and The Dunn No. 1 Gas Unit.
[2] Source of gas depleted.
[3] Effective date: Date of initial delivery under certificate issued in Docket No. CI70-403.
[4] Assignment from Placid Oil Co. to Lone Star Producing Co. (limited from the surface of the soil down to the base of the Travis Peak Formation).
[5] Assignment from R. Lacy, Inc., to Lone Star Producing Co. (Lacy is a nonsignatory co-owner covered under Placid's rate schedule).
[6] Gulf Oil Corp. ratified and adopted Lone Star's contract and desires to be covered by Lone Star's filing.
[7] Amendment adds additional leases to the contract.
[8] Effective date: Date of initial delivery.
[9] Effective date: Date of initial delivery under certificate issued in Docket No. CI70-326.
[10] Ratification of Lone Star Producing Co. contract.

Suggested agreement and undertaking:

BEFORE THE FEDERAL POWER COMMISSION

((Name of respondent)_____)

Docket No.____

AGREEMENT AND UNDERTAKING OF (NAME OF RESPONDENT) TO COMPLY WITH REFUNDING AND REPORTING PROVISIONS OF SECTION 154.102 OF THE COMMISSION'S REGULATIONS UNDER THE NATURAL GAS ACT

(Name of respondent) hereby agrees and undertakes to comply with the refunding and reporting provisions of section 154.102 of the Commission's regulations under the Natural Gas Act insofar as they are applicable to the proceeding in Docket No.____, and has caused this agreement and undertaking to be executed and sealed in its name by a duly authorized officer this _____ day of _____ 196__.

(Name of Respondent)
By _____

Attest:

_____

[F.R. Doc. 70-1521; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket Nos. RP69-35, RP70-20]

PANHANDLE EASTERN PIPE LINE CO.

Order Approving Tracking Procedure of Supplier Rate Changes, Consolidating Proceedings, and Rejecting for Filing Revised Tariff Sheets

JANUARY 30, 1970.

Panhandle Eastern Pipe Line Co. (Panhandle) on December 2, 1969, tendered for filing proposed changes in its FPC Gas Tariff, Original Volume No. 1 [1] to become effective January 2, 1970. Subsequently by letter dated December 19, 1969, Panhandle changed the effective date to February 1, 1970. The proposed changes would increase jurisdictional rates by approximately $1.8 million annually, above the presently effective rates filed in Docket No. RP69-35.

In the instant filing Panhandle also requested authorization to track, without suspension, purchased gas cost changes up to a net aggregate amount of 1.0 cent per Mcf, as incurred during the period ending December 31, 1970.

Panhandle states that the proposed increased rates are being filed to track increased gas supply costs incurred since its rate increase filing in Docket No. RP69-35, and that since these costs will be incurred by January 1, 1970, it requests its proposed tariff sheets be permitted to become effective without suspension. In view of its request that the rates not be suspended, Panhandle suggests that this new filing be consolidated with Docket No. RP69-35 and subject to the Commission's order, issued December 4, 1969, making rates effective on November 20, 1969, in that proceeding. In addition Panhandle states that the tracking authorization is required to protect the Company against increases in purchased gas costs estimated at $3,900,000 during 1970.

In general Panhandle's tracking procedure provides that the company be permitted to file revised tariff sheets through December 31, 1970, changing the commodity components and one-part rates in its G-1, 2, 3; SG-1, 2, 3; LS-1, 2; S-1; SS-1; CS-1; and I-1, 2, 3 Rate Schedules up to a net aggregate increase of 1.00 cent per Mcf to reflect supplier rate changes. Revised tariff sheets would not be filed unless the change from the rates previously in effect is at least 0.1 cent per Mcf. The effective date of any rate change would be the date on which supplier increases are made effective by order of the Commission, or the date on which a decrease is made effective by the supplier, as the case may be. The effective date of Panhandle's tracking rate change would be at least 30 days after the date of filing such change. Any rate changes hereunder would be computed as hereinafter provided.

The $1.8 million rate increase reflected by the revised tariff sheets listed above is based on higher gas supply costs which are due primarily to (1) increased transmission costs, and (2) increased expenses associated with gas shrinkage at Panhandle's Aledo extraction plant.

Since the higher gas supply costs are not based on changes in purchased gas costs, Panhandle's abbreviated filing does not comply with the requirements of § 154.63(b)(3) of the regulations under the Natural Gas Act. We deem it inappropriate at this time to waive § 154.63(b)(3) of the regulations and to accept the revised tariff sheets tendered by Panhandle which would allow the Company to reflect changes in gas supply costs other than purchased gas costs. The rejection of the tendered tariff sheets for filing as a "tracking" increase is without prejudice to the substantive issue whether such costs should be considered in Panhandle's presently pending rate case in Docket No. RP69-35. We are advised that the Staff's proposed cost of service in that docket is based on a test year which will include the appropriate jurisdictional portion of these costs.

With respect to Panhandle's request for authorization to track supplier rate changes it appears appropriate and consistent with our recent orders that such request be granted in the manner prescribed in the ordering paragraphs below.

Since Panhandle's rates are presently the subject of proceedings in Docket No. RP69-35, it appears appropriate that the proposed tracking procedure in Docket No. RP70-20 be consolidated with the RP69-35 proceeding.

The Commission finds:

(1) It is necessary and proper in the public interest that Panhandle be permitted to track changes in supplier rates in the manner and subject to the conditions prescribed herein.

(2) It is necessary and proper in the public interest and to aid in the enforcement of the Natural Gas Act that the revised tariff sheets tendered by Panhandle

[1] Seventh Revised Sheet No. 24-A; Ninth Revised Sheet No. 26-E; 10th Revised Sheet Nos. 26-A, 26-B; 15th Revised Sheet Nos. 4, 7, 10, 13, 14, 16, 17, 20, 22, 29, 31; 16th Revised Sheet Nos. 19, 27; 19th Revised Sheet No. 25.

on December 2, 1969, be rejected for filing without prejudice to consideration of changed gas supply costs in Docket No. RP69–35.

The Commission orders:

(A) Panhandle's revised tariff sheets listed above are hereby rejected for filing without prejudice to consideration of the changed gas supply costs in Docket No. RP69–35.

(B) Pursuant to the authority of the Natural Gas Act, particularly sections 4 and 16 thereof, the Commission's rules of practice and procedure, and regulations under the Natural Gas Act (18 CFR Ch. I), permission is hereby granted for the filing of revised tariff sheets pursuant to Panhandle's proposed tracking procedure as herein conditioned.

(C) The tracking rate filings by Panhandle authorized hereby shall be made pursuant to the following conditions:

(1) Panhandle may from time to time until December 31, 1970, file with the Commission as a part of its FPC Gas Tariff, Original Volume No. 1, revised tariff sheets for its G–1, 2, 3; SG–1, 2, 3; LS–1, 2; S–1; SS–1; CS–1; and I–1, 2, 3 Rate Schedules necessary to reflect increases, and Panhandle shall make such filings to reflect decreases, if any, in the Company's cost of purchased gas computed in accordance with the subsequent provisions of this paragraph (C).

(2) To determine changes in the Company's cost of purchased gas for purposes of tracking filings hereunder, the Company shall determine the difference between (1) the annualized weighted average cost of purchased gas based on actual volumes of gas purchased for a 12-month period ending not less than 60 days nor more than 90 days prior to the effective date of Panhandle's tracking filings and changed suppliers' rates to be effective on or before the effective date of such tracking filing, and (2) the annualized weighted average cost of purchased gas of 20.58 cents per Mcf reflected in the Company's rate filing in Docket No. RP69–35. The change in the Company's cost of purchased gas shall then be determnied by multiplying such difference by the total volumes of gas purchased during the 12-month period utilized for determining the annualized weighted average cost of purchased gas.

(3) The net change in rates under the tracking procedure shall be determined to the nearest one-hundredth (1/100) of a cent by dividing the total change in the Company's cost of purchased gas as determined pursuant to subparagraph (C) (2) above by the Company's total system sales, including appropriate Btu adjustments for volumes consumed at the Liberal and Tuscola extraction plants, for the same 12-month period as was utilized in determining the annualized weighted average cost of purchased gas. Panhandle is authorized to file revised tariff sheets to reflect such net change in rates, provided that no such rate change be filed unless the change from the rates previously in effect is at least one-tenth (1/10) of a cent.

(4) Rate increases or decreases shall be effected by uniform increases or decreases in the commodity components and the one-part rates in Panhandle's Rate Schedules.

(5) Panhandle shall not file tracking increases pursuant to this authorization which provide for a net increase in the Company's rates in excess of 1.00 cent per Mcf over the rates contained in the Company's presently effective rates filed in Docket No. RP69–35.

(6) Revised tariff sheets filed pursuant to this tracking procedure shall become effective not less than 30 days after filing.

(7) Revised tariff sheets filed pursuant to this tracking procedure shall reflect only such supplier rate changes which are effective as of the date of such tracking rate filing or which will become effective pursuant to motions then on file with the Commission on or before the proposed effective date of Panhandle's tracking rate filing.

(8) If as a result of any order of the Commisison which becomes final and no longer subject to review, Panhandle shall receive refunds, including interest, under any supplier rate schedules which are applicable to increased rates collected thereunder and which have been reflected in changes in Panhandle's rates by tracking filings hereunder, Panhandle shall refund to its jurisdictional customers, without further interest thereon, the jurisdictional portion of such amounts within 30 days after accumulation of $200,000 or more, except for the final refund, which shall be made only if the total amount remaining refundable is at least $50,000.

(D) As a condition of this order, Panhandle shall execute and file in triplicate with the Secretary of this Commission within 20 days of the date of this order, its written Agreement and Undertaking to comply with the terms of subparagraph (C) (8) hereof, signed by a responsible officer of the corporation, evidenced by proper authority from its Board of Directors, and accompanied by a certificate showing service of copies thereof upon all purchasers under the tariff sheets involved and upon all parties of record in this proceeding as follows:

AGREEMENT AND UNDERTAKING OF PANHANDLE EASTERN PIPE LINE COMPANY TO COMPLY WITH THE TERMS AND CONDITIONS OF SUBPARAGRAPH (C) (8) OF THE FEDERAL POWER COMMISSION ORDER ISSUED JANUARY 1970 IN DOCKET NO. RP70–20

In conformity with the requirements of the order issued January 1970, in Docket No. RP70–20, Panhandle Eastern Pipe Line Co. hereby agrees and undertakes to comply with the terms and conditions of subparagraph (C) (8) of said order and has caused this agreement and undertaking to be executed and sealed in its name by its officers, thereupon duly authorized in accordance with the terms of the resolution of its Board of Directors, a certified copy of which is appended hereto, this ____ day of ----------, 1970.

PANHANDLE EASTERN PIPE LINE COMPANY

By ----------

ATTEST:

Secretary.

(E) The proposed tracking procedure in Docket No. RP70–20 is hereby consolidated with the proceedings in Docket No. RP69–35 and is subject to the order issued by this Commission in that docket on May 5, 1969, and such further orders as shall be issued in the consolidated proceeding.

By the Commission.

[SEAL] GORDON M. GRANT, *Secretary.*

[F.R. Doc. 70–1523; Filed, Feb. 5, 1970; 8:48 a.m.]

[Docket No. CP69–100]

PENNSYLVANIA GAS AND WATER CO. AND TRANSCONTINENTAL GAS PIPE LINE CORP.

Order Fixing Date of Prehearing Conference, Permitting Intervention, and Making Tennessee Gas Pipeline Co. Respondent

JANUARY 30, 1970.

On December 29, 1969, Pennsylvania Gas and Water Co. (Penn Gas), the applicant in the above-entitled proceeding, filed a motion requesting that the Commission issue an order providing for a prompt hearing on its application in Docket No. CP69–100 [1] which was filed October 9, 1968, pursuant to sections 5(a) and 7(a) of the Natural Gas Act (Act).

The portion of Penn Gas' application filed under section 7(a) of the Act seeks an order from the Commission directing Transcontinental Gas Pipe Line Corp. (Transco) to sell directly to Penn Gas 23,845 Mcf per day of gas (at 14.73 p.s.i.a.) which Transco presently delivers from its facilities into Penn Gas' system for the account of Manufacturers Light and Heat Co. (Manufacturers). Penn Gas is now entitled to purchase up to 29,387 Mcf per day from Manufacturers, but 23,845 Mcf of that total are delivered to Penn Gas by Transco for Manufacturers' account, and Penn Gas contends that since Manufacturers performs no service in connection with the deliveries received directly from Transco's facilities that Manufacturers ought to be eliminated as an unnecessary middleman with respect to all gas delivered to it by Transco. In short, Penn Gas seeks to reduce its purchases from Manufacturers from 29,387 Mcf per day to 5,542 Mcf per day.

The portion of Penn Gas' application filed pursuant to section 5(a) of the Act alleges that since Manufacturers performs no function with respect to deliveries of gas by Transco to it for Manufacturers' account, that Penn Gas is being unduly discriminated against in being required to pay the same rates that other customers pay Manufacturers for gas which is delivered to them directly through Manufacturers' own facilities.

[1] Notice of the application was issued Oct. 17, 1968, and published in the FEDERAL REGISTER on Oct. 24, 1968 (33 F.R. 15719).

Although Penn Gas' application in Docket No. CP69–100 has never been scheduled for hearing, it filed its direct testimony in support of its application in CP69–100 as a part of the evidence which it submitted in Docket No. CP68–364 on the assumption that its motion to consolidate its application for hearing with the one in Docket No. CP68–364 would be granted.[2] Examination of the direct testimony filed in Docket No. CP69–100 shows that a large part of it deals with Penn Gas' allegations that Manufacturers' rates are unjust, unreasonable, and unduly discriminatory because Manufacturers is allegedly providing no service in connection with deliveries to it by Transco for Manufacturers' account. Similarly, some of Penn Gas' testimony in Docket No. CP69–100 is identical with that filed by it as an intervener in Manufacturers' rate proceeding in Dockets Nos. RP69–16, et al.

Since some of the issues raised by Penn Gas as an intervener in Manufacturers' rate case are identical with the rate questions involved in the section 5(a) portion of Penn Gas' application in Docket No. CP69–100, it appeared desirable to delay a hearing on the application in Docket No. CP69–100 until the rate issues raised by the application had been resolved in Manufacturers' rate proceeding. However, Penn Gas' motion for a prompt hearing on its application in Docket No. CP69–100 alleges that it is confronted with a gas-supply emergency because it has been unable to plan its gas-supply arrangements as a result of the Commission's delay in deciding the section 7(a) issues raised by its application in Docket No. CP69–100. Penn Gas claims that the seriousness of its supply situation can be alleviated only by a prompt hearing and decision in Docket No. CP69–100.

In order to prevent the duplication of effort which would occur if identical rate issues were to be decided in two different proceedings, we have, by separate order issued concurrently herewith, severed the portion of Penn Gas' application in Docket No. CP69–100 which relates to section 5 of the Act and have consolidated all such rate issues with Manufacturers' rate proceeding in Docket Nos. RP–69–16, et al., in which Penn Gas has already presented testimony and exhibits in support of its position that Manufacturers' rates and services are unlawful. Consequently, only certificate questions related to Penn Gas' request for an order directing Transco to make sales directly to it, rather than for Manufacturers' account, at two delivery points remain to be decided in this proceeding.

Penn Gas' application in Docket No. CP69–100 indicates that it presently purchases gas from three suppliers: Transco, Manufacturers, and Tennessee Gas Pipeline Co., a division of Tenneco Inc. (Tennessee). Although Tennessee is not named as a respondent in Penn Gas' application, the alleged savings which are claimed to be derived from purchasing gas at Transco's rates, instead of Manufacturers', were computed by Penn Gas by relying in part upon a change in purchase pattern from Tennessee. Since Penn Gas' motion for a prompt hearing raises gas-supply questions, it is important that the evidence at the hearing be based upon realistic gas-supply assumptions and up-to-date market estimates. Therefore, the order herein will prescribe that Tennessee become a respondent to the proceeding in order that evidence can be obtained to determine whether the presumptions inherent in Penn Gas' calculations of savings are based on a realistic evaluation of available gas supplies.

The only petition seeking leave to intervene in the proceeding in Docket No. CP69–100 was timely filed by Manufacturers on November 6, 1968.

The Commission finds:

(1) It is appropriate to grant Manufacturers' petition seeking leave to intervene in the proceeding in Docket No. CP69–100.

(2) Tennessee Gas Pipeline Co., should be made a respondent to the application filed in Docket No. CP69–100 in order that appropriate evidence can be obtained to determine the validity of the assumptions made by Penn Gas with respect to the availability of gas to be purchased from Tennessee.

(3) It is appropriate in the administration of the Natural Gas Act that Penn Gas' motion for a prompt hearing filed December 29, 1969, be granted.

The Commission orders:

(A) The Manufacturers Light and Heat Company is hereby permitted to intervene in this proceeding subject to the rules and regulations of the Commission: *Provided, however*, That the admission of Manufacturers shall not be construed as recognition by the Commission that it might be aggrieved because of any order or orders issued by the Commission in this proceeding.

(B) Tennessee Gas Pipeline Company shall be a respondent to the application filed by Penn Gas in Docket No. CP69–100 and shall present testimony at the hearing concerning its ability to supply the types of service and volumes of gas underlying the gas-supply assumptions inherent in Penn Gas' projections of future gas supplies.

(C) Pennsylvania Gas and Water Company's "Motion for an Order Fixing Date for Hearing on Application" filed December 29, 1969, in Docket No. CP69–100 is granted.

(D) Pursuant to the provisions of Section 1.18 of the Commission's Rules of Practice and Procedure, a prehearing conference before a duly designated presiding examiner shall commence at 10 a.m., e.s.t., on February 3, 1970, in a hearing room of the Federal Power Commission, 441 G Street NW., Washington, D.C. 20426, for the purpose of (1) considering all matters at issue with respect to the portion of Penn Gas' application filed pursuant to section 7(a) of the Natural Gas Act, (2) determining the scope of the evidence which should be presented, (3) fixing dates for service of testimony and exhibits and for commencement of hearing, and (4) entertaining adoption of suggestions which might expedite the proceeding.

By the Commission.

[SEAL] GORDON M. GRANT, *Secretary.*

[F.R. Doc. 70–1520; Filed, Feb. 5, 1970; 8:48 a.m.]

[2] The Commission's order issued Aug. 19, 1969, in Dockets Nos. CP68–364 and CP69–100 denied Penn Gas' motion to consolidate its application with the proceeding in Docket No. CP68–364.

[Docket No. CP70–106]

VALLEY GAS CO.

Order Granting Interventions and Fixing Date for Prehearing Conference

JANUARY 28, 1970.

On October 22, 1969, Valley Gas Co. (applicant) filed an application pursuant to section 7(b) of the Natural Gas Act for permission and approval to abandon natural gas service to Blackstone Gas Co. (Blackstone) all as more fully set forth in the application which is on file with the Commission and open to public inspection.

Applicant was initially authorized to sell natural gas to Blackstone in an order issued by the Commission on January 7, 1954, in Docket No. G–2272. Blackstone is a Massachusetts corporation that distributes natural gas in the communities of Blackstone and Bellingham, Mass. These communities are situated along the Massachusetts-Rhode Island State line. Applicant distributes natural gas in northeastern Rhode Island, with a substantial load in the City of Woonsocket, R.I., which also lies along the Massachusetts-Rhode Island State line. It appears that certain of the mains on the distribution systems of the applicant and Blackstone are connected together at the Rhode Island-Massachusetts border line. Service is rendered by the applicant to Blackstone through these mains.

The applicant wishes to be relieved of the obligation of providing resale gas to Blackstone. It is the position of the applicant that Blackstone can readily acquire all the natural gas it needs to meet its requirements from the Tennessee Gas Transmission Co., a division of Tenneco, Inc. (Tennessee). Applicant alleges in its application that the volume of gas that it is required to provide to Blackstone is relatively small, but that continuing service to Blackstone will create numerous and complicated problems.

Notice of filing of the above-described application has been issued by the Commission's Secretary and published in the FEDERAL REGISTER on November 8, 1969 (see 34 F.R. 18106).

Petitions to intervene were timely filed by Tennessee and Blackstone. Blackstone in its petition to intervene alleges that it is not presently economically feasible to interconnect the communities it serves by the construction of a pipeline within the State of Massachusetts to a connecting point on Tennessee's transmission line. It further contends in its petition to intervene, that if Valley Gas is permitted to abandon service to Blackstone, that 392 of its customers will be deprived of all natural gas service.

Tennessee, as a supplier of natural gas to both Valley Gas and Blackstone, alleges that it has a vital economic interest which will necessarily be affected by the outcome of these proceedings.

It appears that the intervention of Tennessee and Blackstone may be in the public interest.

The Commission is of the opinion that a prehearing conference held before the formal hearing will prove to be beneficial to all of the parties and enable the formal hearing to proceed expeditiously once it has commenced. The Commission will therefore require that a prehearing conference be held relative to the instant proceeding on February 25, 1970.

The Commission finds:

(1) It appears that the participation in this proceeding by Tennessee Gas Transmission Co., and the Blackstone Gas Co., may be in the public interest.

(2) It appears that the scheduling of a prehearing conference prior to the formal hearing may also be in the public interest.

The Commission orders:

(A) Tennessee Gas Transmission Co., a division of Tenneco Inc., and Blackstone Gas Co., are hereby permitted to intervene in this proceeding subject to the rules and regulations of the Commission: *Provided, however,* That the participation of such intervenors shall be limited to matters affecting asserted rights and interests specifically set forth in their petition to intervene: *And, provided, further,* That the admission of such intervenors shall not be construed as recognition by the Commission that they or any of them might be aggrieved because of any order or orders issued by the Commission in this proceeding.

(B) A prehearing conference be convened in the proceeding entitled Valley Gas Company, Docket No. CP70–106, in a hearing room of the Federal Power Commission, 441 G Street NW., Washington, D.C. on February 25, 1970, at 10 a.m., e.s.t. The Chief Examiner will designate an appropriate officer of the Commission to preside at the prehearing conference and at the formal hearing of these matters, pursuant to the Commission's rules of practice and procedure.

By the Commission.

[SEAL] GORDON M. GRANT, *Secretary.*

[F.R. Doc. 70–1516; Filed, Feb. 5, 1970; 8:48 a.m.]

SECURITIES AND EXCHANGE COMMISSION

[812–2617, 812–2618]

MUTUAL OF OMAHA INCOME FUND, INC., AND MUTUAL OF OMAHA GROWTH FUND, INC.

Notice of Filing of Applications for Orders of Exemption

FEBRUARY 2, 1970.

Notice is hereby given that Mutual of Omaha Income Fund, Inc., and Mutual of Omaha Growth Fund, Inc. (hereinafter collectively "Funds"), 3205 Dodge Street, Omaha, Nebr., open-end investment companies registered under the Investment Company Act of 1940 ("Act"); and Mutual of Omaha Fund Management Co. ("Management"), the underwriter for shares of the Funds and a wholly owned subsidiary of Mutual of Omaha Insurance Co. ("Mutual of Omaha"), have filed applications pursuant to section 6(c) of the Act for orders of exemption from the provisions of section 22(d) of the Act. The Funds and Management are collectively sometimes hereafter referred to as "Applicants." All interested persons are referred to the applications on file with the Commission for a statement of the representations therein which are summarized below.

Section 22(d) provides, in relevant part, that an open-end investment company is prohibited from selling a redeemable security issued by it to any person except at a current offering price described in the prospectus. This section has been construed as prohibiting variations in sales loads except on a uniform basis.

Shares of the Funds will ordinarily be offered to the general public at the public offering price which is the then current net asset value plus a sales charge as described in the Funds' prospectuses.

Applicants seek an exemption from section 22(d) to permit the Funds to offer their shares at net asset value without sales charges to the following categories of persons:

1. Salaried employees (employed on a full-time basis for at least 90 days), officers and directors of Mutual of Omaha and its subsidiaries ("Participating Companies").

2. Retired employees (under regular pension or disability retirement program), officers and directors of the Participating Companies.

3. General Agents and soliciting agents (but not including brokers) of any of the Participating Companies who are under written contract to offer the insurance business they solicit to the contracting Participating Company.

4. Full-time employees of such agents serving as such for at least 90 days.

5. Any trust, pension, profit-sharing, deferred compensation, stock purchase and savings or other benefit plan for such persons.

6. The Participating Companies themselves (as listed in Exhibit A to the applications).

The applications state that such sales will be made pursuant to a uniform offer described in the prospectuses of the Funds and will be made only upon the written assurance of the purchaser that the purchase is made for investment purposes and that the securities will not be resold except through redemption or repurchase by or on behalf of the issuer.

Applicants also state that no sales expense will be incurred in the sale of shares for which exemption from the provisions of section 22(d) is sought and that the granting of the requested exemption will not disrupt the orderly distribution of the shares involved, nor unfairly discriminate among investors.

Section 6(c) of the Act permits the Commission to exempt any person, security, or transaction, or any class or classes of persons, securities, or transactions from any provision or provisions of the Act, if and to the extent that such exemption is necessary or appropriate in the public interest and consistent with the protection of investors and the purposes fairly intended by the policy and provisions of the Act.

Notice is further given that any interested person may, not later than February 20, 1970 at 5:30 p.m., submit to the Commission in writing a request for a hearing on the matter accompanied by a statement as to the nature of his interest, the reason for such request and the issues of fact or law proposed to be controverted, or he may request that he be notified if the Commission shall order a hearing thereon. Any such communication should be addressed: Secretary, Securities and Exchange Commission, Washington, D.C. 20549. A copy of such request shall be served personally or by mail (airmail if the person being served is located more than 500 miles from the point of mailing) upon Applicants at the address stated above. Proof of such service (by affidavit or in case of an attorney at law by certificate) shall be filed contemporaneously with the request. At any time after said date, as provided by Rule 0–5 of the rules and regulations promulgated under the Act, an order disposing of the applications herein may be issued by the Commission upon the basis of the information stated in said applications unless an order for a hearing upon said applications shall be issued upon request or upon the Commission's own motion. Persons who request a hearing or advice as to whether a hearing is ordered, will receive notice of further developments in this matter, including the date of the hearing (if ordered) and any postponements thereof.

For the Commission (pursuant to delegated authority).

[SEAL] ORVAL L. DUBOIS, *Secretary.*

[F.R. Doc. 70–1509; Filed, Feb. 5, 1970; 8:47 a.m.]

INTERSTATE COMMERCE COMMISSION

[No. 35214]

ILLINOIS INTRASTATE RAIL FREIGHT RATES AND CHARGES, 1969

Order. At a session of the Interstate Commerce Commission, Division 2, held at its office in Washington, D.C., on the 26th day of January 1970.

By petition filed on December 31, 1969, the common carriers by railroad operating within the State of Illinois aver that the Illinois Commerce Commission has

refused to authorize or to permit increases in rates and charges on freight moving in intrastate commerce corresponding to those authorized by this Commission in Ex Parte No. 259, "Increased Freight Rates, 1968," 332 ICC 714, and they also seek the institution of an investigation with a view to further increasing the intrastate rates to the level authorized by this Commission's order entered November 17, 1969, in Ex Parte No. 262, "Increased Freight Rates, 1969," not printed; and for good cause:

It is ordered, That, pursuant to section 13 of the Interstate Commerce Act, an investigation be, and it is hereby, instituted into the matters and things presented in the petition; and that all common carriers by railroad operating within the State of Illinois subject to the jurisdiction of this Commission be, and they are hereby, made respondents to this proceeding.

It is further ordered, That all persons who intend actively to participate in this proceeding and to file and receive copies of pleadings, shall make known that fact by notifying the Commission in writing on or before February 26, 1970. To conserve time and to avoid unnecessary expense, persons having common interests should endeavor to consolidate their presentation to the greatest extent possible. Individual participation is not precluded; however, mere casual interest does not justify participation. The Commission desires participation only of those who intend to take an active part in the proceeding.

It is further ordered, That as soon as practicable after the date for indicating a desire to participate in the proceeding has passed, the Secretary will serve a list of the names and addresses of all participants.

It is further ordered, That a copy of this order be served upon the respondents; that the State of Illinois be notified of the proceeding by sending a copy of this order by certified mail to the Governor of Illinois, Springfield, Ill., and a copy to the Illinois Commerce Commission, Springfield, Ill.; and that further notice of this proceeding be given to the public by depositing a copy of this order in the office of the Secretary of this Commission at Washington, D.C. and by filing a copy with the Director, Office of the Federal Register, Washington, D.C., for publication in the FEDERAL REGISTER.

And it is further ordered, That this proceeding be assigned for hearing at such time and place as the Commission may hereafter designate.

By the Commission, Division 2.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1473; Filed, Feb. 5, 1970; 8:45 a.m.]

[No. 35199]

KENTUCKY INTRASTATE SWITCHING RATES AND CHARGES, 1969

Order. At a session of the Interstate Commerce Commission, Division 2, held at its office in Washington, D.C., on the 12th day of January 1970.

Upon consideration of the petition filed on December 2, 1969, by Kentucky and Indiana Terminal Railroad Co.; and

It appearing, that the petitioner published, effective May 1, 1968, increased switching and terminal rates and charges applicable to interstate traffic; that it attempted to publish corresponding increased charges applicable to intrastate traffic effective on the same date; and that the Railroad Commission of Kentucky, by its report and order of November 20, 1968, declined to allow the increases sought, authorizing, however, increases on a lower level;

It further appearing, that the petitioner alleges in its petition that: (1) It is being required to render switching services for intrastate traffic at charges which are unjustly and unreasonably low; (2) such charges fail to produce their fair share of earnings sufficient to enable the petitioner to provide adequate and efficient transportation services as required by the Interstate Commerce Act and the National Transportation Policy; (3) an undue burden is thus cast upon interstate commerce to the extent that the intrastate rates and charges are below those for interstate service; (4) the conditions in regard to intrastate transportation are no more favorable than those incident to interstate movements; (5) the increases sought will not result in rates or charges which are unjust or unreasonable; and (6) the increases sought will reduce the contributions which the owner line-haul carriers must make to the petitioner's operating deficit;

And it further appearing, that the matters raised in the petition are sufficient to require an investigation thereof by this Commission;

Wherefore, and for good cause:

It is ordered, That, pursuant to section 13 of the Interstate Commerce Act, an investigation be, and it is hereby, instituted into the matters and things presented in the petition.

It is further ordered, That all persons who wish actively to participate in this proceeding and to file and to receive copies of pleadings shall make known that fact by notifying the Commission in writing on or before February 16, 1970. To conserve time and to avoid unnecessary expense, persons having common interests should endeavor to consolidate their presentation to the greatest extent possible. Individual participation is not precluded; however, mere casual interest does not justify participation. The Commission desires participation only of those who intend to take an active part in the proceeding.

It is further ordered, That as soon as practicable after the date for indicating a desire to participate in the proceeding has past, the Secretary will serve a list of the names and addresses of all persons upon whom service of all pleadings must be made.

It is further ordered, That a copy of this order be served upon the petitioner; that the Commonwealth of Kentucky be notified of the proceeding by sending a copy of this order by certified mail to the Governor of Kentucky, Louisville, Ky., and a copy to the Railroad Commission of Kentucky at Louisville; and that further notice of this proceeding be given to the public by depositing a copy of this order in the office of the Secretary of this Commission at Washington, D.C., and by filing a copy with the Director, Office of the Federal Register, Washington, D.C., for publication in the FEDERAL REGISTER.

And it is further ordered, That this proceeding be assigned for hearing at such time and place as may hereafter be designated.

By the Commission, Division 2.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1471; Filed, Feb. 5, 1970; 8:45 a.m.]

[No. 35210]

NEBRASKA INTRASTATE FREIGHT RATES AND CHARGES, 1969

Order. At a session of the Interstate Commerce Commission, Division 2, held at its office in Washington, D.C., on the 26th day of January 1970.

By petition filed on December 22, 1969, the common carriers by railroad operating within the State of Nebraska aver that the Nebraska State Railway Commission has refused to authorize or to permit increases in rates and charges on grain and grain products, including soybeans, soybean cake and meal, soybean oil, beet or cane sugar, and sugarbeets moving in intrastate commerce corresponding to those authorized by this Commission on interstate commerce in Ex Parte No. 256, Increased Freight Rates, 1967, 332 I.C.C. 280, and Ex Parte No. 259, Increased Freight Rates, 1968, 332 I.C.C. 590 and 714; and for good cause:

It is ordered, That, pursuant to section 13 of the Interstate Commerce Act, an investigation be, and it is hereby, instituted into the matters and things presented in the petition; and that all common carriers by railroad operating within the State of Nebraska subject to the jurisdiction of this Commission be, and they are hereby, made respondents to this proceeding.

It is further ordered, That all persons who intend actively to participate in this proceeding and to file and receive copies of pleadings, shall make known that fact by notifying the Commission in writing on or before February 26, 1970. To conserve time and to avoid unnecessary expense, persons having common interests should endeavor to consolidate their presentation to the greatest extent possible. Individual participation is not precluded, however, mere casual interest does not justify participation. The Commission desires participation only of those who intend to take an active part in the proceeding.

It is further ordered, That as soon as practicable after the date for indicating

a desire to participate in the proceeding has passed, the Secretary will serve a list of the names and addresses of all participants.

It is further ordered, That a copy of this order be served upon the respondents; that the State of Nebraska be notified of the proceeding by sending a copy of this order by certified mail to the Governor of Nebraska, Lincoln, Nebr., and a copy to the Nebraska State Railway Commission, Lincoln, Nebr.; and that further notice of this proceeding be given to the public by depositing a copy of this order in the office of the Secretary of this Commission at Washington, D.C., and by filing a copy with the director, Office of the Federal Register, Washington, D.C., for publication in the FEDERAL REGISTER.

And it is further ordered, That this proceeding be assigned for hearing at such time and place as the Commission may hereafter designate.

By the Commission, Division 2.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1472; Filed, Feb. 5, 1970; 8:45 a.m.]

FOURTH SECTION APPLICATIONS FOR RELIEF

FEBRUARY 3, 1970.

Protests to the granting of an application must be prepared in accordance with Rule 1100.40 of the general rules of practice (49 CFR 1100.40) and filed within 15 days from the date of publication of this notice in the FEDERAL REGISTER.

LONG-AND-SHORT HAUL

FSA No. 41873—*Volcanic ash from, to and between points in WTL territory.* Filed by Western Trunk Line Committee, agent (No. A-2616), for interested rail carriers. Rates on volcanic ash, other than crude, in carloads, as described in the application, from, to, and between points in western trunk-line territory.

Grounds for relief—Commodity relationship, short-line distance formula and grouping.

Tariff—Supplement 91 to Western Trunk Line Committee, agent, tariff ICC A-4669.

FSA No. 41874—*Fish meal from Boucherville, Quebec, Canada, to points in WTL territory.* Filed by Western Trunk Line Committee, agent (No. A-2618), for interested rail carriers. Rates on fish meal, in carloads from Boucherville, Quebec, Canada, to points in western trunk-line territory.

Grounds for relief—Market competition and origin rate relationship.

Tariff—Supplement 11 to Canadian Freight Association tariff ICC 303.

By the Commission.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1530; Filed, Feb. 5, 1970; 8:49 a.m.]

[Notice 18]

MOTOR CARRIER TEMPORARY AUTHORITY APPLICATIONS

FEBRUARY 2, 1970.

The following are notices of filing of applications for temporary authority under section 210a(a) of the Interstate Commerce Act provided for under the new rules of Ex Parte No. MC-67 (49 CFR Part 1131), published in the FEDERAL REGISTER, issue of April 27, 1965, effective July 1, 1965. These rules provide that protests to the granting of an application must be filed with the field official named in the FEDERAL REGISTER publication, within 15 calendar days after the date of notice of the filing of the application is published in the FEDERAL REGISTER. One copy of such protests must be served on the applicant, or its authorized representative, if any, and the protests must certify that such service has been made. The protests must be specific as to the service which such protestant can and will offer, and must consist of a signed original and six copies.

A copy of the application is on file, and can be examined at the Office of the Secretary, Interstate Commerce Commission, Washington, D.C., and also in field office to which protests are to be transmitted.

MOTOR CARRIERS OF PROPERTY

No. MC 682 (Sub-No. 18 TA), filed January 28, 1970. Applicant: BURNHAM VAN SERVICE, INC., Post Office Box 1125, Columbus, Ga. 31902. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Household goods*, as defined by the Commission, between points in Hawaii (restricted to the handling of traffic originating at or destined to out-of-State points), for 180 days. Supporting shipper: Honeywell, Inc., 1400 Soldiers Field Road, Brighton, Mass. 02135. Send protests to: William L. Scroggs, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Room 309, 1252 West Peachtree Street NW., Atlanta, Ga. 30309.

No. MC 2900 (Sub-No. 188 TA), filed January 23, 1970. Applicant: RYDER TRUCK LINES, INC., 2050 Kings Road, Jacksonville, Fla. 32203. Authority sought to operate as a *common carrier*, by motor vehicle, over regular routes, transporting: *General commodities* (except those of unusual value, household goods as defined by the Commission, classes A and B explosives, commodities in bulk, and those requiring special equipment), serving the plantsites of International Paper Co. at or near Ticonderoga, N.Y., as off-route points in connection with applicant's presently authorized operation, for 180 days. NOTE: Applicant intends to tack MC 2900 (Sub-No. 169). Supporting shipper: International Paper Co., 220 East 42d Street, New York, N.Y. 10017. Send protests to: District Supervisor G. H. Fauss, Jr., Bureau of Operations, Interstate Commerce Commission, Box 35008, 400 West Bay Street, Jacksonville, Fla. 32202.

No. MC 107403 (Sub-No. 786 TA), filed January 27, 1970. Applicant: MATLACK, INC., 10 West Baltimore Avenue, Lansdowne, Pa. 19050. Applicant's representative: John Nelson (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Chemicals*, in bulk, from Garyville, La., to points in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Oklahoma, Tennessee, and Texas, for 180 days. Supporting shipper: James E. Carr, Corporate Traffic Manager, Nalco Chemical Co., 6216 West 66th Place, Chicago, Ill. 60638. Send protests to: Ross A. Davis, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 900 U.S. Customhouse, Second and Chestnut Streets, Philadelphia, Pa. 19106.

No. MC 107496 (Sub-No. 762 TA), filed January 22, 1970. Applicant: RUAN TRANSPORT CORPORATION, Third and Keosauqua Way, Des Moines, Iowa 50309. Applicant's representative: H. L. Fabritz (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Animal feed ingredients*, in bulk, in pneumatic tank vehicles, from Crete, Nebr., to Kansas City, Mo., for 150 days. Supporting shipper: The Crete Mills, Division of Lauhoff Grain Co., Crete, Nebr. 68333. Send protests to: Ellis L. Annett, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 677 Federal Building, Des Moines, Iowa 50309.

No. MC 111302 (Sub-No. 55 TA), filed January 22, 1970. Applicant: HIGHWAY TRANSPORT, INC., Post Office Box 79, Powell, Tenn. 37849. Applicant's representative: Paul E. Weaver (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Lime and limestone products*, in bags and in bulk, from Knoxville, Tenn., to Lexington, Ky.; Canton and Enka, N.C.; and Catawba, S.C., for 180 days. Supporting shipper: Foote Mineral Co., Route 100, Exton, Pa. 19341. Send protests to: Joe J. Tate, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 803—1808 West End Building, Nashville, Tenn. 37203.

No. MC 113024 (Sub-No. 84 TA), filed January 27, 1970. Applicant: ARLINGTON J. WILLIAMS, INC., Rural Delivery No. 2, Smyrna, Del. 19977. Applicant's representative: Samuel W. Earnshaw, 833 Washington Building, Washington, D.C. 20005. Authority sought to operate as a *contract carrier*, by motor vehicle, over irregular routes, transporting: *Bathroom and washroom fixtures, sinks, and accessories and attachments therefor*, from Warren, Mich., to Harrisburg, Lansdale, Norristown, Reading, York, and Philadelphia, Pa., commercial zone, including Philadelphia, Pa., for account of Briggs Manufacturing Co., Warren, Mich., for 180 days. Supporting shipper: Briggs Manufacturing Co., 6600 East 15 Mile Road, Warren, Mich.; John A. Runyan, Materials Manager Send protests to: Paul J. Lowry, District

Supervisor, Interstate Commerce Commission, Bureau of Operations, 206 Old Post Office Building, 129 East Main Street, Salisbury, Md. 21801.

No. MC 113666 (Sub-No. 39 TA), filed January 28, 1970. Applicant: FREEPORT TRANSPORT, INC., 1200 Butler Road, Freeport, Pa. 16229. Applicant's representative: Daniel R. Smetanick (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Refractory products*, from Greenville, Pa., to ports of entry at Niagara Falls and Buffalo, N.Y., for furtherance to the Province of Ontario, Canada, for 180 days. Supporting shipper: Universal Refractories Corp., Post Office Box 72, Greenville, Pa. 16125. Send protests to: John J. England, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 2109 Federal Building, 1000 Liberty Avenue, Pittsburgh, Pa. 15222.

No. MC 115322 (Sub-No. 66 TA), filed January 28, 1970. Applicant: REDWING REFRIGERATED, INC., Post Office Box 1698, Sanford, Fla. 32771. Applicant's representative: James E. Wilson, 1735 K Street NW., Washington, D.C. 20006. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Frozen foods*, from the plantsite and storage facilities of Campbell Soup Co., Salisbury, Md., to points in North Carolina, South Carolina, Alabama, Georgia, Florida, and Tennessee, for 180 days. Supporting shipper: Campbell Soup Co., 375 Memorial Avenue, Camden, N.J. Send protests to: District Supervisor G. H. Fauss, Jr., Bureau of Operations, Interstate Commerce Commission, Box 35008, 400 West Bay Street, Jacksonville, Fla. 32202.

No. MC 119577 (Sub-No. 16 TA), filed January 28, 1970. Applicant: OTTAWA CARTAGE, INC., Post Office Box 458, Ottawa, Ill. 61350. Applicant's representative: Albert A. Andrin, 29 South La Salle Street, Chicago, Ill. 60603. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Silica sand*, in bulk, in pneumatic tank vehicles, from Utica, Ill., to Sharon, Pa., for 150 days. Supporting shipper: Bellrose Silica Co., Central Life Building, Post Office Box 460, Ottawa, Ill. 61350. Send protests to: William E. Gallagher, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 219 South Dearborn Street, Chicago, Ill. 60604.

No. MC 124679 (Sub-No. 31 TA), filed January 28, 1970. Applicant: C. R. ENGLAND & SONS, INC., 228 West Fifth South Street, Salt Lake City, Utah 84101. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Yeast and bread making products*, from Oakland, Calif., to points in Oregon, Washington, Idaho, and Utah, for 180 days. Supporting shipper: Universal Foods Corp., Northwest District Office, 725 Army Street, San Francisco, Calif. 94124. Send protests to: John T. Vaughan, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 6201 Federal Building, Salt Lake City, Utah 84111.

No. MC 125375 (Sub-No. 5 TA), filed January 22, 1970. Applicant: F. B. GUEST, doing business as F. B. G. TRANSPORT, Route 5, Box 95A, Covington, Ga. 30209. Applicant's representative: Monty Schumacher, Suite 310, 2045 Peachtree Road NE., Atlanta, Ga. 30309. Authority sought to operate as a *contract carrier*, by motor vehicle, over irregular routes, transporting: *Cottage cheese*, from Rock Island, Ill., to the warehouse of Winn-Dixie Stores, Inc., Louisville, Ky., and *return of damaged or rejected shipments*, for 180 days. NOTE: Applicant intends to tack MC-125375 Sub 1 and Sub 3 TA. Supporting shipper: Borden, Inc., Eastern Iowa-Central Illinois Region, Rock Island, Ill. Send protests to: William L. Scroggs, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Room 309, 1252 West Peachtree Street NW., Atlanta, Ga. 30309.

No. MC 126049 (Sub-No. 7 TA), filed January 22, 1970. Applicant: DODEN TRUCKING COMPANY, INC., Woden, Iowa 50484. Applicant's representative: Clayton L. Wornson, 824 Brick & Tile Building, Mason City, Iowa 50401. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Bulk and packaged ice cream, ice milk, and sherbet; and ice cream, ice milk, sherbet, and fruit flavored novelty items* from Chicago, Ill., to Cedar Rapids, Des Moines, Mason City, and Waterloo, Iowa, for 180 days. Supporting shipper: Borden Dairy & Services Division, Borden, Inc., 2341 Second Avenue, Des Moines, Iowa 50333. Send protests to: Ellis L. Annett, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 677 Federal Building, Des Moines, Iowa 50309.

No. MC 127834 (Sub-No. 49 TA), filed January 22, 1970. Applicant: CHEROKEE HAULING & RIGGING, INC., 540-42 Merritt Avenue, Nashville, Tenn. 37203. Applicant's representative: M. Bryan Stanley (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Aluminum light poles, light pole brackets and parts, and accessories therefor*, from points in Washington County, Va., to points in New York, Pennsylvania, Delaware, Connecticut, and New Jersey, for 150 days. Supporting shipper: Hapco, Post Office Box 547, Abingdon, Va., 24210. Send protests to: Joe J. Tate, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 803, 1808 West End Building, Nashville, Tenn. 37203.

No. MC 127834 (Sub-No. 50 TA), filed January 22, 1970. Applicant: CHEROKEE HAULING & RIGGING, INC., 540-42 Merritt Avenue, Nashville, Tenn. 37203. Applicant's representative: M. Bryan Stanley (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Signs, sign parts, and accessories therefor*, from Galva, Ill., to points in the United States except Alaska and Hawaii, for 150 days. Supporting shipper: Union Oil Company of California, 200 East Golf Road, Palatine, Ill. 60067. Send protests to: Joe J. Tate, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 803, 1808 West End Building, Nashville, Tenn. 37203.

No. MC 134291 TA, filed January 27, 1970. Applicant: JOSEPH R. ST. HILAIRE, doing business as ST. HILAIRE'S DELIVERY SERVICE, 285 Emmett Street, Bristol, Conn. 06010. Applicant's representative: Matthew Storm, 171 Laurel Street, Bristol, Conn. 06010. Authority sought to operate as a *contract carrier*, by motor vehicle, over irregular routes, transporting: *Manuscripts, proofs, page proofs, warren prints, art work, film, and office copies of magazines*, between Bristol, Conn., on the one hand, and, on the other, New York, N.Y., for 150 days. Supporting shipper: Hildreth Press, Inc., a subsidiary of Printing Corporation of America, 50 Emmett Street, Bristol, Conn., 06010. Send protests to: District Supervisor David J. Kiernan, Interstate Commerce Commission, Bureau of Operations, 324 U.S. Post Office Building, 135 High Street, Hartford, Conn. 06101.

MOTOR CARRIER OF PASSENGERS

No. MC 126765 (Sub-No. 1 TA), filed January 28, 1970. Applicant: PAUL SULGER, doing business as SULGER BUS LINE, 200 Canyon Drive, Sierra Vista, Ariz. 85635. Applicant's representative: Anthony C. Vance, 1111 E Street NW., Washington, D.C. 20004. Authority sought to operate as a *common carrier*, by motor vehicle, over regular routes, transporting: *Passengers and their baggage and express*, between Fort Huachuca and Tucson, Ariz., serving all intermediate points from Tucson over U.S. Highway 80 to junction Arizona Highway 90, thence over Arizona Highway 90 to Fort Huachuca, and return over the same route, for 180 days. Supporting shippers: 739 Individuals (military and civilian), A. A. Allen Revivals, Inc., Continental Trailways, Miracle Valley, Ariz. 85645; 1501 South Central Avenue, Los Angeles, Calif. 90021. Send protests to: Andrew V. Baylor, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 3427 Federal Building, Phoenix, Ariz. 85025.

By the Commission.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1529; Filed, Feb. 5, 1970; 8:49 a.m.]

[Notice 19]

MOTOR CARRIER TEMPORARY AUTHORITY APPLICATIONS

FEBRUARY 3, 1970.

The following are notices of filing of applications for temporary authority under section 210a(a) of the Interstate Commerce Act provided for under the new rules of Ex Parte No. MC-67 (49 CFR Part 1131), published in the FEDERAL REGISTER, issue of April 27, 1965, effective July 1, 1965. These rules provide that protests to the granting of an

application must be filed with the field official named in the FEDERAL REGISTER publication, within 15 calendar days after the date of notice of the filing of the application is published in the FEDERAL REGISTER. One copy of such protests must be served on the applicant, or its authorized representative, if any, and the protests must certify that such service has been made. The protests must be specific as to the service which such protestant can and will offer, and must consist of a signed original and six copies.

A copy of the application is on file, and can be examined at the Office of the Secretary, Interstate Commerce Commission, Washington, D.C., and also in field office to which protests are to be transmitted.

MOTOR CARRIERS OF PROPERTY

No. MC 17803 (Sub-No. 11 TA), filed January 28, 1970. Applicant: PREMIER TRUCKING SERVICE CO., 4440 Buckingham Avenue, Omaha, Nebr. 68107. Applicant's representative: Earl H. Scudder, Jr., 605 South 14th Street, Post Office Box 2028, Lincoln, Nebr. 68501. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Hides, pelts, chromes and pieces therefrom*, from the plantsite or facilities utilized by Beefland International, Inc., at or near Council Bluffs, Iowa, to points in Connecticut, Illinois, Kentucky, Maine, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Vermont, Virginia, West Virginia, and Wisconsin, for 150 days. Supporting shipper: Beefland International, Inc., 2700 North 23d Avenue, Council Bluffs, Iowa 51501. Send protests to: Keith P. Kohrs, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 705 Federal Office Building, Omaha, Nebr. 68102.

No. MC 52579 (Sub-No. 121 TA), filed January 29, 1970. Applicant: GILBERT CARRIER CORP., 1 Gilbert Drive, Secaucus, N.J. 07094. Applicant's representative: Wilfred Abel (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Wearing apparel*, loose, on hangers, from Rutherford, Greenfield, Dresden and Trenton, Tenn.; Little Rock, Ark.; Hialeah and Miami, Fla.; to Tucker, Ga., for 180 days. Supporting shipper: Sears, Roebuck & Co., 675 Ponce de Leon Avenue NE., Atlanta, Ga. 30308 (Attention: A. J. Erickson, Assistant Territorial Traffic Manager). Send protests to: District Supervisor Walter J. Grossmann, Bureau of Operations, Interstate Commerce Commission, 970 Broad Street, Newark, N.J. 07102.

No. MC 60087 (Sub-No. 12 TA), filed January 20, 1970. Applicant: CURRY MOTOR FREIGHT LINES, INC., 700 Northeast Third Street, Amarillo, Tex. 79105. Applicant's representative: Grady L. Fox, Amarillo Building, Amarillo, Tex. Authority sought to operate as a *common carrier*, by motor vehicle, over regular routes, transporting: *General commodities*, (a) between Lubbock and Levelland, Tex.; (b) between Plains, Tex., and Lubbock, Tex., over U.S. Highway 380 to Brownfield, Tex., thence over U.S. Highway 62 to Lubbock, Tex., serving the intermediate points of Gomez and Tokio, Tex.; (a) between Lubbock, Whiteface and Morton, Tex., over U.S. Highway 290; (b) between Morton and Muleshoe, Tex., over Texas Highway 214, and to coordinate with other service of the applicant; from Littlefield to Levelland, Tex., over county road; between Levelland and Sundown, Tex., over Smyer; over U.S. Highway 290 Levelland to Smyer; over Farm Road 1632 Smyer to Ropesville; over State Highway 41 Ropesville to Sundown; between Levelland and Lehman, Tex., via Sundown and Plains, over county roads; from Amarillo to Littlefield, Tex., via Hart, Olton, Sudan, and Amherst; (a) between Muleshoe and Friona, Tex., over Texas Highway 214, serving all intermediate points; (b) between Lubbock, Tex., and Olton, Tex., over U.S. Highway 84 to Anton, serving all points between Lubbock and Anton, including Anton, thence over Texas Highway 304 to Olton, serving the intermediate point of Spade; and from Spade, Tex., to Littlefield, Tex., over Texas Highway 54; (c) between Olton, Tex., and Farwell, Tex., over U.S. Highway 70 serving all intermediate points and coordinating such service with its existing service from Lubbock, Tex., to Olton, Tex., and from Muleshoe, Tex., to Bovina, Friona and Farwell, Tex.; (d) between Hart, Tex., and Friona, Tex., over Farm to Market Road 145 to intersection with Texas Highway 214, thence north to Friona over Texas Highway 214, serving all intermediate points; (e) between Bovina and Dimmitt, Tex., over Texas Highway 86; and between Dimmitt and Nazareth, Tex., over Texas Highway 86; and Dimmitt to Hart, over Texas Highway 194; and Dimmitt to Springlake over Texas Highway 51; and Olton to Earth over U.S. Highway 70, serving all intermediate points; for 150 days. NOTE: Applicant intends to tack MC-60087 and interline at Amarillo, Plainview and Lubbock, Tex. Supporting shippers: There are approximately 57 statements of support attached to the application, which may be examined here at the Interstate Commerce Commission in Washington, D.C., or copies thereof which may be examined at the field office named below. Send protests to: Haskell E. Ballard, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 918 Tyler Street, Amarillo, Tex. 79101.

No. MC 94350 (Sub-No. 252 TA), filed January 28, 1970. Applicant: TRANSIT HOMES, INC., Post Office Box 1628, Greenville, S.C. 29602. Applicant's representative: Mitchell King (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Trailers designed* to be drawn by passenger automobiles in initial movements, *and buildings*, in sections mounted on wheeled undercarriages, from points of manufacture, from Smithfield, N.C. to points in the United States, east of the Mississippi River (including Louisiana and Minnesota, and excluding Detroit and Mount Clemens, Mich.), for 180 days. Supporting shipper: U.S.C.O., Inc., Richmond, Va. Send protests to: Arthur B. Abercrombie, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 601A Federal Building, 901 Sumter Street, Columbia, S.C. 29201.

No. MC 107403 (Sub-No. 787 TA), filed January 29, 1970. Applicant: MATLACK, INC., 10 West Baltimore Avenue, Lansdowne, Pa. 19050. Applicant's representative: John Nelson (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Flour*, in bulk, from Highspire, Pa., to Pennsville, N.J., for 180 days. Supporting shipper: Standard Milling Co., 1009 Central Street, Kansas City, Mo. 64105. Send protests to: Ross A. Davis, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 900 U.S. Custom House, Second and Chestnut Streets, Philadelphia, Pa. 19106.

No. MC 116077 (Sub-No. 287 TA), filed January 29, 1970. Applicant: ROBERTSON TANK LINES, INC., 5700 Polk Avenue, Post Office Box 1505, Houston, Tex. 77001. Applicant's representative: J. C. Browder (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Chemicals*, in bulk, from plantsite of Nalco Chemical Company, at or near Garyville, (St. John the Baptist Parish), La., to points in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Oklahoma, Tennessee, and Texas, for 180 days. NOTE: Applicant does not intend to tack with existing authority. Supporting shipper: Nalco Chemical Co., (Mr. James E. Carr, Corporate Traffic Manager), 6216 West 66th Place, Chicago, Ill. 60638. Send protests to: District Supervisor John C. Redus, Bureau of Operations, Interstate Commerce Commission, Post Office Box 61212, Houston, Tex. 77061.

No. MC 117465 (Sub-No. 13 TA), filed January 28, 1970. Applicant: BEAVER EXPRESS SERVICE, INC., doing business as BEAVER EXPRESS, Post Office Box 151, Woodward, Okla. 73801. Applicant's representative: Max G. Morgan, 600 Leininger Building, Oklahoma City, Okla. 73112. Authority sought to operate as a *common carrier*, by motor vehicle, over regular routes, transporting: *General commodities* (except classes A and B explosives), moving in express service, between Liberal, Kans., and the intersection of U.S. Highways 160 and 283; from Liberal over Highway 54 to its junction of U.S. Highway 160; thence over U.S. Highway 160 to its junction with U.S. Highway 283, and return over the same route, for 180 days. NOTE: Carrier intends to tack authority here applied for to that presently held and/or interline with other carriers at Woodward. Supporting shippers: There are approximately 12 statements of support attached to the application, which may be examined here at the Interstate Commerce Commission in Washington, D.C., or copies thereof which may

be examined at the field office named below. Send protests to: Haskell E. Ballard, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 918 Tyler Street, Amarillo, Tex. 79101.

No. MC 117565 (Sub-No. 25 TA), filed January 28, 1970. Applicant: MOTOR SERVICE COMPANY, INC., 237 South Fifth Street, Coshocton, Ohio 43812. Applicant's representative: Louis J. Amato, Central Building, 1033 State Street, Bowling Green, Ky. 42101. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Motor homes*, in initial movements, in truckaway and driveway service, and *rejected or damaged shipments*, on return, from the plantsite of Shasta of Ohio, Apple Creek, Ohio, to points in Montana, Wyoming, Colorado, and New Mexico, and points in the United States east thereof (except Leola, Pa.; Goshen, Ind.; Grapevine, Tex., and Columbia, S.C.), for 180 days. Supporting shipper: Shasta of Ohio, Post Office Box 238, Apple Creek, Ohio 44606. Send protests to: A. M. Culver, Jr., District Supervisor, Interstate Commerce Commission, Bureau of Operations, 255 Federal Building and U.S. Courthouse, 85 Marconi Boulevard, Columbus, Ohio 43215.

No. MC 119754 (Sub-No. 3 TA), filed January 29, 1970. Applicant: STANLEY A. WESTGOR, Wittenberg, Wis. 54499. Applicant's representative: John L. Bruemmber, 121 West Doty Street, Madison, Wis. 53703. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Wooden posts and poles*, between points in Wisconsin, the Upper Peninsula of Michigan, that part of Illinois on and north of Illinois Highway 9, and that part of Minnesota on and east of a line beginning at the Minnesota-Iowa State line and extending along U.S. Highway 169 to junction U.S. Highway 53, north of Virginia, Minn., and thence along U.S. Highway 53 to International Falls, Minn., including International Falls, Minneapolis, and St. Paul, Minn., and points within 5 miles of Minneapolis, and St. Paul, Minn., for 150 days. Supporting shipper: Joslyn Manufacturing and Supply Co., 155 North Wacker Drive, Chicago, Ill. 60606 (E. W. Kocher, General Traffic Manager). Send protests to: District Supervisor Lyle D. Helfer, Interstate Commerce Commission, Bureau of Operations, 135 West Wells Street, Room 807, Milwaukee, Wis. 53203.

No. MC 119767 (Sub-No. 234 TA), filed January 29, 1970. Applicant: BEAVER TRANSPORT CO., 100 South Calumet Street, Burlington, Wis. 53105. Applicant's representative: A. Bryant Torhorst (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Yeast, casein, and whey, and blends and products thereof*, from Juneau, Wis., to points in Illinois, Indiana, Iowa, Minnesota, Michigan, and Ohio, for 180 days. Supporting shipper: Milbrew, Inc., Juneau, Wis. 53039 (N. N. Bernstein, Secretary). Send protests to: District Supervisor Lyle D. Helfer, Interstate Commerce Commission, Bureau of Operations, 135 West Wells Street, Room 807, Milwaukee, Wis. 53203.

No. MC 124078 (Sub-No. 423 TA), filed January 29, 1970. Applicant: SCHWERMAN TRUCKING CO., 611 South 28th Street, Milwaukee, Wis. 53246. Applicant's representative: Richard H. Prevette (same address as above). Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Carbon dioxide*, in shipper-owned trailers, from Lima, Ohio, to Buffalo, Niagara Falls, Rochester and Syracuse, N.Y., for 180 days. Supporting shipper: Airco Industrial Gases, a division of Air Reduction Co., Inc., 575 Mountain Avenue, Murray Hill, N.J. (Robert D. Heward, Transport Equipment Fleet Administrator). Send protests to: District Supervisor Lyle D. Helfer, Interstate Commerce Commission, Bureau of Operations, 135 West Wells Street, Room 807, Milwaukee, Wis. 53203.

No. MC 126714 (Sub-No. 2 TA), filed January 27, 1970. Applicant: SOUTHWEST DELIVERY CO., INC., 304 Columbia Street, Vancouver, Wash. 98660. Authority sought to operate as a *common carrier*, by motor vehicle, over regular routes, transporting: *General commodities*, except those of unusual value, classes A and B explosives, livestock, household goods as defined by the Commission, commodities in bulk, and commodities requiring special equipment, between Portland, Oreg., and Vancouver, Wash., on the one hand, and, on the other hand, Olympia, Tacoma, Seattle, and Everett, Wash., serving all intermediate points, between Olympia and Everett, Wash., over Interstate Highway 5 and/or U.S. Highway 99, for 180 days. NOTE: Applicant proposes to interline traffic at all points sought to be authorized. Supporting shippers: There are approximately (75) statements of support attached to the application, which may be examined here at the Interstate Commerce Commission in Washington, D.C., or copies thereof which may be examined at the field office named below. Send protests to: District Supervisor W. J. Huetig, Interstate Commerce Commission, Bureau of Operations, 450 Multnomah Building, 120 Southwest Fourth Avenue, Portland, Oreg. 97204.

No. MC 133574 (Sub-No. 1 TA), filed January 27, 1970. Applicant: TERRILL TRUCKING COMPANY, 1016 Geneseo Street, Storm Lake, Iowa 50588. Applicant's representative: Earl H. Scudder, Jr., Box 2028, Lincoln, Nebr. 68501. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Meats, meat products, meat byproducts, dairy products and articles distributed by meat packinghouses* as described in sections A, B, and C of appendix I to the *Report in Descriptions in Motor Carrier Certificates*, 61 M.C.C. 209, 766 (except hides and commodities in bulk, in tank vehicles, from Spencer, Iowa, and Hartley, Iowa, to points in Alabama, Georgia, and Florida, for 150 days. Supporting shipper: Spencer Packing Co., Spencer, Iowa. Send protests to: Carroll Russell, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 304 Post Office Building, Sioux City, Iowa 51101.

No. MC 134267 TA (Correction), filed January 12, 1970, published in the FEDERAL REGISTER issue of January 28, 1970, and republished in part, as corrected, this issue. Applicant: GRAHAM TRUCKING CORP., Post Office Box 488, Morgan, Utah 84050. Applicant's representative: Harry D. Pugsley, 400 El Paso Gas Building, Salt Lake City, Utah 84111. NOTE: The purpose of this partial republication is to show the inbound movements to read "from points in West Virginia," etc., in lieu of "from points in Virginia," etc. The rest of the application remains as previously published.

No. MC 134297 TA, filed January 28, 1970. Applicant: S & T VAN AND STORAGE CO., 36 Hegenberger Court, Oakland, Calif. 94621. Applicant's representative: Daniel W. Baker, 405 Montgomery Street, San Francisco, Calif. 94104. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Used household goods*, between points in San Francisco, San Mateo, Santa Clara, Contra Costa, and Alameda, Calif.; restricted (1) to transportation of traffic having a prior or subsequent movement in containers, beyond the points authorized; and (2) to the performance of pickup and delivery service in connection with packing, crating, and containerization or packing, uncrating and decontainerization of such traffic, for 180 days. Supporting shippers: Cartwright Van Lines, Inc., 4250 24th Avenue W., Seattle, Wash. 98199; Dean Van Lines, Inc., 18420 South Santa Fe Avenue, Long Beach, Calif. 90801. Send protests to: District Supervisor Wm. E. Murphy, Interstate Commerce Commission, Bureau of Operations, 450 Golden Gate Avenue, Box 36004.

No. MC 134299 (Sub-No. 1 TA), filed January 29, 1970. Applicant: PETER P. BURKEL, JR., Greensboro, Minn. 56726. Applicant's representative: Gene P. Johnson, 502 First National Bank Building, Fargo, N. Dak. 58102. Authority sought to operate as a *common carrier*, by motor vehicle, over irregular routes, transporting: *Animal and poultry feed and feed ingredients*, dry, from Cold Spring, Dawson, Mankato, Minneapolis, Savage and Thief River Falls, Minn.; West Fargo, N. Dak., and Rock Island, Ill., to the ports of entry on the International Boundary Line between the United States and Canada located in Minnesota and North Dakota, for 180 days. Supporting shippers: Steinbach Hatchery Ltd., Box 1178, Steinbach, Manitoba, Canada; Northwest Pellet Association, Thief River Falls, Minn. 56701. Send protests to: J. H. Ambs, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Post Office Box 2340, Fargo, N. Dak. 58102.

By the Commission.

[SEAL] H. NEIL GARSON, *Secretary.*

[F.R. Doc. 70-1528; Filed, Feb. 5, 1970; 8:49 a.m.]

[Notice 486]

MOTOR CARRIER TRANSFER PROCEEDINGS

FEBRUARY 3, 1970.

Synopses of orders entered pursuant to section 212(b) of the Interstate Commerce Act, and rules and regulations prescribed thereunder (49 CFR Part 1132), appear below:

As provided in the Commission's special rules of practice any interested person may file a petition seeking reconsideration of the following numbered proceedings within 20 days from the date of publication of this notice. Pursuant to section 17(8) of the Interstate Commerce Act, the filing of such a petition will postpone the effective date of the order in that proceeding pending its disposition. The matters relied upon by petitioners must be specified in their petitions with particularity.

No. MC–FC–71731. By order of January 27, 1970, the Motor Carrier Board approved the transfer to A & G Moving and Storage Co., a corporation, Washington, D.C., of Certificates Nos. MC–94769, MC–94769 (Sub-No. 1), and MC–94769 (Sub-No. 2) issued March 5, 1942, March 3, 1942, and June 24, 1959, respectively, to J. W. Woodson, 3507 New Hampshire Avenue NW., Washington, D.C. 20010, authorizing the transportation of: Household goods as defined by the Commission, (1) between points in the District of Columbia and points in Maryland within 50 miles thereof, in a radical movement, (2) between points in the District of Columbia, and points in North Carolina and South Carolina, in a radical movement, and (3) between Washington, D.C., and points in specified counties in Virginia, in a radical movement. Margaret A. Beller, 927 15th Street NW., Washington, D.C. 20005, attorney for transferee.

No. MC–FC–71733. By order of January 27, 1970, the Motor Carrier Board approved the transfer to WAG Freight, Inc., Akron, Ohio, of the operating rights in Permit No. MC–106608 issued January 5, 1960, to W. A. Givens, Akron, Ohio, authorizing the transportation of electrical household appliances, and parts thereof, die castings, advertising matter, office furniture, supplies and equipment, and machinery, supplies, equipment, and materials used in the manufacture of electrical household appliances, electrical household appliance parts, and die castings, over a regular route between North Canton, Ohio, and Chicago, Ill., serving no intermediate points. Dual operations under common control were authorized. John E. Phillips, 1114 First National Bank Building, Canton, Ohio, 44702, attorney for applicants.

No. MC–FC–71825. By order of January 27, 1970, the Motor Carrier Board approved the transfer to Joseph Pestrak and Mary Pestrak, doing business as Perawel Trucking Co., Trenton, N.J., of Certificates Nos. MC–78182 and MC–78182 (Sub-No. 4) issued January 9, 1968, and August 14, 1967, respectively, to Joseph Pestrak, Mary Pestrak, and Frank Pestrak, doing business as Perawel Trucking Co., Trenton, N.J., authorizing the transportation of: General commodities, with the usual exceptions, between specified points and areas in New York, New Jersey, and Pennsylvania. Bert Collins, 140 Cedar Street, New York, N.Y. 10006, practitioner for applicants.

No. MC–FC–71828. By order of January 27, 1970, the Motor Carrier Board approved the transfer to David Gene Lytle, doing business as Holton-St. Joseph Freight Lines, Rural Route 2, Holton, Kans. 66436, of Certificate No. MC–10601 issued May 2, 1942, to J. Van Sweingen, doing business as Holton-St. Joseph Freight Line, Holton, Kans. 66436, authorizing the transportation of: General commodities, with the usual exceptions, and specifically named commodities, between specified points and areas in Kansas and Missouri.

No. MC–FC–71847. By order of January 27, 1970, the Motor Carrier Board approved the transfer to Creager Trucking Co., Inc., Seattle, Wash., of the operating rights in Permit No. MC–129352 issued February 27, 1969, to James Creager, doing business as Creager Trucking Co., Seattle, Wash., authorizing the transportation of flat glass products, from Fresno, Fullerton, and Strathmore, Calif., to points in Grant, Benton, Chelan, and Yakima Counties, Wash., and points in that part of Washington in and west of Whatcom, Skagit, Snohomish, King, Pierce, Lewis, and Skamania Counties. George R. LaBissoniere, 1424 Washington Building, Seattle, Wash. 98101, attorney for applicants.

No. MC–FC–71861. By order of January 28, 1970, the Motor Carrier Board approved the transfer to Vincent A. Vitale, Jr., East Brunswick, N.J., of the operating rights in Permits Nos. MC–2753 and MC–2753 (Sub-No. 2) issued April 25, 1950, and March 29, 1962, respectively, to Vincent A. Vitale, Hillside, N.J., authorizing the transportation of concrete pipe, concrete pipe forms, and concrete pipe manufacturing equipment, from Wharton and East Brunswick, N.J., to points in Pennsylvania, New York, New Jersey, Massachusetts, Connecticut, Maryland, and Delaware within 175 miles of Wharton and East Brunswick, and from Kenilworth, N.J., to points in New York, Connecticut, and Pennsylvania within 125 miles of Kenilworth. Herman B. J. Weckstein, 60 Park Place, Newark, N.J. 07102, attorney for applicants.

[SEAL] H. NEIL GARSON,
Secretary.

[F.R. Doc. 70–1531; Filed, Feb. 5, 1970; 8:49 a.m.]

CUMULATIVE LIST OF PARTS AFFECTED—FEBRUARY

The following numerical guide is a list of parts of each title of the Code of Federal Regulations affected by documents published to date during February.

3 CFR

Page

PROCLAMATIONS:
1677 (see PLO 4762) 2402
3958 2571
3959 2641

EXECUTIVE ORDERS:
11211 (amended by EO 11506) 2501
11282 (superseded by EO 11507) 2576
11288 (superseded by EO 11507) 2576
11368 (see EO 11506) 2501
11506 2501
11507 2573

5 CFR

213 2383, 2643, 2644

7 CFR

301 2577
318 2503
319 2503
724 2504–2506
811 2383
857 2507
907 2578
910 2383

PROPOSED RULES:
52 2668
724 2526
907 2526
1001 2527
1002 2527
1003 2527
1004 2527
1005 2527
1006 2527
1007 2527
1011 2527
1012 2527
1013 2527
1015 2527
1016 2527
1030 2527
1032 2527
1033 2527
1034 2527
1035 2527
1036 2527
1040 2527
1041 2527
1043 2527
1044 2527
1046 2527
1049 2527
1050 2527
1060 2527
1061 2527
1062 2527
1063 2527
1064 2527
1065 2527
1068 2527
1069 2527
1070 2527
1071 2527
1073 2527
1075 2527
1076 2572
1078 2527
1079 2527

7 CFR—Continued

Page

PROPOSED RULES—Continued
1090 2527
1094 2527
1096 2527
1097 2527
1098 2527, 2669
1099 2527
1101 2527
1102 2527
1103 2572
1104 2527
1106 2527
1108 2527
1120 2527
1121 2527
1124 2527
1125 2527
1126 2527
1127 2527
1128 2572
1129 2527
1130 2527
1131 2527
1132 2527
1133 2527
1134 2527
1136 2527
1137 2527
1138 2527

9 CFR

76 2507, 2508, 2644

PROPOSED RULES:
318 2527

12 CFR

265 2383
510 2509
542 2509
543 2509
545 2511
556 2514
562 2514
567 2515
571 2515
582 2515

13 CFR

121 2385

PROPOSED RULES:
113 2596
121 2597

14 CFR

13 2578
39 2517
47 2578
71 2517, 2580–2583, 2645
75 2583, 2584
91 2578
97 2390, 2647

PROPOSED RULES:
21 2412
25 2412
39 2594
71 2595, 2670
73 2595
75 2596
171 2528

16 CFR

Page

13 2385–2387, 2517–2522
15 2655, 2656

PROPOSED RULES:
118 2673

17 CFR

PROPOSED RULES:
230 2672

18 CFR

PROPOSED RULES:
101 2413
201 2413

19 CFR

PROPOSED RULES:
9 2410

20 CFR

PROPOSED RULES:
405 2593

21 CFR

3 2656, 2657
5 2584
120 2585
146b 2657
147 2657
164 2658
191 2659

PROPOSED RULES:
3 2411
141b 2670
146b 2670

29 CFR

8 2387
201 2556
202 2557
203 2561
205 2563
541 2389

32 CFR

536 2659

33 CFR

207 2660

38 CFR

17 2389

39 CFR

PROPOSED RULES:
261 2410
262 2410

41 CFR

5A–2 2399
5A–72 2400
5A–73 2400
5B–3 2585
9–5 2586
14–1 2523
60–2 2586

United States Government Organization MANUAL 1969–70



know your government

Presents essential information about Government agencies (updated and republished annually). Describes the creation and authority, organization, and functions of the agencies in the legislative, judicial, and executive branches. This handbook is an indispensable reference tool for teachers, students, librarians, researchers, businessmen, and lawyers who need current official information about the U.S. Government. The United States Government Organization Manual is the official guide to the functions of the Federal Government, published by the Office of the Federal Register, GSA.

$3.00 per copy. Paperbound, with charts

Order from Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.